All Indications

Effect-Size Predictions

Using Data-free Virtual Clinical Trials

96% accuracy across 604 prospectively validated trials

BioinvestGPT

Evidence Dossier

April 8, 2026

Platform Credentials at a Glance

96%

Prospective Prediction Accuracy

Across 604 prospectively validated trials | Two-sided p < 0.0001

EA **100% Ex-Ante**
Every prediction certified and sent to clients before trial results were known

RG **Industrial Rigor**
Validated against real FDA/EMA clinical readouts

EP **Empirical Certainty**
Statistically significant with two-sided p < 0.0001

Data-Free	White-Box	Head-to-Head	604 Validated
Zero-Patient Input	Root Cause Explained	vs. Standard of Care	Two-Sided p < 0.0001 ● LIVE

STRATEGIC VALUE PILLARS

Zero-Data Advantage

NO DATA SHARING
Predictions require **zero proprietary patient data**, eliminating **IP liability** and privacy friction.

2M VIRTUAL PATIENTS
Pre-built, **clinically validated** virtual cohorts delivering rigorous **effect-size predictions** across all major indications.

Eliminating Blind Spots

SURROGATE DETECTION
Simultaneously predicts early surrogates (**ORR/PFS**) and final efficacy (**OS**) to expose **hidden discordances**.

FUTURE-PROOFING
Benchmarks against **competitor** pipeline drugs to ensure **superiority at launch**, not just at trial start.

Identify Biological Root Cause

BEYOND BLACK-BOX
Every prediction is backed by **biological root cause identification**, not opaque probability scores.

ACTIONABLE DRIVERS
Pinpoints specific **failure/success drivers: target selection, drug design, delivery method, or patient stratification.**

Effect-Size Portfolio Gating Spectrum

All Indications

604 validated trials

HAZARD RATIO GO/NO-GO THRESHOLD SPECTRUM

GO	**Strongly Superior**	HR < 0.3	*Transformative clinical benefit — megablockbuster potential*
GO	**Moderately Superior**	HR 0.3–0.6	*Commercially sufficient — blockbuster potential*
	HR = 0.6 THRESHOLD		
NO-GO	**Weakly Superior**	HR 0.6–0.8	*Marginal benefit — likely insufficient for market differentiation*
NO-GO	**Non-Superior**	HR 0.8–1.0	*No meaningful advantage over current standard of care*
NO-GO	**Inferior to SoC**	HR 1.0–1.2	*Patient harm risk — trial likely to fail primary endpoint*

Configurable Threshold

Clients may select any HR value as the GO/NO-GO boundary based on their commercial case. We use HR = 0.6 as the default threshold for effect-size GO/NO-GO prospective predictions. GO = commercially sufficient effect size; NO-GO = commercially insufficient. See Trial Detail pages for each ex-ante validated prediction.

EX-ANTE PREDICTION ACCURACY

SCALE

492 Drug Assets

83.1% First-in-Class ratio

COVERAGE

267 Sponsors

Public biopharma footprint

LEAD TIME

202 Days

Average advance prediction window

Predictive Performance Intelligence

All Indications

604 prospectively validated GO/NO-GO predictions

– –IMPAIRMENT NO-GO correct rate

Negative Predictive Value (NPV)

99%

370/374 NO-GO predictions validated
`TN / (TN + FN)`

99% of BioinvestGPT NO-GO predictions are prospectively independently validated, signaling **cost savings** from lackluster drugs. A NO-GO signal reliably identifies commercially insufficient FIC/BIC assets before Phase III spend, **preventing impairment write-downs**.

++RELIABILITY GO/NO-GO correct rate

Accuracy

96%

580/604 validated prospective predictions
`(TP + TN) / (TP + TN + FP + FN)`

96% of BioinvestGPT GO/NO-GO predictions are correct for any-stage FIC/BIC assets, **nearly 10 times higher** than the industry's current best level (5–10%). BioinvestGPT prospectively predicts both drug successes and failures with **near-perfect reliability**.

++REVENUE GO correct rate

Positive Predictive Value (PPV)

91%

210/230 GO predictions validated
`TP / (TP + FP)`

91% of BioinvestGPT GO predictions are prospectively independently validated as commercially sufficient drugs. A GO signal identifies **blockbuster FIC/BIC assets** with high reliability, enabling **revenue-maximizing** portfolio predictions.

++RELIABILITY GO/NO-GO bias-free rate

F1-Score

95%

Harmonic mean of Precision and Recall
`2×TP / (2×TP + FP + FN)`

Both GO and NO-GO predictions are almost **equally likely to be correct**, even though **blockbuster drugs are much rarer**. The model does not simply guess "failure" — it **makes the right call on both sides**.



++RELIABILITY GO/NO-GO reliability rate

Diagnostic Odds Ratio (DOR)

971×

971× more likely correct than incorrect
`(TP × TN) / (FP × FN)`

BioinvestGPT GO/NO-GO predictions is **971 times more likely** to **correctly identify blockbuster assets** (true positives) and **rule out commercially insufficient assets** (true negatives), compared with the chance of making an incorrect prediction.



* The F1-Score and DOR for current drug GO/NO-GO prospective prediction approach is estimated based on the industry 10% nomination rate (boehringer-ingelheim.com/science-innovation/human-health-innovation/drug-discovery).

Therapeutic Area Breakdown

All Indications

Exhibit 1

Prediction accuracy remains consistently high across all therapeutic domains

BioinvestGPT's validation dataset spans 7 major therapeutic areas, demonstrating that predictive accuracy is not an artifact of concentration in any single domain.



1. Source: BioinvestGPT validated prediction database. Classification based on clinical readout outcomes.
2. Therapeutic area mapping uses standardized groupings across 7 domains. Accuracy = (TP + TN) / Total.

Sponsors Coverage Breakdown

All Indications

Exhibit 2

Validation spans 267 public biopharma sponsors across all market capitalizations

Coverage spans large-cap through small-cap sponsors, confirming model generalizability is not concentrated in any single company cohort.



Total unique sponsors: 267 | Average accuracy across top sponsors: 96.3%

1. Search sponsor name on data.bioinvestgpt.com to access the company-specific audited timestamped ex-ante predictions and readout validations.

Drug Innovation & Modality Coverage Breakdown

All Indications

Exhibit 3

Validated across 492 distinct drug assets spanning 15 modalities

DRUG CLASSIFICATION

FIRST-IN-CLASS

502

96.0% accuracy

BEST-IN-CLASS

102

96.0% accuracy

DRUG MODALITY DISTRIBUTION



Drug Assets Coverage Breakdown

All Indications

Exhibit 4

Validated across 492 distinct drug assets with consistently high prediction accuracy



Total unique drug assets: 492 | Average accuracy across top drugs: 100.0%

1. Search drug name on data.bioinvestgpt.com to access the drug-specific audited timestamped ex-ante predictions and readout validations.

Temporal Integrity: Prospective Proof

All Indications

Exhibit 5

100% of predictions issued before clinical readout with median lead time of 202 days

LEAD TIME DISTRIBUTION



QUARTERLY PREDICTION VOLUME & CUMULATIVE ACCURACY



All 604 predictions were certified ex-ante, with an average lead time of 202 days before clinical readout. This temporal integrity is cryptographically verifiable and eliminates any possibility of post-hoc fitting.

Competitive Benchmark Analysis

All Indications

Exhibit 6

BioinvestGPT demonstrates multi-order-of-magnitude improvement over industry baselines

CLINICAL DEVELOPMENT SUCCESS RATES



QUANTITATIVE BENCHMARK

Metric	BioinvestGPT	Industry Avg	Context
Accuracy	96.0%	~10-15%	Phase I-to-approval historical rate
Precision (PPV)	91.3%	~11%	Avg drug approval probability
NPV	98.9%	~60%	Combined Phase I–III attrition detection
F1-Score	94.6%	12%	Based on industry 10% nomination rate
DOR	971.3x	0.06x	Based on industry 10% nomination rate
Lead Time	202 days	0 days	Post-hoc industry standard

Note: Industry success rates measure population-level probability of a drug advancing through clinical development phases. BioinvestGPT predicts phase-agnostic effect-size-based clinical benefit using HR = 0.6 as the GO/NO-GO threshold to classify commercially sufficient vs. insufficient drugs, with all predictions certified ex-ante. The comparison illustrates the magnitude of predictive alpha, not a direct methodological equivalence.

REDIRECTABLE R&D CAPITAL

$111.0B

370 of 374 NO-GO predictions validated × $300M avg trial cost

CAPTURED PORTFOLIO VALUE

$210.0B

210 of 230 GO predictions validated × $1B avg revenue

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1756	**Tolebrutinib** **NCTID: NCT04411641** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: CNS-penetrant BTK inhibitor** **Area: Nervous System Diseases** **Indication: Nonrelapsing Secondary Progressive Multiple Sclerosis (NRSPMS)** **Human Patients: 1131** **Sponsor: Sanofi (SNY)**	Date: 19 Aug 2024 Quarter: Q4'24 Batch 12 Technical: FAILURE (statistically insignificant clinical benefit in 6-month CDP against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in 6-month CDP inferior to siponimod)	Readout: 24 Dec 2025 **Lead Time: 492 days in advance** Interpretation: tolebrutinib achieved 31% placebo-adjusted reduction in 6-month (CDP); non-superior to siponimod's 29-33% placebo-adjusted reduction in 6-month CDP in the EXPAND trial NCT01665144 (see add'l link below); FDA issued CRL rejecting Sanofi's NDA for tolebrutinib for NR-SPMS	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1109	**Mitapivat (AG-348)** **NCTID: NCT05031780** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: pyruvate kinase activator** **Area: Hemic and Lymphatic Diseases** **Indication: Sickle Cell Disease** **Human Patients: 286** **Sponsor: Agios Pharmaceuticals (AGIO)**	Date: 28 Jul 2025 Quarter: Q4'25 Batch 4 Technical: partial SUCCESS (statistically maybe significant yet moderate clinical benefit in Hb response rate and SCPCs compared with placebo yet featuring a negative dose-response relationship and moderate toxicity) Commercial: FAILURE (commercially insufficient clinical benefit in Hb response rate/SCPCs/SAEs slightly inferior to the SoC hydroxyurea)	Readout: 19 Nov 2025 **Lead Time: 114 days in advance** Interpretation: mitapivat failed to meet the key primary efficacy endpoint of annualized rate of SCPCs (pain crises) or the key secondary efficacy endpoint PROMIS Fatigue	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1957	**Sotatercept** **NCTID: NCT04945460** **Phase: Phase 2** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: ActRIIA/ACVR2A ligand trap** **Area: Cardiovascular Diseases** **Indication: combined post- and precapillary pulmonary hypertension (CpcPH) due to heart failure with preserved ejection fraction (HFpEF)** **Human Patients: 164** **Sponsor: Merck & Co. (MRK)**	Date: 1 Apr 2025 Quarter: Q2'25 Batch 14a Technical: partial FAILURE (statistically maybe significant yet very weak additive clinical benefit in PVR/6MWD/LVEF compared with placebo as an adjunctive therapy) Commercial: FAILURE (commercially insufficient additive clinical benefit in PVR/6MWD/LVEF inferior to semaglutide as an adjunctive therapy)	Readout: 18 Nov 2025 **Lead Time: 231 days in advance** Interpretation: sotatercept achieved statistical significance in PVR compared with placebo at week 24 (no detailed data and no p-value); yet sotatercept probably didn't achieve statistical significance in 6MWD (not mentioned; no detailed data and no p-value)	Correct Prediction Conclusion: statistically partially significant (weak efficacy in PVR but not 6MWD) and commercially probably insufficient Classification: **True Negative (TN)**
590	**Zanidatamab** **NCTID: NCT05152147** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: biparatopic anti-HER2 inhibitor** **Area: Neoplasms** **Indication: 1L HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers** **Human Patients: 920** **Sponsor: Jazz Pharmaceuticals (JAZZ)**	Date: 19 Jan 2025 Quarter: Q2'25 Batch 3 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS for [zanidatamab + tislelizumab + chemotherapy] at least numerically superior to [zanidatamab + chemotherapy]; both superior to [trastuzumab + chemotherapy]) Commercial: SUCCESS (commercially sufficient clinical benefit in OS for [zanidatamab + tislelizumab + chemotherapy] at least numerically superior to [zanidatamab + chemotherapy]; both superior to [trastuzumab + chemotherapy])	Readout: 17 Nov 2025 **Lead Time: 302 days in advance** Interpretation: zanidatamab + tislelizumab + chemotherapy achieved superiority in both PFS and OS compared with the control arm trastuzumab plus chemotherapy; whereas zanidatamab + chemotherapy achieved superiority in PFS only (not in OS) compared with the control arm trastuzumab plus chemotherapy	Correct Prediction Conclusion: statistically significant (superior PFS for both doublet and triplet combo therapies) and commercially sufficient (superior OS for triplet combo therapy) Classification: **True Positive (TP)**
1909	**Alixorexton (ALKS2680)** **NCTID: NCT06555783** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: OX2R agonist** **Area: Nervous System Diseases** **Indication: Narcolepsy Type 2** **Human Patients: 80** **Sponsor: Alkermes (ALKS)**	Date: 8 Feb 2025 Quarter: Q2'25 Batch 9 Technical: SUCCESS (statistically significant clinical benefit in MWT for NT2 compared with placebo featuring a mild positive dose-response relationship and a moderate positive dose-toxicity relationship) Commercial: SUCCESS (commercially sufficient clinical benefit in MWT for NT2; non-inferior	Readout: 12 Nov 2025 **Lead Time: 277 days in advance** Interpretation: Alixorexton 14mg/18mg met the primary endpoint in MSL on MWT at week 8 ($p<0.05$) and Alixorexton 18mg met the key secondary endpoint in ESS ($p<0.05$)	Correct Prediction Conclusion: statistically significant (featuring a mild positive dose-response relationship) and commercially sufficient (no approved treatment so far) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
		non-superior to ALKS2680/TAK861 in the best-case scenarios of optimal dosing regimens)		
2023	**KRRO-110** **NCTID: NCT06677307** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: oligonucleotide** **MoA: LNP-encapsulated ADAR-dependent mRNA single-base modifier** **Area: Cardiovascular Diseases and Nutritional and Metabolic Diseases** **Indication: Alpha-1 Antitrypsin Deficiency (AATD)** **Human Patients: 64** **Sponsor: Korro Bio (KRRO)**	Date: 14 May 2025 Quarter: Q3'25 Batch 8 Technical: SUCCESS (statistically significant clinical benefit in lung AAT/NE concentration compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in FEV1 moderately inferior to WVE006)	Readout: 12 Nov 2025 **Lead Time: 182 days in advance** Interpretation: KRRO110 produced functional protein that hasn't reached the projected level; so further development has been discontinued for low efficacy	Correct Prediction Conclusion: statistically probably significant and commercially insufficient Classification: **True Negative (TN)**
2048	**Fenebrutinib** **NCTID: NCT04544449** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: CNS-penetrant BTK inhibitor** **Area: Nervous System Diseases** **Indication: Primary Progressive Multiple Sclerosis** **Human Patients: 985** **Sponsor: Roche Group (RHHBY)**	Date: 28 Jul 2025 Quarter: Q4'25 Batch 4 Technical: SUCCESS (statistically significant yet moderate clinical benefit in 12-week CDP compared with placebo) Commercial: SUCCESS (commercially sufficient yet moderate clinical benefit in 12-week CDP moderately superior to ocrelizumab)	Readout: 10 Nov 2025 **Lead Time: 105 days in advance** Interpretation: fenebrutinib met the primary endpoint of delay in the onset of composite confirmed disability progression over a period of at least 120 weeks of treatment; being numerically superior to ocrelizumab	Correct Prediction Conclusion: statistically significant and commercially sufficient (ocrelizumab is the only SoC) Classification: **True Positive (TP)**
1389	**Rosnilimab** **NCTID: NCT06127043** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-PD1 agonist** **Area: Immune System Diseases** **Indication: Moderate to Severe Ulcerative Colitis** **Human Patients: 132** **Sponsor: AnaptysBio (ANAB)**	Date: 28 Jul 2025 Quarter: Q4'25 Batch 5 Technical: FAILURE (statistically insignificant clinical benefit in modified Mayo score or clinical remission compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in modified Mayo score or clinical remission moderately inferior to tulisokibart)	Readout: 10 Nov 2025 **Lead Time: 105 days in advance** Interpretation: rosnilimab failed to meet the primary efficacy endpoint of modified Mayo Score (mMS) compared with placebo	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
782	**Bezuclastinib** **NCTID: NCT05208047** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: TKI inhibitor** **Area: Neoplasms** **Indication: Gastrointestinal Stromal Tumors (GIST** **Human Patients: 442** **Sponsor: Cogent Biosciences (COGT)**	Date: 13 Oct 2023 Quarter: 2H'23 Batch 24 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit)	Readout: 10 Nov 2025 **Lead Time: 759 days in advance** Interpretation: bezuclastinib + sunitinib achieved 16.5 months mPFS vs 9.2 months mPFS achieved by sunitinib mono therapy (p<0.0001); bezuclastinib+sunitinib achieved 46% ORR vs 26% ORR achieved by sunitinib mono therapy (p<0.0001); wait for OS data	Correct Prediction Conclusion: statistically significant (ORR/PFS) and commercially TBD Classification: **True Positive (TP)**
1662	**NBI-1070770** **NCTID: NCT06267846** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: oral anti-NMDAR-NR2B NAM** **Area: Mental Disorders** **Indication: Major Depressive Disorder** **Human Patients: 73** **Sponsor: Neurocrine**	Date: 6 Jul 2024 Quarter: Q3'25 Batch 10 Technical: FAILURE (statistically maybe significant yet very weak additive clinical benefit in MADRS) Commercial: FAILURE (commercially insufficient additive clinical benefit in MADRS inferior to lumateperone)	Readout: 10 Nov 2025 **Lead Time: 492 days in advance** Interpretation: NBI-1070770 failed to meet the primary efficacy endpoint of MADRS compared with placebo	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Biosciences (NBIX)			
1138	**Suvecaltamide** **NCTID: NCT05642442** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: t-type calcium channel antagonist** **Area: Nervous System Diseases** **Indication: Moderate to Severe Residual Tremor in Parkinson's Disease** **Human Patients: 169** **Sponsor: Jazz Pharmaceuticals (JAZZ)**	Date: 21 Nov 2023 Quarter: Q2'25 Batch 3 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 6 Nov 2025 **Lead Time: 716 days in advance** Interpretation: suvecaltamide failed to meet the primary efficacy endpoint of TETRAS composite outcome score compared with placebo (P=0.2363)	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1887	**Tegoprubart** **NCTID: NCT05983770** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-CD40L inhibitor** **Area: Immune System Diseases** **Indication: Prevention of rejection in kidney transplantation** **Human Patients: 127** **Sponsor: Eledon Pharmaceuticals (ELDN)**	Date: 26 Jan 2025 Quarter: Q4'25 Batch 3 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in eGFR at most numerically superior to tacrolimus featuring negative dose-response relationship) Commercial: partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in eGFR/graft survival/BPAR at most numerically superior to tacrolimus)	Readout: 6 Nov 2025 **Lead Time: 284 days in advance** Interpretation: tegoprubart + SoC failed to achieve superiority in eGFR compared with tacrolimus + SoC	Correct Prediction Conclusion: statistically insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1907	**ORX750** **NCTID: NCT06752668** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: OX2R agonist** **Area: Nervous System Diseases** **Indication: Narcolepsy and Idiopathic Hypersomnia** **Human Patients: 96** **Sponsor: Centessa Pharmaceuticals (CNTA)**	Date: 8 Feb 2025 Quarter: Q2'25 Batch 9 Technical: SUCCESS (statistically significant clinical benefit in MWT for NT1 NT2 and IH compared with placebo; featuring a differential positive dose-response relationship (NT1 >> IH > NT2) and a differential positive dose-toxicity relationship (NT2 > IH) Commercial: SUCCESS (commercially sufficient clinical benefit in MWT for NT1 NT2 and IH in observance of differential therapeutic windows (narrow range of high dose for NT2 medium range of medium dose for IH broad range of low dosage for NT1); non-superior to ALKS2680/TAK861 in the best-case scenarios of optimal dosing regimens)	Readout: 5 Nov 2025 **Lead Time: 270 days in advance** Interpretation: ORX750 1.5mg for NT1 achieved a >20 minute change from baseline in mean sleep latency compared with placebo on the MWT at Week 2 (p=0.0026). ORX750 4mg for NT2 achieved a >10 minute change from baseline in mean sleep latency compared with placebo on the MWT at Week 2 (p=0.0193). ORX750 2mg for IH achieved placebo-adjusted improvement in mean sleep latency compared with placebo on the MWT at Week 2 (p=0.0213)	Correct Prediction Conclusion: statistically significant (stronger efficacy in NT1 than in NT2/IH) and commercially probably sufficient Classification: **True Positive (TP)**
1853	**Bemarituzumab** **NCTID: NCT05111626** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: FGFR2B inhibitor** **Area: Neoplasms** **Indication: 1L advanced gastric cancer/ GEJ cancer with FGFR2b over expression** **Human Patients: 515** **Sponsor: Amgen (AMGN)**	Date: 4 Dec 2024 Quarter: Q1'25 Batch 12 Technical: SUCCESS (statistically significant additive clinical benefit in ORR/PFS superior to nivolumab + chemotherapy) Commercial: SUCCESS (commercially sufficient additive clinical benefit in OS superior to nivolumab + chemotherapy)	Readout: 4 Nov 2025 **Lead Time: 335 days in advance** Interpretation: bemarituzumab + chemotherapy + nivolumab failed to deliver sufficient efficacy in PFS/ORR and further development has been discontinued	Missed Prediction Note: due to suboptimal modeling of drug MoA for ORR/PFS that has been permanently improved Conclusion: statistically insignificant (ORR/PFS) and commercially maybe sufficient (OS) Classification: **False Positive (FP)**
1697	**TERN-701** **NCTID: NCT06163430** **Phase: Phase 1** **Class: Best-In-Class**	Date: 24 Jul 2024 Quarter: Q3'24 Batch 19 Technical: SUCCESS (statistically significant clinical benefit in CR)	Readout: 3 Nov 2025 **Lead Time: 467 days in advance** Interpretation: TERN701 achieved 64% MMR at week 24	Correct Prediction Conclusion: statistically probably significant and commercially TBD

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Modality: small molecule **MoA: BCR ABL1 myristoyl-pocket-binding TKI inhibitor** **Area: Neoplasms** **Indication: Relpased/refractory Chronic Myeloid Leukemia** **Human Patients: 100** **Sponsor: Terns Pharmaceuticals (TERN)**	Commercial: partial SUCCESS (commercially sufficient clinical benefit in CR non-superior non-inferior to ELVN001 for CML patients without T315I mutation) partial FAILURE (commercially insufficient clinical benefit in CR inferior to ELVN001 for CML patients with either T315I mutation or asciminib intolerance)		Classification: **True Positive (TP)**
1301	**INKmune** **NCTID: NCT06056791** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: cell therapy** **MoA: NK cell activator** **Area: Neoplasms** **Indication: Metastatic Castration Resistant Prostate Cancer (mCRPC)** **Human Patients: 30** **Sponsor: Inmune Bio (INMB)**	Date: 21 Aug 2024 Quarter: Q4'24 Batch 13 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in ORR/PFS) Commercial: FAILURE (commercially insufficient clinical benefit in OS)	Readout: 30 Oct 2025 **Lead Time: 435 days in advance** Interpretation: INKmune has met its primary endpoint and has not met the "reduction in tumour load" secondary endpoint	Correct Prediction Conclusion: statistically probably insignificant (ORR) and commercially probably insufficient Classification: **True Negative (TN)**
1971	**Gefurulimab (ALXN1720)** **NCTID: NCT05556096** **Phase: Phase 3** **Class: First-In-Class** **Modality: bispecific nanobody** **MoA: bispecific nanobody that targets C5 and albumin** **Area: Immune System Diseases** **Indication: anti-acetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (gMG)** **Human Patients: 260** **Sponsor: AstraZeneca (AZN)**	Date: 11 Apr 2025 Quarter: Q2'25 Batch 14d Technical: SUCCESS (statistically significant clinical benefit in MG-ADL and QMG compared with placebo) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate clinical benefit in MG-ADL and QMG non-superior-non-inferior to efgartigimod)	Readout: 30 Oct 2025 **Lead Time: 202 days in advance** Interpretation: gefurulimab achieved -1.6 placebo-adjusted improvement in MG-ADL total score at week 26 ($p<0.0001$); non-superior-non-inferior to efgartigimod's 1.6-1.7 placebo-adjusted MG-ADL score reduction at week 8-11 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient (non-superior-non-inferior to efgartigimod) Classification: **True Negative (TN)**
1938	**Upadacitinib** **NCTID: NCT06118411** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: pan-JAK inhibitor with higher efficacy against JAK1** **Area: Skin and Connective Tissue Diseases** **Indication: Vitiligo** **Human Patients: 614** **Sponsor: AbbVie (ABBV)**	Date: 24 Feb 2025 Quarter: Q3'25 Batch 1 Technical: SUCCESS (statistically significant clinical benefit in F-VASI75/T-VASI50 for both upadacitinib monotherapy and upadacitinib + NB-UVB combotherapy compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit F-VASI75/T-VASI50 for both upadacitinib monotherapy and upadacitinib + NB-UVB combotherapy moderately superior to ruxolitinib)	Readout: 29 Oct 2025 **Lead Time: 247 days in advance** Interpretation: Upadacitinib 15mg achieved statistically significant 13.5%-15.6% placebo-adjusted T-VASI50 improvement at week 48($p<0.05$); statistically significant 16.5%-19.3% placebo-adjusted F-VASI75 improvement at week 48 ($p<0.05$); and statistically significant 30.5%-35.4% placebo-adjusted F-VASI50 improvement at week 48 (p value undisclosed); no clinical data for ruxolitinib in refractory vitiligo available	Correct Prediction Conclusion: statistically significant and commercially sufficient (no approved SoC for refractory vitiligo) Classification: **True Positive (TP)**
1642	**Ianalumab (VAY736)** **NCTID: NCT05350072** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-BAFFR inhibitor** **Area: Immune System Diseases** **Indication: Sjögren Syndrome** **Human Patients: 276** **Sponsor: Novartis Pharmaceuticals (NVS)**	Date: 2 Jul 2024 Quarter: - Batch - Technical: FAILURE (statistically insignificant additive clinical benefit in ESSDAI as an adjunctive treatment to background therapies) Commercial: FAILURE (commercially insufficient additive clinical benefit inferior to iscalimab that's further inferior to rituximab in ESSDAI as an adjunctive treatment to background therapies)	Readout: 29 Oct 2025 **Lead Time: 484 days in advance** Interpretation: Ianalumab achieved -1.3 placebo-adjusted difference in ESSDAI score at week 48 ($p=0.05$); inferior to iscalimab 300mg that achieved -3.0 placebo-adjusted difference in ESSDAI score at week 24 ($p=0.0090$; see add'l link below)	Correct Prediction Conclusion: statistically borderline significant and commercially probably insufficient (inferior to iscalimab) Classification: **True Negative (TN)**
1150	**Encaleret**	Date: 26 Jan 2025 Quarter: Q2'25 Batch 6	Readout: 29 Oct 2025 **Lead Time: 276 days in advance**	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT05680818 **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: CaSR antagonist** **Area: Endocrine System Diseases** **Indication: Autosomal Dominant Hypocalcemia Type 1 (ADH1)** **Human Patients: 67** **Sponsor: BridgeBio Pharma (BBIO)**	Technical: partial SUCCESS (statistically significant clinical benefit in cCa/24-hr UCa at most numerically superior to SoC yet with a negative dose-response relationship) Commercial: partial FAILURE (commercially maybe sufficient yet very weak clinical benefit in QTcF/SF36 non-superior to SoC)	Interpretation: encaleret achieved superiority in the primary endpoint of the proportion of participants achieving both normal cCa and normal 24-hr UCa at week 24 compared with standard-of-care treatments (76% vs 4% p<0.0001); yet encaleret failed to achieve superiority in key efficacy endpoints such as QTcF or SF-36 (data not disclosed)	Conclusion: statistically significant and commercially probably insufficient Classification: **True Negative (TN)**
1116	**NTLA-2001 (nex-z)** **NCTID: NCT04601051** **Phase: Phase 1** **Class: First-In-Class** **Modality: gene therapy** **MoA: NP-delivered CRISPR-Cas9 reducing TTR production** **Area: Nervous System Diseases** **Indication: Patients With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN) and With Transthyretin Amyloidosis-Related Cardiomyopathy (ATTR-CM)** **Human Patients: 72** **Sponsor: Intellia Therapeutics (NTLA)**	Date: 23 Jul 2023 Quarter: 2H'23 Batch 11 Technical: partial FAILURE (statistically insignificant clinical benefit in 6MWT for cardiomyopathy or in 10MWT for polyneuropathy) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 27 Oct 2025 **Lead Time: 827 days in advance** Interpretation: nex-z phase 3 clinical trials in ATTR-CM (MAGNITUDE) and ATTR-PN (MAGNITUDE-2) have been paused due to grade 4 hepatotoxicity in a patient	Correct Prediction Conclusion: statistically insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1890	**BBP-418 (Ribitol)** **NCTID: NCT05775848** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: prodrug ribitol** **Area: Musculoskeletal Diseases** **Indication: Limb-Girdle Muscular Dystrophy Type 2I (LGMD2I)** **Human Patients: 81** **Sponsor: BridgeBio Pharma (BBIO)**	Date: 26 Jan 2025 Quarter: Q2'25 Batch 6 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in NSAD/10MWR compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in NSAD/10MWR non-superior to FKRP gene therapy)	Readout: 27 Oct 2025 **Lead Time: 274 days in advance** Interpretation: BBP418 achieved 0.27m/s placebo-adjusted improvement in 100MTT (p<0.0001);which is below the MCID threshold (>=0.55m/s placebo-adjusted improvement in 100MTT; calculated using the 112.2(127.9) baseline 100MTT of patients in the FORTIFY trial (see add'l link below) and the 1/3 SD MCID definition (doi.org/10.1212/WNL.92.15_supplement.S33.003)	Correct Prediction Conclusion: statistically significant yet weak clinical benefit and commercially probably insufficient Classification: **True Negative (TN)**
2024	**Petosemtamab (MCLA-158)** **NCTID: NCT03526835** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-EGFR-LGR5 bispecific antibody** **Area: Neoplasms** **Indication: 1L/2L/3L metastatic colorectal cancer (mCRC)** **Human Patients: 523** **Sponsor: Merus (MRUS)**	Date: 16 May 2025 Quarter: Q3'25 Batch 9 Technical: SUCCESS (statistically significant clinical benefit in PFS/ORR for petosemtamab monotherapy non-inferior to FTD-TPI + bevacizumab in the 3L MSS mCRC clinical setting) SUCCESS (statistically significant clinical benefit in PFS/ORR for petosemtamab + FOLFIRI/FOLFOX slightly-to-moderately superior to FOLFIRI/FOLFOX + bevacizumab in the 1L/2L MSS mCRC clinical setting) Commercial: SUCCESS (commercially sufficient clinical benefit in OS for petosemtamab monotherapy moderately-to-strongly superior to FTD-TPI + bevacizumab in the 3L MSS mCRC clinical setting) SUCCESS (commercially sufficient clinical benefit in OS for petosemtamab + FOLFIRI/FOLFOX moderately superior to FOLFIRI/FOLFOX + bevacizumab in the 1L/2L MSS mCRC clinical setting)	Readout: 24 Oct 2025 **Lead Time: 161 days in advance** Interpretation: Petosemtamab plus FOLFOX/FOLFIRI for 1L mCRC achieved 50-80% ORR (8/10 with 3 unconfirmed) slightly-to-moderately superior to 53% achieved by bevacizumab plus FOLFOX/FOLFIRI (see add'l link below); Petosemtamab plus FOLFOX/FOLFIRI for 2L mCRC achieved 46-62% cORR (6/13 with 2 unconfirmed) moderately-to-strongly superior to 11% achieved by bevacizumab plus FOLFOX/FOLFIRI (10.1093/annonc/mdv197); Petosemtamab mono therapy achieved 10% cORR (2/20) slightly superior to 6.1% cORR achieved by FTD–TPI plus bevacizumab (10.1056/NEJMoa2214963)	Correct Prediction Conclusion: statistically significant (superior-to-SoC ORR for 1L/2L/3L mCRC) and commercially TBD Classification: **True Positive (TP)**
2017	**XmAb819**	Date: 13 May 2025 Quarter: Q3'25 Batch 7	Readout: 24 Oct 2025 **Lead Time: 164 days in advance**	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT05433142 **Phase: Phase 1** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: bispecific antibody that binds both ENPP3 and CD3** **Area: Neoplasms** **Indication: 2L+ advanced clear cell renal cell carcinoma (ccRCC)** **Human Patients: 95** **Sponsor: Xencor (XNCR)**	Technical: FAILURE (statistically insignificant clinical benefit in ORR/PFS compared with placebo with moderate toxicity) Commercial: FAILURE (commercially insufficient clinical benefit in OS strongly inferior to cabozantinib)	Interpretation: XmAb819 achieved 20% cORR (4/20) with 1 Grade 4 TEAE (5%); which is non-superior to the SoC cabozantinib that achieved 21% cORR (see add'l link below)	Conclusion: statistically probably insignificant (non-superior ORR) and commercially TBD Classification: **True Negative (TN)**
1906	**VTX3232** **NCTID: NCT06771115** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: CNS-penetrant NLRP3 inhibitor** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity without type 2 diabetes** **Human Patients: 176** **Sponsor: Ventyx Biosciences (VTYX)**	Date: 8 Feb 2025 Quarter: Q2'25 Batch 9 Technical: FAILURE (statistically insignificant (additive) clinical benefit in weight loss compared with placebo despite moderate toxicity) Commercial: FAILURE (commercially insufficient (additive) clinical benefit in weight loss/tolerability inferior to semaglutide monotherapy)	Readout: 22 Oct 2025 **Lead Time: 256 days in advance** Interpretation: VTX3232 failed to achieve statistical significance in weight reduction either as monotherapy or as add-on treatment to semaglutide	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1649	**Secukinumab** **NCTID: NCT05767034** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-IL17A inhibitor** **Area: Immune System Diseases** **Indication: Polymyalgia Rheumatica (PMR)** **Human Patients: 381** **Sponsor: Novartis Pharmaceuticals (NVS)**	Date: 2 Jul 2024 Quarter: Q4'25 Batch 6 Technical: SUCCESS (statistically signifiant additive clinical benefit in sustained remission in combination with 24wk prednisone taper regimen; though secukinumab's additive efficacy for PMR would be smaller than that for GCA) Commercial: SUCCESS (commercially sufficient additive clinical benefit in sustained remission superior to tocilizumab in combination with 24wk prednisone taper regimen)	Readout: 22 Oct 2025 **Lead Time: 477 days in advance** Interpretation: Secukinumab + SoC met the primary endpoint and all secondary endpoints at week 52 compared with SoC alone	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
843	**mRNA-1647** **NCTID: NCT05085366** **Phase: Phase 3** **Class: First-In-Class** **Modality: Vaccine** **MoA: mRNA vaccine for Cytomegalovirus** **Area: Infections** **Indication: Cytomegalovirus Infection** **Human Patients: 7454** **Sponsor: ModernaTX (MRNA)**	Date: 14 May 2024 Quarter: Q3'24 Batch 9 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 22 Oct 2025 **Lead Time: 526 days in advance** Interpretation: mRNA-1647 failed to meet the primary efficacy endpoint of preventing CMV infection compared with placebo and further development has been discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
579	**AL001** **NCTID: NCT04374136** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-SORT1 inhibitor** **Area: Nervous System Diseases** **Indication: Frontotemporal Dementia due to a progranulin gene mutation (FTD-GRN)** **Human Patients: 110** **Sponsor: Alecto (ALEC)**	Date: 28 Jul 2025 Quarter: Q4'25 Batch 3 Technical: FAILURE (statistically insignificant clinical benefit in CDR + NACC FTLD-SB compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in CDR + NACC FTLD-SB)	Readout: 21 Oct 2025 **Lead Time: 85 days in advance** Interpretation: AL001 failed to meet the primary endpoint of slowing FTD-GRN progression	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1945	**Gedatolisib** **NCTID: NCT05501886**	Date: 27 Mar 2025 Quarter: Q2'25 Batch 13a	Readout: 20 Oct 2025 **Lead Time: 207 days in advance**	Correct Prediction Conclusion: statistically significant

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 3 **Class: First-In-Class** **Modality: small molecule** **MoA: dual mTOR/PI3K inhibitor** **Area: Neoplasms** **Indication: PIK3CA WT and MT advanced or metastatic HR+/ HER2- breast can** **Human Patients: 701** **Sponsor: Celcuity (CELC)**	Technical: partial SUCCESS (statistically significant yet moderate additive clinical benefit in ORR/PFS for gedatolisib + fulvestrant + palbociclib moderately superior to SoC alpelisib + fulvestrant for PIK3CA MT population slightly superior to SoCfulvestrant for PIK3CA WT population despite with additional gedatolisib-related toxicity) partial FAILURE (statistically insignificant additive clinical benefit in ORR/PFS for gedatolisib + fulvestrant non-superior to SoC fulvestrant for both PIK3CA MT population and PIK3CA WT with additional gedatolisib-related toxicity) Commercial: partial FAILURE (commercially insufficient additive clinical benefit in OS for gedatolisib + fulvestrant + palbociclib at most numerically superior to SoC alpelisib + fulvestrant for PIK3CA MT population and non-superior to SoC fulvestrant for PIK3CA WT population despite with additional gedatolisib-related toxicity) FAILURE (commercially insufficient additive clinical benefit in OS for gedatolisib + fulvestrant non-inferior to SoC for both PIK3CA MT population PIK3CA WT population with additional gedatolisib-related toxicity)	Interpretation: gedatolisib + palbociclib + fulvestrant ("gedatolisib triplet") achieved 9.3 months mPFS strongly superior to 2.0 months achieved by fulvestrant monotherapy (HR= 0.24; P<0.0001) yet achieved 23.7 months mOS only numerically superior to 18.5 months achieved by fulvestrant monotherapy (HR=0.69 P=0.1328); wait for MT population data	(superior mPFS) and commercially insufficient (non-superior mOS) Classification: **True Negative (TN)**
2011	**Zanzalintinib** **NCTID: NCT05425940** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: multi-receptor TKI** **Area: Neoplasms** **Indication: 2L MSI-high Metastatic Colorectal Cancer** **Human Patients: 901** **Sponsor: Exelixis (EXEL)**	Date: 7 May 2025 Quarter: Q3'25 Batch 6 Technical: partial FAILURE (statistically maybe significant yet very weak clinical benefit for XL092 + atezolizumab in ORR/PFS at most numerically superior to regorafenib) Commercial: FAILURE (commercially insufficient clinical benefit for XL092 + atezolizumab in OS non-superior to regorafenib)	Readout: 20 Oct 2025 **Lead Time: 166 days in advance** Interpretation: zanzalintinib + atezolizumab achieved statistically significant yet very weak OS in the ITT population (HR = 0.8 p=0.0045) yet statistically insignificant OS in the subset of patients without liver metastates (p = 0.087); compared with the regorafenib mono therapy	Correct Prediction Conclusion: partially statistically significant and commercially insufficient Classification: **True Negative (TN)**
1786	**Tiragolumab** **NCTID: NCT04513925** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-TIGIT inhibitor** **Area: Neoplasms** **Indication: Non-small Cell Lung Cancer (NSCLC)** **Human Patients: 829** **Sponsor: Roche Group (RHHBY)**	Date: 15 Sep 2024 Quarter: Q4'24 Batch 17b Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR/PFS numerically superior to durvalumab monotherapy) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS non-superior to durvalumab monotherapy)	Readout: 18 Oct 2025 **Lead Time: 398 days in advance** Interpretation: tiragolumab + atezolizumab failed to achieve the primary endpoint non-superior to the SoC durvalumab in either mPFS (14.2 months vs 13.8 months) or OS (not reached vs 54.8 months)	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1121	**Ciforadenant** **NCTID: NCT05501054** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: adenosine A2a Receptor Antagonist** **Area: Neoplasms** **Indication: 1L metastatic renal cell cancer (RCC)** **Human Patients: 50** **Sponsor: Corvus Pharmaceuticals (CRVS)**	Date: 8 May 2025 Quarter: Q3'25 Batch 6 Technical: FAILURE (statistically insignificant additive clinical benefit to nivolumab + ipilimumab in ORR/PFS compared with placebo) Commercial: FAILURE (commercially insufficient additive clinical benefitS to nivolumab + ipilimumab in OS)	Readout: 17 Oct 2025 **Lead Time: 162 days in advance** Interpretation: ciforadenant + ipilimumab + nivolumab achieved 46% ORR and 11 months mPFS; non-superior to ipilimumab + nivolumab that achieved 42% ORR and 11.6 months mPFS (see add'l link below); ciforadenant + ipilimumab + nivolumab achieved a numerical improvement of OS HR by 0.05 compared with ipilimumab + nivolumab (0.69 vs 0.74)	Correct Prediction Conclusion: statistically insignificant (non-superior ORR/PFS) and commercially insufficient (non-superior OS) Classification: **True Negative (TN)**
1952	**Orforglipron**	Date: 30 Mar 2025 Quarter: Q3'25 Batch 1	Readout: 15 Oct 2025 **Lead Time: 199 days in advance**	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT06109311 **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: oral GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Type 2 diabetes inadequately controlled with titrated insulin glargine; with or without metformin and/or SGLT-2 inhibitors** **Human Patients: 546** **Sponsor: Eli Lilly and Company (LLY)**	Technical: SUCCESS (statistically significant clinical benefit in HbA1c and weight reduction compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit as an oral therapy in HbA1c and weight reduction non-superior-non-inferior to semaglutide/GSBR1290 with numerically-inferior-to-semaglutide tolerability)	Interpretation: orforglipron 36mg achieved 1.1% placebo-adjusted A1C reduction at week 40	Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1949	**Orforglipron** **NCTID: NCT06192108** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: oral GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Type 2 diabetes inadequately controlled on metformin** **Human Patients: 962** **Sponsor: Eli Lilly and Company (LLY)**	Date: 30 Mar 2025 Quarter: Q3'25 Batch 1 Technical: SUCCESS (statistically significant clinical benefit in HbA1c and weight reduction compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit as an oral therapy in HbA1c and weight reduction moderately superior to dapagliflozin)	Readout: 15 Oct 2025 **Lead Time: 199 days in advance** Interpretation: orforglipron 36mg achieved 1.7% A1C reduction at week 40; superior to 0.8% A1C reduction at week 40 achieved by dapagliflozin	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1849	**Zolbetuximab (IMAB362)** **NCTID: NCT03816163** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-CLDN18.2 inhibitor** **Area: Neoplasms** **Indication: 1L metastatic pancreatic adenocarcinoma (PDAC)** **Human Patients: 393** **Sponsor: Astellas Pharma (ALPMY)**	Date: 3 Dec 2024 Quarter: Q1'25 Batch 12 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR/PFS due to dose-limiting toxicity whose degree depends on claudin 18.2 expression levels) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS non-superior to SoC alone)	Readout: 14 Oct 2025 **Lead Time: 315 days in advance** Interpretation: zolbetuximab + gemcitabine plus nab-paclitaxel failed to achieve superiority in OS compared with zolbetuximab + gemcitabine plus nab-paclitaxel alone	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1940	**BOTOX** **NCTID: NCT05216250** **Phase: Phase 2** **Class: First-In-Class** **Modality: biologic toxin** **MoA: botulinum toxin type A** **Area: Nervous System Diseases** **Indication: Upper Limb Essential Tremor** **Human Patients: 174** **Sponsor: AbbVie (ABBV)**	Date: 24 Feb 2025 Quarter: Q2'25 Batch 12a Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in TREDS-R compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in TREDS-R/TETRAS UL inferior to propranolol)	Readout: 6 Oct 2025 **Lead Time: 224 days in advance** Interpretation: BOTOX achieved -1 placebo-adjusted improvement in TREDS-R total unilateral score (-2.61 vs -1.61 p=0.029); which is smaller than the 0.5-SD MCID threshold (>=4.2 point for TREDS-R)	Correct Prediction Conclusion: statistically significant weak clinical benefit and commercially probably insufficient (below-MCID improvement) Classification: **True Negative (TN)**
2053	**Evolocumab** **NCTID: NCT03872401** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-PCSK9 inhibitor** **Area: Cardiovascular Diseases** **Indication: Patients with cardiovascular risk** **Human Patients: 12301** **Sponsor: Amgen (AMGN)**	Date: 31 Jul 2025 Quarter: Q4'25 Batch 6 Technical: SUCCESS (statistically significant clinical benefit in MACE compared with placebo) Commercial: partial SUCCESS (commercially sufficient yet moderate clinical benefit in MACE slightly superior to semaglutide yet moderately inferior to retatrutide)	Readout: 2 Oct 2025 **Lead Time: 63 days in advance** Interpretation: evolocumab + SoC met its primary endpoint in MACE reduction compared with SoC alone (detailed data undisclosed)	Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**
2055	**MET097**	Date: 1 Aug 2025	Readout: 29 Sep 2025	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT06712836 **Phase: Phase 2** **Class: Best-In-Class** **Modality: peptide** **MoA: long-acting GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity without type 2 diabetes** **Human Patients: 225** **Sponsor: Metsera (MTSR)**	Quarter: Q4'25 Batch 6 Technical: SUCCESS (statistically significant clinical benefit in weight reduction compared with placebo) Commercial: partial SUCCESS (commercially sufficient yet moderate clinical benefit in weight reduction slightly superior to tirzepatide yet slightly inferior to retatrutide)	**Lead Time: 59 days in advance** Interpretation: MET097i 1.2mg achieved 14.1% placebo-adjusted weight reduction at week 28 and 18.9%/3.8%/17.0% placebo-adjusted nausea/diarrhea/vomiting at week 12 in VESPER-3; slightly superior to 13% placebo-adjusted weight reduction at week 28 and non-inferior to 21.5%/16.7%/10.5% placebo-adjusted nausea/diarrhea/vomiting at week 72 achieved by tirzepatide 15mg (see add'l link below)	Conclusion: statistically significant and commercially sufficient (slightly superior to tirzepatide) Classification: **True Positive (TP)**
1036	**EDP-938 (zelicapavir)** **NCTID: NCT05568706** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: RSV N-protein inhibitor** **Area: Infections** **Indication: Respiratory Syncytial Virus (RSV)** **Human Patients: 186** **Sponsor: Enanta Pharmaceuticals (ENTA)**	Date: 10 May 2024 Quarter: Q3'24 Batch 4 Technical: SUCCESS (statistically significant yet moderate clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit with non-superior-to-palivizumab efficacy)	Readout: 29 Sep 2025 **Lead Time: 507 days in advance** Interpretation: zelicapavir failed to meet the primary endpoint in the time to resolution of the LRTD subset of four symptoms while meeting multiple secondary endpoints in PGI-S score and 2-day faster resolution	Correct Prediction Conclusion: statistically partially insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1947	**KPI-012** **NCTID: NCT05727878** **Phase: Phase 2** **Class: First-In-Class** **Modality: protein biologic** **MoA: human bone marrow mesenchymal stem cell secretome** **Area: Eye Diseases** **Indication: Persistent corneal epithelial defect (PCED)** **Human Patients: 103** **Sponsor: Kala Bio (KALA)**	Date: 27 Mar 2025 Quarter: Q2'25 Batch 13a Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in complete healing compared with placebo featuring a negative dose-response relationship) Commercial: partial FAILURE (commercially insufficient clinical benefit in complete healing; yet there is no FDA-approved treatment for PCED)	Readout: 29 Sep 2025 **Lead Time: 186 days in advance** Interpretation: KPI-012 failed to meet the primary efficacy endpoint in complete healing compared with placebo	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1992	**Sonelokimab** **NCTID: NCT06411899** **Phase: Phase 3** **Class: Best-In-Class** **Modality: nanobody biologic** **MoA: trivalent nanobody that binds IL17A IL17F and serum albumin** **Area: Immune System Diseases** **Indication: Moderate to Severe Hidradenitis Suppurativa** **Human Patients: 422** **Sponsor: MoonLake Immunotherapeutics (MLTX)**	Date: 26 Apr 2025 Quarter: Q3'25 Batch 2 Technical: SUCCESS (statistically significant clinical benefit in HiSCR75 compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in HiSCR75 slightly superior to bimekizumab and moderately superior to brivekimig)	Readout: 28 Sep 2025 **Lead Time: 155 days in advance** Interpretation: sonelokimab has achieved 18.3% placebo-adjusted HiSCR75; slightly superior to 18% placebo-adjusted HiSCR75 achieved by bimekizumab (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially sufficient (slightly superior to bimekizumab) Classification: **True Positive (TP)**
2047	**Carbetocin Nasal Spray** **NCTID: NCT06173531** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: intranasally delivered peptide as a synthetic analog of oxytocin** **Area: Nervous System Diseases** **Indication: Hyperphagia in Prader-Willi Syndrome (PWS)** **Human Patients: 170** **Sponsor: ACADIA Pharmaceuticals (ACAD)**	Date: 28 Jul 2025 Quarter: Q4'25 Batch 4 Technical: SUCCESS (statistically significant clinical benefit in HQCT compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in HQCT slightly-to-moderately superior to diazoxide choline)	Readout: 24 Sep 2025 **Lead Time: 58 days in advance** Interpretation: Carbetocin failed to meet the primary efficacy endpoint compared with placebo	Missed Prediction Note: due to suboptimal disease modeling of PWS that has been permanently improved Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1886	**ZYN002** **NCTID: NCT04977986** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: cannabidiol gel** **Area: Nervous System Diseases** **Indication: Fragile X Syndrome** **Human Patients: 215** **Sponsor: Harmony Biosciences (HRMY)**	Date: 26 Jan 2025 Quarter: Q2'25 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in ABC-C FXS only for patients with complete FMR1 methylation) Commercial: SUCCESS (commercially sufficient yet weak clinical benefit in ABC-C FXS only for patients with complete FMR1 methylation due to no FDA approved drug on the market)	Readout: 24 Sep 2025 **Lead Time: 241 days in advance** Interpretation: ZYN002 failed to meet the primary efficacy endpoint compared with placebo	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1936	**iberdomide** **NCTID: NCT04975997** **Phase: Phase 3** **Class: Best-In-Class** **Modality: molecular glue degrader** **MoA: cereblon E3 ligase modulator that degrades IKZF1 and IKZF3** **Area: Neoplasms** **Indication: Relapsed or Refractory Multiple Myeloma** **Human Patients: 864** **Sponsor: Bristol Myers Squibb (BMY)**	Date: 4 Apr 2025 Quarter: Q3'25 Batch 1 Technical: SUCCESS (statistically significant additive clinical benefit to daratumumab + dexamethasone (Iber-Dd) in ORR/PFS moderately superior to bortezomib + daratumumab + dexamethasone (DVd) and non-superior-non-inferior to belantamab mafodotin + pomalidomide + dexamethasone(BPd)) Commercial: SUCCESS (commercially sufficient additive clinical benefit to daratumumab + dexamethasone (Iber-Dd) in OS moderately superior bortezomib + daratumumab + dexamethasone (DVd) and slightly superior to belantamab mafodotin + pomalidomide + dexamethasone(BPd))	Readout: 23 Sep 2025 **Lead Time: 172 days in advance** Interpretation: iberdomide in combination with daratumumab and dexamethasone (IberDd) achieved a statistically significant superiority in MRD negativity (a deeper assessment than ORR) compared with the central arm of daratumumab/ bortezomib/dexamethasone (DVd); wait for OS data	Correct Prediction Conclusion: statistically significant (MRD negativity/ORR) and commercially TBD Classification: **True Positive (TP)**
2029	**MBX2109 (Canvuparatide)** **NCTID: NCT06465108** **Phase: Phase 2** **Class: First-In-Class** **Modality: peptide** **MoA: long-acting PTH prodrug** **Area: Endocrine System Diseases** **Indication: Hypoparathyroidism** **Human Patients: 64** **Sponsor: MBX Biosciences (MBX)**	Date: 1 Jun 2025 Quarter: Q3'25 Batch 12 Technical: FAILURE (statistically insignificant additive clinical benefit to SoC in the composite endpoint compared with placebo) Commercial: FAILURE (commercially insufficient additive clinical benefit to SoC in the composite endpoint moderately inferior to eneboparatide)	Readout: 22 Sep 2025 **Lead Time: 113 days in advance** Interpretation: Canvuparatide achieved 63% response rate at week 12 (32% placebo-adjusted response rate p=0.042) in the composite primary endpoint (normal-ranged ADsCa maintenance and independence from conventional therapy); moderately inferior to eneboparatide that achieved 88% response rate at week 12 in the same composite primary endpoint (see add'l link below)	Correct Prediction Conclusion: statistically borderline significant and commercially probably insufficient (inferior to eneboparatide) Classification: **True Negative (TN)**
2013	**Zilganersen (ION373)** **NCTID: NCT04849741** **Phase: Phase 3** **Class: First-In-Class** **Modality: antisense oligonucleotide (ASO)** **MoA: degrades GFAP mRNA** **Area: Nervous System Diseases** **Indication: Alexander Disease (AxD)** **Human Patients: 54** **Sponsor: Ionis Pharmaceuticals (IONS)**	Date: 7 May 2025 Quarter: Q3'25 Batch 6 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in 10MWT compared with placebo) Commercial: partial SUCCESS (commercially maybe sufficient yet weak clinical benefit in 10MWT at most near the minimal clinically important difference MCID)	Readout: 22 Sep 2025 **Lead Time: 138 days in advance** Interpretation: Zilganersen achieved a statistically significant improvement in 10MWT at week 61 (mean difference 33.3% p=0.0412)	Correct Prediction Conclusion: statistically borderline significant and commercially maybe sufficient (depending on whether 10MWT improvement exceeds MCID) Classification: **True Negative (TN)**
1468	**VS-01** **NCTID: NCT05900050** **Phase: Phase 2** **Class: First-In-Class** **Modality: fluid** **MoA: liposomal-based intro-peritoneal fluid** **Area: Digestive System Diseases**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 4 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 19 Sep 2025 **Lead Time: 583 days in advance** Interpretation: VS-01's further development has been discontinued for insufficient benefit/risk profile	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Indication: Acute-on-Chronic Liver Failure and Ascites **Human Patients: 15** **Sponsor: Genfit (GNFT)**			
1950	**Orforglipron** **NCTID: NCT06045221** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: oral GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Type 2 Diabetes Inadequately Controlled With Metformin** **Human Patients: 1698** **Sponsor: Eli Lilly and Company (LLY)**	Date: 30 Mar 2025 Quarter: Q3'25 Batch 1 Technical: SUCCESS (statistically significant clinical benefit in HbA1c and weight reduction compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit as an oral therapy in HbA1c and weight reduction non-superior-non-inferior to semaglutide with numerically-inferior-to-semaglutide tolerability)	Readout: 17 Sep 2025 **Lead Time: 171 days in advance** Interpretation: orforglipron 36mg achieved 9.2% weight reduction; 2.2% A1C reduction; and 9.8% discontinuation rate at week 52; non-superior-non-inferior to 9.2% weight reduction; 2.0% A1C reduction; and est. 10% discontinuation rate at week 52 achieved by semaglutide oral 50mg (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially sufficient (comparable efficacy and tolerability of orforglipron 36mg vs. oral semaglutide 50mg) Classification: **True Positive (TP)**
1856	**Brivekimig (SAR442970)** **NCTID: NCT05849922** **Phase: Phase 2** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: bispecific antibody that inhibits both TNFalpha and OX40L** **Area: Immune System Diseases** **Indication: Hidradenitis Suppurativa** **Human Patients: 86** **Sponsor: Sanofi (SNY)**	Date: 7 Dec 2024 Quarter: Q1'25 Batch 13 Technical: SUCCESS (statistically significant clinical benefit in HiSCR50 score against placebo) Commercial: partial SUCCESS (commercially sufficient yet moderate clinical benefit in HiSCR50 score superior to adalimumab/povorcitinib yet non-superior to sonelokimab/bimekizumab/secukinumab)	Readout: 17 Sep 2025 **Lead Time: 284 days in advance** Interpretation: Brivekimig has achieved 30% placebo-adjusted HiSCR50 and 22% placebo-adjusted HiSCR90; superior to 24% placebo-adjusted HiSCR50 (10.1056/NEJMoa1504370) and 15% placebo-adjusted HiSCR90 achieved by adalimumab (10.1001/jamadermatol.2021.2905); yet non-superior to 24% placebo-adjusted HiSCR50 (10.1016/S0140-6736(24)00101-6) and 32% placebo-adjusted HiSCR90 achieved by bimekizumab (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient Classification: **True Negative (TN)**
1132	**Brepocitinib** **NCTID: NCT05437263** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: JAK1/TYK2 inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Dermatomyositis** **Human Patients: 241** **Sponsor: Roivant Sciences (ROIV)**	Date: 14 May 2025 Quarter: Q3'25 Batch 8 Technical: partial SUCCESS (statistically significant additive clinical benefit in TIS score compared with placebo for previously untreated patients) partial FAILURE (statistically insignificant clinical benefit in TIS score compared with placebo for previously treated patients) Commercial: partial SUCCESS (commercially sufficient additive clinical benefit in TIS score compared with placebo for previously untreated patients) partial FAILURE (commercially insufficient clinical benefit in TIS score compared with placebo for previously treated patients)	Readout: 17 Sep 2025 **Lead Time: 126 days in advance** Interpretation: brepocitinib 30mg achieved 15.3 placebo-adjusted improvement in TIS at week 52 (p=0.0006)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1871	**icotrokinra (JNJ-2113)** **NCTID: NCT06220604** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: oral anti-IL23R antagonist** **Area: Immune System Diseases** **Indication: Moderate to Severe Plaque Psoriasis** **Human Patients: 731** **Sponsor: Johnson & Johnson / Protagonist Therapeutics (JNJ / PTGX)**	Date: 14 Jan 2025 Quarter: Q2'25 Batch 1 Technical: SUCCESS (statistically significant clinical benefit in IGA0/PASI90 superior to deucravacitinib) Commercial: partial SUCCESS (commercially sufficient yet moderate clinical benefit in IGA0/PASI90 non-superior to bimekizumab)	Readout: 17 Sep 2025 **Lead Time: 246 days in advance** Interpretation: icotrokinra achieved 56% placebo-adjusted PASI90 at week 16 (p<0.0001); superior to deucravacitinib in the same trial; yet inferior to bimekizumab's 90% placebo-adjusted PASI90 at week 16 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially sufficient (oral) Classification: **True Positive (TP)**
1870	**icotrokinra (JNJ-2113)**	Date: 14 Jan 2025	Readout: 17 Sep 2025	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT06143878 **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: oral anti-IL23R antagonist** **Area: Immune System Diseases** **Indication: Moderate to Severe Plaque Psoriasis** **Human Patients: 774** **Sponsor: Johnson & Johnson / Protagonist Therapeutics (JNJ / PTGX)**	Quarter: Q2'25 Batch 1 Technical: SUCCESS (statistically significant clinical benefit in IGA0/PASI90 superior to deucravacitinib) Commercial: partial SUCCESS (commercially sufficient yet moderate clinical benefit in IGA0/PASI90 non-superior to bimekizumab)	**Lead Time: 246 days in advance** Interpretation: icotrokinra achieved 51% placebo-adjusted PASI90 at week 16 (p<0.0001) superior to deucravacitinib in the same trial; yet inferior to bimekizumab's 90% placebo-adjusted PASI90 at week 16 (see add'l link below)	Conclusion: statistically significant and commercially sufficient (oral) Classification: **True Positive (TP)**
2000	**Intravenous Efzofitimod** **NCTID: NCT05415137** **Phase: Phase 3** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: NRP2 agonist** **Area: Respiratory Tract Diseases** **Indication: Pulmonary Sarcoidosis** **Human Patients: 268** **Sponsor: aTyr Pharma (ATYR)**	Date: 3 May 2025 Quarter: Q3'25 Batch 4 Technical: SUCCESS (statistically significant additive clinical benefit to OCS in FVC/KSQ-Lung compared with placebo) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate additive clinical benefit to OCS in FVC/KSQ-Lung slightly inferior to methotrexate +OCS)	Readout: 15 Sep 2025 **Lead Time: 135 days in advance** Interpretation: Efzofitimod failed to achieve the primary endpoint of replacing OCS compared with placebo at week 48 (-2.57mg vs -3.52 mg; p=0.3313); moderately inferior to methotrexate whose efficacy in FVC achieved non-inferiority compared with OCS and thus could replace OCS (see add'l link below); Efzofitimod + OCS achieved 4.17 improvement in KSQ-Lung score at week 48 (10.36 vs 6.19; p=0.0479)	Correct Prediction Conclusion: statistically partially significant and commercially maybe sufficient Classification: **True Negative (TN)**
1929	**Rezatapopt (PC14586)** **NCTID: NCT04585750** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: p53 reactivator** **Area: Neoplasms** **Indication: advanced Solid Tumors Harboring a TP53 Y220C Mutation** **Human Patients: 300** **Sponsor: PMV Pharmaceuticals (PMVP)**	Date: 14 Feb 2025 Quarter: Q2'25 Batch 11 Technical: partial SUCCESS (statistically significant yet moderate clinical benefit as monotherapy in ORR/PFS compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit as monotherapy in OS non-superior to SoC)	Readout: 10 Sep 2025 **Lead Time: 208 days in advance** Interpretation: Rezatapopt achieved 33% ORR; moderately superior to chemotherapy that achieved 10-20% ORR for advanced solid tumors (see add'l link below); wait for OS data	Correct Prediction Conclusion: statistically significant (superior ORR) and commercially TBD Classification: **True Positive (TP)**
2051	**Zipalertinib (TAS6417)** **NCTID: NCT05967689** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: 3rd-gen pan-mutant wt-sparing EGFR TKI** **Area: Neoplasms** **Indication: ex20in-mt advanced or metastatic Non-Small Cell Lung Cancer (NSCLC)** **Human Patients: 224** **Sponsor: Taiho Oncology / Cullinan Therapeutics (CGEM)**	Date: 31 Jul 2025 Quarter: Q4'25 Batch 6 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS compared with placebo at least numerically superior to osimertinib for cohort A/B/C/D) Commercial: SUCCESS (commercially sufficient clinical benefit in OS slightly-to-moderately superior to osimertinib for cohort A/B/C/D)	Readout: 9 Sep 2025 **Lead Time: 40 days in advance** Interpretation: Zipalertinib achieved a 62.5% ORR for 1L ex20in-mt NSCLC; moderately superior to osimertinib that achieved 25% ORR (see add'l link below); Zipalertinib achieved 21.9% ORR for 2L ex20in-mt NSCLCs; moderately superior to osimertinib that achieved 5% ORR (see DOI-10.1016/j.jtocrr.2022.100459); wait for OS data	Correct Prediction Conclusion: statistically significant (superior ORR/PFS) and commercially TBD Classification: **True Positive (TP)**
1729	**Pumitamig (BNT327)** **NCTID: NCT06449209** **Phase: Phase 2** **Class: First-In-Class** **Modality: bispecific antibody (bsAb)** **MoA: anti-PDL1 and anti-VEGF** **Area: Neoplasms** **Indication: untreated extended-stage small-cell lung cancer (ES-SCLC)** **Human Patients: 110** **Sponsor: BioNTech (BNTX)**	Date: 9 Aug 2025 Quarter: Q4'25 Batch 5 Technical: partial SUCCESS (statistically significant yet moderate additive clinical benefit in ORR/PFS numerically superior to ICI+chemotherapy as 1L treatment and numerically superior to chemotherapy as 2L/3L treatment) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate additive clinical benefit in OS numerically superior to ICI+chemotherapy as 1L treatment and numerically superior to	Readout: 8 Sep 2025 **Lead Time: 30 days in advance** Interpretation: Pumitamig + chemotherapy achieved 76.3% cORR and 6.8 months mPFS; numerically superior to the SoC atezolizumab + chemotherapy that achieved 60% cORR and 5.2 months mPFS (see add'l link below); wait for OS data	Correct Prediction Conclusion: statistically significant (numerically superior in ORR/PFS) and commercially TBD Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
		chemotherapy as 2L/3L treatment)		
1955	**Pirtobrutinib (LOXO-305)** **NCTID: NCT05023980** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: non-covalent BTK inhibitor** **Area: Neoplasms** **Indication: Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)** **Human Patients: 309** **Sponsor: Eli Lilly and Company (LLY)**	Date: 30 Mar 2025 Quarter: Q2'25 Batch 13b Technical: partial SUCCESS (statistically significant clinical benefit in ORR/PFS slightly superior to rituximab + bendamustine; slightly inferior to zanubrutinib/venetoclax + obinutuzumab) Commercial: FAILURE (commercially insufficient clinical benefit in OS non-superior to rituximab + bendamustine; slightly inferior to zanubrutinib/venetoclax + obinutuzumab)	Readout: 8 Sep 2025 **Lead Time: 162 days in advance** Interpretation: pirtobrutinib achieved superiority in PFS compared with bendamustine plus rituximab; wait for detailed PFS data for comparison with zanubrutinib/venetoclax + obinutuzumab; wait for OS data	Correct Prediction Conclusion: statistically significant (superior PFS compared with bendamustine plus rituximab) and commercially TBD Classification: **True Positive (TP)**
1908	**Alixorexton (ALKS 2680)** **NCTID: NCT06358950** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: OX2R agonist** **Area: Nervous System Diseases** **Indication: Narcolepsy Type 1** **Human Patients: 92** **Sponsor: Alkermes (ALKS)**	Date: 8 Feb 2025 Quarter: Q2'25 Batch 9 Technical: SUCCESS (statistically significant clinical benefit in MWT for NT1 compared with placebo featuring a positive dose-response relationship) Commercial: SUCCESS (commercially sufficient clinical benefit in MWT for NT1 non-inferior non-superior to ORX750/TAK861 in the best-case scenarios of optimal dosing regimens)	Readout: 7 Sep 2025 **Lead Time: 211 days in advance** Interpretation: Alixorexton met the primary endpoint in MSL on MWT at week 6 (24 min for 4mg with p=0.01; 26 minutes for 6mg with p<0.0001; 28 minutes for 8mg with p<0.0001) and the key secondary endpoint in ESS (-6.4 for 4mg with p=0.01; -8.7 for 6mg with p<0.0001; -8.3 for 8mg with p<0.0001)	Correct Prediction Conclusion: statistically significant and commercially sufficient (no approved treatment so far) Classification: **True Positive (TP)**
1101	**Inhaled Treprostinil** **NCTID: NCT05255991** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: synthetic analog of prostacyclin** **Area: Respiratory Tract Diseases** **Indication: Idiopathic Pulmonary Fibrosis** **Human Patients: 597** **Sponsor: United Therapeutics (UTHR)**	Date: 28 Jul 2025 Quarter: Q4'25 Batch 4 Technical: SUCCESS (statistically significant clinical benefit in FVC and OS compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in FVC and OS moderately superior to nerandomilast)	Readout: 2 Sep 2025 **Lead Time: 36 days in advance** Interpretation: Tyvaso as an add-on treatment achieved a 95.6mL placebo-adjusted improvement in absolute FVC at week 52 (p<0.0001); moderately superior to nerandomilast that achieved a 68.8mL placebo-adjusted improvement in absolute FVC at week 52 (p<0.0001) (see add'l link below)	Correct Prediction Conclusion: statistically significant (FVC) and commercially sufficient (moderately superior to nerandomilast in FVC) Classification: **True Positive (TP)**
1406	**Olezarsen** **NCTID: NCT05552326** **Phase: Phase 3** **Class: Best-In-Class** **Modality: antisense oligonucleotide (ASO)** **MoA: GalNAc3-conjugated anti-APOC3** **Area: Cardiovascular Diseases and Nutritional and Metabolic Diseases** **Indication: Severe Hypertriglyceridemia** **Human Patients: 446** **Sponsor: Ionis Pharmaceuticals (IONS)**	Date: 3 Jan 2024 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit non-superior non-inferior to plozasiran)	Readout: 2 Sep 2025 **Lead Time: 608 days in advance** Interpretation: Olezarsen achieved 55-73% placebo-adjusted reduction in fasting triglycerides (p<0.0001) and 85% placebo-adjusted reduction in acute pancreatitis attacks (p<0.0001); non-superior-non-inferior to plozasiran that achieved 61-63% placebo-adjusted reduction in fasting triglycerides (p<0.001) and 83% placebo-adjusted reduction in acute pancreatitis attacks (p=0.03)(see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially sufficient (non-superior-non-inferior to plozasiran) Classification: **True Positive (TP)**
1965	**Baxdrostat** **NCTID: NCT06034743** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: selective aldosterone synthase inhibitor** **Area: Cardiovascular Diseases** **Indication: Uncontrolled or resistant hypertension**	Date: 11 Apr 2025 Quarter: Q2'25 Batch 14d Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit in seated SBP with a negative dose-response relationship) Commercial: FAILURE (commercially insufficient additive clinical benefit in	Readout: 30 Aug 2025 **Lead Time: 141 days in advance** Interpretation: baxdrostat 2mg + SoC achieved 9.8 mmHg placebo-adjusted reduction in seated SBP at week 12 for uncontrolled or resistant hypertension (p<0.001); and 10.3 mmHg seated SBP at week 12 for resistant hypertension (p<0.0001 in Bax24 trial); which are non-superior	Correct Prediction Conclusion: statistically significant (weak additive efficacy) and commercially maybe sufficient (more benefit for resistant hypertension than for uncontrolled hypertension) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Human Patients: 796 **Sponsor: AstraZeneca (AZN)**	seated SBP for the mixed uncontrolled/resistant hypertension patients without further resistance/biomarker-based stratifications; as baxdrostat; which is non-inferior non-superior to lorundrostat; could deliver commercially sufficient additive clinical benefit only for either resistant hypertension patients or uncontrolled hypertension patients featuring aberrant plasma aldosterone level/aldosterone-to-renin ratio)	to 6-12 mmHg placebo-adjusted 24hr ABPM reduction achieved by adding a third therapy to two standard anti-hypertension medications (see add'l link below and DOI-10.1016/j.ejim.2023.04.021)	
2008	**Zilebesiran** **NCTID: NCT06272487** **Phase: Phase 2** **Class: First-In-Class** **Modality: siRNA** **MoA: GalNAc-conjugated siRNA against liver-expressed AGT** **Area: Cardiovascular Diseases** **Indication: Uncontrolled hypertension** **Human Patients: 375** **Sponsor: Alnylam Pharmaceuticals / Roche (ALNY/RHHBY)**	Date: 06 May 2025 Quarter: Q3'25 Batch 5 Technical: partial FAILURE (statistically maybe significant yet very weak additive clinical benefit to SoC in seated SBP compared with placebo) Commercial: partial FAILURE (commercially maybe sufficient yet very weak additive clinical benefit to SoC in seated SBP moderately inferior to low-dose baxdrostat/lorundrostat + SoC)	Readout: 30 Aug 2025 **Lead Time: 116 days in advance** Interpretation: zilebesiran didn't achieve statistical significance with 5.0 mmHg placebo-adjusted reduction in seated SBP at week 12 for uncontrolled hypertension (p=0.0431); moderately inferior to baxdrostat that achieved 9.8 mmHg placebo-adjusted reduction in seated SBP at week 12 for uncontrolled or resistant hypertension (p<0.001) (see add'l link below and DOI-10.1016/j.ejim.2023.04.021)	Correct Prediction Conclusion: statistically insignificant and commercially insufficient (inferior to baxdrostat) Classification: **True Negative (TN)**
1375	**AMX0035** **NCTID: NCT06122662** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: sodium phenylbutyrate + taurursodiol** **Area: Nervous System Diseases** **Indication: Progressive Supranuclear Palsy** **Human Patients: 110** **Sponsor: Amylyx Pharmaceuticals (AMLX)**	Date: 26 Apr 2025 Quarter: Q2'25 Batch 14e Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in PSPRS compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in PSPRS though no FDA approved drug is available)	Readout: 27 Aug 2025 **Lead Time: 123 days in advance** Interpretation: AMX0035 failed to meet any primary or secondary endpoint; further development discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
2015	**VK2735** **NCTID: NCT06828055** **Phase: Phase 2** **Class: Best-In-Class** **Modality: peptide** **MoA: oral GLP1R/GIPR dual agonist** **Area: Nutritional and Metabolic Diseases** **Indication: obesity without type 2 diabetes** **Human Patients: 280** **Sponsor: Viking Therapeutics (VKTX)**	Date: 8 May 2025 Quarter: Q3'25 Batch 6 Technical: SUCCESS (statistically significant clinical benefit in weight reduction compared with placebo with superior-to-tirzepatide tolerability) Commercial: SUCCESS (commercially sufficient clinical benefit in weight reduction non-superior-non-inferior to retatrutide; moderately superior to tirzepatide; and strongly superior to orforglipron/GSBR1290/cagrisema)	Readout: 26 Aug 2025 **Lead Time: 110 days in advance** Interpretation: VK2735 oral 90mg achieved 9.8% placebo-adjusted weight reduction and 7% placebo-adjusted discontinuation rate at week 13; superior to 5.5% placebo-adjusted weight reduction at week 13 and superior to 7.7% placebo-adjusted discontinuation rate at week 72 achieved by orforglipron 36mg (see add'l link below); superior to 6.2% placebo-adjusted weight reduction at week 13 yet inferior to 3.6% placebo-adjusted discontinuation rate at week 72 achieved by tirzepatide 15mg (10.1056/NEJMoa2206038)	Correct Prediction Conclusion: statistically significant and commercially sufficient (strongly superior efficacy compared with both orforglipron and tirzepatide and non-inferior tolerability compared with orforglipron) Classification: **True Positive (TP)**
1954	**Orforglipron** **NCTID: NCT05872620** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: oral GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity or Overweight and Type 2 Diabetes** **Human Patients: 1613** **Sponsor: Eli Lilly and Company (LLY)**	Date: 30 Mar 2025 Quarter: Q3'25 Batch 1 Technical: SUCCESS (statistically significant clinical benefit in weight reduction and HbA1c compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit as an oral therapy in HbA1c and weight reduction non-superior-non-inferior to semaglutide/GSBR1290 with numerically-inferior-to-semaglutide	Readout: 26 Aug 2025 **Lead Time: 149 days in advance** Interpretation: orforglipron 36mg achieved 8.3% placebo-adjusted weight reduction and 6% placebo-adjusted discontinuation rate at week 72; overall non-superior-non-inferior to 6.2% placebo-adjusted weight reduction and 3.3% placebo-adjusted discontinuation rate at week 68 achieved by semaglutide 2.4mg (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially sufficient (slightly superior efficacy yet slightly inferior tolerability compared with semaglutide; thus commercially more competitive for obesity with T2DM than for obesity without T2DM) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
		tolerability)		
1996	**Z-1018** **NCTID: NCT06569823** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: Vaccine** **MoA: subunit vaccine comprising gE antigen with CpG 1018 adjuvant** **Area: Infections** **Indication: Shingles** **Human Patients: 764** **Sponsor: Dynavax Technologies (DVAX)**	Date: 3 May 2025 Quarter: Q3'25 Batch 3 Technical: FAILURE (statistically significant clinical benefit in immunogenicity superior to placebo yet non-superior to Shingrix) Commercial: FAILURE (commercially insufficient clinical benefit in herpes zoster risk reduction moderately inferior to Shingrix)	Readout: 21 Aug 2025 **Lead Time: 110 days in advance** Interpretation: Z-1018 achieved a composite vaccine response rate of 89.7%; slightly inferior to Shingrix that achieved a composite vaccine response rate of 90.3% in the same trial	Correct Prediction Conclusion: statistically significant and commercially insufficient (non-superior to Shingrix) Classification: **True Negative (TN)**
1207	**Barzolvolimab (CDX-0159)** **NCTID: NCT05774184** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-cKIT inhibitor** **Area: Immune System Diseases** **Indication: Eosinophilic Esophagitis (EoE)** **Human Patients: 86** **Sponsor: Celldex Therapeutics (CLDX)**	Date: 15 May 2025 Quarter: Q3'25 Batch 9 Technical: SUCCESS (statistically significant clinical benefit in DSQ compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in DSQ slightly superior to dupilumab)	Readout: 19 Aug 2025 **Lead Time: 96 days in advance** Interpretation: barzolvolimab failed to achieve the primary efficacy endpoint in DSQ (p=0.33)	Missed Prediction Note: due to suboptimal disease model that has been permanently improved Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**
1418	**Inclacumab** **NCTID: NCT04927247** **Phase: Phase 3** **Class: Best-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-P-selectin mAb inhibitor** **Area: Hemic and Lymphatic Diseases** **Indication: Sickle Cell Disease and Recurrent Vaso-occlusive Crises** **Human Patients: 243** **Sponsor: Pfizer (PFE)**	Date: 15 Jan 2024 Quarter: Q1'24 Batch 15 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 15 Aug 2025 **Lead Time: 578 days in advance** Interpretation: inclacumab failed to achieve meet the primary efficacy endpoint compared with placebo	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1721	**SGR-2921** **NCTID: NCT05961839** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: CDC7 inhibitor** **Area: Neoplasms** **Indication: Relapsed/ Acute Myeloid Leukemia or Myelodysplastic Syndrome** **Human Patients: 66** **Sponsor: Schrödinger (SDGR)**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 4 Technical: FAILURE (statistically insignificant (additive) clinical benefit in ORR/PFS) Commercial: FAILURE (commercially insufficient (additive) clinical benefit in OS)	Readout: 14 Aug 2025 **Lead Time: 373 days in advance** Interpretation: SGR-2921's further development has been discontinued due to unfavourable clinical benefit/risk profile	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1500	**Troriluzule** **NCTID: NCT04641143** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: riluzole prodrug** **Area: Mental Disorders** **Indication: Obsessive Compulsive Disorder** **Human Patients: 700** **Sponsor: Biohaven Pharmaceuticals (BHVN)**	Date: 6 Mar 2024 Quarter: Q2'24 Batch 11 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 11 Aug 2025 **Lead Time: 523 days in advance** Interpretation: troriluzole failed to achieve the efficacy primary endpoint	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1499	**Troriluzule** **NCTID: NCT04693351** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: riluzole prodrug** **Area: Mental Disorders** **Indication: Obsessive Compulsive Disorder** **Human Patients: 589** **Sponsor: Biohaven Pharmaceuticals (BHVN)**	Date: 6 Mar 2024 Quarter: Q2'24 Batch 11 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 11 Aug 2025 **Lead Time: 523 days in advance** Interpretation: troriluzole failed to achieve the efficacy primary endpoint	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1953	**Orforglipron** **NCTID: NCT05869903** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: oral GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity or Overweight With Weight-Related Comorbidities** **Human Patients: 3127** **Sponsor: Eli Lilly and Company (LLY)**	Date: 30 Mar 2025 Quarter: Q3'25 Batch 1 Technical: SUCCESS (statistically significant clinical benefit in weight reduction and HbA1c compared with placebo) Commercial: partial SUCCESS (commercially sufficient clinical benefit as an oral therapy in HbA1c and weight reduction non-superior-non-inferior to semaglutide/GSBR1290 with slightly-inferior-to-semaglutide tolerability)	Readout: 7 Aug 2025 **Lead Time: 130 days in advance** Interpretation: orforglipron 36mg achieved 11.5% placebo-adjusted weight reduction and 7.7% placebo-adjusted discontinuation rate at week 72; slightly inferior to 15.1% placebo-adjusted weight reduction 3.7 % placebo-adjusted discontinuation rate at week 72 achieved by semaglutide 2.4mg (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient (slightly inferior efficacy yet moderately inferior tolerability compared with semaglutide) Classification: **True Negative (TN)**
1805	**CardiolRx** **NCTID: NCT05180240** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral cannabidiol** **Area: Cardiovascular Diseases** **Indication: Acute Myocarditis** **Human Patients: 109** **Sponsor: Cardiol Therapeutics (CRDL)**	Date: 19 Oct 2024 Quarter: Q1'25 Batch 2 Technical: partial SUCCESS (statistically maybe significant yet moderate clinical benefit in LVEF/KCCQ/mortality against placebo) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in LVEF/KCCQ/mortality non-superior to beta blockers yet there is no FDA approved treatments specifically for acute myocarditis)	Readout: 6 Aug 2025 **Lead Time: 291 days in advance** Interpretation: CardiolRx has met the ECV primary endpoint (p=0.0538) and has not met its GLS primary endpoint	Correct Prediction Conclusion: statistically maybe significant and commercially maybe sufficient Classification: **True Negative (TN)**
625	**AT-1501 (Tegoprubart)** **NCTID: NCT05027906** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-CD40L inhibitor** **Area: Immune System Diseases** **Indication: prevention of rejection in kidney transplantation** **Human Patients: 48** **Sponsor: Eledon Pharmaceuticals (ELDN)**	Date: 26 Jan 2025 Quarter: Q2'25 Batch 6 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in eGFR compared with placebo featuring negative dose-response relationship) Commercial: partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in eGFR/graft survival/BPAR at most numerically superior to tacrolimus)	Readout: 6 Aug 2025 **Lead Time: 192 days in advance** Interpretation: tegoprubart stablized eGFR at 63 mL/min/1.73 m2 and achieved -4.11 iBox score at 12 months; both are numerically superior to calcineurin inhibitors (e.g. tacrolimus) that stabilised eGFR at at 53 mL/min/1.73 m2 and achieved -2.98 iBox score at 12 months	Correct Prediction Conclusion: statistically maybe significant (iBox) and commercially maybe sufficient (weak efficacy in eGFR) Classification: **True Negative (TN)**
727	**Tirzepatide** **NCTID: NCT04255433** **Phase: Phase 3** **Class: Best-In-Class** **Modality: peptide** **MoA: GLP1R/GIPR dual agonist** **Area: Cardiovascular Diseases and Nutritional and Metabolic Diseases** **Indication: Type 2 Diabetes Mellitus (T2DM) and heart disease** **Human Patients: 13299** **Sponsor: Eli Lilly and Company**	Date: 18 Feb 2024 Quarter: Q2'24 Batch 7 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit superior to dulaglutide in MACE-3 endpoint for obese diabetic cardiovascular patients)	Readout: 31 Jul 2025 **Lead Time: 529 days in advance** Interpretation: Tirzepatide achieved 8% dulaglutide-adjusted reduction in MACE-3 (HR = 0.92 p=0.086); 16% dulaglutide-adjsuted reduction in time to all-cause death (HR=0.84; p=0.002); and 28% placebo-adjusted reduction in MACE-3 (HR = 0.72); superior to semaglutide's 20% placebo-adjusted reduction in MACE-3 in SELECT trial (see add'l link below)	Correct Prediction Conclusion: statistically insignificant (numerically superior to dulaglutide) and commercially sufficient (numerically superior to semaglutide) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	(LLY)			
1944	**VYN201 (repibresib)** **NCTID: NCT06493578** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: BET inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Non-segmental Vitiligo** **Human Patients: 200** **Sponsor: Vyne Therapeutics (VYNE)**	Date: 27 Mar 2025 Quarter: Q2'25 Batch 12b Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in F-VASI50/T-VASI50 compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in F-VASI50/T-VASI50 inferior to baricitinib/ruxolitinib/upadacitinib)	Readout: 30 Jul 2025 **Lead Time: 125 days in advance** Interpretation: repibresib failed to achieve the primary endpoint in F-VASI50 at week 24	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1937	**Upadacitinib** **NCTID: NCT06012240** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: pan-JAK inhibitor with higher efficacy against JAK1** **Area: Skin and Connective Tissue Diseases** **Indication: Alopecia Areata** **Human Patients: 1500** **Sponsor: AbbVie (ABBV)**	Date: 24 Feb 2025 Quarter: Q3'25 Batch 1 Technical: SUCCESS (statistically significant clinical benefit in SALT<=20 compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in SALT<=20/SALT<=10 moderately superior to baricitinib)	Readout: 30 Jul 2025 **Lead Time: 156 days in advance** Interpretation: Upadacitinib achieved 50.9% placebo-adjusted SALT20 response at week 24; moderately superior to ritlecitinib that achieved 29.1% placebo-adjusted SALT20 response at week 24 (see add'l link below) and moderately superior to baricitinib that achieved 28% placebo-adjusted SALT20 response at week 24 (see DOI-10.1056/NEJMoa2110343)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1956	**Pirtobrutinib (LOXO-305)** **NCTID: NCT05254743** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: non-covalent BTK inhibitor** **Area: Neoplasms** **Indication: Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)** **Human Patients: 662** **Sponsor: Eli Lilly and Company (LLY)**	Date: 30 Mar 2025 Quarter: Q2'25 Batch 13b Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in ORR/PFS at most slightly superior to ibrutinib) Commercial: FAILURE (commercially insufficient clinical benefit in OS non-superior to ibrutinib)	Readout: 29 Jul 2025 **Lead Time: 121 days in advance** Interpretation: pirtobrutinib achieved non-inferiority in ORR compared with ibrutinib; wait for PFS/OS data	Correct Prediction Conclusion: statistically insignificant (non-superior) and commercially TBD Classification: **True Negative (TN)**
1630	**Pociredir** **NCTID: NCT05169580** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: EED-PRC2 inhibitor** **Area: Hemic and Lymphatic Diseases** **Indication: sickle cell disease** **Human Patients: 70** **Sponsor: Fulcrum Therapeutics (FULC)**	Date: 25 Jun 2024 Quarter: Q4'24 Batch 9 Technical: FAILURE (statistically insignificant clinical benefit with high toxicity) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 29 Jul 2025 **Lead Time: 399 days in advance** Interpretation: Pociredir achieved 16% HbF response at week 12 that are strongly inferior to Casgevy's 37% HbF response at week 12 (see add'l link below)	Correct Prediction Conclusion: statistically probably insignificant and commercially insufficient Classification: **True Negative (TN)**
1844	**ATI-2138** **NCTID: NCT06585202** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral anti-ITK and anti-JAK3 dual inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Moderate to Severe Atopic Dermatitis** **Human Patients: 14** **Sponsor: Aclaris Therapeutics (ACRS)**	Date: 10 Nov 2024 Quarter: Q1'25 Batch 10 Technical: SUCCESS (statistically significant clinical benefit in EASI75 against placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in EASI75 superior to dupilumab and superior to upadacitinib)	Readout: 29 Jul 2025 **Lead Time: 261 days in advance** Interpretation: ATI2138 achieved 77.1% mean EASI score improvement at week 12 ($p<0.001$); superior to dupilumab's 67.5% mean EASI score improvement at week 12 (see add'l link below); and superior to upadacitinib's 69.2% mean EASI score improvement at week 12-16 (see DOI-10.1016/j.ad.2024.10.067)	Correct Prediction Conclusion: statistically significant and commercially probably sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1561	**Onvansertib** **NCTID: NCT06106308** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: PLK1 inhibitor** **Area: Neoplasms** **Indication: KRAS/NRAS-mutant 1L mCRC** **Human Patients: 113** **Sponsor: Cardiff Oncology (CRDF)**	Date: 24 Apr 2024 Quarter: Q3'24 Batch 2 Technical: FAILURE (statistically insignificant additive clinical benefit in ORR with additive toxicity) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS with additive toxicity)	Readout: 29 Jul 2025 **Lead Time: 461 days in advance** Interpretation: onvansertib 30mg + chemotherapy + bevacizumab achieved 49% cORR that's numerically superior to 30% cORR achieved by chemotherapy + bevacizumab (no p-value provided); onvansertib 30mg + chemotherapy + bevacizumab achieved statistically insignificant mPFS improvement compared with chemotherapy + bevacizumab (no p-value provided)	Correct Prediction Conclusion: statistically probably insignificant and commercially TBD (wait for OS data) Classification: **True Negative (TN)**
1990	— **NCTID: NCT05686239** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: Inidascamine (RL-007)** **Area: Nervous System Diseases** **Indication: Cognitive Impairment Associated With Schizophrenia** **Human Patients: 242** **Sponsor: ATAI Life Sciences (ATAI)**	Date: 24.Apr.25 Quarter: Q3'25 Batch 2 Technical: FAILURE (statistically maybe significant yet very weak additive clinical benefit in MCCB compared with placebo) Commercial: FAILURE (commercially insufficient additive clinical benefit in MCCB inferior to KarXT)	Readout: 25 Jul 2025 Lead Time: — Interpretation: inidascamine failed to achieve the primary endpoint in MCCB score at week 6	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
2020	**KB304** **NCTID: NCT06724900** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: HSV1 gene therapy delivering COL3A1 and ELN transgenes** **Area: Skin and Connective Tissue Diseases** **Indication: Moderate to Severe Wrinkles of the Décolleté** **Human Patients: 376** **Sponsor: Krystal Biotech (KRYS)**	Date: 13.May.25 Quarter: Q3'25 Batch 8 Technical: FAILURE (statistically insignificant clinical benefit in wrinkle reduction compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in wrinkle reduction slightly inferior to KB301)	Readout: 24 Jul 2025 Lead Time: — Interpretation: KB304 achieved numerically higher subject-reported >=1 point GAIS improvement at three months (72.7% vs 14.3%; no p-value reported); no data reported for improvements in wrinkle severity such as JDWS	Correct Prediction Conclusion: statistically maybe insignificant (no p-value reported) and commercially TBD Classification: **True Negative (TN)**
1935	**Luspatercept** **NCTID: NCT04717414** **Phase: Phase 3** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: recombinant fusion protein ActRIIB/ACVR2B ligand trap** **Area: Hemic and Lymphatic Diseases** **Indication: Myelofibrosis-Associated Anemia** **Human Patients: 313** **Sponsor: Bristol-Myers Squibb (BMY)**	Date: 19 Feb 2025 Quarter: Q2'25 Batch 12a Technical: SUCCESS (statistically significant additive clinical benefit to concomitant JAK2 inhibitors in RBC-TI proportion for >=8 weeks compared with placebo) Commercial: SUCCESS (commercially sufficient additive clinical benefit to concomitant JAK2 inhibitors in RBC-TI proportion for >=8 weeks)	Readout: 18 Jul 2025 **Lead Time: 149 days in advance** Interpretation: Luspatercept failed to achieve the primary endpoint of RBC transfusion independence (p=0.0674)	Missed Prediction Note: due to suboptimal disease model of RBC-transfusion-requiring anaemia associated with myeloprolifera… Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**
1751	**belantamab mafodotin** **NCTID: NCT04484623** **Phase: Phase 3** **Class: First-In-Class** **Modality: ADC** **MoA: anti-BCMA ADC** **Area: Neoplasms** **Indication: Relapsed/ Multiple Myeloma** **Human Patients: 302** **Sponsor: GlaxoSmithKline (GSK)**	Date: 15 Aug 2024 Quarter: Q4'24 Batch 7 Technical: partial SUCCESS (statistically significant additive clinical benefit in PFS superior to bortezomib when combined with pomalidomide + dexamethasone) partial FAILURE (statistically insignificant additive clinical benefit in ORR non-superior to bortezomib) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS non-superior to bortezomib when combined with pomalidomide + dexamethasone)	Readout: 17 Jul 2025 **Lead Time: 336 days in advance** Interpretation: belantamab mafodotin + bortezomib + dexamethasone (BVd) achieved 48% reduction in the risk of progression (PFS HR = 0.52 p=0.0001)) and statistically insignificant reduction in the risk of death (OS HR = 0.77 p = 0.1896) compared with daratumumab + bortezomib + dexamethasone (DVd)	Correct Prediction Conclusion: statistically significant (PFS) and commercially insufficient (FDA disapproval recommendation due to overall insufficient OS benefit given insignificant OS in DREAMM 8 despite significant OS in DREAMM 7) Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1750	**belantamab mafodotin** **NCTID: NCT04246047** **Phase: Phase 3** **Class: First-In-Class** **Modality: ADC** **MoA: anti-BCMA ADC** **Area: Neoplasms** **Indication: Relapsed/ Multiple Myeloma** **Human Patients: 494** **Sponsor: GlaxoSmithKline (GSK)**	Date: 15 Aug 2024 Quarter: Q4'24 Batch 7 Technical: partial SUCCESS (statistically significant additive clinical benefit in PFS superior to daratumumab when combined with bortezomib + dexamethasone) partial FAILURE (statistically insignificant additive clinical benefit in ORR non-superior to daratumumab) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS non-superior to daratumumab when combined with bortezomib + dexamethasone)	Readout: 17 Jul 2025 **Lead Time: 336 days in advance** Interpretation: belantamab mafodotin + bortezomib + dexamethasone (BVd) achieved 59% reduction in the risk of progression (PFS HR = 0.41 p<0.001)) and 42% reduction in the risk of death (OS HR=0.58 p=0.00023) compared with daratumumab + bortezomib + dexamethasone (DVd)	Correct Prediction Conclusion: statistically significant (PFS) and commercially insufficient (FDA disapproval recommendation due to overall insufficient OS benefit given insignificant OS in DREAMM 8 despite significant OS in DREAMM 7) Classification: **True Negative (TN)**
1968	**CAEL-101 (anselamimab)** **NCTID: NCT04504825** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: IgG1 monoclonal antibody that binds to a conformational neoepitope contained with the first 18 amino acids of misfolded human immunoglobulin light chains** **Area: Cardiovascular Diseases** **Indication: AL amyloidosis** **Human Patients: 125** **Sponsor: AstraZeneca (AZN)**	Date: 11 Apr 2025 Quarter: Q2'25 Batch 14d Technical: partial FAILURE (statistically maybe significant yet very weak additive clinical benefit to CyBorD in all-cause mortality/frequency of hospitalization/KCCQ/6MWT compared with placebo) Commercial: FAILURE (commercially insufficient additive clinical benefit to CyBorD in all-cause mortality/frequency of hospitalization/KCCQ/6MWT inferior to daratumumab + CyBorD)	Readout: 16 Jul 2025 **Lead Time: 96 days in advance** Interpretation: Anselamimab failed to achieve the primary endpoint	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1967	**CAEL-101 (anselamimab)** **NCTID: NCT04512235** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: IgG1 monoclonal antibody that binds to a conformational neoepitope contained with the first 18 amino acids of misfolded human immunoglobulin light chains** **Area: Cardiovascular Diseases** **Indication: AL amyloidosis** **Human Patients: 281** **Sponsor: AstraZeneca (AZN)**	Date: 11 Apr 2025 Quarter: Q2'25 Batch 14d Technical: partial FAILURE (statistically maybe significant yet very weak additive clinical benefit to CyBorD in all-cause mortality/frequency of hospitalization/KCCQ/6MWT compared with placebo) Commercial: FAILURE (commercially insufficient additive clinical benefit to CyBorD in all-cause mortality/frequency of hospitalization/KCCQ/6MWT inferior to daratumumab + CyBorD)	Readout: 16 Jul 2025 **Lead Time: 96 days in advance** Interpretation: Anselamimab failed to achieve the primary endpoint	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1911	**TAK861** **NCTID: NCT06470828** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: OX2R agonist** **Area: Nervous System Diseases** **Indication: Narcolepsy Type 1** **Human Patients: 168** **Sponsor: Takeda (TAK)**	Date: 8 Feb 2025 Quarter: Q2'25 Batch 11 Technical: SUCCESS (statistically significant clinical benefit in MWT for NT1 compared with placebo featuring a positive dose-response relationship) Commercial: SUCCESS (commercially sufficient clinical benefit in MWT for NT1 non-inferior non-superior to ORX750/ALKS2680 in the best-case scenarios of optimal dosing regimens)	Readout: 14 Jul 2025 **Lead Time: 156 days in advance** Interpretation: TAK861 met all primary and secondary endpoints	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1910	**TAK861** **NCTID: NCT06505031** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: OX2R agonist** **Area: Nervous System Diseases** **Indication: Narcolepsy Type 1** **Human Patients: 105**	Date: 8 Feb 2025 Quarter: Q2'25 Batch 11 Technical: SUCCESS (statistically significant clinical benefit in MWT for NT1 compared with placebo featuring a positive dose-response relationship) Commercial: SUCCESS	Readout: 14 Jul 2025 **Lead Time: 156 days in advance** Interpretation: TAK861 met all primary and secondary endpoints	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Takeda (TAK)	(commercially sufficient clinical benefit in MWT for NT1 non-inferior non-superior to ORX750/ALKS2680 in the best-case scenarios of optimal dosing regimens)		
1995	**briquilimab** **NCTID: NCT06592768** **Phase: Phase 1** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: aglycosylated anti-cKIT inhibitor** **Area: Respiratory Tract Diseases** **Indication: Allergic Asthma** **Human Patients: 17** **Sponsor: Jasper Therapeutics (JSPR)**	Date: 26 Apr 2025 Quarter: Q3'25 Batch 3 Technical: partial FAILURE (statistically maybe significant yet very weak clinical benefit in allergy-induced LAR/EAR compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit allergy-induced LAR/EAR non-superior to SoC)	Readout: 7 Jul 2025 **Lead Time: 72 days in advance** Interpretation: briquilimab's further development has been discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
780	**Bezuclastinib** **NCTID: NCT05186753** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: cKIT D816V-mutation inhibitor** **Area: Neoplasms** **Indication: Indolent or Smoldering Systemic Mastocytosis** **Human Patients: 237** **Sponsor: Cogent Biosciences (COGT)**	Date: 14 Jan 2025 Quarter: Q3'25 Batch 2 Technical: SUCCESS (statistically significant additive clinical benefit in MS2D2 non-superior-to avapritinib) Commercial: SUCCESS (commercially sufficient additive clinical benefit featuring superior-to-avapritinib efficacy in OS and superior-to-avapritinib toxicity)	Readout: 7 Jul 2025 **Lead Time: 174 days in advance** Interpretation: bezuclastinib achieved placebo-adjusted -8.9 point in TSS/MS2D2 at week 24 (-24.3 bezuclastinib vs -15.4 placebo; 58% improvement over placebo; p= 0.0002); numerically superior to avapritinib's placebo-adjusted -6.4 point in TSS/MS2D2 at week 24 (-15.6 avapritinib vs -9.2 placebo; 70% improvement over placebo; p < 0.003) (see add'l link below)	Correct Prediction Conclusion: statistically significant (TSS/MS2D2) and commercially TBD (wait for OS data) Classification: **True Positive (TP)**
1882	**APG777** **NCTID: NCT06395948** **Phase: Phase 2** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: YTE-and-LALA-modified anti-IL13 inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: moderate-to-severe Atopic Dermatitis** **Human Patients: 431** **Sponsor: Apogee Therapeutics (APGE)**	Date: 23 Jan 2025 Quarter: Q2'25 Batch 5 Technical: SUCCESS (statistically significant clinical benefit in EASI75 compared with placebo) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate clinical benefit in EASI75 at least numerically superior to lebrikizumab yet still inferior to upadacitinib)	Readout: 7 Jul 2025 **Lead Time: 165 days in advance** Interpretation: APG777 achieved 42.3% placebo-adjusted EASI75 at week 16 (p < 0.001); numerically superior to lebrikizumab's 38% placebo-adjusted EASI75 at week 16 averaged from two phase 3 trials (see 10.1056/NEJMoa2206714); and inferior to upadacitinib's nearly 60% placebo-adjusted EASI75 at week 24 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1692	**BPL-003** **NCTID: NCT05870540** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: intranasal 5-MeO-DMT** **Area: Mental Disorders** **Indication: Treatment Resistant Depression** **Human Patients: 196** **Sponsor: atai Life Sciences (ATAI)**	Date: 24 Apr 2025 Quarter: Q3'25 Batch 2 Technical: SUCCESS (statistically significant clinical benefit in MADRS compared with placebo) Commercial: partial SUCCESS (commercially sufficient clinical benefit non-superior-non-inferior to GH001; moderately superior to esketamine + SNRI/SSRI; yet moderately inferior to CYB003)	Readout: 1 Jul 2025 **Lead Time: 68 days in advance** Interpretation: BPL003 (8mg) achieved statistically significant -12.1 points MADRS reduction at Day 29 (p = 0.0025); superior to esketamine that achieved placebo-adjusted -9 points MADRS reduction at Day 8 (see add'l link below); yet non-superior to –15.5 points MADRS reduction at Day 8 by GH001 (p<0.0001)	Correct Prediction Conclusion: statistically significant and commercially sufficient (superior to esketamine) Classification: **True Positive (TP)**
1300	**XPro1595** **NCTID: NCT05318976** **Phase: Phase 2** **Class: First-In-Class** **Modality: recombinant protein biologic** **MoA: biologic soluble TNFalpha neutralizer** **Area: Nervous System Diseases** **Indication: Early Alzheimer's**	Date: 21 Aug 2024 Quarter: Q1'25 Batch 11 Technical: partial SUCCESS (statistically maybe significant yet moderate clinical benefit in EMACC for neuroinflammation-biomarker-stratified mild AD patients) Commercial: partial SUCCESS (commercially maybe sufficient yet	Readout: 30 Jun 2025 **Lead Time: 313 days in advance** Interpretation: XPro1595 did not meet the primary cognitive endpoint EMACC in the mITT population; yet a clinical benefit in EMACC (effect size 0.27) is observed for early Alzheimer's patients with two or more biomarkers of inflammation at baseline	Correct Prediction Conclusion: statistically insignificant and commercially probably insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Disease With Biomarkers of Inflammation **Human Patients: 208** **Sponsor: Inmune Bio (INMB)**	moderate clinical benefit in CDR/ADCS-ADL at most numerically superior to lecanemab for neuroinflammation-biomarker-stratified mild AD patients)		
492	**ARCT810** **NCTID: NCT05526066** **Phase: Phase 2** **Class: First-In-Class** **Modality: mRNA medicine** **MoA: LNP-delivered OTC** **Area: Nervous System Diseases** **Indication: Ornithine Transcarbamylase Deficiency (OTCD)** **Human Patients: 8** **Sponsor: Arcturus Therapeutics (ARCT)**	Date: 14 Feb 2024 Quarter: Q4'24 Batch 8 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 30 Jun 2025 **Lead Time: 502 days in advance** Interpretation: ARCT810 achieved -2.5 µmol/L/day glutamine levels and +14.7% RUF (p=0.026)	Correct Prediction Conclusion: statistically significant and commercially probably sufficient (no FDA approved drug for OTCD) Classification: **True Positive (TP)**
1415	**Marstacimab** **NCTID: NCT05611801** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-TFPI mAb inhibitor** **Area: Hematologic Diseases** **Indication: Hemophilia A Hemophilia B** **Human Patients: 100** **Sponsor: Pfizer (PFE)**	Date: 15 Jan 2024 Quarter: Q1'24 bespoke Batch Q1'24 bespoke Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit more for patients with inhibitors)	Readout: 26 Jun 2025 **Lead Time: 528 days in advance** Interpretation: marstacimab achieved 93% reduction in ABR over 12 months superior to on-demand treatment (1.39 vs 19.78 p < 0.0001) and achieved superiority in all bleeding-related secondary endpoints	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1339	**Pemvidutide** **NCTID: NCT05989711** **Phase: Phase 2** **Class: First-In-Class** **Modality: peptide** **MoA: GLP1R/GCGR dual agonist** **Area: Nutritional and Metabolic Diseaseses** **Indication: Non-Alcoholic Steatohepatitis (NASH)** **Human Patients: 190** **Sponsor: Altimmune (ALT)**	Date: 14 Jan 2025 Quarter: Q2'25 Batch 2 Technical: SUCCESS (statistically significant clinical benefit in both NASH resolution and fibrosis improvement compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in both NASH resolution and fibrosis improvement inferior to tirzepatide)	Readout: 26 Jun 2025 **Lead Time: 163 days in advance** Interpretation: pemvidutide achieved 8.6% placebo-adjusted fibrosis improvement with no worsening of steatohepatitis (statistically insignificant) and 33% placebo-adjusted steatohepatitis resolution with no worsening of fibrosis (p<0.0001 at week 24; inferior to tirzepatide's 21% and 52% delta at week 52 (see add'l link below); and inferior to efruxifermin's 21% and 61% delta at week 24 (see DOI-10.1001/jamanetworkopen.2022.31982)	Correct Prediction Conclusion: partially statistically significant and commercially insufficient Classification: **True Negative (TN)**
1824	**SAR444656 (KT-474)** **NCTID: NCT06028230** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: E3ligase-binding IRAK4 degrader** **Area: Immune System Diseases** **Indication: Moderate to Severe Hidradenitis Suppurativa** **Human Patients: 70** **Sponsor: Kymera Therapeutics / Sanofi (KYMR / SNY)**	Date: 4 Nov 2024 Quarter: Q1'25 Batch 6 Technical: SUCCESS (statistically significant yet moderate clinical benefit in HiSCR50 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in HiSCR50 non-superior to adalimumab and inferior to sonelokimab/bimekizumab/secukinumab)	Readout: 25 Jun 2025 **Lead Time: 233 days in advance** Interpretation: SAR444656's further development is discontinued	Correct Prediction Conclusion: statistically TBD and commercially insufficient Classification: **True Negative (TN)**
1822	**SAR444656 (KT-474)** **NCTID: NCT06058156** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: E3ligase-binding IRAK4 degrader** **Area: Skin and Connective Tissue Diseases** **Indication: Moderate to Severe Atopic Dermatitis**	Date: 4 Nov 2024 Quarter: Q1'25 Batch 6 Technical: SUCCESS (statistically significant clinical benefit in EASI75 against placebo) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in EASI75 superior to adalimumab and non-superior to upadacitinib)	Readout: 25 Jun 2025 **Lead Time: 233 days in advance** Interpretation: SAR444656's further development is discontinued	Correct Prediction Conclusion: statistically TBD and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Human Patients: 70 **Sponsor: Kymera Therapeutics / Sanofi (KYMR / SNY)**			
1248	**Zidesamtinib (NVL-520)** **NCTID: NCT05118789** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: CNS-penetrant mutant-selective ROS1 inhibitor** **Area: Neoplasms** **Indication: Advanced NSCLC and Other Solid Tumors** **Human Patients: 359** **Sponsor: Nuvalent (NUVL)**	Date: 15 Aug 2024 Quarter: Q4'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS against placebo non-inferior to repotrectinib for tumors with ROS1 fusion without TRK fusion) Commercial: SUCCESS (commercially sufficient clinical benefit in OS superior to repotrectinib for tumors with ROS1 fusion without TRK fusion)	Readout: 24 Jun 2025 **Lead Time: 313 days in advance** Interpretation: Zidesamtinib achieved 44% ORR; superior to pembrolizumab + ipilimumab that achieved 20-30% confirmed ORR for EGFRwt advanced NSCLC patients (see DOI-10.1016/j.lungcan.2018.12.015) and slightly superior to repotrectinib that achieved 38% ORR for ROS1-positive advanced NSCLC (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**
1820	**Rezpegaldesleukin (Rezpeg)** **NCTID: NCT06136741** **Phase: Phase 2** **Class: First-In-Class** **Modality: PEGylated peptide** **MoA: pegylated recombinant protein IL2 agonist** **Area: Skin and Connective Tissue Diseases** **Indication: Moderate to Severe Atopic Dermatitis** **Human Patients: 396** **Sponsor: Nektar Therapeutics (NKTR)**	Date: 3 Nov 2024 Quarter: Q1'25 Batch 6 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in EASI75 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in EASI75 inferior to dupilumab or upadacitinib)	Readout: 24 Jun 2025 **Lead Time: 233 days in advance** Interpretation: rezpegaldesleukin achieved 25% placebo-adjusted EASI75 at week 16; inferior to dupilumab nearly 40% placebo-adjusted EASI75 at week 16 (see DOI-10.1056/NEJMoa1610020); and inferior to upadacitinib's nearly 60% placebo-adjusted EASI75 at week 24 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially insufficient (inferior to both dupilumab and upadacitinib) Classification: **True Negative (TN)**
1875	**ST920** **NCTID: NCT04046224** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV2/6-delivered GLA gene therapy** **Area: Nervous System Diseases** **Indication: Fabry Disease** **Human Patients: 33** **Sponsor: Sangamo Therapeutics (SGMO)**	Date: 19 Jan 2025 Quarter: Q2'25 Batch 3 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in eGFR compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in eGFR inferior to pegunigalsidase alfa)	Readout: 24 Jun 2025 **Lead Time: 156 days in advance** Interpretation: ST920 achieved a positive yet statistically insignificant eGFR slope at week 52	Correct Prediction Conclusion: statistically maybe insignificant and commercially TBD Classification: **True Negative (TN)**
1438	**COMP360** **NCTID: NCT05624268** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: 5HT2AR agonist** **Area: Mental Disorders** **Indication: treatment-resistant depression (TRD)** **Human Patients: 255** **Sponsor: Compass Pathways (CMPS)**	Date: 11 Feb 2025 Quarter: Q2'25 Batch 1 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to SoC and to 5-MeO-DMT)	Readout: 23 Jun 2025 **Lead Time: 132 days in advance** Interpretation: COMP360 achieved statistically significant -3.6 points MADRS reduction at Week 6(p <0.001); inferior to esketamine that achieved placebo-adjusted -9 points MADRS reduction at Day 8 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1720	**Apitegromab** **NCTID: NCT06445075** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: latent myostatin inhibitor** **Area: Nutritional and Metabolic Diseases** **Indication: GLP1RA-related Muscle Preservation for Overweight and Obesity** **Human Patients: 100**	Date: 6 Aug 2024 Quarter: - Batch - Technical: SUCCESS (statistically significant additive clinical benefit in weight reduction; total lean body mass preservation; and total fat body mass reduction) Commercial: SUCCESS (commercially sufficient additive clinical benefit in weight reduction; total lean body mass preservation; and total fat body mass reduction;	Readout: 18 Jun 2025 **Lead Time: 316 days in advance** Interpretation: apitegromab achieved a placebo-adjusted 15.6% reduction of muscle loss percentage (p=0.001) at week 24 superior to tirzepatide; and a placebo-adjusted 15.8% increase of fat loss percentage at week 24 superior to tirzepatide; and a placebo-adjusted 1.1% weight gain at week 24 compared with tirzepatide	Correct Prediction Conclusion: statistically significant and commercially sufficient (85% fat mass/15% lean mass compared to tirzepatide alone (70% fat mass/30% lean mass) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Scholar Rock (SRRK)	superior to semaglutide/tirzepatide monotherapy)		
1905	**VTX3232** **NCTID: NCT06556173** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: CNS-penetrant NLRP3 inhibitor** **Area: Nervous System Diseases** **Indication: early Parkinson's Disease (PD)** **Human Patients: 11** **Sponsor: Ventyx Biosciences (VTYX)**	Date: 8 Feb 2025 Quarter: Q2'25 Batch 9 Technical: FAILURE (statistically insignificant clinical benefit in MDS-UPDRS compared with placebo featuring moderate toxicity) Commercial: FAILURE (commercially insufficient clinical benefit in MDS-UPDRS compared with levodopa/tavapadon monotherapy)	Readout: 17 Jun 2025 **Lead Time: 129 days in advance** Interpretation: VTX3232's improvement in MDS-UPDRS Parts II and III combined score at week 6 was neither disclosed nor statistically significant; non-superior to -10.2 improvement in MDS-UPDRS total score achieved by Levodopa at week 26 (see add'l link below)	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1393	**Lorundrosta** **NCTID: NCT06150924** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: aldosterone synthase inhibitor** **Area: Cardiovascular Diseases** **Indication: hypertension and Chronic Kidney Disease (CKD) with albuminuria** **Human Patients: 60** **Sponsor: Mineralys Therapeutics (MLYS)**	Date: 26 Jul 2024 Quarter: Q1'25 Batch 4 Technical: SUCCESS (statistically significant additive clinical benefit in AOBP SBP) Commercial: SUCCESS (commercially sufficient additive clinical benefit in AOBP SBP for lorundrostat + dapagliflozin combotherapy adjunctive treatment which would be non-superior to lorundrostat monotherapy adjunctive treatment)	Readout: 17 Jun 2025 **Lead Time: 326 days in advance** Interpretation: lorundrostat + dapagliflozin achieved a 7.5 mmHg placebo-adjusted reduction in systolic blood pressure at week 4 (p=0.0024)	Correct Prediction Conclusion: statistically significant and commercially probably sufficient Classification: **True Positive (TP)**
1881	**SPY072** **NCTID: NCT06622070** **Phase: Phase 1** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-TL1A inhibitor** **Area: Immune System Diseases** **Indication: rheumatoid arthritis (RA); psoriatic arthritis (PsA); axial spondyloarthritis (axSpA)** **Human Patients: 56** **Sponsor: Spyre Therapeutics (SYRE)**	Date: 22 Jan 2025 Quarter: Q2'25 Batch 4 Technical: SUCCESS (statistically significant yet moderate clinical benefit in clinical remission and endoscopic response compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in clinical remission and endoscopic response inferior to MK7240/TEV574)	Readout: 17 Jun 2025 **Lead Time: 146 days in advance** Interpretation: SPY072 achieved a comparable PK to SPY002 without >= Grade 2 TEAEs	Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**
1880	**SPY002** **NCTID: NCT06672718** **Phase: Phase 1** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-TL1A inhibitor** **Area: Immune System Diseases** **Indication: Ulcerative Colitis** **Human Patients: 56** **Sponsor: Spyre Therapeutics (SYRE)**	Date: 22 Jan 2025 Quarter: Q2'25 Batch 4 Technical: SUCCESS (statistically significant yet moderate clinical benefit in clinical remission and endoscopic response compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in clinical remission and endoscopic response inferior to MK7240/TEV574)	Readout: 17 Jun 2025 **Lead Time: 146 days in advance** Interpretation: SPY002 achieved a 75-day half-life which is more than 3-fold greater than 1st-gen anti-TL1As; without >= Grade 2 TEAEs	Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**
1623	**Venetoclax** **NCTID: NCT04401748** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: BCL2 inhibitor** **Area: Neoplasms** **Indication: 1L higher-risk myelodysplastic syndrome (HR-MDS)** **Human Patients: 531** **Sponsor: AbbVie (ABBV)**	Date: 24 Feb 2025 Quarter: Q2'25 Batch 12a Technical: SUCCESS (statistically significant additive clinical benefit in CR) Commercial: SUCCESS (commercially sufficient additive clinical benefit in OS)	Readout: 16 Jun 2025 **Lead Time: 112 days in advance** Interpretation: venetoclax + azacitidine failed to meet the primary endpoint of OS (HR = 0.908 p = 0.3772) compared with azacitidine alone	Missed Prediction Note: due to suboptimal modelling of venetoclax's MoA for 1L HR-MDS that has been permanently improved Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1712	**Briquilimab** **NCTID: NCT06353971** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-cKIT mAb inhibitor** **Area: Immune System Diseases** **Indication: Chronic Inducible Urticaria** **Human Patients: 27** **Sponsor: Jasper Therapeutics (JSPR)**	Date: 31 Jul 2024 Quarter: Q3'24 Batch 21 Technical: SUCCESS (statistically significant clinical benefit in provocation threshold) Commercial: FAILURE (commercially insufficient clinical benefit in provocation threshold inferior to barzolvolimab)	Readout: 14 Jun 2025 **Lead Time: 318 days in advance** Interpretation: briquilimab achieved 92% CR; which is slightly inferior to the 95% CR achieved by barzolvolimab (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially insufficient (slightly inferior to barzolvolimab) Classification: **True Negative (TN)**
1722	**SGR1505** **NCTID: NCT05544019** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: allosteric MALT1 inhibitor** **Area: Neoplasms** **Indication: relapsed/refractory B-cell malignancies** **Human Patients: 52** **Sponsor: Schrödinger (SDGR)**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 4 Technical: SUCCESS (statistically significant (additive) clinical benefit in ORR/PFS) Commercial: SUCCESS (commercially sufficient (additive) clinical benefit in OS)	Readout: 12 Jun 2025 **Lead Time: 310 days in advance** Interpretation: SGR1505 achieved a 22% ORR for median 4L+ patients	Correct Prediction Conclusion: statistically significant and commercially TBD (wait for OS data) Classification: **True Positive (TP)**
968	**Efgartigimod** **NCTID: NCT05523167** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: antibody fragment biologic** **MoA: anti-FcRn antibody fragment** **Area: Immune System Diseases** **Indication: Active Idiopathic Inflammatory Myopathy** **Human Patients: 265** **Sponsor: argenx (ARGX)**	Date: 11 Jul 2024 Quarter: Q3'24 Batch 16 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 11 Jun 2025 **Lead Time: 335 days in advance** Interpretation: efgartigimod achieved 14.8 placebo-adjusted improvement in mean TIS score (50.45 vs 35.65; P=0.0004); which is below the MCID threshold (>=20 point for TIS score)	Correct Prediction Conclusion: statistically significant yet weak clinical benefit and commercially insufficient Classification: **True Negative (TN)**
1351	**Efgartigimod** **NCTID: NCT05817669** **Phase: Phase 2** **Class: First-In-Class** **Modality: antibody fragment biologic** **MoA: anti-FcRn antibody fragment** **Area: Immune System Diseases** **Indication: Primary Sjögren's Syndrome** **Human Patients: 34** **Sponsor: argenx (ARGX)**	Date: 30 Nov 2023 Quarter: Q1'24 Batch 4 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 11 Jun 2025 **Lead Time: 559 days in advance** Interpretation: efgartigimod failed to achieve statistical significance in ESSDAI compared with placebo (-7.0 vs -4.0)	Correct Prediction Conclusion: statistically insignificant and commercially probably insufficient Classification: **True Negative (TN)**
436	**treprostinil palmitil inhalation powder (TPIP)** **NCTID: NCT05147805** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: synthetic prostacyclin analog** **Area: Respiratory Tract Diseases** **Indication: Pulmonary Arterial Hypertension** **Human Patients: 102** **Sponsor: Insmed Incorporated (INSM)**	Date: 1 Jan 2024 Quarter: Q1'24 Batch 12 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 10 Jun 2025 **Lead Time: 526 days in advance** Interpretation: TPIP achieved a 35% placebo-adjusted reduction from baseline in pulmonary vascular resistance (PVR) and 35.5 meters placebo-adjusted improvement in 6MWD (p=0.003) at week 16; slightly superior to sotatercept's 33 meters placebo-adjusted improvement in 6MWD at week 16 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially probably sufficient Classification: **True Positive (TP)**
1776	**Navepegritide** **NCTID: NCT06433557**	Date: 29 Aug 2024 Quarter: Q4'24 Batch 15	Readout: 9 Jun 2025 **Lead Time: 284 days in advance**	Correct Prediction Conclusion: statistically significant

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 2 **Class: Best-In-Class** **Modality: peptide** **MoA: long-lasting c-type natriuretic peptide** **Area: Musculoskeletal Diseases** **Indication: children with achondroplasia (ACH)** **Human Patients: 22** **Sponsor: Ascendis Pharma (ASND)**	Technical: SUCCESS (statistically significant additive clinical benefit in AGV against placebo) Commercial: SUCCESS (commercially sufficient additive clinical benefit in AGV at least numerically superior to vosoritide)	Interpretation: navepegritide + lonapegsomatropin achieved 9.14cm/year mean AGV for treatment-naive patients; superior to vosoritide's 4cm/year mean AGV for treatment-naive patients (see add'l link below)	and commercially probably sufficient Classification: **True Positive (TP)**
1262	**Iluzanebart (VGL101)** **NCTID: NCT05677659** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: TREM2 agonist** **Area: Nervous System Diseases** **Indication: Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia** **Human Patients: 20** **Sponsor: Vigil Neuroscience (VIGL)**	Date: 12 May 2024 Quarter: Q1'25 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 4 Jun 2025 **Lead Time: 388 days in advance** Interpretation: Iluzanebart failed to achieve statistically significant clinical benefit in primary efficacy endpoints	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1688	**SCD-044** **NCTID: NCT04566666** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: highly selective second-gen S1PR1 agonist** **Area: Immune System Diseases** **Indication: Moderate to Severe Plaque Psoriasis** **Human Patients: 263** **Sponsor: Sun Pharmaceutical (SUNPHARMA)**	Date: 18 Jul 2024 Quarter: Q3'24 Batch 18 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in EASI90 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in PASI90 inferior to bimekizumab and non-superior to ustekinumab)	Readout: 2 Jun 2025 **Lead Time: 319 days in advance** Interpretation: SCD044 failed to achieve statistically significant clinical benefit in PASI75 compared with placebo; further development discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1687	**SCD-044** **NCTID: NCT04684485** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: highly selective second-gen S1PR1 agonist** **Area: Skin and Connective Tissue Diseases** **Indication: Moderate to Severe Atopic Dermatitis** **Human Patients: 250** **Sponsor: Sun Pharmaceutical (SUNPHARMA)**	Date: 18 Jul 2024 Quarter: Q3'24 Batch 18 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in EASI75 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in EASI75 inferior to dupilumab and non-superior to baricitinib)	Readout: 2 Jun 2025 **Lead Time: 319 days in advance** Interpretation: SCD044 failed to achieve statistically significant clinical benefit in EASI75 compared with placebo; further development discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1650	**177Lu-PSMA-617** **NCTID: NCT04720157** **Phase: Phase 3** **Class: First-In-Class** **Modality: radionuclide drug conjugate** **MoA: anti-PSMA radionuclide drug conjugates** **Area: Neoplasms** **Indication: 1L PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)** **Human Patients: 1145** **Sponsor: Novartis Pharmaceuticals (NVS)**	Date: 2 Jul 2024 Quarter: - Batch - Technical: FAILURE (statistically insignificant additive clinical benefit in rPFS) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS)	Readout: 2 Jun 2025 **Lead Time: 335 days in advance** Interpretation: pluvicto + SoC achieved statistically significant clinical benefit in PFS compared with SoC alone; yet failed to achieve statistically significant clinical benefit in OS compared with SoC alone	Correct Prediction Conclusion: statistically significant (PFS) and commercially insufficient (non-superior OS) Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
670	**LYR210** **NCTID: NCT05295459** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: long-acting glucocorticoid receptor agonist** **Area: Respiratory Tract Diseases** **Indication: Chronic Rhinosinusitis** **Human Patients: 182** **Sponsor: Lyra Therapeutics (LYRA)**	Date: 27 Mar 2025 Quarter: Q2'25 Batch 13a Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in 3CS compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in 3CS)	Readout: 2 Jun 2025 **Lead Time: 67 days in advance** Interpretation: LYR210 achieved statistically significant clinical benefit in 3CS (-0.90; p=0.00209) and SNOT22 reduction (-8.7 p=0.0101) at week 24 in patients with/without nasal polyps; inferior to dupilumab's -14 placebo-adjusted SNOT22 reduction at week 24 (see add'l link below)	Correct Prediction Conclusion: statistically significant (yet weak efficacy) and commercially probably insufficient (inferior to dupilumab) Classification: **True Negative (TN)**
1823	**KT621** **NCTID: NCT06673667** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: E3ligase-binding STAT6 degrader** **Area: Skin and Connective Tissue Diseases** **Indication: moderate-to-severe atopic dermatitis** **Human Patients: 120** **Sponsor: Kymera Therapeutics (KYMR)**	Date: 27 Mar 2025 Quarter: Q2'25 Batch 12b Technical: partial SUCCESS (statistically significant yet weak clinical benefit in EASI75 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in EASI75 at most slightly superior to dupilumab and inferior to upadacitinib)	Readout: 2 Jun 2025 **Lead Time: 67 days in advance** Interpretation: KT621 achieved median TARC reduction up to 37% at day 14; inferior to dupilumab's 55%-65% TARC reduction at day 14 (see add'l link below)	Correct Prediction Conclusion: statistically significant (yet weak efficacy) and commercially probably insufficient (inferior to dupilumab) Classification: **True Negative (TN)**
1884	**Atacicept** **NCTID: NCT04716231** **Phase: Phase 3** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: recombinant fusion protein anti-BAFF and anti-APRIL inhibitor** **Area: Immune System Diseases** **Indication: IgA Nephropathy** **Human Patients: 376** **Sponsor: Vera Therapeutics (VERA)**	Date: 23 Jan 2025 Quarter: Q2'25 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet moderate clinical benefit in UPCR compared with placebo inferior to budesonide/sparsentan/iptacopan) Commercial: FAILURE (commercially insufficient clinical benefit in eGFR inferior to budesonide/sparsentan/iptacopan)	Readout: 2 Jun 2025 **Lead Time: 130 days in advance** Interpretation: tacicept achieved 42% placebo-adjusted UPCR at week 36 (p<0.0001); slightly inferior to sparsentan's 45% placebo-adjusted UPCR at week 36 (using 5% UPCR reduction in the placebo group (see add'l link below); eGFR data pending	Correct Prediction Conclusion: statistically significant (yet weak UPCR slightly inferior to sparsentan) and commercially TBD (eGFR data pending) Classification: **True Negative (TN)**
820	**IMA203** **NCTID: NCT03686124** **Phase: Phase 1** **Class: First-In-Class** **Modality: cell therapy** **MoA: autologous anti-PRAME TCR-T cell therapy** **Area: Neoplasms** **Indication: Recurrent Refractory Solid Tumors** **Human Patients: 476** **Sponsor: Immatics (IMTX)**	Date: 29 Jul 2024 Quarter: Q3'24 Batch 20 Technical: SUCCESS (statistically significant (additive) clinical benefit in ORR/PFS) Commercial: partial SUCCESS (commercially maybe sufficient yet weak (additive) clinical benefit in OS)	Readout: 31 May 2025 **Lead Time: 306 days in advance** Interpretation: IMA203 achieved 56% cORR and 6.1 months mPFS that are moderately superior to SoC chemotherapy's 3.7 months mPFS and 10% ORR; IMA203 achieved 15.9 months mOS that's slightly superior to SoC chemotherapy's 14 months mOS (see add'l link below)	Correct Prediction Conclusion: statistically significant (ORR/PFS) and commercially maybe sufficient (slightly superior OS) Classification: **True Positive (TP)**
1981	**Itepekimab** **NCTID: NCT04751487** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: IgG4P anti-IL33 inhibitor** **Area: Respiratory Tract Diseases** **Indication: Chronic Obstructive Pulmonary Disease (COPD)** **Human Patients: 1239** **Sponsor: Sanofi (SNY)**	Date: 15 May 2024 Quarter: Q3'25 Batch 1 Technical: FAILURE (statistically insignificant additive clinical benefit to SoC in AECOPD/FEV1/TEAE compared with placebo) Commercial: FAILURE (commercially insufficient additive clinical benefit to SoC in AECOPD/FEV1/TEAE inferior to mepolizumab)	Readout: 30 May 2025 **Lead Time: 380 days in advance** Interpretation: Itepekimab (every four weeks) + SoC achieved a statistically insignificant 12% placebo-adjusted reduction in AECOPD and -7% placebo-adjusted reduction in TEAE at week 52 compared with SoC alone; strongly inferior to mepolizumab's 21% placebo-adjusted reduction in AECOPD and 3% placebo-adjusted reduction in TEAE at week 52 compared with SoC alone (see add'l link below)	Correct Prediction Conclusion: statistically insignificant and commercially insufficient (strongly inferior to mepolizumab) Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1980	**Itepekimab** **NCTID: NCT04701983** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: IgG4P anti-IL33 inhibitor** **Area: Respiratory Tract Diseases** **Indication: Chronic Obstructive Pulmonary Disease (COPD)** **Human Patients: 1127** **Sponsor: Sanofi (SNY)**	Date: 18 Apr 2024 Quarter: Q3'25 Batch 1 Technical: FAILURE (statistically insignificant additive clinical benefit to SoC in AECOPD/FEV1/TEAE compared with placebo) Commercial: FAILURE (commercially insufficient additive clinical benefit to SoC in AECOPD/FEV1/TEAE inferior to mepolizumab)	Readout: 30 May 2025 **Lead Time: 407 days in advance** Interpretation: Itepekimab (every four weeks) + SoC achieved a statistically significant 21% placebo-adjusted reduction in AECOPD and 0% placebo-adjusted reduction in TEAE at week 52 compared with SoC alone; slightly inferior to mepolizumab's 21% placebo-adjusted reduction in AECOPD and 3% placebo-adjusted reduction in TEAE at week 52 compared with SoC alone (see add'l link below)	Correct Prediction Conclusion: statistically significant (yet weak efficacy) and commercially insufficient (slightly inferior to mepolizumab) Classification: **True Negative (TN)**
1667	**Ivonescimab** **NCTID: NCT06396065** **Phase: Phase 3** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-PD-1 and anti-VEGF** **Area: Neoplasms** **Indication: 2L advanced EGFR-mutant NSCLC** **Human Patients: 420** **Sponsor: Summit Therapeutics (SMMT)**	Date: 9 Aug 2024 Quarter: Q4'24 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR/PFS non-superior to carboplatin + pemetrexed combotherapy) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate additive clinical benefit in OS numerically superior to carboplatin + pemetrexed combotherapy)	Readout: 30 May 2025 **Lead Time: 294 days in advance** Interpretation: ivonescimab + chemotherapy achieved statistically significant clinical benefit in PFS compared with the SoC chemotherapy (HR=0.52; p<0.0001); yet failed to achieve statistically significant clinical benefit in OS compared with the SoC chemotherapy (HR=0.79 p=0.057)	Correct Prediction Conclusion: statistically significant (PFS) and commercially insufficient (non-superior OS) Classification: **True Negative (TN)**
1782	**Patritumab Deruxtecan** **NCTID: NCT05338970** **Phase: Phase 3** **Class: First-In-Class** **Modality: ADC** **MoA: anti-HER3 ADC conjugated with a TOP1 inhibitor payload** **Area: Neoplasms** **Indication: advanced NSCLC** **Human Patients: 586** **Sponsor: Daiichi Sankyo Company / Merck & Co. (DSNKY/MRK)**	Date: 9 Sep 2024 Quarter: Q4'24 Batch 16 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in ORR/PFS numerically superior to chemotherapy yet numerically inferior to BL-B01D1); partial FAILURE (statistically insignificant clinical benefit in tolerability inferior to chemotherapy yet numerically superior to BL-B01D1) Commercial: FAILURE (commercially insufficient clinical benefit in OS inferior to chemotherapy yet numerically superior to BL-B01D1)	Readout: 29 May 2025 **Lead Time: 262 days in advance** Interpretation: patritumab deruxtecan failed to achieve statistically significant clinical benefit in OS compared with the SoC chemotherapy; and achieved 5.8 months mPFS; slightly superior to 5.6 months mPFS achieved by the SoC chemotherapy (HR = 0.77 (see add'l link below); BLA voluntarily withdrawn	Correct Prediction Conclusion: statistically significant yet weak efficacy (PFS) and commercially insufficient (non-superior OS) Classification: **True Negative (TN)**
1214	**Cibotercept (KER-012)** **NCTID: NCT05975905** **Phase: Phase 2** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: fusion protein modified ActRIIB/ACVR2B ligand trap** **Area: Respiratory Tract Diseases** **Indication: Pulmonary Arterial Hypertension (PAH)** **Human Patients: 113** **Sponsor: Keros Therapeutics (KROS)**	Date: 13 Dec 2024 Quarter: Q2'25 Batch 2 Technical: partial FAILURE (statistically maybe significant yet very weak additive clinical benefit in PVR with on-target toxicity) Commercial: partial FAILURE (commercially maybe sufficient yet very weak additive clinical benefit in 6MWD)	Readout: 29 May 2025 **Lead Time: 167 days in advance** Interpretation: cibotercept's further development has been discontinued probably due to insufficient benefit-risk profile	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1419	**Quadrivalent modRNA vaccine** **NCTID: NCT05540522** **Phase: Phase 3** **Class: First-In-Class** **Modality: Vaccine** **MoA: Quadrivalent anti-hemagglutinin mRNA vaccine** **Area: Infections** **Indication: Influenza** **Human Patients: 45789** **Sponsor: Pfizer (PFE)**	Date: 15 Jan 2024 Quarter: Q1'24 bespoke Batch Q1'24 bespoke Technical: partial SUCCESS (statistically significant clinical benefit for A/H3N2 for >=65 ysd participants) partial FAILURE (statistically insignificant clinical benefit for B/Victoria; B/Yamagata; and A/H1N1 for >=65 ysd participants) Commercial: partial SUCCESS (commercially sufficient yet moderate	Readout: 28 May 2025 **Lead Time: 499 days in advance** Interpretation: qIRV failed to achieve non-inferiority in anti-ILI efficacy compared with SoC licensed QIV for people >= 65 years	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
		clinical benefit with non-inferior-to-SoC anti-ILI efficacy for A/H3N2 for >=65 ysd participants) partial FAILURE (commercially insufficient clinical benefit with inferior-to-adjuvanted SoC anti-ILI efficacy for B/Victoria; B/Yamagata; and A/H1N1 for >=65 ysd participants)		
1270	**Birtamimab** **NCTID: NCT04973137** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-mis-light-chain** **Area: Nutritional and Metabolic Diseases** **Indication: AL amyloidosis** **Human Patients: 220** **Sponsor: Prothena Biosciences (PRTA)**	Date: 14 Jul 2024 Quarter: Q4'24 Batch 11 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 23 May 2025 **Lead Time: 313 days in advance** Interpretation: birtamimab failed to meet the primary endpoint of time to all-cause mortality or the secondary endpoints	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1672	**Trodelvy (sacituzumab govitecan-hziy)** **NCTID: NCT05382299** **Phase: Phase 3** **Class: First-In-Class** **Modality: ADC** **MoA: anti-TROP2 ADC with SN38 payload** **Area: Neoplasms** **Indication: 1L metastatic Triple-Negative Breast Cancer (TNBC)** **Human Patients: 540** **Sponsor: Gilead Sciences (GILD)**	Date: 9 Jul 2024 Quarter: Q3'24 Batch 15 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in PFS/ORR maybe superior to chemotherapy) Commercial: FAILURE (commercially insufficient clinical benefit in OS non-superior to chemotherapy)	Readout: 23 May 2025 **Lead Time: 318 days in advance** Interpretation: trodelvy achieved statistically significant superior-to-chemotherapy clinical benefit in PFS (without disclosure of the specific data and p-value; indicating probably weak efficacy in PFS); OS data not mature yet no OS detriment was observed	Correct Prediction Conclusion: statistically probably weakly significant (PFS) and commercially TBD (pending OS data); Classification: **True Negative (TN)**
1462	**Petosemtamab (MCLA-158)** **NCTID: NCT03526835** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-EGFR-LGR5 bispecific antibody** **Area: Neoplasms** **Indication: 1L R/M HNSCC** **Human Patients: 567** **Sponsor: Merus (MRUS)**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 3 Technical: SUCCESS (statistically significant additive clinical benefit as 1L treatment for HNSCC) Commercial: SUCCESS (commercially sufficient additive clinical benefit as 1L treatment in OS superior to chemo + pembrolizumab)	Readout: 22 May 2025 **Lead Time: 463 days in advance** Interpretation: petosemtamab + pembrolizumab achieved 63% ORR; 9 months mPFS; and 79% 12-month OS; superior to pembrolizumab + chemotherapy's 36% ORR; 5.8 months mPFS; and 53% 12-month OS (see add'l link below)	Correct Prediction Conclusion: statistically significant (ORR/PFS) and commercially sufficient (superior OS) Classification: **True Positive (TP)**
1773	**Ficerafusp Alfa (BCA101)** **NCTID: NCT04429542** **Phase: Phase 1** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: bispecific antibody with anti-EGFR and anti-TGFbeta targets** **Area: Neoplasms** **Indication: EGFR-driven Advanced Solid Tumors** **Human Patients: 292** **Sponsor: Bicara Therapeutics (BCAX)**	Date: 26 Aug 2024 Quarter: - Batch - Technical: partial SUCCESS (statistically significant (additive) clinical benefit in ORR/PFS numerically superior to cetuximab yet inferior to petosemtamab as monotherapy or in combination with pembrolizumab) Commercial: FAILURE (commercially insufficient (additive) clinical benefit in OS inferior to chemotherapy/cetuximab/petosemtamab as monotherapy or in combination with pembrolizumab)	Readout: 22 May 2025 **Lead Time: 269 days in advance** Interpretation: ficerafusp alfa + pembrolizumab achieved 54% ORR; 7.4 months mPFS; and 61.5% 12-month OS (see DOI-10.1200/JCO.2025.43.16_suppl.601); inferior to petosemtamab + pembrolizumab's 63% ORR; 9 months mPFS; and 79% 12-month OS (see add'l link below)	Correct Prediction Conclusion: statistically significant (ORR/PFS) and commercially insufficient (inferior-to-petosemtamab OS) Classification: **True Negative (TN)**
1801	**Hydronidone (F351)** **NCTID: NCT05115942** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: SMAD7 agonist** **Area: Infections**	Date: 15 Oct 2024 Quarter: Q1'25 Batch 1 Technical: SUCCESS (statistically significant clinical benefit in fibrosis improvement against placebo despite negative dose-response relationship for high doses)	Readout: 22 May 2025 **Lead Time: 219 days in advance** Interpretation: hydronidone achieved 23% placebo-adjusted fibrosis improvement at week 52; superior to tirzepatide's 21% delta at week 52 (see add'l link below) and	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Indication: Chronic Viral Hepatitis B **Human Patients: 248** **Sponsor: Gyre Therapeutics (GYRE)**	Commercial: SUCCESS (commercially sufficient clinical benefit in fibrosis improvement superior to tirzepatide)	efruxifermin's 21% delta at week 24 (see 10.1001/jamanetworkopen.2022.31982)	
1812	**Avutometinib (VS-6766)** **NCTID: NCT05669482** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: MEK inhibitor** **Area: Neoplasms** **Indication: 1L Pancreatic Ductal Adenocarcinoma (PDAC)** **Human Patients: 40** **Sponsor: Verastem (VSTM)**	Date: 26 Oct 2024 Quarter: Q1'25 Batch 3 Technical: SUCCESS (statistically significant additive clinical benefit in ORR/PFS superior to SoC chemotherapy alone) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS non-superior to SoC chemotherapy alone)	Readout: 22 May 2025 **Lead Time: 208 days in advance** Interpretation: avutometinib + defactinib + gemcitabine plus nab-paclitaxel (GnP) achieved 83% ORR (10/12); superior to GnP's 63% ORR for 1L PDAC (see add'l link below)	Correct Prediction Conclusion: statistically significant (ORR) and commercially TBD (PFS/OS data pending) Classification: **True Positive (TP)**
1617	**enpatoran (M5049)** **NCTID: NCT05162586** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: TLR7/8 dual inhibitor** **Area: Immune System Diseases** **Indication: systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE)** **Human Patients: 456** **Sponsor: Merck KGaA (MKKGY)**	Date: 14 May 2024 Quarter: Q3'24 Batch 10 Technical: SUCCESS (statistically significant additive clinical benefit in CLASI-A for CLE and BICLA for SLE) Commercial: SUCCESS (commercially sufficient additive clinical benefit in CLASI-A for CLE and BICLA for SLE)	Readout: 21 May 2025 **Lead Time: 372 days in advance** Interpretation: enpatoran has met the primary endpoint for both the CLE cohort (p=0.0002) and predefined subpopulations in the SLE cohort	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1838	**Pacibekitug (TOUR006)** **NCTID: NCT06362759** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-IL6 inhibitor** **Area: Urogenital Diseases** **Indication: Chronic Kidney Disease and Elevated High-Sensitivity C-Reactive Protein (Hs-CRP)** **Human Patients: 143** **Sponsor: Tourmaline Bio (TRML)**	Date: 9 Nov 2024 Quarter: Q1'25 Batch 9 Technical: SUCCESS (statistically significant yet moderate clinical benefit in hs-CRP reduction against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in UACR/UPCR/eGFR inferior to finerenone)	Readout: 20 May 2025 **Lead Time: 192 days in advance** Interpretation: pacibekitug achieved more than 70% placebo-adjusted hs-CRP >=50% reduction at day 90 (p<0.0001)	Correct Prediction Conclusion: statistically significant and commercially TBD (UACR/UPCR/eGFR data pending) Classification: **True Positive (TP)**
2021	**PM359** **NCTID: NCT06559176** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: cell therapy** **MoA: prime-editor-mediated MCF1-delGT-mutation-corrected CD34+ autologous hematopoietic stem cells** **Area: Immune System Diseases** **Indication: Chronic Granulomatous Disease (CGD)** **Human Patients: 12** **Sponsor: Prime Medicine (PRME)**	Date: 13 May 2025 Quarter: Q3'25 Batch 8 Technical: SUCCESS (statistically significant clinical benefit in OS/infection frequency reduction/active infection resolution/GvHD/autoimmune process frequency/active autoimmune process resolution compared with placebo) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate clinical benefit in OS/infection frequency reduction/active infection resolution/GvHD/autoimmune process frequency/active autoimmune process resolution non-superior to interferon gamma)	Readout: 19 May 2025 **Lead Time: 6 days in advance** Interpretation: PM359's further development has been discontinued probably due to insufficient benefit-risk profile	Correct Prediction Conclusion: statistically probablysignificant and commercially probably insufficient Classification: **True Negative (TN)**
1313	**Govorestat (AT007)** **NCTID: NCT05397665** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: small molecule**	Date: 2 Nov 2023 Quarter: 2H'23 Batch 27 Technical: FAILURE (statistically insignificant clinical benefit)	Readout: 18 May 2025 **Lead Time: 563 days in advance** Interpretation: govorestat failed to deliver statistically significant 10MWRT improvement at month 12	Correct Prediction Conclusion: statistically insignificant and commercially insufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	MoA: Aldose Reductase inhibitor **Area: Nervous System Diseases** **Indication: Hereditary Neuropathy Caused by SORD Deficiency** **Human Patients: 56** **Sponsor: Applied Therapeutics (APLT)**	Commercial: FAILURE (commercially insufficient clinical benefit)	compared with placebo	Classification: **True Negative (TN)**
1781	**ADCT-602** **NCTID: NCT03698552** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: ADC** **MoA: anti-CD22 ADC conjugated with a PBD-dimer cytotoxin SG3249** **Area: Neoplasms** **Indication: Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia (ALL)** **Human Patients: 57** **Sponsor: ADC Therapeutics (ADCT)**	Date: 9 Sep 2024 Quarter: Q4'24 Batch 16 Technical: SUCCESS (statistically significant clinical benefit in CR/CRi/ORR/PFS against placebo yet non-superior non-inferior to inotuzumab ozogamicin) Commercial: FAILURE (commercially insufficient clinical benefit in OS non-superior non-inferior to inotuzumab ozogamicin)	Readout: 14 May 2025 **Lead Time: 247 days in advance** Interpretation: ADCT602's further development has been discontinued due to insufficient benefit-risk profile	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1220	**Aficamten** **NCTID: NCT05767346** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: cardic myosin inhibitor** **Area: Cardiovascular Diseases** **Indication: Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)** **Human Patients: 175** **Sponsor: Cytokinetics (CYTK)**	Date: 27 Mar 2025 Quarter: Q2'25 Batch 12b Technical: SUCCESS (statistically significant clinical benefit in pVO2-CPET and NYHA compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in pVO2-CPET and NYHA moderately superior to metoprolol succinate)	Readout: 13 May 2025 **Lead Time: 47 days in advance** Interpretation: aficamten achieve statistically significant clinical benefit in pVO2 compared with metoprolol	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1895	**Belrestotug** **NCTID: NCT06472076** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-TIGIT inhibitor** **Area: Neoplasms** **Indication: PDL1 high Non-small-cell Lung Cancer (NSCLC)** **Human Patients: 1000** **Sponsor: GlaxoSmithKline / iTeos Therapeutics (GSK / ITOS)**	Date: 30 Jan 2025 Quarter: Q2'25 Batch 7 Technical: FAILURE (statistically insignificant additive clinical benefit in ORR/PFS non-superior to pembrolizumab monotherapy) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS inferior to pembrolizumab monotherapy)	Readout: 13 May 2025 **Lead Time: 103 days in advance** Interpretation: belrestotug + dostarlimab failed to achieve statistically significant clinical benefit in PFS compared with dostarlimab mono therapy	Correct Prediction Conclusion: statistically insignificant (PFS) and commercially insufficient Classification: **True Negative (TN)**
444	**VIR-2218 (elebsiran) VIR-3434 (tobevibart)** **NCTID: NCT04856085** **Phase: Phase 2** **Class: First-In-Class** **Modality: siRNA and monoclonal antibody (mAb)** **MoA: anti-HBx-HBV siRNA and anti-HBsAg mAb inhibitor** **Area: Infections** **Indication: Chronic hepatitis B viral infection** **Human Patients: 244** **Sponsor: Vir Biotechnology (VIR)**	Date: 14 Aug 2024 Quarter: Q4'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit in TEAE and HBsAg against placebo for which VIR-2218 is non-superior-non-inferior to bepirovirsen) Commercial: FAILURE (commercially insufficient clinical benefit in HBV DNA suppression non-superior to SoC)	Readout: 9 May 2025 **Lead Time: 268 days in advance** Interpretation: VIR2218 + VIR3434 achieved functional cure (HBsAg absence and HBV DNA absence) in 4% participants at week 24; inferior to bepirovirsen that achieved functional cure in 10% participants at week 24 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially probably insufficient (non-superior to bepirovirsen) Classification: **True Negative (TN)**
1797	**Soquelitinib** **NCTID: NCT06345404** **Phase: Phase 1**	Date: 10 Nov 2024 Quarter: Q1'25 Batch 10 Technical: SUCCESS (statistically	Readout: 8 May 2025 **Lead Time: 179 days in advance** Interpretation: soquelitinib achieved	Correct Prediction Conclusion: statistically significant and commercially sufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: First-In-Class **Modality: small molecule** **MoA: anti-ITK inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: atopic dermatitis** **Human Patients: 64** **Sponsor: Corvus Pharmaceuticals (CRVS)**	significant clinical benefit in EASI75 against placebo) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in EASI75 superior to adalimumab and non-inferior to upadacitinib)	63% placebo-adjusted EASI75 at week 4; superior to dupilumab nearly 40% placebo-adjusted EASI75 at week 16 (see add'l link below); and non-inferior to upadacitinib's nearly 60% placebo-adjusted EASI75 at week 24 (see 10.1016/S0140-6736(21)00588-2)	(non-inferior to upadacitinib) Classification: **True Positive (TP)**
1317	**VCAR33** **NCTID: NCT05984199** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: cell therapy** **MoA: allogeneic anti-CD33 CAR-T cell therapy** **Area: Neoplasms** **Indication: Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant** **Human Patients: 38** **Sponsor: Vor Biopharma (VOR)**	Date: 7 Nov 2023 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 8 May 2025 **Lead Time: 548 days in advance** Interpretation: VCAR33's further development has been discontinued	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1316	**VOR33** **NCTID: NCT04849910** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: cell therapy** **MoA: allogeneic CRISPAR/CAS9 genome-edited anti-CD33 HSPC cell therapy VOR33 + anti-CD33 ADC mylotarg** **Area: Neoplasms** **Indication: CD33+ acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS)** **Human Patients: 67** **Sponsor: Vor Biopharma (VOR)**	Date: 7 Nov 2023 Quarter: 2H'23 Batch 27 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 8 May 2025 **Lead Time: 548 days in advance** Interpretation: VOR33 + mylotarg's further development has been discontinued	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1620	**CT1812** **NCTID: NCT05893537** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: allosteric sigma-2 receptor antagonist** **Area: Eye Diseases** **Indication: geographic atrophy (GA) secondary to dry age-related macular degeneration** **Human Patients: 100** **Sponsor: Cognition Therapeutics (CGTX)**	Date: 15 May 2024 Quarter: - Batch - Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 8 May 2025 **Lead Time: 358 days in advance** Interpretation: CT1812 achieved 28.6% slower GA lesion growth compared with placebo yet not statistically significant; and CT1812 discontinued further development in GA (see add'l link below)	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
557	**PTC518** **NCTID: NCT05358717** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: HTT mRNA degradation** **Area: Nervous System Diseases** **Indication: Huntington's Disease** **Human Patients: 252** **Sponsor: PTC Therapeutics (PTCT)**	Date: 5 Mar 2024 Quarter: Q2'24 Batch 10 Technical: SUCCESS (statistically significant clinical benefit in lowering tHTT level) Commercial: FAILURE (commercially insufficient clinical benefit in UHDRS-TFC score)	Readout: 5 May 2025 **Lead Time: 426 days in advance** Interpretation: PTC518 failed to deliver statistically significant improvement in the efficacy endpoint cUHDRS at month 12	Correct Prediction Conclusion: statistically significant (mHTT) and commercially insufficient (UHDRS) Classification: **True Negative (TN)**
1240	**Eftilagimod alpha** **NCTID: NCT04811027**	Date: 4 Sep 2023 Quarter: 2H'23 Batch 17	Readout: 5 May 2025 **Lead Time: 609 days in advance**	Correct Prediction Conclusion: statistically significant

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 2 **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: a Soluble LAG-3 Fusion Protein** **Area: Neoplasms** **Indication: Recurrent or Metastatic HNSCC** **Human Patients: 171** **Sponsor: Immutep (IMMP)**	Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit)	Interpretation: efti + pembrolizumab achieved 17.6 months mOS; superior to 10.7 months mOS achieved by cetuximab + chemotherapy or 11.3 months mOS achieved by anti-PD1 therapy + chemotherapy	and commercially sufficient Classification: **True Positive (TP)**
1850	**botaretigene sparoparvovec (bota-vec)** **NCTID: NCT04671433** **Phase: Phase 3** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV5 gene therapy delivering RPGR transgene** **Area: Eye Diseases** **Indication: X-linked retinitis pigmentosa (XLRP)** **Human Patients: 97** **Sponsor: Johnson & Johnson (JNJ)**	Date: 3 Dec 2024 Quarter: Q1'25 Batch 12 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in VMA/BCVA against placebo) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in VMA/BCVA superior to 4D-125; given that no gene therapy has been approved for XLRP and Elevidys's label expansion has been approved for DMD despite very weak efficacy data)	Readout: 5 May 2025 **Lead Time: 153 days in advance** Interpretation: bota-vec failed to achieve statistically significant improvement in vision-guided mobility compared with placebo	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1592	**REC-2282** **NCTID: NCT05130866** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: HDAC inhibitor** **Area: Neoplasms** **Indication: Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas** **Human Patients: 92** **Sponsor: Recursion Pharmaceuticals (RXRX)**	Date: 11 May 2024 Quarter: Q4'24 Batch 1 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit with inferior-to-microsurgery/radiosurgery efficacy)	Readout: 5 May 2025 **Lead Time: 359 days in advance** Interpretation: REC2282 failed to achieve statistically significant improvement in efficacy whose further development has thus been discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1591	**REC-994** **NCTID: NCT05085561** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: superoxide dismutase small molecule mimetic** **Area: Nervous System Diseases** **Indication: Cerebral Cavernous Malformation (CCM)** **Human Patients: 62** **Sponsor: Recursion Pharmaceuticals (RXRX)**	Date: 11 May 2024 Quarter: Q3'24 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit with a negative dose-response relationship) Commercial: FAILURE (commercially insufficient clinical benefit with inferior-to-microsurgery/radiosurgery efficacy)	Readout: 5 May 2025 **Lead Time: 359 days in advance** Interpretation: REC994 failed to achieve statistically significant improvement in efficacy whose further development has thus been discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1818	**REC-4881** **NCTID: NCT05552755** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral non-ATP-competitive MEK1/MEK2 inhibitor** **Area: Neoplasms** **Indication: Familial Adenomatous Polyposis (FAP)** **Human Patients: 67** **Sponsor: Recursion Pharmaceuticals (RXRX)**	Date: 3 Nov 2024 Quarter: Q1'25 Batch 6 Technical: partial SUCCESS (statistically maybe significant yet moderate clinical benefit in polyp burden at week 12 against placebo with a positive duration-response relationship) Commercial: SUCCESS (commercially sufficient clinical benefit in in polyp burden at week 24 superior to celecoxib)	Readout: 4 May 2025 **Lead Time: 182 days in advance** Interpretation: REC4881 achieved a median 43% reduction in polyp burden at week 13; superior to celecoxib's 28% reduction in polyp burden at week 24 (see add'l link below)	Correct Prediction Conclusion: statistically probably significant and commercially probably sufficient Classification: **True Positive (TP)**
1963	**BREZTRI (PT010)** **NCTID: NCT04609904** **Phase: Phase 3**	Date: 11 Apr 2025 Quarter: Q2'25 Batch 14d Technical: SUCCESS (statistically	Readout: 2 May 2025 **Lead Time: 21 days in advance** Interpretation: BREZTRI achieved	Correct Prediction Conclusion: statistically significant and commercially sufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: Best-In-Class **Modality: small molecule** **MoA: triple-combination inhaler therapy of budesonide; glycopyrronium; and formoterol fumarate** **Area: Respiratory Tract Diseases** **Indication: Inadequately Controlled Severe Asthma** **Human Patients: 2187** **Sponsor: AstraZeneca (AZN)**	significant clinical benefit in FEV1 moderately superior to PT009/Symbicort) Commercial: SUCCESS (commercially sufficient clinical benefit in annualized rate of severe asthma exacerbation moderately superior to PT009/Symbicort; slightly superior to dupilumab; and non-superior-non-inferior to tezepelumab)	statistically significant improvement in annualized rate of severe asthma exacerbation; superior to the ICS/LABA SoC treatment	Classification: **True Positive (TP)**
1962	**BREZTRI (PT010)** **NCTID: NCT04609878** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: triple-combination inhaler therapy of budesonide; glycopyrronium; and formoterol fumarate** **Area: Respiratory Tract Diseases** **Indication: Inadequately Controlled Severe Asthma** **Human Patients: 2274** **Sponsor: AstraZeneca (AZN)**	Date: 11 Apr 2025 Quarter: Q2'25 Batch 14d Technical: SUCCESS (statistically significant clinical benefit in FEV1 moderately superior to PT009/Symbicort) Commercial: SUCCESS (commercially sufficient clinical benefit in annualized rate of severe asthma exacerbation moderately superior to PT009/Symbicort; slightly superior to dupilumab; and non-superior-non-inferior to tezepelumab)	Readout: 2 May 2025 **Lead Time: 21 days in advance** Interpretation: BREZTRI achieved statistically significant improvement in annualized rate of severe asthma exacerbation; superior to the ICS/LABA SoC treatment	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1868	**IMU-838** **NCTID: NCT05054140** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: DHODH inhibitor and NURR1 activator** **Area: Nervous System Diseases** **Indication: Progressive Multiple Sclerosis (PMS)** **Human Patients: 450** **Sponsor: Immunic (IMUX)**	Date: 14 Jan 2025 Quarter: Q2'25 Batch 2 Technical: FAILURE (statistically insignificant clinical benefit in EDSS/CDP compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in EDSS/CDP inferior to tolebrutinib)	Readout: 30 Apr 2025 **Lead Time: 106 days in advance** Interpretation: IMU838 failed to achieve statistically significant EDSS improvement compared with placebo	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1827	**XmAb942** **NCTID: NCT06619990** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-TL1A inhibitor** **Area: Immune System Diseases** **Indication: Ulcerative Colitis** **Human Patients: 300** **Sponsor: Xencor (XNCR)**	Date: 22 Jan 2025 Quarter: Q2'25 Batch 4 Technical: SUCCESS (statistically significant yet moderate clinical benefit in MMS compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in MMS inferior to PRA023/TEV574)	Readout: 29 Apr 2025 **Lead Time: 97 days in advance** Interpretation: XmAb942 achieved a half-life estimate of greater than 71 days and sufficient tolerability	Correct Prediction Conclusion: statistically significant (tolerability) and commercially TBD Classification: **True Positive (TP)**
1093	**Evorpacept (ALX148)** **NCTID: NCT04675294** **Phase: Phase 2** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: CD47 blocker** **Area: Neoplasms** **Indication: Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)** **Human Patients: 189** **Sponsor: ALX Oncology (ALXO)**	Date: 25 Jun 2024 Quarter: Q4'24 Batch 8 Technical: FAILURE (statistically insignificant clinical benefit as 1L treatment in ORR non-superior to pembrolizumab + chemotherapy) Commercial: FAILURE (commercially insufficient additive clinical benefit as 1L treatment in 12-month OS non-superior to pembrolizumab + chemotherapy)	Readout: 25 Apr 2025 **Lead Time: 304 days in advance** Interpretation: evorpacept + SoC failed to achieve statistically significant clinical beneift in ORR/PFS/OS compared with SoC alone	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1092	**Evorpacept (ALX148)** **NCTID: NCT04675333** **Phase: Phase 2** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: CD47 blocker** **Area: Neoplasms**	Date: 25 Jun 2024 Quarter: Q4'24 Batch 8 Technical: FAILURE (statistically insignificant clinical benefit as 1L treatment in ORR non-superior to pembrolizumab + chemotherapy)	Readout: 25 Apr 2025 **Lead Time: 304 days in advance** Interpretation: evorpacept + SoC failed to achieve statistically significant clinical beneift in ORR/PFS/OS compared with SoC alone	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Indication: Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) **Human Patients: 172** **Sponsor: ALX Oncology (ALXO)**	Commercial: FAILURE (commercially insufficient additive clinical benefit as 1L treatment in 12-month OS non-superior to pembrolizumab + chemotherapy)		
1857	**Amlitelimab** **NCTID: NCT06118099** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-OX40L inhibitor** **Area: Immune System Diseases** **Indication: Moderate to Severe Hidradenitis Suppurativa** **Human Patients: 90** **Sponsor: Sanofi (SNY)**	Date: 7 Dec 2024 Quarter: Q1'25 Batch 13 Technical: SUCCESS (statistically significant clinical benefit in HiSCR50 score against placebo) Commercial: FAILURE(commercially insufficient clinical benefit in HiSCR50 score non-superior to adalimumab/povorcitinib and inferior to SAR442970/sonelokimab/bimekizumab/secukinumab)	Readout: 24 Apr 2025 **Lead Time: 138 days in advance** Interpretation: amlitelimab's HiSCR50 is inferior to brivekimig (SAR442970)'s HiSCR50; so amlitelimab further development is discontinued	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1973	**Balinatunfib** **NCTID: NCT06073119** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: TNFalpha inhibitor** **Area: Immune System Diseases** **Indication: moderate to severe plaque psoriasis** **Human Patients: 221** **Sponsor: Sanofi (SNY)**	Date: 18 Apr 2025 Quarter: Q3'25 Batch 1 Technical: partial SUCCESS (statistically significant yet moderate clinical benefit in PASI75 compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in PASI75/PASI90 moderately inferior to bimekizumab/ixekizumab and slightly inferior to icotrokinra)	Readout: 24 Apr 2025 **Lead Time: 6 days in advance** Interpretation: balinatunfib failed to achieve the primary endpoint of PASI75 at week 12	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1958	**Adjunctive KarXT** **NCTID: NCT05145413** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: fixed-dose combination of xanomeline and trospium chloride KarXT** **Area: Nervous System Diseases** **Indication: treatment-resistant schizophrenia** **Human Patients: 396** **Sponsor: Bristol-Myers Squibb (BMS)**	Date: 2 Apr 2025 Quarter: Q2'25 Batch 14b Technical: SUCCESS (statistically significant additive clinical benefit in PANSS compared with placebo) Commercial: SUCCESS (commercially sufficient additive clinical benefit in PANSS moderately superior to lumateperone)	Readout: 22 Apr 2025 **Lead Time: 20 days in advance** Interpretation: KarXT + SoC failed to deliver additional clinical benefit in PANSS total score at week 6 compared with SoC alone	Missed Prediction Note: due to suboptimal disease modelling of schizophrenia not uncontrollable by standard therapies; whic… Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**
1948	**Orforglipron** **NCTID: NCT05971940** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: once-daily oral GLPR1 agonist** **Area: Nutritional and Metabolic Diseases** **Indication: type 2 diabetes** **Human Patients: 559** **Sponsor: Eli Lilly and Company (LLY)**	Date: 30 Mar 2025 Quarter: Q2'25 Batch 13b Technical: SUCCESS (statistically significant clinical benefit in HbA1c and weight reduction compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit as an oral therapy in HbA1c and weight reduction non-superior-non-inferior to semaglutide/GSBR1290 with numerically-inferior-to-semaglutide tolerability)	Readout: 15 Apr 2025 **Lead Time: 16 days in advance** Interpretation: orforglipron 36mg achieved 6.3% placebo-adjusted weight reduction and 1.4% placebo-adjusted HbA1c reduction at week 40; which is numerically superior to semaglutide 2.4mg's 6.2% placebo-adjusted weight reduction and 1.2% placebo-adjusted HbA1c reduction at week 40 (see add'l link below) orforglipron 36mg achieved 7% placebo-adjusted adverse-effect-caused discontinuation discontinuation rate; slightly inferior to semaglutide 2.4mg's 5% placebo-adjusted adverse-effect-caused discontinuation rate	Correct Prediction Conclusion: statistically significant and commercially sufficient (non-sueprior-non-inferior to semaglutide 2.4mg) Classification: **True Positive (TP)**
1757	**Amlitelimab** **NCTID: NCT05421598** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-OX40L inhibitor** **Area: Respiratory Tract Diseases**	Date: 19 Aug 2024 Quarter: Q4'24 Batch 12 Technical: SUCCESS (statistically significant additive clinical benefit in annualized rate of severe exacerbation)	Readout: 14 Apr 2025 **Lead Time: 238 days in advance** Interpretation: amlitelimab failed to meet the primary endpoint of annualized exacerbation rate at week 48	Missed Prediction Note: due to suboptimal disease modelling of asthma not uncontrollable by background therapies that have … Conclusion: statistically

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Indication: Moderate-to-severe Asthma **Human Patients: 446** **Sponsor: Sanofi (SNY)**	Commercial: SUCCESS (commercially sufficient additive clinical benefit in FEV1/ACQ5)		insignificant and commercially insufficient Classification: **False Positive (FP)**
1755	**Danuglipron** **NCTID: NCT06153758** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: once-daily oral GLPR1 agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 33** **Sponsor: Pfizer (PFE)**	Date: 15 Aug 2024 Quarter: Q4'24 Batch 11 Technical: partial SUCCESS (statistically significant clinical benefit in weight reduction for healthy obese patients against placebo despite being at least numerically inferior to orforglipron/GSBR1290) Commercial: partial SUCCESS (commercially sufficient clinical benefit in muscle retention and cardio protection for healthy obese patients at least numerically superior to orforglipron/GSBR1290)	Readout: 14 Apr 2025 **Lead Time: 242 days in advance** Interpretation: danuglipron discontinued further development based on the totality of efficacy and toxicity information; thus at least inferior to orforglipron	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1830	**VERVE102** **NCTID: NCT06164730** **Phase: Phase 1** **Class: First-In-Class** **Modality: gene therapy** **MoA: LNP-delivered GalNAc-conjugated anti-PCSK9 base editing gene therapy** **Area: Nutritional and Metabolic Diseases** **Indication: heterozygous familial hypercholesterolemia (HeFH) and/or premature coronary artery disease (CAD)** **Human Patients: 36** **Sponsor: Verve Therapeutics (VERV)**	Date: 9 Nov 2024 Quarter: Q1'25 Batch 8 Technical: partial SUCCESS (statistically significant yet moderate clinical benefit in lowering LDL-C) Commercial: FAILURE (commercially insufficient clinical benefit in lowering LDL-C due to non-superior-to-SoC efficacy and inferior-to-SoC toxicity; despite the superiority of VERVE-102 over VERVE-101)	Readout: 14 Apr 2025 **Lead Time: 156 days in advance** Interpretation: VERVE102 achieved a mean reduction in blood LDL-C of 53% without any SAEs; which is inferior to the 76% LDL-C reduction achieved by evolocumab (see add'l link below); and superior to VERVE101 that has one grade 3 TEAE	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1959	**Mavacamten** **NCTID: NCT05582395** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: cardiac myosin inhibitor** **Area: Cardiovascular Diseases** **Indication: non-obstructive hypertrophic cardiomyopathy (nHCM)** **Human Patients: 580** **Sponsor: Bristol-Myers Squibb (BMY)**	Date: 2 Apr 2025 Quarter: Q2'25 Batch 14b Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in KCCQ compared with placebo) Commercial: partial SUCCESS (commercially maybe sufficient yet weak clinical benefit in KCCQ moderately inferior to aficamten)	Readout: 14 Apr 2025 **Lead Time: 12 days in advance** Interpretation: mavacamten failed to meet either the KCCQ-23 CSS or the pVO2 primary endpoints	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1332	**Setmelanotide** **NCTID: NCT05774756** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: MC4R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Acquired Hypothalamic Obesity** **Human Patients: 120** **Sponsor: Rhythm Pharmaceuticals (RYTM)**	Date: 20 Nov 2023 Quarter: Q1'25 Batch 8 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 7 Apr 2025 **Lead Time: 504 days in advance** Interpretation: setmelanotide achieved a 19.8% placebo-adjusted difference in BMI reduction at week 52 ($p<0.0001$)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1195	**Tovecimig (CTX009)** **NCTID: NCT05506943** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: bispecific antibody**	Date: 3 Nov 2024 Quarter: Q1'25 Batch 4 Technical: SUCCESS (statistically significant additive clinical benefit in ORR/PFS superior to paclitaxel	Readout: 1 Apr 2025 **Lead Time: 149 days in advance** Interpretation: tovecimig + paclitaxel achieved 17.1% ORR superior to 5.3% ORR for paclitaxel alone	Correct Prediction Conclusion: statistically significant (ORR) and commercially TBD (OS pending)

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	MoA: bispecific antibody that inhibits both DLL4 and VEGF-A **Area: Neoplasms** **Indication: advanced billiard tract cancers** **Human Patients: 150** **Sponsor: Compass Therapeutics (CMPX)**	monotherapy regardless of DLL4 baseline expression) Commercial: partial SUCCESS (commercially sufficient additive clinical benefit in OS superior to paclitaxel monotherapy for high-DLL4-baseline-expression patients) partial FAILURE (commercially insufficient additive clinical benefit in OS non-superior to paclitaxel monotherapy for low-DLL4-baseline-expression patients)	(p=0.031); PFS and OS data not mature yet	Classification: **True Positive (TP)**
1199	**OPT-302** **NCTID: NCT04757610** **Phase: Phase 3** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: recombinant fusion protein as anti-VEGFC and anti-VEGFD trap** **Area: Eye Diseases** **Indication: Neovascular Age-related Macular Degeneration (nAMD)** **Human Patients: 986** **Sponsor: Opthea Limited (OPT)**	Date: 14 Jan 2025 Quarter: Q2'25 Batch 2 Technical: FAILURE (statistically maybe significant yet very weak additive clinical benefit in BCVA) Commercial: FAILURE (commercially insufficient additive clinical benefit in BCVA)	Readout: 31 Mar 2025 **Lead Time: 76 days in advance** Interpretation: OPT302 + ranibizumab failed to achieve statistical significance in BCVA compared with ranibizumab monotherapy	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1599	**VAX24** **NCTID: NCT05844423** **Phase: Phase 2** **Class: First-In-Class** **Modality: Vaccine** **MoA: 24-valent pneumococcal conjugate antigen-based vaccine** **Area: Infections** **Indication: invasive pneumococcal disease prevention** **Human Patients: 802** **Sponsor: Vaxcyte (PCVX)**	Date: 12 May 2024 Quarter: Q1'25 Batch 3 Technical: SUCCESS (statistically significant clinical benefit non-inferior-and-non-superior-to PCV15/PCV20) Commercial: SUCCESS (commercially sufficient clinical benefit non-inferior-and-non-superior-to PCV15/PCV20)	Readout: 31 Mar 2025 **Lead Time: 323 days in advance** Interpretation: VAX24 mid-dose met the non-inferiority criteria on relative seroconversion rates compared with PCV20	Correct Prediction Conclusion: statistically significant and commercially sufficient (non-inferior-and-non-superior) Classification: **True Positive (TP)**
552	**Relacorilant** **NCTID: NCT05257408** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: oral non-sterioidal glucocorticoid receptor antagonist** **Area: Neoplasms** **Indication: platinum-resistant ovarian cancer** **Human Patients: 381** **Sponsor: Corcept Therapeutics (CORT)**	Date: 14 Apr 2024 Quarter: Q4'24 Batch 9 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 31 Mar 2025 **Lead Time: 351 days in advance** Interpretation: relacorilant + chemotherapy achieved statistical significance in both PFS improvement (HR=0.70 p=0.008) and OS improvement (HR=0.69 p=0.012) compared with chemotherapy alone	Missed Prediction Note: due to suboptimal indication-specific glucocorticoid receptor modelling that has been permanently i… Conclusion: statistically significant and commercially sufficient Classification: **False Negative (FN)**
705	**muvalaplin** **NCTID: NCT05565742** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: anti-Lp(a) inhibitor** **Area: Cardiovascular Diseases** **Indication: atherosclerotic cardiovascular disease** **Human Patients: 216** **Sponsor: Eli Lilly and Company (LLY)**	Date: 21 Aug 2022 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 30 Mar 2025 **Lead Time: 952 days in advance** Interpretation: lepodisiran met the primary endpoint by achieving a 93.9% placebo-adjusted reduction in Lp(a) levels with the highest tested dose (400mg)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1531	**Semaglutide**	Date: 24 Mar 2024	Readout: 29 Mar 2025	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT04560998 **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: GLP1R agonist** **Area: Cardiovascular Diseases** **Indication: type 2 diabetes and peripheral artery disease** **Human Patients: 792** **Sponsor: Novo Nordisk (NVO)**	Quarter: Q2'24 Batch 13 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit)	**Lead Time: 370 days in advance** Interpretation: semaglutide achieved a 13% placebo-adjusted improvement in maximum walking distance (p=0.0004) and 39.9 meter step incline walking distance improvement at week 52	Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1392	**Lorundrostat** **NCTID: NCT05769608** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: aldosterone synthase inhibitor** **Area: Cardiovascular Diseases** **Indication: uncontrolled hypertension** **Human Patients: 285** **Sponsor: Mineralys Therapeutics (MLYS)**	Date: 26 Jul 2024 Quarter: Q1'25 Batch 4 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit in ABPM SBP with a negative dose-response relationship) Commercial: FAILURE (commercially insufficient additive clinical benefit in AOBP SBP for the mixed uncontrolled/resistant hypertension patients without further resistance/biomarker-based stratifications; as we predict that lorundrostat (which is non-inferior non-superior to baxodrostat) could deliver commercially sufficient additive clinical benefit only for either resistant hypertension patients or uncontrolled hypertension patients featuring aberrant plasma aldosterone level/aldosterone-to-renin ratio)	Readout: 29 Mar 2025 **Lead Time: 246 days in advance** Interpretation: lorundrostat achieved 7.9mmHg (50mg p =0.001) or 6.4mmHg (50-100mg p=0.006) placebo-adjusted 24hr ABPM reduction at week 12 featuring a negative dose-response relationship; which is non-superior to 6-12 mmHg placebo-adjusted 24hr ABPM reduction achieved by adding a third therapy to two standard anti-hypertension medications (see add'l link below)	Correct Prediction Conclusion: statistically significant (yet weak efficacy) and commercially insufficient Classification: **True Negative (TN)**
847	**Itolizumab** **NCTID: NCT05263999** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-CD6 inhibitor** **Area: Immune System Diseases** **Indication: Acute Graft Versus Host Diseas (aGVHD)** **Human Patients: 158** **Sponsor: Equillium (EQ)**	Date: 18 Feb 2024 Quarter: Q2'24 Batch 7 Technical: SUCCESS (statistically significant yet moderate additive clinical benefit) Commercial: partial SUCCESS (commercially maybe sufficient additive clinical benefit)	Readout: 27 Mar 2025 **Lead Time: 403 days in advance** Interpretation: itolizumab + corticosteroids met several key secondary endpoints (CR) at day 99 yet failed to meet primary endpoint (CR) at day 29 compared with corticosteroids monotherapy	Correct Prediction Conclusion: statistically partially significant and commercially maybe sufficient Classification: **True Negative (TN)**
971	**Amivantamab** **NCTID: NCT04487080** **Phase: Phase 3** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: bispecific antibody anti-EGFR and anti-MET inhibitor** **Area: Neoplasms** **Indication: EGFR-mutant Non-Small Cell Lung Cancer (NSCLC)** **Human Patients: 1074** **Sponsor: Johnson & Johnson (JNJ)**	Date: 5 Apr 2023 Quarter: Q2'2023 Batch 12 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (non-superior)	Readout: 26 Mar 2025 **Lead Time: 721 days in advance** Interpretation: amivantamab + lazertinib achieve statistically significant clinical benefit in mOS (HR = 0.75 p <0.005) cor osimertinib; In contrast amivantamab + lazertinib has 12% grade >=3 SAE; inferior to 1% grade >=3 SAE for osimertinib; The overall clinical benefit of amivantamab + lazertinib is grade 1 negligible (according to ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE V1.1 EVALUATION FORM 2A (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially probably insufficient (negligible OS benefit) Classification: **True Negative (TN)**
1725	**Simufilam** **NCTID: NCT05026177** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: FLNA inhibitor** **Area: Nervous System Diseases** **Indication: Mild-to-Moderate Alzheimer's Disease** **Human Patients: 1125**	Date: 6 Aug 2024 Quarter: - Batch - Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in ADAS-COG12/ADCS-ADL23 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in ADAS-COG12/ADCS-ADL23 inferior	Readout: 25 Mar 2025 **Lead Time: 231 days in advance** Interpretation: simufilam failed to meet primary efficacy endpoints ADAS-COG12 and ADCS-ADL at week 76	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Cassava Sciences (SAVA)	to lecanemab)		
1200	**OPT-302** **NCTID: NCT04757636** **Phase: Phase 3** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: recombinant fusion protein as anti-VEGFC and anti-VEGFD trap** **Area: Eye Diseases** **Indication: Neovascular Age-related Macular Degeneration (nAMD)** **Human Patients: 998** **Sponsor: Opthea Limited (OPT)**	Date: 14 Jan 2025 Quarter: Q2'25 Batch 2 Technical: FAILURE (statistically maybe significant yet very weak additive clinical benefit in BCVA) Commercial: FAILURE (commercially insufficient additive clinical benefit in BCVA)	Readout: 24 Mar 2025 **Lead Time: 69 days in advance** Interpretation: OPT302 + aflibercept failed to achieve statistical significance in BCVA compared with aflibercept mono therapy	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1814	**MRT-6160** **NCTID: NCT06597799** **Phase: Phase 1** **Class: First-In-Class** **Modality: molecular glue degrader** **MoA: anti-VAV1 molecular glue degrader** **Area: Immune System Diseases** **Indication: autoimmune diseases** **Human Patients: 76** **Sponsor: Monte Rosa Therapeutics (GLUE)**	Date: 3 Nov 2024 Quarter: Q1'25 Batch 4 Technical: SUCCESS (statistically signifiant clinical benefit against placebo for certain treatment-naïve and treatment-refractory autoimmune diseases) Commercial: SUCCESS (commercially sufficient clinical benefit for certain treatment-naïve and treatment-refractory autoimmune diseases superior to the corresponding SoCs)	Readout: 20 Mar 2025 **Lead Time: 137 days in advance** Interpretation: MRT6160 achieved >90% VAV1 degradation	Correct Prediction Conclusion: statistically significant (safety) and commercially TBD Classification: **True Positive (TP)**
1249	**MRT-2359** **NCTID: NCT05546268** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: molecular glue degrader** **MoA: anti-GSPT1 molecular glue degrader** **Area: Neoplasms** **Indication: MYC-driven advanced solid tumours** **Human Patients: 174** **Sponsor: Monte Rosa Therapeutics (GLUE)**	Date: 30 Sep 2023 Quarter: 2H'23 Batch 18 Technical: FAILURE (statistically maybe significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 20 Mar 2025 **Lead Time: 537 days in advance** Interpretation: MRT2359 achieved 8% ORR (1/13) for MYC-positive patients and 3% ORR (1/37) for all patients; further development in SCLC; NSCLC; NE tumors discontinued due to low efficacy except for AR-resistant CRPC	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1658	**OAV101 (AVXS-101)** **NCTID: NCT05089656** **Phase: Phase 3** **Class: First-In-Class** **Modality: gene therapy** **MoA: rAAV9-mediated gene therapy with SMN1 transgene** **Area: Nervous System Diseases** **Indication: Type 2 Spinal Muscular Atrophy (SMA)** **Human Patients: 127** **Sponsor: Novartis Pharmaceuticals (NVS)**	Date: 1 Jul 2024 Quarter: Q3'24 Batch 14 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit in HFMSE at week 52) Commercial: FAILURE (commercially insufficient clinical benefit in HFMSE at week 52 inferior to nusinersen)	Readout: 19 Mar 2025 **Lead Time: 261 days in advance** Interpretation: OAV101 achieved 1.88 point placebo-adjusted improvement in HFMSE score (p=0.0074); inferior to nusinersen's 4.9 point placebo-adjusted improvement in HFMSE score (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially insufficient (1.88 point is below the 3-point minimal threshold of clinically meaningful improvement in HFMSE score (DOI -10.1007/s40120-024-00653-2) Classification: **True Negative (TN)**
1166	**Batoclimab** **NCTID: NCT05581199** **Phase: Phase 2** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-FcRn mAb inhibitor** **Area: Immune System Diseases** **Indication: Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)** **Human Patients: 277**	Date: 19 Oct 2024 Quarter: Q1'25 Batch 2 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit non-superior to efgartigimod)	Readout: 19 Mar 2025 **Lead Time: 151 days in advance** Interpretation: batoclimab achieved 81% responder rate at week 12 for patients whose IgG was 70%; whereas efgartigimod achieved 67% responder rate at week 12 for all patients regardless of IgG reduction levels; no plan to seek regulatory approval for marketing batoclimab	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Immunovant Sciences (IMVT)			
1162	**Batoclimab** **NCTID: NCT05403541** **Phase: Phase 3** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-FcRn mAb inhibitor** **Area: Immune System Diseases** **Indication: generalized myasthenia gravis (gMG)** **Human Patients: 240** **Sponsor: Immunovant Sciences (IMVT)**	Date: 19 Oct 2024 Quarter: Q1'25 Batch 2 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit non-superior to efgartigimod)	Readout: 19 Mar 2025 **Lead Time: 151 days in advance** Interpretation: batoclimab achieved 2 placebo-adjusted MG-ADL score reduction at week 12 ($p < 0.001$) ; numerically superior to efgartigimod's 1.6-1.7 placebo-adjusted MG-ADL score reduction at week 8-11 (see add'l link below) no plan to seek regulatory approval for marketing batoclimab	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient Classification: **True Negative (TN)**
1811	**Povorcitinib (INCB054707)** **NCTID: NCT05620836** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: JAK1 inhibitor** **Area: Immune System Diseases** **Indication: Moderate to Severe Hidradenitis Suppurativa** **Human Patients: 619** **Sponsor: Incyte Corporation (INCY)**	Date: 26 Oct 2024 Quarter: Q1'25 Batch 3 Technical: SUCCESS (statistically significant yet moderate clinical benefit in HiSCR50 score against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in HiSCR50 score non-superior to adalimumab and inferior to sonelokimab/bimekizumab/secukinumab)	Readout: 17 Mar 2025 **Lead Time: 142 days in advance** Interpretation: povorcitinib has achieved a 13.7% placebo-adjusted HiSCR50; non-superior to 15.6%-31.3% placebo-adjusted HiSCR50 achieved by adalimumab (DOI-10.1056/NEJMoa1504370) and inferior to 22% placebo-adjusted HiSCR50 achieved by bimekizumab (see add'l link below)	Correct Prediction Conclusion: statistically significant yet commercially insufficient Classification: **True Negative (TN)**
1810	**Povorcitinib (INCB054707)** **NCTID: NCT05620823** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: JAK1 inhibitor** **Area: Immune System Diseases** **Indication: Moderate to Severe Hidradenitis Suppurativa** **Human Patients: 608** **Sponsor: Incyte Corporation (INCY)**	Date: 26 Oct 2024 Quarter: Q1'25 Batch 3 Technical: SUCCESS (statistically significant yet moderate clinical benefit in HiSCR50 score against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in HiSCR50 score non-superior to adalimumab and inferior to sonelokimab/bimekizumab/secukinumab)	Readout: 17 Mar 2025 **Lead Time: 142 days in advance** Interpretation: povorcitinib has achieved a 10.9% placebo-adjusted HiSCR50; non-superior to 15.6%-31.3% placebo-adjusted HiSCR50 achieved by adalimumab (DOI-10.1056/NEJMoa1504370) and inferior to 22% placebo-adjusted HiSCR50 achieved by bimekizumab (see add'l link below)	Correct Prediction Conclusion: statistically significant yet commercially insufficient Classification: **True Negative (TN)**
1864	**Eneboparatide (AZP-3601)** **NCTID: NCT05778071** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: PTH1R agonist** **Area: Endocrine System Diseases** **Indication: Chronic Hypoparathyroidism (HypoPT)** **Human Patients: 165** **Sponsor: AstraZeneca (AZN)**	Date: 12 Dec 2024 Quarter: Q1'25 Batch 13b Technical: SUCCESS (statistically significant clinical benefit in the composite endpoint compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in both supplement independence and hypercalciuria)	Readout: 17 Mar 2025 **Lead Time: 95 days in advance** Interpretation: eneboparatide has met the composite primary endpoint	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1000	**AOC1044 (del-zota)** **NCTID: NCT05670730** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: antibody-conjugated antisense oligonucleotide ASO** **MoA: antibody–oligonucleotide conjugate that binds the transferrin receptor 1 (TfR1) to deliver a PMO into muscle cells; inducing exon 44 skip restoring functional dystrophin synthesis** **Area: Musculoskeletal Diseases** **Indication: Duchenne Muscular Dystrophy (DMD)**	Date: 7 Jul 2024 Quarter: Q3'24 Batch 13 Technical: SUCCESS (statistically significant clinical benefit in dystrophin protein level) Commercial: FAILURE (commercially insufficient clinical benefit in the registrational endpoint 6MWD non-superior and non-inferior to DYNE251 or SRP5051)	Readout: 17 Mar 2025 **Lead Time: 253 days in advance** Interpretation: del-zota achieved a statistically significant increase of 25% dystrophin production and 40% in exon 44 skipping; 6MWD data immature	Correct Prediction Conclusion: statistically significant (dystrophin) and commercially TBD (6MWD) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Human Patients: 70 **Sponsor: Avidity Biosciences (RNA)**			
1836	**Luveltamab Tazevibulin** **NCTID: NCT06555263** **Phase: Phase 2** **Class: First-In-Class** **Modality: antibody-drug conjugate (ADC)** **MoA: anti-FOLR1 ADC conjugated with SC209 payload** **Area: Neoplasms** **Indication: Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)** **Human Patients: 43** **Sponsor: Sutro Biopharma (STRO)**	Date: 9 Nov 2024 Quarter: Q1'25 Batch 9 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in ORR/PFS) Commercial: FAILURE (commercially sufficient clinical benefit in OS inferior to SoC)	Readout: 13 Mar 2025 **Lead Time: 124 days in advance** Interpretation: luvelta's further development has been discontinued due to insufficient benefit-risk profile	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1424	**Vepdegestrant** **NCTID: NCT05909397** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: PROTAC-based ER degrader** **Area: Neoplasms** **Indication: 1L ER+HER2- advanced breast cancer** **Human Patients: 59** **Sponsor: Arvinas / Pfizer (ARVN / PFE)**	Date: 15 Jan 2024 Quarter: Q1'24 bespoke Batch Q1'24 bespoke Technical: partial SUCCESS (statistically maybe significant additive clinical benefit) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit non-superior-to Letrozole as 1L treatment)	Readout: 11 Mar 2025 **Lead Time: 421 days in advance** Interpretation: vepdegestrant + palbociclib's further development has been discontinued probably due to uncompetitive clinical benefit compared with vepdegestrant + atirmociclib	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1423	**Vepdegestrant** **NCTID: NCT05654623** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: PROTAC-based ER degrader** **Area: Neoplasms** **Indication: ER+HER2- advanced breast cancer** **Human Patients: 624** **Sponsor: Arvinas / Pfizer (ARVN / PFE)**	Date: 15 Jan 2024 Quarter: Q3'24 Batch 8 Technical: SUCCESS (statistically significant clinical benefit as 2L treatment) Commercial: SUCCESS (commercially sufficient clinical benefit superior to fulvestrant as 2L treatment)	Readout: 11 Mar 2025 **Lead Time: 421 days in advance** Interpretation: vepdegestrant met the primary endpoint in PFS (HR < 0.60) for ESR1m population but not the ITT population; OS data not mature	Missed Prediction Note: tentatively missed prediction for PFS only ; ultimately could still be correct prediction should OS… Conclusion: statistically insignificant (PFS) and commercially TBD Classification: **False Positive (FP)**
1673	**HexaBody-CD38 (GEN3014)** **NCTID: NCT04824794** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-CD38 mAb with Fc-domain-specific E430G mutation** **Area: Neoplasms** **Indication: relapsed or refractory multiple myeloma (RRMM)** **Human Patients: 130** **Sponsor: Genmab / Johnson & Johnson (GMAB / JNJ)**	Date: 9 Jul 2024 Quarter: Q3'24 Batch 15 Technical: SUCCESS (statistically significant clinical benefit in PFS/ORR superior to daratumumab for RRMM) Commercial: SUCCESS (commercially sufficient clinical benefit in CR/OS superior to daratumumab for RRMM)	Readout: 10 Mar 2025 **Lead Time: 244 days in advance** Interpretation: GEN3014 achieved 55% ORR and 7% CR; superior to 52% ORR and 2% CR achieved by the daratumumab arm	Correct Prediction Conclusion: statistically significant (ORR) and commercially probably sufficient (CR) Classification: **True Positive (TP)**
794	**ARO-C3** **NCTID: NCT05083364** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: siRNA-GalNAc conjugate**	Date: 14 Feb 2024 Quarter: Q4'24 Batch 6 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 10 Mar 2025 **Lead Time: 390 days in advance** Interpretation: ARO-C3 achieved 87% C3 reduction; 89% UPCR reduction at week 24 without SAEs	Correct Prediction Conclusion: statistically probably significant and commercially TBD (pending eGFR data) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	that supresses APOC3 mRNA **Area: Immune System Diseases** **Indication: IgA nephropathy** **Human Patients: 62** **Sponsor: Arrowhead Pharmaceuticals (ARWR)**			
1869	**icotrokinra (JNJ-2113)** **NCTID: NCT06049017** **Phase: Phase 2** **Class: First-In-Class** **Modality: peptide** **MoA: anti-IL23R antagonist** **Area: Immune System Diseases** **Indication: Moderately to Severely Active Ulcerative Colitis** **Human Patients: 252** **Sponsor: Johnson & Johnson / Protagonist Therapeutics (JNJ / PTGX)**	Date: 14 Jan 2025 Quarter: Q2'25 Batch 1 Technical: FAILURE (statistically insignificant clinical benefit in clinical response/remission compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in clinical response/remission)	Readout: 10 Mar 2025 **Lead Time: 55 days in advance** Interpretation: icotrokinra achieved 20.1% placebo-adjusted clinical remission rate at week 12 (p<0.001); inferior to PRA023 (tulisokibart) that achieved 25% placebo-adjusted clinical remission rate at week 12 for UC patients (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially insufficient (inferior to PRA023) Classification: **True Negative (TN)**
1394	**Lorundrostat** **NCTID: NCT06153693** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: aldosterone synthase inhibitor** **Area: Cardiovascular Diseases** **Indication: Uncontrolled and Resistant Hypertension** **Human Patients: 1083** **Sponsor: Mineralys Therapeutics (MLYS)**	Date: 26 Jul 2024 Quarter: Q1'25 Batch 4 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in AOBP SBP with a negative dose-response relationship) Commercial: partial SUCCESS (commercially maybe sufficient additive clinical benefit in AOBP SBP for the mixed uncontrolled/resistant hypertension patients possibly with poorly controlled obesity/diabetes without further resistance/biomarker-based stratifications; as we predict that lorundrostat (which is non-inferior non-superior to baxodrostat) could deliver commercially sufficient additive clinical benefit only for either resistant hypertension patients or uncontrolled hypertension patients featuring aberrant plasma aldosterone level/aldosterone-to-renin ratio)	Readout: 10 Mar 2025 **Lead Time: 227 days in advance** Interpretation: lorundrostat achieved 9.1mmHg (50mg p <0.0001; 50-100mg insignificant) placebo-adjusted AOBP reduction at week 6 featuring a negative dose-response relationship	Correct Prediction Conclusion: statistically significant and commercially sufficient for mix patients Classification: **True Positive (TP)**
1518	**CagriSema** **NCTID: NCT05394519** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: combo amylin analog + GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Overweight Obesity Type 2 Diabetes Mellitus** **Human Patients: 1200** **Sponsor: Novo Nordisk (NVO)**	Date: 31 Jan 2025 Quarter: Q1'25 Batch 13c Technical: SUCCESS (statistically significant clinical benefit in HbA1c and weight reduction compared with placebo yet featuring negative morbidity-response relationship and negative age-response relationship for obese T2DM patients) Commercial: FAILURE (commercially insufficient clinical benefit in HbA1c and weight reduction at most numerically superior to semaglutide for obese T2DM patients)	Readout: 10 Mar 2025 **Lead Time: 38 days in advance** Interpretation: CagriSema achieved 10.3% placebo-adjusted weight loss at week 68; which is superior to semaglutide that achieved 6.2% placebo-adjusted weight loss at week 68 (DOI-10.1016/S0140-6736(21)00213-0); yet inferior to tirzepatide achieved 12.2% placebo-adjusted weight loss at week 68 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially insufficient (superior to semaglutide yet inferior to tirzaptide) Classification: **True Negative (TN)**
1860	**Rocatinlimab** **NCTID: NCT05724199** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-OX40 inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Moderate-to-sever Atopic Dermatitis** **Human Patients: 746**	Date: 7 Dec 2024 Quarter: Q1'25 Batch 13 Technical: SUCCESS (statistically significant additive clinical benefit in vIGA-AD/EASI75 against placebo with positive dose-response relationship) Commercial: partial SUCCESS (commercially sufficient yet moderate additive clinical benefit in vIGA-AD/ EASI75 (higher dose); superior to	Readout: 8 Mar 2025 **Lead Time: 91 days in advance** Interpretation: rocatinlimab (low dose) achieved 30.4% placebo-adjusted EASI75 at week 24; inferior to dupilumab nearly 40% placebo-adjusted EASI75 at week 16 (see 10.1056/NEJMoa1610020); and inferior to upadacitinib's nearly 60% placebo-adjusted EASI75 at week 24 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient (inferior to upadacitinib) Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Amgen (AMGN)	dupilumab +TCS/TCI yet inferior to upadacitinib +TCS/TCI)		
1859	**Rocatinlimab** **NCTID: NCT05398445** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-OX40 inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Moderate-to-sever Atopic Dermatitis** **Human Patients: 769** **Sponsor: Amgen (AMGN)**	Date: 7 Dec 2024 Quarter: Q1'25 Batch 13 Technical: SUCCESS (statistically significant clinical benefit in vIGA-AD/EASI75 against placebo with positive dose-response relationship) Commercial: partial SUCCESS (commercially sufficient yet moderate clinical benefit in vIGA-AD/ EASI75 (higher dose); superior to dupilumab yet inferior to upadacitinib)	Readout: 8 Mar 2025 **Lead Time: 91 days in advance** Interpretation: rocatinlimab achieved 29.5% placebo-adjusted EASI75 at week 24; inferior to upadacitinib's nearly 60% placebo-adjusted EASI75 at week 24 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially maybe insufficient (inferior to upadacitinib) Classification: **True Negative (TN)**
1586	**Ompenaclid** **NCTID: NCT05983367** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: SLC6A8 inhibitor** **Area: Neoplasms** **Indication: 2L RAS-mutant Metastatic Colorectal Cancer (mCRC)** **Human Patients: 70** **Sponsor: Merck KGaA (MKKGY)**	Date: 8 May 2024 Quarter: - Batch - Technical: FAILURE (statistically insignificant additive clinical benefit to bevacizumab + chemotherapy in ORR) Commercial: FAILURE (commercially insufficient additive clinical benefit to bevacizumab + chemotherapy in OS)	Readout: 7 Mar 2025 **Lead Time: 303 days in advance** Interpretation: ompenaclid received negative topline data and discontinued further development	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1506	**Aticaprant** **NCTID: NCT05550532** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: selective KOR antagonist** **Area: Mental Disorders** **Indication: Major Depressive Disorder (MDD)** **Human Patients: 444** **Sponsor: Johnson & Johnson (JNJ)**	Date: 18 Mar 2024 Quarter: Q2'24 Batch 12 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit inferior to quetiapine or lumateperone)	Readout: 6 Mar 2025 **Lead Time: 353 days in advance** Interpretation: aticaprant discontinued further development due to insufficient efficacy	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1430	**Aticaprant** **NCTID: NCT05455684** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: selective KOR antagonist** **Area: Mental Disorders** **Indication: Major Depressive Disorder (MDD)** **Human Patients: 513** **Sponsor: Johnson & Johnson (JNJ)**	Date: 19 Jan 2024 Quarter: Q2'24 Batch 12 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit inferior to quetiapine or lumateperone)	Readout: 6 Mar 2025 **Lead Time: 412 days in advance** Interpretation: aticaprant discontinued further development due to insufficient efficacy	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1015	**Rusfertide** **NCTID: NCT05210790** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: peptide mimetic of hepcidin** **Area: Neoplasms** **Indication: Polycythemia Vera (PV)** **Human Patients: 250** **Sponsor: Protagonist Therapeutics (PTGX)**	Date: 26 Oct 2024 Quarter: Q1'25 Batch 2 Technical: SUCCESS (statistically significant additive clinical benefit in phlebotomy eligibility superior to both phlebotomy alone and phlebotomy + hydroxyurea/ruxolitinib) Commercial: SUCCESS (commercially sufficient additive clinical benefit in PROMIS Short Form score superior to both phlebotomy alone and phlebotomy + hydroxyurea/ruxolitinib)	Readout: 3 Mar 2025 **Lead Time: 128 days in advance** Interpretation: rusfertide as an add-on treatment has met both the primary endpoint with 44% placebo-adjusted improvement in clinical response rate ($p<0.0001$) and four key secondary endpoints (phlebotomy/hematocrit control/PROMIS Fatigue SF8a/MFSAF TSS-7)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1622	**Ulixacaltamide**	Date: 15 May 2024	Readout: 28 Feb 2025	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT06087276 **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: T-type calcium channels blocker** **Area: Nervous System Diseases** **Indication: Essential Tremor** **Human Patients: —** **Sponsor: Praxis Precision Medicines (PRAX)**	Quarter: Q3'24 Batch 12 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	**Lead Time: 289 days in advance** Interpretation: ulixacaltamide discontinued further development due to insufficient efficacy at pre-define interim analysis	Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1663	**AXS07 (meloxicam and rizatriptan)** **NCTID: NCT05550207** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: COX antagonist and 5HT1B/5HT1D agonist** **Area: Nervous System Diseases** **Indication: Migraine** **Human Patients: 100** **Sponsor: Axsome Therapeutics (AXSM)**	Date: 6 Aug 2024 Quarter: Q3'24 Batch 13 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to meloxicam/rizatriptan monotherapy)	Readout: 24 Feb 2025 **Lead Time: 202 days in advance** Interpretation: AXS07 achieved >24-hour sustained pain relief for 31.2% more patients than after oral CGRPs ($p<0.001$) and statistically significant mTOQ4 total score superior to oral CGRP inhibitors ($p<0.001$)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1558	**PGN-EDODM1** **NCTID: NCT06204809** **Phase: Phase 1** **Class: First-In-Class** **Modality: peptide-conjugated antisense oligonucleotide ASO** **MoA: anti-DMPK-CUG-repeats-specific oligonucleotide** **Area: Musculoskeletal Diseases** **Indication: Myotonic Dystrophy Type 1** **Human Patients: 32** **Sponsor: PepGen (PEPG)**	Date: 24 Apr 2024 Quarter: Q3'24 Batch 2 Technical: SUCCESS (statistically significant clinical benefit in spliceopathy) Commercial: partial SUCCESS (commercially maybe sufficient yet weak clinical benefit with superior-to-AOC1001 efficacy in terms of vHOT and muscle strength despite non-superior-to-AOC1001 toxicity)	Readout: 24 Feb 2025 **Lead Time: 306 days in advance** Interpretation: PGN-EDODM1 achieved 29.1% mean splicing correction without improved functional outcomes at day 28 (trends only)	Correct Prediction Conclusion: statistically significant (splicing correction) and commercially maybe sufficient yet weak (functional outcome) Classification: **True Negative (TN)**
1877	**SPN820 (NV-5138)** **NCTID: NCT05066672** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: mTORC1 activator** **Area: Mental Disorders** **Indication: treatment-resistant depression** **Human Patients: 400** **Sponsor: Supernus Pharmaceuticals (SUPN)**	Date: 19 Jan 2025 Quarter: Q2'25 Batch 4 Technical: FAILURE (statistically insignificant clinical benefit in MADRS compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit in MADRS inferior to lumateperone)	Readout: 18 Feb 2025 **Lead Time: 30 days in advance** Interpretation: SPN820 failed to achieve statistical significance in MADRS total score	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
511	**casdatifan (AB521)** **NCTID: NCT05536141** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: HIF2alpha inhibitor** **Area: Neoplasms** **Indication: 3L treatment for metastatic clear cell renal cell carcinoma (ccRCC)** **Human Patients: 302** **Sponsor: Arcus Biosciences (RCUS)**	Date: 14 Feb 2025 Quarter: Q2'25 Batch 11 Technical: SUCCESS (statistically significant (additive) clinical benefit in ORR/PFS compared with placebo) Commercial: SUCCESS (commercially sufficient (additive) clinical benefit in OS non-inferior to cabozantinib as a monotherapy and superior to cabozantinib as a combotherapy)	Readout: 15 Feb 2025 **Lead Time: 1 days in advance** Interpretation: casdatifan 100mg QD achieved 33% ORR and >6.8 months mPFS; superior to belzutifan that achieved 22% ORR and 5.6 months mPFS; as 3L treatment for ccRCC (10.1056/NEJMoa2313906) and non-inferior to cabozantinib that acheived 21% ORR and 7.4m mPFS as 3L treatment for ccRCC (see the add'l link below)	Correct Prediction Conclusion: statistically significant and commercially TBD (wait for OS data) Classification: **True Positive (TP)**
1803	**CRB701** **NCTID: NCT06265727**	Date: 19 Oct 2024 Quarter: Q1'25 Batch 1	Readout: 14 Feb 2025 **Lead Time: 118 days in advance**	Correct Prediction Conclusion: statistically significant

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 1 Phase 2 **Class: Best-In-Class** **Modality: ADC** **MoA: anti-nectin4** **Area: Neoplasms** **Indication: 2L treatment for nectin4-overexpressing advanced solid tumors** **Human Patients: 420** **Sponsor: Corbus Pharmaceuticals (CRBP)**	Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS in 2L/3L clinical setting non-inferior-non-superior to enfortumab vedotin for nectin4-overexpressing advance solid tumors) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in OS non-inferior-non-superior to enfortumab vedotin in 2L/3L clinical setting for nectin4-overexpressing advance solid tumors that don't have FDA-approved drugs)	Interpretation: CRB701 monotherapy achieved 44% ORR as 2L treatment for mUC patients previously treated with enfortumab vedotin (EV); comparable to EV monotherapy that achieve 37.5%-46.8% ORR as 2L treatment for mUC patients previously treated with chemo + anti-PD1 therapies (see add'l link below and DOI-10.1007/s00432-024-05717-2)	(in ORR non-superior non-inferior to EV) and commercially TBD (wait for OS data) Classification: **True Positive (TP)**
1841	**ALTO-300** **NCTID: NCT05922878** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: MT1/MIT2 agonist and 5HT2C antagonist** **Area: Mental Disorders** **Indication: Major Depressive Disorder** **Human Patients: 200** **Sponsor: Alto Neuroscience (ANRO)**	Date: 9 Nov 2024 Quarter: Q1'25 Batch 9 Technical: partial SUCCESS (statistically maybe significant yet weak (additive) clinical benefit in MADRS) Commercial: FAILURE (commercially insufficient additive clinical benefit in MADRS inferior to lumateperone)	Readout: 12 Feb 2025 **Lead Time: 95 days in advance** Interpretation: ALTO-300 passed futility test yet failed to achieve sufficient efficacy at interim analysis; an increase of 50 biomarker positive patients are needed in the final analysis whose topline results are expected in mid-2026	Correct Prediction Conclusion: statistically maybe significant (yet weak efficacy) and commercially maybe insufficient Classification: **True Negative (TN)**
1388	**Rosnilimab** **NCTID: NCT06041269** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: PD1 mAb agonist** **Area: Immune System Diseases** **Indication: Rheumatoid Arthritis** **Human Patients: 420** **Sponsor: AnaptysBio (ANAB)**	Date: 14 Nov 2024 Quarter: Q1'25 Batch 3 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 12 Feb 2025 **Lead Time: 90 days in advance** Interpretation: rosnilimab failed to achieve statistical significance in placebo-adjusted ACR50/ACR70 at week 12; inferior to upadacitinib that achieved 28% placebo-adjusted ACR50 and 21% placebo-adjusted ACR70 at week 12 (see add'l link below)	Correct Prediction Conclusion: statistically insignificant (ACR50 at week 12 as the prespecified efficacy endpoint) and commercially insufficient Classification: **True Negative (TN)**
1861	**AZD0171** **NCTID: NCT04999969** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-LIF inhibitor** **Area: Neoplasms** **Indication: 1L treatment for advanced pancreatic ductal adenocarcinoma (PDAC)** **Human Patients: 126** **Sponsor: AstraZeneca (AZN)**	Date: 7 Dec 2024 Quarter: Q1'25 Batch 13 Technical: SUCCESS (statistically significant additive clinical benefit in ORR/PFS compared with chemotherapy alone) Commercial: SUCCESS (commercially sufficient additive clinical benefit in OS superior to chemotherapy alone)	Readout: 6 Feb 2025 **Lead Time: 61 days in advance** Interpretation: AZD0171 + durvalumab + chemotherapy hasn't met the efficacy threshold and further development discontinued without disclosure of data	Missed Prediction Note: due to suboptimal drug MoA model that has been permanently corrected Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**
1087	**Ziftomenib** **NCTID: NCT05735184** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: MENIN-MLL1 inhibitor** **Area: Neoplasms** **Indication: R/R NPM1-m Acute Myeloid Leukemia** **Human Patients: 212** **Sponsor: Kura Oncology (KURA)**	Date: 26 Oct 2024 Quarter: Q1'25 Batch 2 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in CR/EFS) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS)	Readout: 5 Feb 2025 **Lead Time: 102 days in advance** Interpretation: ziftomenib achieved statistically significant CR/CRh without disclosing the actual CR/CRh data (which usually indicates unremarkable results); probably inferior to venetoclax + azacitidine's 24-38% CR/CRh (see the add'l link below) combotherapy TBD	Correct Prediction Conclusion: statistically significant and commercially probably insufficient (as monotherapy) Classification: **True Negative (TN)**
1683	**Monlunabant (INV202)** **NCTID: NCT05514548** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule**	Date: 17 Jul 2024 Quarter: Q3'24 Batch 18 Technical: partial FAILURE (statistically insignificant additive clinical benefit in UACR) partial	Readout: 5 Feb 2025 **Lead Time: 203 days in advance** Interpretation: monlunabant failed to achieve statistical significance in uACR compared with placebo	Correct Prediction Conclusion: statistically insignificant and commercially insufficient; correct prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	MoA: peripherally selective beta-arrestin-2-biased CB1 inverse agonist **Area: Urogenital Diseases** **Indication: Diabetic Kidney Disease** **Human Patients: 265** **Sponsor: Novo Nordisk (NVO)**	SUCCESS (statistically significant yet moderate additive clinical benefit in UPCR) Commercial: FAILURE (commercially insufficient additive clinical benefit in eGFR)		Classification: **True Negative (TN)**
1680	**ordesekimab (AMG714/PRV015)** **NCTID: NCT04424927** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-IL15 inhibitor** **Area: Nutritional and Metabolic Diseases** **Indication: Non-responsive Celiac Disease** **Human Patients: 226** **Sponsor: Amgen / Sanofi (AMGN / SNY)**	Date: 14 Jul 2024 Quarter: Q3'24 Batch 17 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit in CeD PRO) Commercial: FAILURE (commercially insufficient clinical benefit in CeD PRO)	Readout: 4 Feb 2025 **Lead Time: 205 days in advance** Interpretation: ordesekimab failed to achieved statistical significance for primary or secondary endpoints	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1777	**Cemiplimab** **NCTID: NCT05208944** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: telomere-targeting agent THIO** **Area: Neoplasms** **Indication: 3L advanced NSCLC** **Human Patients: 182** **Sponsor: Maia Biotechnology (MAIA)**	Date: 2 Sep 2024 Quarter: Q4'24 Batch 15 Technical: partial SUCCESS (statistically significant moderate additive clinical benefit in ORR/PFS as 3L+ treatment) partial FAILURE (statistically maybe significant yet very weak additive clinical benefit in ORR/PFS as 2L treatment) Commercial: partial SUCCESS (commercially sufficient yet moderate additive clinical benefit in OS in combination with cemiplimab superior to chemotherapy + cemiplimab as 3L+ treatment) partial FAILURE (commercially insufficient additive clinical benefit in OS in combination with cemiplimab non-superior to chemotherapy + cemiplimab as 2L treatment)	Readout: 4 Feb 2025 **Lead Time: 155 days in advance** Interpretation: THIO + cemiplimab achieved 16.9 months mOS (12.5 months mOS as the 95% CI lower bound); superior to the SoC chemotherapy that achieved 10.1 months mOS (see the add'l link below). wait for 2L data.	Correct Prediction Conclusion: statistically significant and commercially sufficient (3L) Classification: **True Positive (TP)**
1265	**GH001** **NCTID: NCT05800860** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: psychedelic 5-MeO-DMT** **Area: Mental Disorders** **Indication: treatment-resistant depression** **Human Patients: 80** **Sponsor: GH Research (GHRS)**	Date: 5 Jun 2024 Quarter: Q3'24 Batch 14 Technical: partial SUCCESS (statistically significant yet moderate clinical benefit) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate clinical benefit)	Readout: 3 Feb 2025 **Lead Time: 243 days in advance** Interpretation: GH001 achieved statistically significant placebo-adjusted –15.5 points MADRS reduction at Day 8 ($p<0.0001$); superior to esketamine that achieved placebo-adjusted -9 points MADRS reduction at Day 8 (DOI-10.1001/jamapsychiatry.2017.3739)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1631	**iscalimab (CFZ533)** **NCTID: NCT0390552** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-CD40 inhibitor** **Area: Immune System Diseases** **Indication: Sjogren's Syndrome** **Human Patients: 273** **Sponsor: Novartis (NVS)**	Date: 1 Jul 2024 Quarter: Q3'24 Batch 14 Technical: FAILURE (statistically insignificant clinical benefit in ESSDAI or ESSPRI) Commercial: FAILURE (commercially insufficient clinical benefit in ESSDAI or ESSPRI inferior to efgartigimod that's further inferior to rituximab)	Readout: 31 Jan 2025 **Lead Time: 214 days in advance** Interpretation: iscalimab in cohort 1 failed to achieve statistical significance in dose-response relationship for ESSDAI in 3/4 models; iscalimab 600mg in cohort 2 failed to achieve statistical significance in ESSPRI improvement compared with placebo ($p=0.12$). Hence; iscalimab hasn't met the efficacy threshold and further development discontinued	Correct Prediction Conclusion: statistically partially insignificant (cohort 1) and commercially insufficient (cohort 2) Classification: **True Negative (TN)**
1632	**LNA043** **NCTID: NCT04864392**	Date: 1 Jul 2024 Quarter: Q3'24 Batch 14	Readout: 31 Jan 2025 **Lead Time: 214 days in advance**	Correct Prediction Conclusion: statistically probably

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 2 **Class: First-In-Class** **Modality: small molecule** **MoA: ANGPLT3 agonist** **Area: Immune System Diseases** **Indication: Knee Osteoarthritis** **Human Patients: 583** **Sponsor: Novartis (NVS)**	Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit in medial knee cartilage thickness at week 104) Commercial: FAILURE (commercially insufficient clinical benefit inferior to semaglutide in WOMAC pain or 6MWD at week 104)	Interpretation: LNA043 hasn't met the efficacy threshold and further development discontinued without disclosure of data	insignificant and commercially insufficient Classification: **True Negative (TN)**
1633	**LNA043** **NCTID: NCT04814368** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: ANGPLT3 agonist** **Area: Immune System Diseases** **Indication: Knee Osteoarthritis** **Human Patients: 23** **Sponsor: Novartis (NVS)**	Date: 1 Jul 2024 Quarter: Q3'24 Batch 14 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit in cartilage volume or KOOS) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 31 Jan 2025 **Lead Time: 214 days in advance** Interpretation: LNA043 + canakinumab hasn't met the efficacy threshold and further development discontinued without disclosure of data	Correct Prediction Conclusion: statistically probably insignificant and commercially insufficient Classification: **True Negative (TN)**
1636	**Secukinumab** **NCTID: NCT05722522** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-IL17A inhibitor** **Area: Nervous System Diseases** **Indication: Rotator Cuff Tendinopathy** **Human Patients: 33** **Sponsor: Novartis (NVS)**	Date: 1 Jul 2024 Quarter: Q3'24 Batch 14 Technical: FAILURE (statistically insignificant additive clinical benefit in WORC-PSD as an adjunctive therapy to SoC) Commercial: FAILURE (commercially insufficient additive clinical benefit in WORC-PSD as an adjunctive therapy to SoC)	Readout: 31 Jan 2025 **Lead Time: 214 days in advance** Interpretation: secukinumab hasn't met the efficacy threshold and further development discontinued without disclosure of data	Correct Prediction Conclusion: statistically probably insignificant and commercially insufficient Classification: **True Negative (TN)**
1657	**XXB750** **NCTID: NCT05562934** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: long-acting NPR1 agonist** **Area: Cardiovascular Diseases** **Indication: Resistant Hypertension** **Human Patients: 191** **Sponsor: Novartis (NVS)**	Date: 1 Jul 2024 Quarter: Q3'24 Batch 14 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit in mean 24hr SBP at week 12 with moderate toxicity) Commercial: FAILURE (commercially insufficient additive clinical benefit in mean 24hr SBP at week 12 inferior to baxdrostat)	Readout: 31 Jan 2025 **Lead Time: 214 days in advance** Interpretation: XXB750 hasn't met the efficacy threshold and further development discontinued without disclosure of data	Correct Prediction Conclusion: statistically probably insignificant and commercially insufficient Classification: **True Negative (TN)**
1081	**ZN-c3 (azenosertib)** **NCTID: NCT05743036** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: Wee1 inhibitor** **Area: Neoplasms** **Indication: BRAF V600E mutant colorectal cancer** **Human Patients: 44** **Sponsor: Zentalis Pharmaceuticals (ZNTL)**	Date: 25 Jun 2024 Quarter: Q3'24 Batch 14 Technical: partial SUCCESS (statistically significant additive clinical benefit in patients with high CCNE1 expression) Commercial: FAILURE (commercially insufficient additive clinical benefit regardless of CCNE1 expression)	Readout: 29 Jan 2025 **Lead Time: 218 days in advance** Interpretation: azenosertib + encorafenib + cetuximab achieved 35-41% confirmed ORR as 1L treatment yet 0% confirmed ORR as 2L treatment. Hence; azenosertib + encorafenib + cetuximab hasn't met the efficacy threshold and further development discontinued	Correct Prediction Conclusion: statistically probably insignificant (combotherapy for patients not stratified by CCNE1 expression) yet weak additive efficacy and commercially insufficient (combotherapy discontinued) Classification: **True Negative (TN)**
1076	**ZN-c3 (azenosertib)** **NCTID: NCT05198804** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: Wee1 inhibitor** **Area: Neoplasms** **Indication: 2L advanced ovarian cancer** **Human Patients: 117** **Sponsor: Zentalis Pharmaceuticals (ZNTL)**	Date: 25 Jun 2024 Quarter: Q3'24 Batch 14 Technical: partial SUCCESS (statistically significant additive clinical benefit in patients with high CCNE1 expression) Commercial: overall FAILURE (commercially insufficient additive clinical benefit regardless of CCNE1 expression)	Readout: 29 Jan 2025 **Lead Time: 218 days in advance** Interpretation: azenosertib monotherapy 400mg QD5/2 achieved a 31.3% confirmed ORR (5/16) in CCNE1+ patients; azenosertib + niraparib hasn't met the efficacy threshold and further development discontinued	Correct Prediction Conclusion: statistically partially significant (monotherapy for CCNE1+ patients only) yet weak additive efficacy and commercially probably insufficient (combotherapy discontinued) Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
526	**Sirexatamab (DKN-01)** **NCTID: NCT05480306** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-DKK1 inhibitor** **Area: Neoplasms** **Indication: 2L MSS Colorectal Cancer** **Human Patients: 189** **Sponsor: Leap Therapeutics (LPTX)**	Date: 28 Apr 2024 Quarter: Q3'24 Batch 4 Technical: FAILURE (statistically maybe significant yet very weak additive clinical benefit to SoC in PFS) Commercial: FAILURE (commercially insufficient additive clinical benefit to SoC in OS)	Readout: 28 Jan 2025 **Lead Time: 275 days in advance** Interpretation: sirexatamab + bevacizumab + chemotherapy achieved a 12% delta in confirmed ORR (35% vs 23%); compared with bevacizumab + chemotherapy	Correct Prediction Conclusion: statistically maybe significant yet weak additive efficacy and commercially probably insufficient (weak additive ORR) Classification: **True Negative (TN)**
525	**Sirexatamab (DKN-01)** **NCTID: NCT04363801** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-DKK1 inhibitor** **Area: Neoplasms** **Indication: Gastric or Gastroesophageal Cancer** **Human Patients: 232** **Sponsor: Leap Therapeutics (LPTX)**	Date: 28 Apr 2024 Quarter: Q3'24 Batch 4 Technical: FAILURE (statistically maybe significant yet very weak additive clinical benefit to SoC in PFS) Commercial: FAILURE (commercially insufficient additive clinical benefit to SoC in OS)	Readout: 28 Jan 2025 **Lead Time: 275 days in advance** Interpretation: sirexatamab + tislelizumab + chemotherapy achieved a 3% delta in confirmed ORR (52% vs 49% in average) and -2.5 months delta in PFS (8.69 months in average vs 11.2 months in average) compared with tislelizumab + chemotherapy (though the median PFS for tislelizumab plus chemotherapy in the Phase 3 Rationale-305 study was 6.9 months (95% CI- 5.7; 7.2); further developments discontinued due to weak efficacy	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1717	**Enobosarm** **NCTID: NCT06282458** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: nonsteroidal selective androgen receptor modulator** **Area: Nutritional and Metabolic Diseaseses** **Indication: Muscle Loss Obesity** **Human Patients: 150** **Sponsor: Veru (VERU)**	Date: 13 Oct 2024 Quarter: Q1'25 Batch 1 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in lowering the reduction of total lean body mass with the toxicity of weakening muscle strength) Commercial: FAILURE (commercially insufficient additive clinical benefit with inferior-to-semaglutide reduction in total fat mass)	Readout: 27 Jan 2025 **Lead Time: 106 days in advance** Interpretation: Enobosarm achieved a placebo-adjusted 2.9% reduction of muscle loss (p=0.002) superior to semaglutide; yet a placebo-adjusted 2.3% improvement of fat loss (p=0.096) non-superior to semaglutide; and a placebo-adjusted 0.3kg less weight loss slightly inferior to semaglutide	Correct Prediction Conclusion: statistically significant and commercially maybe insufficient (weak efficacy) Classification: **True Negative (TN)**
1813	**AK006** **NCTID: NCT06072157** **Phase: Phase 1** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-SIGLEC6 inhibitor** **Area: Immune System Diseases** **Indication: Chronic Spontaneous Urticaria** **Human Patients: 136** **Sponsor: Allakos (ALLK)**	Date: 3 Nov 2024 Quarter: Q1'25 Batch 4 Technical: FAILURE (statistically insignifiant clinical benefit in UAS7/ISS7 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in UAS7/ISS7 inferior to barzolvolimab)	Readout: 27 Jan 2025 **Lead Time: 85 days in advance** Interpretation: AK006 failed to demonstrate therapeutic efficacy and further developments discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1851	**Semaglutide** **NCTID: NCT05646706** **Phase: Phase 3** **Class: Best-In-Class** **Modality: pepetide** **MoA: GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 1407** **Sponsor: Novo Nordisk (NVO)**	Date: 3 Dec 2024 Quarter: Q1'25 Batch 12 Technical: SUCCESS (statistically significant clinical benefit in overall/stratified weight reduction against placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in overall/stratified weight reduction superior to semaglutide 2.4mg; superior to tirzepatide; yet inferior to VK2735)	Readout: 17 Jan 2025 **Lead Time: 45 days in advance** Interpretation: semaglutide 7.2mg achieved 18.3% placebo-adjusted weight reduction at week 72; thus superior to 15.1% placebo-adjusted weight reduction at week 72 achieved by semaglutide 2.4mg (higher than 12.5% placebo-adjusted weight reduction at week 68 achieved by semaglutide 2.4mg in the pivotal trial DOI-10.1056/NEJMoa2032183); inferior to 20.1% placebo-adjusted weight reduction at week 72 achieved by tirzepatide	Correct Prediction Conclusion: statistically significant and commercially probably sufficient Classification: **True Positive (TP)**
921	**Emiltatug Ledadotin (XMT-1660)**	Date: 14 Apr 2024 Quarter: Q3'24 Batch 1	Readout: 10 Jan 2025 **Lead Time: 271 days in advance**	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT05377996 **Phase: Phase 1** **Class: First-In-Class** **Modality: antibody-drug conjugate (ADC)** **MoA: DAR-6 anti-B7-H4 ADC with an AF-HPA payload** **Area: Neoplasms** **Indication: Triple Negative Breast Cancer Breast Cancer Endometrial Cancer Ovarian Cancer Fallopian Tube Cancer Primary Peritoneal Cavity Cancer Adenoid Cystic Carcinoma** **Human Patients: 319** **Sponsor: Mersana Therapeutics (MRSN)**	Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit with high toxicity) Commercial: FAILURE (commercially insufficient clinical benefit in OS)	Interpretation: XMT1660 achieved 19% confirmed ORR for all B7-H4 high patients across all doses (11/57)	Conclusion: statistically maybe significant yet weak clinical efficacy (low ORR) and commercially probably insufficient Classification: **True Negative (TN)**
1264	**GH001** **NCTID: NCT05804708** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: psychedelic 5-MeO-DMT** **Area: Mental Disorders** **Indication: Postpartum Depression** **Human Patients: 10** **Sponsor: GH Research (GHRS)**	Date: 5 Jun 2024 Quarter: Q3'24 Batch 14 Technical: partial SUCCESS (statistically significant yet moderate clinical benefit) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate clinical benefit)	Readout: 10 Jan 2025 **Lead Time: 219 days in advance** Interpretation: GH001 achieved statistically significant of –35.4 points MADRS reduction at Day 8 ($p<0.0001$; placebo data not disclosed)	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient (pending placebo data disclosure to evaluate efficacy competitiveness) Classification: **True Positive (TP)**
1263	**GH001** **NCTID: NCT05839509** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: psychedelic 5-MeO-DMT** **Area: Mental Disorders** **Indication: Bipolar II Disorder** **Human Patients: 6** **Sponsor: GH Research (GHRS)**	Date: 5 Jun 2024 Quarter: Q3'24 Batch 14 Technical: partial SUCCESS (statistically significant yet moderate clinical benefit) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate clinical benefit)	Readout: 10 Jan 2025 **Lead Time: 219 days in advance** Interpretation: GH001 achieved statistically significant -16.8 points MADRS reduction at Day 8($p=0.0099$; superior to -8 points MADRS reduction at Day 8 achieved by quetiapine; though absolute MADRS reduction values are not directly comparable due to varying placebo effects especially for psychiatric disorders	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient (pending placebo data disclosure to evaluate efficacy competitiveness) Classification: **True Positive (TP)**
1808	**Imvotamab** **NCTID: NCT06524687** **Phase: Phase 1** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-CD3 anti-CD20 T-cell engager** **Area: Musculoskeletal Diseases** **Indication: Idiopathic Inflammatory Myopathies** **Human Patients: 2** **Sponsor: IGM Biosciences (IGMS)**	Date: 26 Oct 2024 Quarter: - Batch - Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in MMT8 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in MMT8)	Readout: 9 Jan 2025 **Lead Time: 75 days in advance** Interpretation: Imvotamab failed to demonstrate sufficient efficacy and further development discontinued accordingly	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1807	**Imvotamab** **NCTID: NCT06041568** **Phase: Phase 1** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-CD3 anti-CD20 T-cell engager** **Area: Immune System Diseases** **Indication: Severe Systemic Lupus Erythematosus** **Human Patients: 17** **Sponsor: IGM Biosciences (IGMS)**	Date: 26 Oct 2024 Quarter: - Batch - Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in BICLA/SRI4 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in BICLA/SRI4)	Readout: 9 Jan 2025 **Lead Time: 75 days in advance** Interpretation: Imvotamab failed to demonstrate sufficient efficacy and further development discontinued accordingly	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1806	**Imvotamab**	Date: 26 Oct 2024 Quarter: Q1'25 Batch 2	Readout: 9 Jan 2025 **Lead Time: 75 days in advance**	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT06087406 **Phase: Phase 1** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-CD3 anti-CD20 T-cell engager** **Area: Immune System Diseases** **Indication: Moderate to Severe Rheumatoid Arthritis** **Human Patients: 33** **Sponsor: IGM Biosciences (IGMS)**	Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in DAS28-CRP or ACR20 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in DAS28-CRP or ACR20)	Interpretation: Imvotamab failed to demonstrate sufficient efficacy and further development discontinued accordingly	Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1711	**Briquilimab** **NCTID: NCT06162728** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-cKIT mAb inhibitor** **Area: Immune System Diseases** **Indication: Chronic Spontaneous Urticaria** **Human Patients: 80** **Sponsor: Jasper Therapeutics (JSPR)**	Date: 31 Jul 2024 Quarter: Q3'24 Batch 21 Technical: SUCCESS (statistically significant clinical benefit in UAS7) Commercial: FAILURE (commercially insufficient clinical benefit in UAS7 inferior to barzolvolimab)	Readout: 8 Jan 2025 **Lead Time: 161 days in advance** Interpretation: briquilimab highest dose 180mg Q8W achieved 21% placebo-adjusted CR at week 12 vs. 31% placebo-adjusted CR at week 12 achieved by barzolvolimab highest dose in NCT05368285 vs 27% placebo-adjusted CR at week 12 achieved by omalizumab in ASTERIA I study (DOI-0.1038/jid.2014.306)	Correct Prediction Conclusion: statistically significant and commercially insufficient (inferior to both omalizumab an barzolvolimab) Classification: **True Negative (TN)**
1449	**daxdilimab** **NCTID: NCT05368103** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-ILT7 inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Alopecia Areata** **Human Patients: 30** **Sponsor: Amgen (AMGN)**	Date: 5 Feb 2024 Quarter: Q1'24 Batch 17 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 7 Jan 2025 **Lead Time: 337 days in advance** Interpretation: daxdilimab achieved 13.3% SALT20 response at week 24; which would be inferior to ritlecitinib that achieved 29.1% placebo-adjusted SALT20 response at week 24 (see the add'l link below); Further development has been discontinued	Correct Prediction Conclusion: statistically probably insignificant (no placebo arm) and commercially insufficient Classification: **True Negative (TN)**
1487	**DNL343** **NCTID: NCT05842941** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: transferrin-receptor-mediated BBB-crossing EIF2beta activator** **Area: Nervous System Diseases** **Indication: Amyotrophic Lateral Sclerosis** **Human Patients: 249** **Sponsor: Denali Therapeutics / AbbVie (DNLI / ABBV)**	Date: 27 Feb 2024 Quarter: Q4'24 Batch 2 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 6 Jan 2025 **Lead Time: 314 days in advance** Interpretation: DNL343 failed to achieve its primary efficacy endpoint	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1576	**Navacaprant (NMRA-335140)** **NCTID: NCT06029426** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: KOR antagonist** **Area: Mental Disorders** **Indication: Major Depressive Disorder** **Human Patients: 332** **Sponsor: Neumora Therapeutics (NMRA)**	Date: 14 Aug 2024 Quarter: Q4'24 Batch 2 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit non-superior non-inferior to aticaprant; yet inferior to lumateperone)	Readout: 2 Jan 2025 **Lead Time: 141 days in advance** Interpretation: navacaprant failed to meet the primary efficacy endpoint MADRS total score compared to placebo; non-superior to aticaprant that achieved borderline statistical significance in MADRS total score in phase 2 trial (p=0.044)	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1852	**Obexelimab** **NCTID: NCT05786573** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody**	Date: 4 Dec 2024 Quarter: Q1'25 Batch 12b Technical: partial SUCCESS (statistically significant yet weak clinical benefit in durable Hgb	Readout: 31 Dec 2024 **Lead Time: 27 days in advance** Interpretation: obexelimab achieved an increase of >1g/dL of haemoglobin in 62.5% patients at week 24; inferior	Correct Prediction Conclusion: statistically significant and commercially insufficient (inferior to rituximab)

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	MoA: bifunction monoclonal antibody targeting CD19 and activating FcgammaRIIb **Area: Hemic and Lymphatic Diseases** **Indication: Warm Autoimmune Hemolytic Anemia** **Human Patients: 134** **Sponsor: Zenas BioPharma (ZBIO)**	response against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in durable Hgb response inferior to rituximab)	to rituximab that achieved an increase of >1g/dL of haemoglobin in 100% patients at week 8 (see add'l link below); obexelimab discontinued further development	Classification: **True Negative (TN)**
898	**AXS-05** **NCTID: NCT05557409** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: NMDAR antagonist & sigma-1 receptor agonist** **Area: Nervous System Diseases** **Indication: Alzheimer's Disease Agitation** **Human Patients: 350** **Sponsor: Axsome Therapeutics (AXSM)**	Date: 6 Jul 2024 Quarter: Q3'24 Batch 13 Technical: SUCCESS (statistically significant clinical benefit in CMAI) Commercial: SUCCESS (commercially sufficient clinical benefit in CMAI definitely non-inferior to and maybe superior to brexpiprazole)	Readout: 30 Dec 2024 **Lead Time: 177 days in advance** Interpretation: AXS05 failed to meet any primary and secondary efficacy endpoints	Missed Prediction Note: due to suboptimal drug MoA modelling that has been permanently improved Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**
1514	**CagriSema** **NCTID: NCT06131437** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: combo amylin analog + GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 800** **Sponsor: Novo Nordisk (NVO)**	Date: 21 Aug 2024 Quarter: Q4'24 Batch 13 Technical: SUCCESS (statistically significant clinical benefit in weight reduction superior to tirzepatide yet non-superior to VK2735 for nondiabetic obese young population) Commercial: SUCCESS (commercially sufficient clinical benefit in total lean body mass preservation and total fat body mass reduction/change in waist circumference superior to tirzepatide yet non-superior to VK2735 for nondiabetic obese young population)	Readout: 20 Dec 2024 **Lead Time: 121 days in advance** Interpretation: CagriSema achieved 20.4% placebo-adjusted weight loss at week 68; which is superior to semaglutide that achieved 13.8% placebo-adjusted weight loss at week 68 and cagrilintide that achieved 9.5% placebo-adjsuted weight loss at week 68 as the active control arm; tirzepatide achieved 19.5% placebo-adjusted weight loss at week 68 (DOI- 10.1056/NEJMoa2206038); VK2735 achieved 13.1% placebo-adjusted weight loss at week 13 (see add'l link below); superior to tirzepatide's 7% placebo-adjusted weight loss at week 13 and probably superior to CagriSema's undisclosed (yet estimated to be 8-10%) placebo-adjusted weight loss at week 13	Correct Prediction Conclusion: statistically significant and commercially sufficient (numerically superior to tirzaptide yet probably non-superior to VK2735) Classification: **True Positive (TP)**
1517	**CagriSema** **NCTID: NCT05567796** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: combo amylin analog + GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 3400** **Sponsor: Novo Nordisk (NVO)**	Date: 24 Mar 2024 Quarter: Q3'24 Batch 18 Technical: SUCCESS (statistically significant clinical benefit in weight reduction) Commercial: SUCCESS (commercially sufficient clinical benefit with superior-to-semaglutide-and-cagrilintide efficacy weight reduction)	Readout: 20 Dec 2024 **Lead Time: 271 days in advance** Interpretation: CagriSema achieved 20.4% placebo-adjusted weight loss at week 68; which is superior to semaglutide that achieved 13.8% placebo-adjusted weight loss at week 68 and cagrilintide that achieved 9.5% placebo-adjsuted weight loss at week 68 as the active control arm; tirzepatide achieved 19.5% placebo-adjusted weight loss at week 68 (DOI- 10.1056/NEJMoa2206038); VK2735 achieved 13.1% placebo-adjusted weight loss at week 13 (see add'l link below); superior to tirzepatide's 7% placebo-adjusted weight loss at week 13 and probably superior to CagriSema's undisclosed (yet estimated to be 8-10%) placebo-adjusted weight loss at week 13	Correct Prediction Conclusion: statistically significant and commercially sufficient (numerically superior to tirzaptide yet probably non-superior to VK2735) Classification: **True Positive (TP)**
1744	**Belapectin** **NCTID: NCT04365868** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: small molecule**	Date: 10 Aug 2024 Quarter: Q4'24 Batch 6 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in esophageal	Readout: 20 Dec 2024 **Lead Time: 132 days in advance** Interpretation: belapectin failed to achieve statistical significance in the primary endpoint of esophageal	Correct Prediction Conclusion: statistically insignificant and commercially insufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	MoA: galectin-3 inhibitor **Area: Nutritional and Metabolic Diseases** **Indication: Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated Steatohepatitis (MASH)** **Human Patients: 357** **Sponsor: Galectin Therapeutics (GALT)**	varices prevention) Commercial: FAILURE (commercially insufficient clinical benefit in esophageal varices prevention inferior to beta blockers)	varices compared with placebo	Classification: **True Negative (TN)**
1390	**Dostarlimab (TSR-042)** **NCTID: NCT03602859** **Phase: Phase 3** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-PD1 mAb inhibitor** **Area: Neoplasms** **Indication: 1L combotherapy treatment for advanced ovarian cancer** **Human Patients: 1402** **Sponsor: GSK (GSK)**	Date: 15 Aug 2024 Quarter: Q4'24 Batch 7 Technical: SUCCESS (statistically significant additive clinical benefit in ORR/PFS) Commercial: FAILURE (commercially maybe sufficient yet very weak additive clinical benefit in OS)	Readout: 20 Dec 2024 **Lead Time: 127 days in advance** Interpretation: dostarlimab + SoC + niraparib +/ bevacizumab achieved statistical significance in PFS yet failed to achieve statistical significance in OS; compared with SoC + niraparib +/ bevacizumab	Correct Prediction Conclusion: statistically significant (PFS) and commercially insufficient (OS) Classification: **True Negative (TN)**
1485	**PYX106** **NCTID: NCT05718557** **Phase: Phase 1** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-SIGLEC-15 inhibitor** **Area: Neoplasms** **Indication: dvanced solid tumors** **Human Patients: 60** **Sponsor: Pyxis Oncology (PYXS)**	Date: 9 Apr 2024 Quarter: Q3'24 Batch 12 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in PFS/OS/ORR) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 19 Dec 2024 **Lead Time: 254 days in advance** Interpretation: PYX106 is safe yet probably ineffective (no ORR data disclosed for 45 patients) and its further development discontinued	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1694	**REGN9933** **NCTID: NCT05618808** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-Factor-XI inhibitor** **Area: Cardiovascular Diseases** **Indication: Venous thromboembolism (VTE)** **Human Patients: 373** **Sponsor: Regeneron Pharmaceuticals (REGN)**	Date: 22 Jul 2024 Quarter: Q3'24 Batch 19 Technical: partial SUCCESS (statistically significant clinical benefit in reduction of major bleeding incidence superior to enoxaparin/apixaban) partial FAILURE (statistically maybe insignificant clinical benefit in non-bleeding TEAE maybe inferior to enoxaparin/apixaban) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in reduction of venous thromboembolism incidence non-superior to enoxaparin/apixaban)	Readout: 19 Dec 2024 **Lead Time: 150 days in advance** Interpretation: REGN9933 achieved 17% VTE event rate; superior to enoxaparin's 21% VTE event rate yet inferior to apixaban's 12% VTE event rate; REGN9933 achieved 22% AE rate; inferior to enoxaparin's 21% AE rate yet superior to apixaban's 25% AE rate	Correct Prediction Conclusion: statistically significant and commercially insufficient (non-superior to enoxaparin/apixaban in a crowded market) Classification: **True Negative (TN)**
1854	**Suzetrigine (VX-548)** **NCTID: NCT06176196** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral Nav1.8/SCN10A inhibitor** **Area: Nervous System Diseases** **Indication: Painful Lumbosacral Radiculopathy** **Human Patients: 218** **Sponsor: Vertex Pharmaceuticals (VRTX)**	Date: 7 Dec 2024 Quarter: Q1'25 Batch 13 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in NPRS at week 12 against placebo) partial FAILURE (statistically insignificant clinical benefit in DSIS at week 12 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in NPRS/DSIS/TEAE non-superior to NSAIDs and inferior to epidural steroid injection)	Readout: 19 Dec 2024 **Lead Time: 12 days in advance** Interpretation: suzetrigine achieved non-superior-non-inferior-to-placebo efficacy in NPRS at week 12 (-2.02 vs -1.98 without disclosing p-value); DSIS data not disclosed	Correct Prediction Conclusion: statistically insignificant (NPRS) and commercially insufficient Classification: **True Negative (TN)**
1368	**Prasinezumab** **NCTID: NCT04777331** **Phase: Phase 2**	Date: 30 Nov 2023 Quarter: Q3'24 Batch 17 Technical: FAILURE (commercially	Readout: 19 Dec 2024 **Lead Time: 385 days in advance** Interpretation: prasinezumab failed to	Correct Prediction Conclusion: statistically insignificant and commercially

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: First-In-Class **Modality: monoclonal antibody** **MoA: anti-alpha-synuclein** **Area: Nervous System Diseases** **Indication: Early Parkinson's Disease** **Human Patients: 586** **Sponsor: Prothena / Roche (PRTA/ RHHBY)**	insufficient clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	meet any primary and secondary efficacy endpoints	insufficient Classification: **True Negative (TN)**
1708	**KB707** **NCTID: NCT06228326** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: intratumorally injected HSV1-delivered IL2 and IL12** **Area: Neoplasms** **Indication: advanced non-small cell lung cancer (NSCLC)** **Human Patients: 140** **Sponsor: Krystal Biotech (KRYS)**	Date: 31 Jul 2024 Quarter: Q3'24 Batch 21 Technical: partial SUCCESS (statistically maybe significant clinical benefit in ORR/PFS) Commercial: FAILURE (commercially insufficient clinical benefit in OS)	Readout: 18 Dec 2024 **Lead Time: 140 days in advance** Interpretation: KB707 achieved 27% confirmed ORR (6/33) for any advanced NSCLC patients; non-superior to pembrolizumab + ipilimumab that achieved 20-30% confirmed ORR for EGFRwt advanced NSCLC patients (10.1016/j.lungcan.2018.12.015) and inferior to osimertinib that achieved 71% ORR for EGFRmut advanced NSCLC patients (10.1056/NEJMoa1612674); OS data pending	Correct Prediction Conclusion: statistically significant yet weak (in ORR) and commercially probably insufficient (in ORR with OS data pending) Classification: **True Negative (TN)**
1619	**CT1812** **NCTID: NCT05225415** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: allosteric sigma-2 receptor antagonist** **Area: Nervous System Diseases** **Indication: Dementia With Lewy Bodies** **Human Patients: 130** **Sponsor: Cognition Therapeutics (CGTX)**	Date: 15 May 2024 Quarter: Q3'24 Batch 10 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit despite tolerable toxicity) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 18 Dec 2024 **Lead Time: 217 days in advance** Interpretation: CT1812 met the safety primary endpoint with trends only of cognitive/functional improvements	Correct Prediction Conclusion: statistically significant (safety) and commercially probably insufficient (efficacy) Classification: **True Negative (TN)**
1701	**duvakitug (TEV'574/SAR447189)** **NCTID: NCT05499130** **Phase: Phase 2** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-TL1A mAb inhibitor** **Area: Immune System Diseases** **Indication: Severe Ulcerative Colitis and Crohn's Disease** **Human Patients: 290** **Sponsor: Teva Pharmaceuticals / Sanofi (TEVA / SNY)**	Date: 27 Jul 2024 Quarter: Q4'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit in clinical remission and endoscopic response against placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in clinical remission and endoscopic response non-superior and non-inferior to PRA023)	Readout: 17 Dec 2024 **Lead Time: 143 days in advance** Interpretation: duvakitug (high-dose) achieved 27.4% placebo-adjusted clinical remission rate at week 14 (p=0.003) for UC patients; numerically superior to PRA023 that achieved 25% placebo-adjusted clinical remission rate at week 12 for UC patients; duvakitug (high-dose) achieved 34.8% placebo-adjusted clinical remission rate at week 14 (p<0.001) for CD patients; numerically superior to PRA023 that achieved 33.1% placebo-adjusted clinical remission rate at week 12 for CD patients (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
428	**AFM24** **NCTID: NCT05109442** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: EGFR x CD16A tetravalent NK cell engager** **Area: Neoplasms** **Indication: Selected Advanced/Metastatic EGFR-expressing Cancers** **Human Patients: 148** **Sponsor: Affimed (AFMD)**	Date: 29 Feb 2024 Quarter: Q2'24 Batch 9 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit for refractory/relapsed EGFRwt and EGFRmut solid tumors)	Readout: 17 Dec 2024 **Lead Time: 292 days in advance** Interpretation: FM24 + atezolizumab achieved 18% confirmed ORR (6/33) for EGFRwt advanced NSCLC patients; numerically inferior to pembrolizumab + ipilimumab that achieved 20-30% confirmed ORR (10.1016/j.lungcan.2018.12.015); AFM24 + atezolizumab achieved 24% confirmed ORR (4/17) for EGFRmut advanced NSCLC patients; inferior to osimertinib that achieved 71% ORR (10.1056/NEJMoa1612674)	Correct Prediction Conclusion: statistically significant yet weak (in ORR) and commercially insufficient Classification: **True Negative (TN)**
1129	**Lonapegsomatropin**	Date: 29 Aug 2024	Readout: 16 Dec 2024	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT05690386 **Phase: Phase 2** **Class: Best-In-Class** **Modality: peptide** **MoA: long-lasting growth hormone** **Area: Urogenital Diseases** **Indication: Turner Syndrome** **Human Patients: 48** **Sponsor: Ascendis Pharma (ASND)**	Quarter: Q4'24 Batch 15 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to daily somatropin)	**Lead Time: 109 days in advance** Interpretation: lonapegsomatropin met the primary endpoint of annualized height velocity at week 26; similar to daily somatropin	Conclusion: statistically significant and commercially probably sufficient Classification: **True Positive (TP)**
1567	**minzasolmin (UCB0599)** **NCTID: NCT04658186** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: ASYN-misfolding inhibitor** **Area: Nervous System Diseases** **Indication: Early-stage Parkinson's Disease** **Human Patients: 496** **Sponsor: UCB Biopharma (UCB)**	Date: 26 Apr 2024 Quarter: Q4'24 Batch 7 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit in MDS-UPDRS) Commercial: FAILURE (commercially insufficient clinical benefit with inferior-to-levodopa efficacy in MDS-UPDRS)	Readout: 16 Dec 2024 **Lead Time: 234 days in advance** Interpretation: minzasolmin failed to meet any primary and secondary efficacy endpoints	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1719	**LYT100** **NCTID: NCT05321420** **Phase: Phase 2** **Class: Best-In-Class** **Modality: deuterated formulation** **MoA: a deuterated form of pirfenidone** **Area: Respiratory Tract Diseases** **Indication: Idiopathic Pulmonary Fibrosis** **Human Patients: 240** **Sponsor: PureTech (PRTC)**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 3 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in FVC against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in FVC inferior to pirfenidone)	Readout: 16 Dec 2024 **Lead Time: 132 days in advance** Interpretation: LYT100 550mg TID (equivalent to the approved pirfenidone 801 mg TID) achieved a 1.62% placebo-adjusted improvement in FVCpp; at least numerically inferior to the SoC (pirfenidone 801mg TID) that achieved a 1.97% placebo-adjusted improvement in FVCpp	Correct Prediction Conclusion: statistically significant yet weak (in FVCpp) and commercially insufficient (inferior to pirfenidone); Classification: **True Negative (TN)**
1251	**Sevasemten (EDG-5506)** **NCTID: NCT05291091** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral selective fast skeletal muscle myosin inhibitor** **Area: Musculoskeletal Diseases** **Indication: Becker Muscular Dystrophy** **Human Patients: 170** **Sponsor: Edgewise Therapeutics (EWTX)**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 2 Technical: SUCCESS (statistically significant clinical benefit in TNNI2) Commercial: FAILURE (commercially insufficient clinical benefit in either NSAA or 6MWD)	Readout: 16 Dec 2024 **Lead Time: 132 days in advance** Interpretation: sevasemten achieved 77% reduction in plasma TNNI2 ($p<0.001$); sevasemten failed to achieved statistically significant improvement in NSAA ($p=0.16$).	Correct Prediction Conclusion: statistically significant (TNNI2) and commercially insufficient (NSAA) Classification: **True Negative (TN)**
1467	**veligrotug (VRDN-001)** **NCTID: NCT06021054** **Phase: Phase 3** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-IGF1R mAb inhibitor** **Area: Eye Diseases** **Indication: Chronic Thyroid Eye Disease** **Human Patients: 188** **Sponsor: Viridian Therapeutics (VRDN)**	Date: 14 Feb 2024 Quarter: Q4'24 Batch 2 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially sufficient clinical benefit non-superior to Tepezza)	Readout: 16 Dec 2024 **Lead Time: 306 days in advance** Interpretation: veligrotug achieved 48% placebo-adjusted PRR at week 15; non-superior to teprotumumab (Tepezza) that achieved 65% placebo-adjusted PRR at week 15 (DOI-10.1056/NEJMoa1910434); veligrotug further achieved 31% placebo-adjusted diplopia responder rate at week 15 ($p=0.0006$); non-superior to teprotumumab that achieved 48% placebo-adjusted diplopia responder rate at week 15 (DOI-10.1056/NEJMoa1910434)	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient (non-superior to teprotumumab) Classification: **True Positive (TP)**
1409	**CTI-1601** **NCTID: NCT05579691** **Phase: Phase 2** **Class: First-In-Class**	Date: 7 Jan 2024 Quarter: Q1'24 Batch 14 Technical: partial SUCCESS (statistically significant yet weak	Readout: 16 Dec 2024 **Lead Time: 344 days in advance** Interpretation: nomlabofusp achieved early trends yet very weak	Correct Prediction Conclusion: statistically maybe significant yet weak (mFARS) and commercially probably insufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Modality: fusion protein biologic **MoA: TAT-delivered FXN recombinant fusion protein** **Area: Nervous System Diseases** **Indication: Friedreich Ataxia** **Human Patients: 28** **Sponsor: Larimar Therapeutics (LRMR)**	clinical benefit due to TAT delivery) Commercial: FAILURE (commercially insufficient clinical benefit inferior to omaveloxolone)	improvements in mFARS	Classification: **True Negative (TN)**
1421	**Palbociclib** **NCTID: NCT02947685** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: CDK4/6 inhibitor** **Area: Neoplasms** **Indication: HR+/HER2+ advanced breast cancer** **Human Patients: 496** **Sponsor: Pfizer (PFE)**	Date: 15 Jan 2024 Quarter: Q1'24 Batch 15 Technical: partial SUCCESS (statistically significant additive clinical benefit in PFS but not in OS) Commercial: partial SUCCESS (commercially sufficient yet limited additive clinical benefit in PFS but not in OS)	Readout: 13 Dec 2024 **Lead Time: 333 days in advance** Interpretation: palbociclib + anti-HER2 therapy + endocrine therapy achieved 44.3 months mPFS; superior to anti-HER2 therapy + endocrine therapy that achieved 29.1 months mPFS (p=0.0074); OS analysis remains inmature yet palbociclib's improvement in 5-year survival rate is small (74.3% vs 69.8% HR 0.86; 95% CI)	Correct Prediction Conclusion: statistically significant (in PFS) and commercially TBD (wait for OS data) Classification: **True Positive (TP)**
1770	**BBI-825** **NCTID: NCT06299761** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: RNR inhibitor** **Area: Neoplasms** **Indication: advanced solid tumours with resistance oncogene amplifications** **Human Patients: 42** **Sponsor: Boundless Bio (BOLD)**	Date: 29 Aug 2024 Quarter: - Batch - Technical: FAILURE (statistically insignificant clinical benefit in ORR/PFS) Commercial: FAILURE (commercially insufficient clinical benefit in OS)	Readout: 12 Dec 2024 **Lead Time: 105 days in advance** Interpretation: BBI825's further development has been discontinued due to insufficient benefit-risk profile	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1451	**INCB000928** **NCTID: NCT04455841** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: anti-ALK2/ACVR1 inhibitor** **Area: Hemic and Lymphatic Diseases** **Indication: Anemia Due to Myeloproliferative Disorders** **Human Patients: 84** **Sponsor: Incyte Corporation (INCY)**	Date: 6 Feb 2024 Quarter: Q1'24 Batch 17 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in anemia response) partial FAILURE (statistically insignificant additive clinical benefit in PFS) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 12 Dec 2024 **Lead Time: 310 days in advance** Interpretation: INCB000928 + ruxolitinib failed to improve anemia in MF patients	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
851	**lunresertib (RP-6306) and camonsertib (RP-3500)** **NCTID: NCT04855656** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: PKMYT1 inhibitor and ATR inhibitor** **Area: Neoplasms** **Indication: Advanced Solid Tumors** **Human Patients: 364** **Sponsor: Repare Therapeutics (RPTX)**	Date: 18 Jan 2023 Quarter: 1H'23 Batch 1 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 12 Dec 2024 **Lead Time: 694 days in advance** Interpretation: lunresertib + camonsertib achieved 18.5% confirmed ORR (5/27) for endometrial cancer; which is non-superior to pembrolizumab + lenvatinib that achieved 38% ORR (DOI-10.6004/jadpro.2022.13.1.4); lunresertib + camonsertib achieved 16.7% confirmed ORR (4/24) for platinum-resistant ovarian cancer; which is inferior to chemotherapy + bevacizumab that achieved 27.3% ORR	Correct Prediction Conclusion: statistically maybe significant yet weak (in ORR) and commercially insufficient (in ORR) Classification: **True Negative (TN)**
1243	**EDIT-301** **NCTID: NCT05444894** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: cell therapy** **MoA: AsCas12a-mediated HBG1-HBG2-promoter-deletion CD34+ autologous**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 4 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially insufficient clinical benefit non-superior to Casgevy)	Readout: 12 Dec 2024 **Lead Time: 302 days in advance** Interpretation: EDIT301's further development discontinued without a commercial partner	Correct Prediction Conclusion: statistical significance undisclosed and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	hematopoietic stem and progenitor cell therapy **Area: Hemic and Lymphatic Diseases** **Indication: Transfusion-Dependent Beta Thalassemia** **Human Patients: 9** **Sponsor: Editas Medicine (EDIT)**			
1242	**EDIT-301** **NCTID: NCT04853576** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: cell therapy** **MoA: AsCas12a-mediated HBG1-HBG2-promoter-deletion CD34+ autologous hematopoietic stem and progenitor cell therapy** **Area: Hemic and Lymphatic Diseases** **Indication: severe sickle cell disease** **Human Patients: 45** **Sponsor: Editas Medicine (EDIT)**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 4 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially insufficient clinical benefit non-superior to Casgevy)	Readout: 12 Dec 2024 **Lead Time: 302 days in advance** Interpretation: EDIT301's further development discontinued without a commercial partner	Correct Prediction Conclusion: statistical significance undisclosed and commercially insufficient Classification: **True Negative (TN)**
1706	**Nebulization (KB408)** **NCTID: NCT06049082** **Phase: Phase 1** **Class: First-In-Class** **Modality: inhaled formulation** **MoA: inhaled replication-defective HSV1-delivered SERPINA1** **Area: Cardiovascular Diseases and Nutritional and Metabolic Diseases** **Indication: Alpha 1-Antitrypsin Deficiency (AATD)** **Human Patients: 12** **Sponsor: Krystal Biotech (KRYS)**	Date: 31 Jul 2024 Quarter: Q3'24 Batch 21 Technical: partial SUCCESS (statistically significant clinical benefit in lung AAT concentration) partial FAILURE (statistically insignificant clinical benefit in lung NE level) Commercial: FAILURE (commercially insufficient clinical benefit in FEV1)	Readout: 12 Dec 2024 **Lead Time: 134 days in advance** Interpretation: KB408 achieved 5.3-9.7 micromolar mean total AAT protein; inferior to the 10.8 micromolar mean total AAT protein achieved by WVE006	Correct Prediction Conclusion: statistically significant (AAT concentration) and commercially TBD (wait for FEV1 data) Classification: **True Positive (TP)**
551	**Dazucorilant** **NCTID: NCT05407324** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: lipid selective glucocorticoid receptor antagonist** **Area: Nervous System Diseases** **Indication: Amyotrophic Lateral Sclerosis (ALS)** **Human Patients: 249** **Sponsor: Corcept Therapeutics (CORT)**	Date: 14 Apr 2024 Quarter: Q4'24 Batch 9 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 11 Dec 2024 **Lead Time: 241 days in advance** Interpretation: dazucorilant failed to achieve its primary efficacy endpoint	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1387	**ANB032** **NCTID: NCT05935085** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-BTLA mAb agonist** **Area: Skin and Connective Tissue Diseases** **Indication: Atopic Dermatitis** **Human Patients: 160** **Sponsor: AnaptysBio (ANAB)**	Date: 30 Aug 2024 Quarter: Q4'24 Batch 15 Technical: partial SUCCESS (statistically significant yet weak clinical benefit in EASI75) Commercial: FAILURE (commercially insufficient clinical benefit in EASI75 non-superior to dupilumab inferior to upadacitinib/NM26)	Readout: 11 Dec 2024 **Lead Time: 103 days in advance** Interpretation: ANB032 failed to achieve achieved statistical significance in placebo-adjusted EASI75 at week 14	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1686	**Imlunestrant**	Date: 17 Jul 2024 Quarter: Q3'24 Batch 18	Readout: 11 Dec 2024 **Lead Time: 147 days in advance**	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT04975308 **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: oral next-gen SERD** **Area: Neoplasms** **Indication: 2L HR+/HER2- Metastatic Breast Cancer** **Human Patients: 866** **Sponsor: Eli Lilly and Company (LLY)**	Technical: partial SUCCESS (statistically significant clinical benefit in PFS/OS non-superior non-inferior to fulvestrant/exemestane) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in combination with abemaciclib as all-oral regimens; despite non-superior efficacy in PFS/OS compared with fulvestrant/exemestane + abemaciclib)	Interpretation: imlunestrant + SoC failed to achieve statistical significance in PFS compared with SoC alone in all patients (5.6 months vs 5.5 months; p=0.12); imlunestrant + abemaciclib achieved statistical significance in PFS compared with imlunestrant alone in all patients (9.4 months vs 5.5 months p<0.001); OS data immature	Conclusion: partially statistically insignificant (monotherapy in PFS) and partially statistically significant (combotherapy in PFS) and commercially TBD (wait for OS data) Classification: **True Positive (TP)**
420	**CAN2409** **NCTID: NCT02768363** **Phase: Phase 2** **Class: First-In-Class** **Modality: oncolytic viral gene therapy** **MoA: AAV-mediated intratumoral delivery of HSV-TK as an oncolytic viral therapy** **Area: Neoplasms** **Indication: newly diagnosed prostate cancer** **Human Patients: 187** **Sponsor: Candel Therapeutics (CADL)**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 4 Technical: FAILURE (statistically insignificant clinical benefit in PFS) Commercial: FAILURE (commercially insufficient clinical benefit in OS)	Readout: 11 Dec 2024 **Lead Time: 127 days in advance** Interpretation: CAN2409 failed achieved statistically significance in DFS	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
421	**CAN2409** **NCTID: NCT01436968** **Phase: Phase 3** **Class: First-In-Class** **Modality: oncolytic viral gene therapy** **MoA: AAV-mediated intratumoral delivery of HSV-TK as an oncolytic viral therapy** **Area: Neoplasms** **Indication: localized prostate cancer** **Human Patients: 711** **Sponsor: Candel Therapeutics (CADL)**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 4 Technical: FAILURE (statistically insignificant additive clinical benefit in DFS) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS)	Readout: 11 Dec 2024 **Lead Time: 127 days in advance** Interpretation: CAN2409 + RT achieved statistically significant 14.5% relative improvement in DFS at month 54 (not the prespecified month 60) over RT alone (p=0.0155); CAN2409 + RT probably failed to achieve statistical significance in OS improvement (no mentioning of OS data in the topline readout)	Correct Prediction Conclusion: statistically significant yet weak (borderline for DFS) and commercially insufficient (for OS) Classification: **True Negative (TN)**
1187	**izokibep** **NCTID: NCT05384249** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small protein scaffold-based biologic** **MoA: IL-17A Inhibitior** **Area: Eye Diseases** **Indication: uveitis** **Human Patients: 96** **Sponsor: ACELYRIN (SLRN)**	Date: 7 Dec 2024 Quarter: Q1'25 Batch 13 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in time to treatment failure and BCVA compared with corticosteroids alone) Commercial: FAILURE (commercially insufficient additive clinical benefit in time to treatment failure and BCVA inferior to adalimumab + corticosteroids)	Readout: 10 Dec 2024 **Lead Time: 3 days in advance** Interpretation: izokibep failed to achieve statistical significance in the primary efficacy endpoint of time to treatment failure and secondary efficacy endpoint BCVA	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1716	**Bempikibart (ADX-914)** **NCTID: NCT06018428** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-IL7Ralpha mAb inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Severe Alopecia Areata** **Human Patients: 40** **Sponsor: Q32 Bio (QTTB)**	Date: 14 Aug 2024 Quarter: Q4'24 Batch 1 Technical: FAILURE (statistically insignificant clinical benefit in SALT score against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in SALT score inferior to baricitinib)	Readout: 10 Dec 2024 **Lead Time: 118 days in advance** Interpretation: bempikibart probably failed to achieve statistical significance in the primary efficacy endpoint SALT score at week 24 (16% vs 2% placebo with a p=0.045 after excluding three placebo patients)	Correct Prediction Conclusion: statistically probably significant and commercially probably insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1715	**Bempikibart (ADX-914)** **NCTID: NCT05509023** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-IL7Ralpha mAb inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Atopic Dermatitis** **Human Patients: 102** **Sponsor: Q32 Bio (QTTB)**	Date: 14 Aug 2024 Quarter: Q4'24 Batch 1 Technical: FAILURE (statistically insignificant clinical benefit in EASI75 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in EASI75 inferior to dupilumab)	Readout: 10 Dec 2024 **Lead Time: 118 days in advance** Interpretation: bempikibart failed to achieve statistical significance in the primary efficacy endpoint EASI at week 14	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
913	**Tildacerfont** **NCTID: NCT04544410** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: CRF1R antagonist** **Area: Urogenital Diseases** **Indication: Adult Congenital Adrenal Hyperplasia (CAH)** **Human Patients: 90** **Sponsor: Spruce Biosciences (SPRB)**	Date: 30 Nov 2023 Quarter: - Batch - Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 10 Dec 2024 **Lead Time: 376 days in advance** Interpretation: ildacerfont did not achieve statistical significance in GC level reduction	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
912	**Tildacerfont** **NCTID: NCT05128942** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: CRF1R antagonist** **Area: Urogenital Diseases** **Indication: pediatric Congenital Adrenal Hyperplasia (CAH)** **Human Patients: 70** **Sponsor: Spruce Biosciences (SPRB)**	Date: 30 Nov 2023 Quarter: Q1'24 Batch 5 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 10 Dec 2024 **Lead Time: 376 days in advance** Interpretation: tildacerfont did not achieve statistical significance in A4/GC level reduction	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1012	**Obicetrapib** **NCTID: NCT05142722** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: selective CETP inhibitor** **Area: Nutritional and Metabolic Diseases** **Indication: Atherosclerotic Cardiovascular Disease (ASCVD) / Heterozygous familial hypercholesterolemia (HeFH)** **Human Patients: 2532** **Sponsor: NewAmsterdam Pharma (NAMS)**	Date: 12 May 2024 Quarter: Q4'24 Batch 10 Technical: FAILURE (statistically insignificant additive clinical benefit of obicetrapib in MACE or cardiovascular hospitalization with significantly increased toxicity-driven mortality) Commercial: FAILURE (commercially insufficient additive clinical benefit of obicetrapib in MACE or cardiovascular hospitalization with significantly increased toxicity-driven mortality)	Readout: 10 Dec 2024 **Lead Time: 212 days in advance** Interpretation: obicetrapib + SoC did not achieve statistical significance in MACE reduction compared with SoC alone (0.79 HR)	Correct Prediction Conclusion: statistically insignificant (insignificant MACE reduction benefit) and commercially insufficient (insufficient MACE reduction benefit) Classification: **True Negative (TN)**
522	**Palazestrant (OP-125)** **NCTID: NCT05508906** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: CERAN and SERD** **Area: Neoplasms** **Indication: 2L treatment for HR+/HER2- Metastatic Breast Cancer** **Human Patients: 155** **Sponsor: Olema Pharmaceuticals (OLMA)**	Date: 18 Jun 2023 Quarter: 2H'23 Batch 6 Technical: partial SUCCESS (statistically significant additive clinical benefit for OP-1250 + ribociclib) partial FAILURE (statistically insignificant additive clinical benefit for OP-1250 + alpelisib) Commercial: partial SUCCESS (commercially sufficient additive clinical benefit for OP-1250 + ribociclib) partial FAILURE (commercially insufficient additive clinical benefit for OP-1250 + alpelisib)	Readout: 10 Dec 2024 **Lead Time: 541 days in advance** Interpretation: palazestrant + ribociclib achieved 27% ORR (10/37); superior to both sacituzumab govitecan's 21% ORR and chemotherapy's 14% ORR (see add'l link below); no data disclosed for OP-1250 + alpelisib	Correct Prediction Conclusion: statistically significant and commercially TBD (wait for OS data) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1762	**Neflamapimod** **NCTID: NCT05869669** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: p38alpha inhibitor** **Area: Nervous System Diseases** **Indication: Dementia With Lewy Bodies** **Human Patients: 160** **Sponsor: CervoMed (CRVO)**	Date: 19 Aug 2024 Quarter: Q4'24 Batch 12 Technical: partial FAILURE (statistically maybe significant yet very weak additive clinical benefit in CDR-SB) Commercial: FAILURE (commercially insufficient additive clinical benefit in MSD-UPDRS3)	Readout: 10 Dec 2024 **Lead Time: 113 days in advance** Interpretation: neflamapimod failed to meet the primary efficacy endpoint CDR-SB; no data disclosed for MSD-UPDRS3	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1490	**AFM28** **NCTID: NCT05817058** **Phase: Phase 1** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: CD123 x CD16A tetravalent NK cell engager** **Area: Neoplasms** **Indication: Relapsed/ Acute Myeloid Leukemia** **Human Patients: 30** **Sponsor: Affimed (AFMD)**	Date: 29 Feb 2024 Quarter: Q2'24 Batch 9 Technical: FAILURE (statistically insignificant clinical benefit in ORR/CR) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 9 Dec 2024 **Lead Time: 284 days in advance** Interpretation: AFM28 achieved 31% CR/CRi (5/16 for 250mg and 300mg); inferior to SoC that achieved 69% CR/CRi (see add'l link below)	Correct Prediction Conclusion: statistically maybe significant and commercially insufficient Classification: **True Negative (TN)**
1550	**R906289 Monosodium (R289 Na)** **NCTID: NCT05308264** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: IRAK1/IRAK4 inhibitor** **Area: Neoplasms** **Indication: R/R Lower-risk Myelodysplastic Syndromes (LR MDS) that have exhausted all the other treatment options** **Human Patients: 34** **Sponsor: Rigel Pharmaceuticals (RIGL)**	Date: 15 Apr 2024 Quarter: Q4'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 9 Dec 2024 **Lead Time: 238 days in advance** Interpretation: R289 achieved 40% hematologic responses (4 mg QD) and 30% RBC-TI mg QD) for 8 week and 1 Grade3 AST/Grade4 ALT TEAE	Correct Prediction Conclusion: statistically significant and commercially TBD (wait for OS data) Classification: **True Positive (TP)**
1456	**Tavapadon** **NCTID: NCT04223193** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: a selective D1R/D5R partial agonist** **Area: Nervous System Diseases** **Indication: early Parkinson's Disease** **Human Patients: 304** **Sponsor: AbbVie (ABBV)**	Date: 14 Feb 2024 Quarter: Q3'24 Batch 8 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially sufficient additive clinical benefit superior to levodopa for patients who receive tavapadon + MAOB inhibitor combotherapy) partial FAILURE (commercially insufficient clinical benefit non-superior to levodopa for patients who receive tavapadon monotherapy)	Readout: 9 Dec 2024 **Lead Time: 299 days in advance** Interpretation: tavapadon monotherapy achieved -9.1 improvement (p< 0.0001) in MDS-UPDRS Parts II and III combined score at week 26; non-superior to -10.2 improvement in MDS-UPDRS total score achieved by Levodopa at week 26 (no data announced for tavapadon + MAOA combotherapy)	Correct Prediction Conclusion: statistically significant and commercially insufficient (as monotherapy) Classification: **True Negative (TN)**
1038	**zelicapavir (EDP-938)** **NCTID: NCT04816721** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: RSV nucleoprotein inhibitor** **Area: Infections** **Indication: respiratory syncytial virus (RSV)** **Human Patients: 96** **Sponsor: Enanta Pharmaceuticals (ENTA)**	Date: 10 May 2024 Quarter: Q3'24 Batch 4 Technical: SUCCESS (statistically significant yet moderate clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit with non-superior-to-palivizumab efficacy)	Readout: 9 Dec 2024 **Lead Time: 213 days in advance** Interpretation: zelicapavir achieved statistical significance in primary and secondary virology endpoints compared with placebo (peak 0.7-1.4 log viral load decline compared with placebo); no efficacy endpoint data has been disclosed.	Correct Prediction Conclusion: statistically significant and commercially TBD (wait for efficacy data) Classification: **True Positive (TP)**
1679	**REL-1017** **NCTID: NCT06011577**	Date: 14 Jul 2024 Quarter: Q3'24 Batch 17	Readout: 9 Dec 2024 **Lead Time: 148 days in advance**	Correct Prediction Conclusion: statistically

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 3 **Class: First-In-Class** **Modality: small molecule** **MoA: GLUN1-GLUN2D antagonist** **Area: Mental Disorders** **Indication: major depressive disorder (MDD)** **Human Patients: 340** **Sponsor: Relmada Therapeutic (RLMD)**	Technical: FAILURE (statistically insufficient additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Interpretation: REL-1017 will be discontinued for lack of efficacy	insignificant and commercially insufficient Classification: **True Negative (TN)**
1739	**Anitocabtagene-autoleucel** **NCTID: NCT05396885** **Phase: Phase 2** **Class: First-In-Class** **Modality: CAR-T therapy** **MoA: anti-BCMA D-Domain CAR-T cell therapy** **Area: Neoplasms** **Indication: Relapsed or Refractory Multiple Myeloma** **Human Patients: 110** **Sponsor: Arcellx (ACLX)**	Date: 10 Aug 2024 Quarter: Q4'24 Batch 6 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS non-superior to Carvykti) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in CR/OS non-superior to Carvykti)	Readout: 9 Dec 2024 **Lead Time: 121 days in advance** Interpretation: anito-cell achieved 97% ORR and 62% CR/sCR; non-superior to Carvykti that achieved 98% ORR and 67% sCR	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient (non-superior to Carvykti) Classification: **True Negative (TN)**
1111	**Mitapivat** **NCTID: NCT04770779** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: small molecule PKR activator** **Area: Hemic and Lymphatic Diseases** **Indication: Transfusion-Dependent Alpha- or Beta-Thalassemia (±- c** **Human Patients: 258** **Sponsor: Agios Pharmaceuticals (AGIO)**	Date: 14 Nov 2023 Quarter: Q2'24 Batch 2 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 8 Dec 2024 **Lead Time: 390 days in advance** Interpretation: all endpoints met with 30.4% of patients achieved a transfusion reduction response (50% reduction during any 12-week period); compared to 12.6% of patients in the placebo arm with 2-sided p= 0.0003 (vs 50% achieved by Reblozyl in phase 3 BELIEVE trial NCT02604433) hepatocellular toxicity identified as a potential risk	Overall Correct Prediction Conclusion: statistically significant yet commercially insufficient Classification: **True Negative (TN)**
1685	**tirzepatide** **NCTID: NCT05822830** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: GLP1R/GIPR-biased dual agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 700** **Sponsor: Eli Lilly and Company (LLY)**	Date: 17 Jul 2024 Quarter: Q3'24 Batch 18 Technical: SUCCESS (statistically significant clinical benefit in overall weight reduction superior to semaglutide) Commercial: SUCCESS (commercially sufficient clinical benefit in stratified weight reduction superior to semaglutide)	Readout: 4 Dec 2024 **Lead Time: 140 days in advance** Interpretation: tirzepatide achieved 20.2% weight loss at week 72; which is superior to semaglutide that achieved 13.7% weight loss at week 72 as the active control arm; tirzepatide achieved superiority over semaglutide in all the five key secondary endpoints (e.g. 31.6% of people taking tirzepatide achieved at least 25% body weight loss compared to 16.1% of those taking semaglutide)	Correct Prediction Conclusion: statistically significant (weight loss) and commercially sufficient (superior to semaglutide's efficacy) Classification: **True Positive (TP)**
383	**REL-1017** **NCTID: NCT04855747** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: GLUN1-GLUN2D antagonist** **Area: Mental Disorders** **Indication: Major Depressive Disorder Depression (MDD)** **Human Patients: 340** **Sponsor: Relmada Therapeutics (RLMD)**	Date: 14 Jul 2024 Quarter: Q3'24 Batch 17 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 4 Dec 2024 **Lead Time: 143 days in advance** Interpretation: REL-1017 is found unlikely to meet the primary efficacy endpoint of adding significant clinical benefit in MADRS10 score	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1763	**Namilumab** **NCTID: NCT05314517**	Date: 21 Aug 2024 Quarter: Q4'24 Batch 13	Readout: 3 Dec 2024 **Lead Time: 104 days in advance**	Correct Prediction Conclusion: statistically

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 2 **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-GM-CSF mAb inhibitor** **Area: Respiratory Tract Diseases** **Indication: Chronic Pulmonary Sarcoidosis** **Human Patients: 107** **Sponsor: Roivant Sciences (ROIV)**	Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in sarcoidosis worsening against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in sarcoidosis worsening inferior to oral corticosteroid)	Interpretation: namilumab failed to achieve the primary efficacy endpoint	insignificant and commercially insufficient Classification: **True Negative (TN)**
1175	**RMC-6236** **NCTID: NCT05379985** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: tri-complex RAS(ON) multi-selective inhibitor** **Area: Neoplasms** **Indication: RAS Mutant Advanced Solid Tumors** **Human Patients: 614** **Sponsor: Revolution Medicines (RVMD)**	Date: 16 Jul 2023 Quarter: 2H'23 Batch 11 Technical: - Commercial: FAILURE (commercially insufficient clinical benefit non-superior to RAS(OFF) inhibitors)	Readout: 2 Dec 2024 **Lead Time: 505 days in advance** Interpretation: RMC6236 achieved 9% ORR (9% ORR is low and probably non-superior to KRAS(OFF) G12C inhibitors)	Correct Prediction Conclusion: statistically maybe significant and commercially probably insufficient Classification: **True Negative (TN)**
1176	**RMC-6291** **NCTID: NCT05462717** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: tri-complex RAS(ON) multi-selective inhibitor** **Area: Neoplasms** **Indication: Colorectal Cancer (CRC) patients previously treated with KRAS(OFF) G12C inhibitors** **Human Patients: 222** **Sponsor: Revolution Medicines (RVMD)**	Date: 16 Jul 2023 Quarter: 2H'23 Batch 11 Technical: - Commercial: FAILURE (commercially insufficient clinical benefit non-superior to RAS(OFF) inhibitors)	Readout: 2 Dec 2024 **Lead Time: 505 days in advance** Interpretation: RMC6291 achieved 0% ORR (0% ORR means non-superior to KRAS(OFF) G12C inhibitors)	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
985	**NovoTTF-200T** **NCTID: NCT03377491** **Phase: Phase 3** **Class: First-In-Class** **Modality: medical device** **MoA: a device delivering low-intensity; wave-like; alternating electric fields to tumor sites** **Area: Neoplasms** **Indication: Pancreatic Cancer** **Human Patients: 571** **Sponsor: Novocure (NVCR)**	Date: 21 Aug 2024 Quarter: Q4'24 Batch 13 Technical: FAILURE (statistically maybe significant yet very weak additive clinical benefit in PFS) Commercial: partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in OS)	Readout: 2 Dec 2024 **Lead Time: 103 days in advance** Interpretation: TTFields + SoC achieved 16.20 months mOS compared with 14.16 months in patients who received SoC alone (p=0.039); no PFS data announced in topline readout (usually indicating unremarkable PFS data)	Correct Prediction Conclusion: statistically significant (PFS data pending) and commercially sufficient (weakly superior OS) Classification: **True Positive (TP)**
1669	**JANX007** **NCTID: NCT05519449** **Phase: Phase 1** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-PSMA/CD3 protease-activated albumin-binding TCE** **Area: Neoplasms** **Indication: Metastatic Castration-Resistant Prostate Cancer (mCRPC)** **Human Patients: 105** **Sponsor: Janux Therapeutics (JANX)**	Date: 9 Jul 2024 Quarter: Q3'24 Batch 15 Technical: SUCCESS (statistically significant yet weak clinical benefit in ORR/PFS/rPFS against placebo) Commercial: partial FAILURE (commercially insufficient clinical benefit in ORR/PFS/rPFS inferior to Pluvicto) partial SUCCESS (commercially maybe sufficient yet weak clinical benefit in OS maybe superior to Pluvicto)	Readout: 2 Dec 2024 **Lead Time: 146 days in advance** Interpretation: JANX007 achieved 7.4 months PFS (median 5L); which is inferior to 8.5months PFS achieved by Lu-117-PSMA-617 + SoC (median 3L); JANX007 probably achieved 25% confirmed ORR (2/8; inferred from the reported 50% ORR that glossed over the number of confirmed and unconfirmed responses); which is inferior to 30% ORR achieved by Lu-117-PSMA-617 + SoC (median 3L)	Correct Prediction Conclusion: statistically significant yet weak and commercially TBD (wait for OS data) Classification: **True Negative (TN)**
1442	**MariTide (AMG133)**	Date: 3 Feb 2024	Readout: 26 Nov 2024	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT05669599 **Phase: Phase 2** **Class: First-In-Class** **Modality: antibody fragment biologic** **MoA: antibody-peptide conjugate that activates GLP1R via peptide and inhibits GIPR via antibody** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity Overweight Type 2 Diabetes Mellitus** **Human Patients: 592** **Sponsor: Amgen (AMGN)**	Quarter: Q3'24 Batch 11 Technical: partial SUCCESS (statistically significant clinical benefit in weight loss) partial FAILURE (statistically insignificant clinical benefit in HbA1c reduction) Commercial: FAILURE (commercially insufficient clinical benefit due to inferior-to-tirzepatide/semaglutide long-term detrimental toxicity for both nondiabetic and diabetic patients; despite superior-to-tirzepatide/semaglutide efficacy in morbid weight loss)	**Lead Time: 297 days in advance** Interpretation: MariTide achieved 20% weight loss with 11% TEAE-related discontinuation for obese nondiabetic patients; numerically superior to the tirzepatide's 19.5% weight loss yet inferior to tirzepatide 6.2% TEAE-related discontinuation for obese nondiabetic patients at week 52 (10.1056/NEJMoa2206038); superior to the semaglutide's 13.4% weight loss yet inferior to semaglutide's 5-8% TEAE-related discontinuation for obese nondiabetic patients at week 52 (see add link for semaglutide's data on Lancet)	Conclusion: statistically significant(weight loss) and commercially insufficient (inferior to tirzepatide/semaglutide tolerability) Classification: **True Negative (TN)**
1761	**Capivasertib** **NCTID: NCT04493853** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: pan-ATK small molecule inhibitor** **Area: Neoplasms** **Indication: Hormone-Sensitive Prostate Cancer** **Human Patients: 1012** **Sponsor: AstraZeneca (AZN)**	Date: 19 Aug 2024 Quarter: Q4'24 Batch 12 Technical: SUCCESS (statistically significant additive clinical benefit in rPFS) Commercial: partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in OS)	Readout: 26 Nov 2024 **Lead Time: 99 days in advance** Interpretation: capivasertib + SoC achieved superior rPFS compared with SoC alone; OS data not mature	Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**
1429	**Tiragolumab** **NCTID: NCT04294810** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-TIGIT mAb inhibitor** **Area: Neoplasms** **Indication: Non-Small Cell Lung Cancer** **Human Patients: 620** **Sponsor: Roche Group (RHHBY)**	Date: 18 Jan 2024 Quarter: Q1'24 Batch 16 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS)	Readout: 26 Nov 2024 **Lead Time: 313 days in advance** Interpretation: tiragolumab failed to achieve additive clinical benefit in OS	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
568	**PTC857** **NCTID: NCT05349721** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: ALOX15 inhibitor** **Area: Nervous System Diseases** **Indication: Amyotrophic Lateral Sclerosis (ALS)** **Human Patients: 307** **Sponsor: PTC Therapeutics (PTCT)**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 1 Technical: FAILURE (statistically insignificant additive clinical benefit in ALSFRS-R) Commercial: FAILURE (commercially insufficient additive clinical benefit in ALSFRS-R)	Readout: 26 Nov 2024 **Lead Time: 112 days in advance** Interpretation: PTC857 failed to achieve any primary or secondary efficacy endpoints	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1621	**Taldefgrobep alfa** **NCTID: NCT05337553** **Phase: Phase 3** **Class: First-In-Class** **Modality: recombinant protein biologic** **MoA: selective ACVR2B antagonist** **Area: Nervous System Diseases** **Indication: Spinal Muscular Atrophy (SMA)** **Human Patients: 269** **Sponsor: Biohaven (BHVN)**	Date: 15 May 2024 Quarter: Q3'24 Batch 11 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit in MFM32)	Readout: 25 Nov 2024 **Lead Time: 194 days in advance** Interpretation: taldefgrobep alfa + SoC failed to achieved the MFM32 primary efficacy endpoint at week 48 compared with SoC alone	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
580	**AL002**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 3	Readout: 25 Nov 2024 **Lead Time: 111 days in advance**	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT04592874 **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-TREM2 mAb activator** **Area: Nervous System Diseases** **Indication: Alzheimer's Disease** **Human Patients: 381** **Sponsor: Alector / AbbVie (ALEC/ABBV)**	Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to lecanemab)	Interpretation: AL002 failed to meet primary efficacy endpoints CDR-SB	Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1724	**Simufilam** **NCTID: NCT04994483** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: misfolded FLNA inhibitor** **Area: Nervous System Diseases** **Indication: Alzheimer's Disease** **Human Patients: 804** **Sponsor: Cassava Sciences (SAVA)**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 4 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in ADAS-COG12/ADCS-ADL23 against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in ADAS-COG12/ADCS-ADL23 inferior to lecanemab)	Readout: 25 Nov 2024 **Lead Time: 111 days in advance** Interpretation: simufilam failed to meet primary efficacy endpoints ADAS-COG12 and ADCS-ADL at week 52	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1383	**SAGE-718 (dalzanemdor)** **NCTID: NCT05107128** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: NMDAR PAM** **Area: Nervous System Diseases** **Indication: Huntington's Disease** **Human Patients: 189** **Sponsor: Sage Therapeutics (SAGE)**	Date: 20 Apr 2024 Quarter: Q3'24 Batch 1 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 20 Nov 2024 **Lead Time: 214 days in advance** Interpretation: dalzanemdor failed to meet the primary efficacy endpoint	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1596	**obicetrapib** **NCTID: NCT06005597** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: selective CETP inhibitor** **Area: Nutritional and Metabolic Diseases** **Indication: familial hypercholesterolemia (HeFH) and/or atherosclerotic cardiovascular disease (ASCVD)** **Human Patients: 407** **Sponsor: NewAmsterdam Pharma (NAMS)**	Date: 12 May 2024 Quarter: Q1'25 Batch 4 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit of obicetrapib in LDL-C reduction) Commercial: FAILURE (commercially insufficient additive clinical benefit of obicetrapib in MACE with significantly increased toxicity-driven mortality; The MACE-based clinical benefit of obicetrapib + ezetimibe + SoC is inferior to that of SoC + ezetimibe or SoC alone)	Readout: 20 Nov 2024 **Lead Time: 192 days in advance** Interpretation: obicetrapib + ezetimibe + SoC achieved 48.6% LDL-C reduction at day 84; which is superior to ezetimibe + SoC or SoC alone (yet weaker than 54-59% reduction as the market concensus for strong efficacy); obicetrapib achieved 7% TEAE; which is inferior to ezetimibe + SoC (3%) or SoC alone (4%)	Correct Prediction Conclusion: statistically significant yet weak and commercially TBD (no MACE data available) Classification: **True Positive (TP)**
1484	**PYX-201** **NCTID: NCT05720117** **Phase: Phase 1** **Class: First-In-Class** **Modality: ADC** **MoA: anti-fibronectin-EDB ADC with cathepsin B-cleavage mediated release of auristatin payload** **Area: Neoplasms** **Indication: advanced solid tumor** **Human Patients: 80** **Sponsor: Pyxis Oncology (PYXS)**	Date: 9 Apr 2024 Quarter: Q2'24 Batch 14 Technical: FAILURE (statistically insignificant clinical benefit in PFS/OS/ORR) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 20 Nov 2024 **Lead Time: 225 days in advance** Interpretation: PYX201 achieved 26% ORR for advanced solid tumors; which is inferior to other targeted therapies for advanced solid tumors; e.g. 56% ORR of Enhertu for HER2+ advanced solid tumors (refer to additional press link for AstraZeneca's data)	Correct Prediction Conclusion: statistically maybe significant and commercially insufficient (weak efficacy) Classification: **True Negative (TN)**
1752	**linerixibat** **NCTID: NCT04950127** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: ASBT/IBAT inhibitor**	Date: 13 Aug 2024 Quarter: Q4'24 Batch 7 Technical: partial SUCCESS (statistically maybe significant yet moderate clinical benefit in cholestatic pruritus against placebo)	Readout: 19 Nov 2024 **Lead Time: 98 days in advance** Interpretation: linerixibat achieved the primary endpoint of itch score reduction at week 24 (no specific data or p-value disclosed)	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Area: Immune System Diseases **Indication: Cholestatic Pruritus (CP)** **Human Patients: 238** **Sponsor: GSK (GSK)**	Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in cholestatic pruritus non-superior non-inferior to odevixibat/volixibat)		
445	**VIR-2218 (elebsiran) VIR-3434 (tobevibart)** **NCTID: NCT05461170** **Phase: Phase 2** **Class: First-In-Class** **Modality: siRNA and monoclonal antibody (mAb)** **MoA: anti-HBx-HBV siRNA and anti-HBsAg mAb inhibitor** **Area: Infections** **Indication: Chronic Hepatitis D Infection** **Human Patients: 124** **Sponsor: Vir Biotechnology (VIR)**	Date: 14 Aug 2024 Quarter: Q4'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit in HDV RNA suppression against placebo for which VIR-2218 is non-superior-non-inferior to bepirovirsen) Commercial: FAILURE (commercially insufficient clinical benefit in HDV RNA suppression non-superior to SoC)	Readout: 19 Nov 2024 **Lead Time: 97 days in advance** Interpretation: elebsiran + tobevibart achieved 41% HDV RNA TND at week 24; which is inferior to 46% HDV RNA TND at week 24 achieved by 10-mg bulevirtide + PEG IFN-alfa-2a (DOI-10.1056/NEJMoa2314134)	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1562	**Dapirolizumab Pegol** **NCTID: NCT04294667** **Phase: Phase 3** **Class: First-In-Class** **Modality: fab biologic** **MoA: anti-CD40L PEGylated fab** **Area: Immune System Diseases** **Indication: Systemic Lupus Erythematosus (SLE)** **Human Patients: 321** **Sponsor: UCB SA (UCB)**	Date: 26 Apr 2024 Quarter: Q3'24 Batch 3 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 19 Nov 2024 **Lead Time: 207 days in advance** Interpretation: dapirolizumab achieved 14.9% placebo-adjusted BICLA at week 48 as an add-on the SoC (p=0.011) yet the key secondary endpoint BICLA at week 24 not met (usually BICLA at week 24 is the primary efficacy endpoint).	Correct Prediction Conclusion: statistically insignificant (in BICLA at week 24) and commercially insufficient Classification: **True Negative (TN)**
1709	**NGN101** **NCTID: NCT05228145** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV9-delivered CLN5 trans gene** **Area: Nervous System Diseases** **Indication: CLN5 Batten Disease** **Human Patients: 6** **Sponsor: Neurogene (NGNE)**	Date: 31 Jul 2024 Quarter: Q4'24 Batch 10 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in UBDRS or visual acuity) Commercial: FAILURE (commercially insufficient clinical benefit in UBDRS or visual acuity)	Readout: 18 Nov 2024 **Lead Time: 110 days in advance** Interpretation: NGN101's further development has been discontinued	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1584	**INCB000262 (EP262)** **NCTID: NCT06077773** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: MRGPRX2 antagonist** **Area: Immune System Diseases** **Indication: chronic spontaneous urticaria (CSU)** **Human Patients: 154** **Sponsor: Incyte Corporation (INCY)**	Date: 28 Apr 2024 Quarter: Q3'24 Batch 16 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit with inferior-to-barzolvolimab efficacy)	Readout: 18 Nov 2024 **Lead Time: 204 days in advance** Interpretation: enrolment paused due to preclinical toxicity findings of INCB000262	Correct Prediction Conclusion: statistically probably insignificant and commercially insufficient Classification: **True Negative (TN)**
1575	**INCB000547 (EP547)** **NCTID: NCT05525520** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: MRGPRX4 antagonist** **Area: Immune System Diseases** **Indication: Cholestatic Pruritus (CP)** **Human Patients: 62** **Sponsor: Incyte Corporation**	Date: 28 Apr 2024 Quarter: Q3'24 Batch 4 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit in cholestatic pruritus reduction with a negative dose-response relationship) Commercial: FAILURE (commercially insufficient clinical benefit with inferior-to-SoC efficacy in cholestatic pruritus reduction)	Readout: 18 Nov 2024 **Lead Time: 204 days in advance** Interpretation: INCB000547's further development will be discontinued due to weak clinical benefit (no detailed data disclosure)	Correct Prediction Conclusion: statistically probably insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	(INCY)			
1684	**Tirzepatide (LY3298176)** **NCTID: NCT04847557** **Phase: Phase 3** **Class: First-In-Class** **Modality: synthetic peptide** **MoA: GLP1R/GIPR-biased dual agonist** **Area: Cardiovascular Diseases and Nutritional and Metabolic Diseases** **Indication: Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity** **Human Patients: 731** **Sponsor: Eli Lilly and Company (LLY)**	Date: 17 Jul 2024 Quarter: Q3'24 Batch 18 Technical: SUCCESS (statistically significant additive clinical benefit in KCCQ/mortality/heart failure as an adjunctive therapy) Commercial: SUCCESS (commercially sufficient additive clinical benefit in 6MWD superior to semaglutide as an adjunctive therapy)	Readout: 16 Nov 2024 **Lead Time: 122 days in advance** Interpretation: -38% risk reduction in composite endpoint (DOI-10.1056/NEJMoa2410027) and 6.8-9.8 point improvement in KCCQ-CSS by week 52 (vs 7.5 by week 52 for semaglutide in Butler et Al. 2024 LANCET); 30.3m and 15.9m placebo-adjusted efficacy/regimen 6WMD (vs 18.2m and 14.3m achieved by semaglutide by week 52 Butler et Al. 2024 LANCET)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
444	**VIR-2218 (elebsiran) VIR-3434 (tobevibart)** **NCTID: NCT04856085** **Phase: Phase 2** **Class: First-In-Class** **Modality: siRNA and monoclonal antibody (mAb)** **MoA: anti-HBx-HBV siRNA and anti-HBsAg mAb inhibitor** **Area: Infections** **Indication: Chronic hepatitis B viral infection** **Human Patients: 244** **Sponsor: Vir Biotechnology (VIR)**	Date: 14 Aug 2024 Quarter: Q4'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit in TEAE and HBsAg against placebo for which VIR-2218 is non-superior-non-inferior to bepiroviren) Commercial: FAILURE (commercially insufficient clinical benefit in HBV DNA suppression non-superior to SoC)	Readout: 15 Nov 2024 **Lead Time: 93 days in advance** Interpretation: elebsiran + tobevibart achieved 16% HBsAg loss and elebsiran + tobevibart + PEG-IFNalpha achieved 22% HBsAg loss; of which elebsiran's about 7% HBsAg loss (see the data in the add link) is non-superior to bepiroviren's 9-10% HBsAg loss (N Engl J Med DOI- 10.1056/NEJMoa2210027)	Correct Prediction Conclusion: statistically significant (HBsAg loss) and commercially TBD (pending HBV DNA suppression data) Classification: **True Positive (TP)**
1103	**OTX-2002** **NCTID: NCT05497453** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: mRNA medicine** **MoA: LNP-encapsulated mRNAs of ZF-DNMT and ZF-KRAB proteins** **Area: Neoplasms** **Indication: advanced solid tumor** **Human Patients: 190** **Sponsor: Omega Therapeutics (OMGA)**	Date: 27 Feb 2024 Quarter: Q2'24 Batch 9 Technical: partial SUCCESS (statistically significant yet weak clinical benefit for OTX2002 monotherapy and OTX2002 combotherapies) Commercial: FAILURE (commercially insufficient additive clinical benefit due to the inferior-to-atezolizumab+bevacizumab efficacy of OTX2002 combotherapies)	Readout: 14 Nov 2024 **Lead Time: 261 days in advance** Interpretation: OTX2002 achieved 50% DCR for HCC in line with historical benchmark range for approved TKIs and PD1 monotherapies (29-65%) and its further development is discontinued	Correct Prediction Conclusion: statistically probably significant and commercially insufficient (weak efficacy) Classification: **True Negative (TN)**
1371	**NXP800** **NCTID: NCT05226507** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: anti-HSF1 inhibitor** **Area: Neoplasms** **Indication: ADRI1a-mutated ovarian cancer** **Human Patients: 61** **Sponsor: Nuvectis Pharma (NVCT)**	Date: 8 Dec 2023 Quarter: Q1'24 Batch 10 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 14 Nov 2024 **Lead Time: 342 days in advance** Interpretation: NXP800 achieved at most 9% ORR (1/11 unconfirmed); which is non-superior to the 8-13% ORR by nivolumab or PLD/GEM (Journal of Clinical Oncology DOI-10.1200/JCO.21.00334)	Correct Prediction Conclusion: statistically significant yet weak and commercially insufficient Classification: **True Negative (TN)**
1604	**LTI-03** **NCTID: NCT05954988** **Phase: Phase 1** **Class: First-In-Class** **Modality: peptide** **MoA: CAV1-like peptide** **Area: Respiratory Tract Diseases** **Indication: Idiopathic Pulmonary Fibrosis (IPF)** **Human Patients: 24**	Date: 12 May 2024 Quarter: Q3'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit with superior-to-bexotegrast efficacy in FVC)	Readout: 13 Nov 2024 **Lead Time: 185 days in advance** Interpretation: LTI03 is safe and achieved statistical significant in four of eight IPF biomarkers for cohort 1 and cohort 2	Correct Prediction Conclusion: statistically significant (safety) and commercially TBD Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Aileron Therapeutics (ALRN)			
1779	**Letetresgene autoleucel (lete-cel; GSK3377794)** **NCTID: NCT03967223** **Phase: Phase 2** **Class: First-In-Class** **Modality: cell therapy** **MoA: anti-NY-ESO-1 TCR T-cell therapy** **Area: Neoplasms** **Indication: advanced synovial sarcoma (SS) or myxoid/round cell liposarcoma (MRCLS)** **Human Patients: 103** **Sponsor: Adaptimmune Therapeutics (ADAP)**	Date: 9 Sep 2024 Quarter: Q4'24 Batch 16 Technical: partial SUCCESS (statistically maybe significant yet moderate additive clinical benefit in ORR/PFS as 1L treatment with moderate toxicity) SUCCESS (statistically significant additive clinical benefit in ORR/PFS as 2L treatment with moderate toxicity) Commercial: partial FAILURE (commercially insufficient additive clinical benefit in OS as 1L treatment) partial SUCCESS (commercially maybe sufficient yet weak additive clinical benefit in OS as 2L treatment)	Readout: 13 Nov 2024 **Lead Time: 65 days in advance** Interpretation: lete-cel + SoC as 2L treatment achieved 42% ORR and 5.3 months PFS which is superior to the SoC alone (1L data not reported)	Correct Prediction Conclusion: statistically significant (2L) and commercially TBD (2L OS not mature) Classification: **True Positive (TP)**
1616	**Pimicotinib(ABSK021)** **NCTID: NCT05804045** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: anti-CSF1R inhibitor** **Area: Neoplasms** **Indication: tenosynovial giant cell tumor (TGCT)** **Human Patients: 90** **Sponsor: Merck KGaA (MKKGY)**	Date: 14 May 2024 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to pexidartinib)	Readout: 12 Nov 2024 **Lead Time: 182 days in advance** Interpretation: pimicotinib achieved 50.8% placebo-adjusted ORR at week 25 (p<0.0001); which is superior to pexidartinib's 39% placebo-adjusted ORR at week 25 (P<0.0001)	Correct Prediction Conclusion: statistically significant and commercially sufficient; correct prediction Classification: **True Positive (TP)**
1624	**Tamibarotene** **NCTID: NCT04797780** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: RARalpha agonist** **Area: Neoplasms** **Indication: Myelodysplastic Syndrome with RARA gene overexpression** **Human Patients: 550** **Sponsor: Syros Pharmaceuticals (SYRS)**	Date: 15 May 2024 Quarter: Q3'24 Batch 10 Technical: FAILURE (statistically insignificant additive clinical benefit in in CR) Commercial: FAILURE (commercially insufficient additive clinical benefit OS)	Readout: 12 Nov 2024 **Lead Time: 181 days in advance** Interpretation: Tamibarotene failed to achieve additional benefit in CR as the primary efficacy endpoint	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
943	**Revumenib (SNDX-5613)** **NCTID: NCT04065399** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: MENIN-MLL1 inhibitor** **Area: Neoplasms** **Indication: mNPM1-mutant relapsed/refractory Leukemias** **Human Patients: 413** **Sponsor: Syndax Pharmaceuticals (SNDX)**	Date: 18 Jun 2023 Quarter: 2H'23 Batch 6 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 12 Nov 2024 **Lead Time: 513 days in advance** Interpretation: Revumenib achieved 23% CR/CRh; which is inferior to CLT019's 81% CR	Correct Prediction Conclusion: statistically significant and commercially insufficient (non-superior efficacy compared with SoC) Classification: **True Negative (TN)**
1710	**NGN-401** **NCTID: NCT05898620** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV9-delivered miRNA-regulated MECP2 gene therapy** **Area: Nervous System Diseases** **Indication: Rett Syndrome** **Human Patients: 16**	Date: 31 Jul 2024 Quarter: Q4'24 Batch 10 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 11 Nov 2024 **Lead Time: 103 days in advance** Interpretation: low-dose NGN401 achieved 2-score CGI-I from baseline; high-dose NGN401 achieved 33.3% SAE (1/3)	Correct Prediction Conclusion: statistically probably significant (yet weak overall clinical benefit considering both efficacy and toxicity) and commercially probably insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Neurogene (NGNE)			
1457	**Emraclidine (CVL-231)** **NCTID: NCT05227703** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: a selective CNS-penetrant CHRM4 PAM** **Area: Nervous System Diseases** **Indication: schizophrenia** **Human Patients: 372** **Sponsor: AbbVie (ABBV)**	Date: 14 Feb 2024 Quarter: Q3'24 Batch 8 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 11 Nov 2024 **Lead Time: 271 days in advance** Interpretation: emraclidine failed to achieved the primary efficacy endpoint PANSS at week 6	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1458	**Emraclidine (CVL-231)** **NCTID: NCT05227690** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: a selective CNS-penetrant CHRM4 PAM** **Area: Nervous System Diseases** **Indication: schizophrenia** **Human Patients: 372** **Sponsor: AbbVie (ABBV)**	Date: 14 Feb 2024 Quarter: Q3'24 Batch 8 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 11 Nov 2024 **Lead Time: 271 days in advance** Interpretation: emraclidine failed to achieved the primary efficacy endpoint PANSS at week 6	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1444	**tezepelumab** **NCTID: NCT04851964** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-TSLP inhibitor** **Area: Respiratory Tract Diseases** **Indication: pancreas Neoplasm** **Stomach Neoplasm** **Gastrointestinal Neoplasms** **Digestive System Neoplasm** **Neoplasms by Site Neoplasms** **Human Patients: 416** **Sponsor: Amgen / AstraZeneca (AMGN/AZN)**	Date: 5 Feb 2024 Quarter: Q3'24 Batch 11 Technical: SUCCESS (statistically significant yet moderate additive clinical benefit) Commercial: SUCCESS (commercially sufficient yet moderate additive clinical benefit)	Readout: 8 Nov 2024 **Lead Time: 277 days in advance** Interpretation: tezepelumab achieved the efficacy primary endpoint of total endoscopic nasal polyp score at week 52 and mean nasal obstruction score by week 52	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1780	**Mipasetamab Uzoptirine (ADCT-601)** **NCTID: NCT05389462** **Phase: Phase 1** **Class: First-In-Class** **Modality: ADC** **MoA: anti-AXL ADC conjugated with a PBD-dimer cytotoxin SG3199** **Area: Neoplasms** **Indication: advanced solid tumours** **Human Patients: 128** **Sponsor: ADC Therapeutics (ADCT)**	Date: 9 Sep 2024 Quarter: Q4'24 Batch 16 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR/PFS for advanced solid tumors regardless of AXL amplification status in 2L/3L clinical settings) SUCCESS (statistically significant clinical benefit in ORR/PFS superior to chemotherapy for advanced solid tumors with AXL amplification in 2L/3L clinical settings) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS for advanced solid tumors regardless of AXL amplification status in 2L/3L clinical settings) partial FAILURE (commercially maybe sufficient yet very weak clinical benefit in OS at most numerically superior to chemotherapy for advanced solid tumors with AXL amplification in 2L/3L clinical settings)	Readout: 7 Nov 2024 **Lead Time: 59 days in advance** Interpretation: ADCT601's further development has been discontinued due to insufficient benefit-risk profile	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**
1471	**NKX019** **NCTID: NCT05020678** **Phase: Phase 1** **Class: First-In-Class** **Modality: cell therapy**	Date: 15 Feb 2024 Quarter: Q2'24 Batch 6 Technical: FAILURE (statistically insignificant clinical benefit)	Readout: 7 Nov 2024 **Lead Time: 266 days in advance** Interpretation: NKX019's further development has been forgone based on data review	Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	MoA: allogeneic anti-CD19 CAR-NK cell therapy **Area: Neoplasms** **Indication: relapsed/refractory B cell malignancies** **Human Patients: 150** **Sponsor: Nkarta (NKTX)**	Commercial: FAILURE (commercially insufficient clinical benefit inferior to anti-CD19 CAR-T cell therapies)		Classification: **True Negative (TN)**
1217	**SRP-5051** **NCTID: NCT04004065** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: Menin-MLL1 inhibitor** **Area: Musculoskeletal Diseases** **Indication: Duchenne Muscular Dystrophy (DMD)** **Human Patients: 62** **Sponsor: Sarepta Therapeutics (SRPT)**	Date: 11 Aug 2023 Quarter: 2H'23 Batch 12 Technical: partial SUCCESS (statistically significant clinical benefit in dystrophin level) Commercial: FAILURE (commercially insufficient clinical benefit in 6MWD)	Readout: 6 Nov 2024 **Lead Time: 453 days in advance** Interpretation: SRP5051 resulted in a mean absolute dystrophin expression of 5.17% at week 28; yet its further development has been discontinued due to unremarkable benefit-risk data	Correct Prediction Conclusion: statistically partially significant (dystrophin expression) and commercially insufficient (weak efficacy) Classification: **True Negative (TN)**
1018	**TNG462** **NCTID: NCT05732831** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: selective MTAP-mull-cell-specific PRMT5 inhibitor** **Area: Neoplasms** **Indication: MTAP-deleted Solid Tumors** **Human Patients: 159** **Sponsor: Tango Therapeutics (TNGX)**	Date: 28 Jul 2024 Quarter: Q3'24 Batch 20 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS) Commercial: SUCCESS (commercially sufficient clinical benefit in OS)	Readout: 6 Nov 2024 **Lead Time: 101 days in advance** Interpretation: TNG462 achieved 43% ORR for relapsed/refractory cholangiocarcinoma; superior to 5% ORR achieved by second-line chemotherapy for advanced biliary tract cancer; including cholangiocarcinoma (Lancet DOI-10.1016/S1470-2045(21)00027-9)	Correct Prediction Conclusion: statistically significant and commercially probably sufficient Classification: **True Positive (TP)**
1019	**TNG908** **NCTID: NCT05275478** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: selective MTAP-mull-cell-specific PRMT5 inhibitor** **Area: Neoplasms** **Indication: MTAP-deleted Solid Tumors** **Human Patients: 192** **Sponsor: Tango Therapeutics (TNGX)**	Date: 28 Jul 2024 Quarter: Q3'24 Batch 20 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS) Commercial: partial SUCCESS (commercially maybe sufficient yet weak clinical benefit in OS)	Readout: 6 Nov 2024 **Lead Time: 101 days in advance** Interpretation: TNG908 exhibited overall weak efficacy (active for non-CNS solid tumors yet inactive for GBM)	Correct Prediction Conclusion: statistically maybe significant and commercially insufficient Classification: **True Negative (TN)**
357	**Lumateperone** **NCTID: NCT04959032** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: 5HT2AR antagonist** **Area: Nervous System Diseases** **Indication: Schizophrenia relapse prevention** **Human Patients: 228** **Sponsor: Intra-Cellular Therapies (ITCI)**	Date: 23 Sep 2022 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 5 Nov 2024 **Lead Time: 774 days in advance** Interpretation: Lumateperone achieved a 22.2% placebo-adjusted lower relapse of schizophrenia (16.4% vs 38.6%; p=0.0002)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1434	**BEAM-101** **NCTID: NCT05456880** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: base editing gene therapy** **MoA: autologous CD34+ A-to-G**	Date: 20 Jan 2024 Quarter: Q3'24 Batch 10 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially	Readout: 5 Nov 2024 **Lead Time: 290 days in advance** Interpretation: BEAM101 achieved ~66% and ~11.8 g/dL HbF response at month 6; which are superior to Casgevy's 45% and 5.8 g/dL HbF response at month 6	Correct Prediction Conclusion: statistically significant yet overall weak due to better efficacy and worse safety and commercially TBD Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	HBG1/HBG2 promoter base edited hematopoietic stem cells **Area: Hemic and Lymphatic Diseases** **Indication: Sickle Cell Disease** **Human Patients: 15** **Sponsor: Beam Therapeutics (BEAM)**	insufficient clinical benefit inferior to Casgevy)	(10.1056/NEJMoa2309676); yet a patient died from the necessary busulfan conditioning for BEAM101; inferior to Csgevy's safety; VOC data are premature	
1759	**AZD5004** **NCTID: NCT06555822** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 15** **Sponsor: AstraZeneca (AZN)**	Date: 19 Aug 2024 Quarter: Q4'24 Batch 12 Technical: partial FAILURE (statistically significant clinical benefit in weight reduction for healthy obese patients against placebo despite being at least numerically inferior to orfoglipron/GSBR1290) Commercial: partial SUCCESS (commercially sufficient clinical benefit in muscle retention and cardio protection for healthy obese patients at least numerically superior to orfoglipron/GSBR1290)	Readout: 5 Nov 2024 **Lead Time: 78 days in advance** Interpretation: AZD5004 achieved 5.8% weight reduction in more than four weeks (no placebo arm data); thus inferior to VK2735's 6.8% weight reduction at day 28 (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially probably insufficient Classification: **True Negative (TN)**
1497	**AZD6234** **NCTID: NCT06132841** **Phase: Phase 1** **Class: First-In-Class** **Modality: peptide** **MoA: long-lasting amylin analog** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 76** **Sponsor: AstraZeneca (AZN)**	Date: 6 Mar 2024 Quarter: Q2'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit in weight loss) Commercial: FAILURE (commercially insufficient clinical benefit for repeated-dose AZD6234; which is inferior to semaglutide with increasing toxicity for elderly obese population with comorbidities)	Readout: 5 Nov 2024 **Lead Time: 244 days in advance** Interpretation: AZD6234 achieved statistically significant reduction in weight compared to placebo (no specific number or p-value)	Correct Prediction Conclusion: statistically significant and commercially probably insufficient (no disclosure of data usually indicates weak efficacy) Classification: **True Negative (TN)**
1496	**AZD6234** **NCTID: NCT05511025** **Phase: Phase 1** **Class: First-In-Class** **Modality: peptide** **MoA: long-lasting amylin analog** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 54** **Sponsor: AstraZeneca (AZN)**	Date: 6 Mar 2024 Quarter: Q2'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit in weight loss) Commercial: FAILURE (commercially insufficient clinical benefit for single-dose AZD6234+acetaminophen; which is non-inferior to semaglutide for nondiabetic obese population and inferior to semaglutide for diabetic obese population)	Readout: 5 Nov 2024 **Lead Time: 244 days in advance** Interpretation: AZD6234 achieved statistically significant reduction in weight compared to placebo (no specific number or p-value)	Correct Prediction Conclusion: statistically significant and commercially probably insufficient (no disclosure of data usually indicates weak efficacy) Classification: **True Negative (TN)**
1298	**SC291** **NCTID: NCT05878184** **Phase: Phase 1** **Class: Best-In-Class** **Modality: CAR-T therapy** **MoA: anti-CD19 CAR T cell therapy** **Area: Neoplasms** **Indication: r/r B-cell malignancies** **Human Patients: 16** **Sponsor: Sana Biotechnology (SANA)**	Date: 21 Oct 2024 Quarter: 2H'23 Batch 24 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit due to inferior efficacy for NHL and non-superior efficacy for CLL compared with other anti-CD19 CAR T cell therapies)	Readout: 4 Nov 2024 **Lead Time: 14 days in advance** Interpretation: SC291 development discontinued without further disclosure of data	Correct Prediction Conclusion: statistically probably significant and commercially insufficient Classification: **True Negative (TN)**
1330	**Setmelanotide** **NCTID: NCT04963231** **Phase: Phase 2** **Class: First-In-Class** **Modality: peptide** **MoA: MC4R agonist** **Area: Nutritional and Metabolic**	Date: 20 Nov 2023 Quarter: 2H'23 Batch 29 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical	Readout: 4 Nov 2024 **Lead Time: 350 days in advance** Interpretation: setmelanotide achieved 55% placebo-adjusted higher proportion of patients who achieved 5% BMI reduction	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Diseases **Indication: Hypothalamic Obesity** **Human Patients: 164** **Sponsor: Rhythm Pharmaceuticals (RYTM)**	benefit)		
1523	**Semaglutide** **NCTID: NCT04822181** **Phase: Phase 3** **Class: First-In-Class** **Modality: pepetide** **MoA: GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Non-alcoholic Steatohepatitis** **Human Patients: 1200** **Sponsor: Novo Nordisk (NVO)**	Date: 24 Mar 2024 Quarter: Q3'24 Batch 18 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially sufficient yet modest clinical benefit of semaglutide inferior-to-tirzepatide/efruxifermin for non-cirrhotic NASH)	Readout: 1 Nov 2024 **Lead Time: 222 days in advance** Interpretation: Semaglutide achieved 14.5% placebo-adjusted fibrosis improvement with no worsening of steatohepatitis and 28.8% placebo-adjusted steatohepatitis resolution with no worsening of fibrosis at week 72; inferior to tirzepatide's 21% and 52% delta at week 52 (DOI-10.1056/NEJMoa2401943) ; and inferior to efruxifermin's 21% and 61% delta at week 24 (see 10.1001/jamanetworkopen.2022.31982)	Correct Prediction Conclusion: statistically significant and commercially insufficient (inferior to tirzepatide/efruxifermin) Classification: **True Negative (TN)**
1353	**Efgartigimod** **NCTID: NCT05810961** **Phase: Phase 2** **Class: First-In-Class** **Modality: antibody fragment biologic** **MoA: FcRn receptor inhibitor** **Area: Immune System Diseases** **Indication: Membranous Nephropathy** **Human Patients: 8** **Sponsor: argenx (ARGX)**	Date: 30 Nov 2023 Quarter: - Batch - Technical: partial SUCCESS (statistically significant yet moderate clinical benefit in UPCR) partial FAILURE (statistically insignificant clinical benefit in eGFR) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 31 Oct 2024 **Lead Time: 336 days in advance** Interpretation: efgartigimod failed to achieve sufficient clinical benefit and further development discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1569	**Bepranemab** **NCTID: NCT04867616** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-tau mAb inhibitor** **Area: Nervous System Diseases** **Indication: Alzheimer's Disease** **Human Patients: 466** **Sponsor: UCB Biopharma (UCB)**	Date: 26 Apr 2024 Quarter: Q3'24 Batch 3 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit in CDR-SB for early AD patients) Commercial: FAILURE (commercially insufficient clinical benefit with inferior-to-donanemab/lecanemab in CDR-SB for early AD patients)	Readout: 31 Oct 2024 **Lead Time: 188 days in advance** Interpretation: Bepranemab did not meet the primary efficacy endpoint CDR-SB.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1788	**Trontinemab (RO7126209)** **NCTID: NCT04639050** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: bispecific antibody** **MoA: bispecific anti-abeta and anti-TfR1 antibody** **Area: Nervous System Diseases** **Indication: Mild to Moderate Alzheimer's Disease** **Human Patients: 285** **Sponsor: Roche Group (RHHBY)**	Date: 15 Sep 2024 Quarter: Q4'24 Batch 17b Technical: SUCCESS (statistically significant clinical benefit in brain amyloid load reduction) Commercial: FAILURE (commercially insufficient clinical benefit in CDR-SB/ADAS-Cog13 inferior to lecanemab)	Readout: 30 Oct 2024 **Lead Time: 45 days in advance** Interpretation: trontinemab achieved strong effect in amyloid load reduction at week 28 (-107 CL at 36 mg/kg vs -3 CL in placebo); no data available for CDR-SB/ADAS-Cog13	Correct Prediction Conclusion: statistically significant (in amyloid beta reduction) and commercially TBD (wait for CDR-SB/ADAS-Cog13 data) Classification: **True Positive (TP)**
1448	**Fipaxalparant (HZN825)** **NCTID: NCT05032066** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: LPAR1 antagonist** **Area: Respiratory Tract Diseases** **Indication: Idiopathic Pulmonary Fibrosis (IPF)** **Human Patients: 153** **Sponsor: Amgen (AMGN)**	Date: 5 Feb 2024 Quarter: Q3'24 Batch 11 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to bexotegrast)	Readout: 30 Oct 2024 **Lead Time: 268 days in advance** Interpretation: fipaxalparant failed to achieve any primary/secondary endpoints and further development discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
546	**Relacorilant** **NCTID: NCT04308590** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: oral non-sterioidal glucocorticoid receptor antagonist** **Area: Endocrine System Diseases** **Indication: Hypercortisolism** **Human Patients: 137** **Sponsor: Corcept Therapeutics (CORT)**	Date: 16 Jul 2023 Quarter: 2H'23 Batch 10 Technical: FAILURE (statistical insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 30 Oct 2024 **Lead Time: 472 days in advance** Interpretation: relacorilant failed to achieve the mean SBP primary efficacy endpoint against placebo	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
711	**Peresolimab** **NCTID: NCT05516758** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: PD1 agonist** **Area: Immune System Diseases** **Indication: Rheumatoid Arthritis** **Human Patients: 491** **Sponsor: Eli Lilly and Company (LLY)**	Date: 26 Nov 2022 Quarter: - Batch - Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 30 Oct 2024 **Lead Time: 704 days in advance** Interpretation: peresolimab terminated without data disclosure despite positive phase2a data in 2023 (DOI- 10.1056/NEJMoa2209856)	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1696	**aldesleukin** **NCTID: NCT06096090** **Phase: Phase 2** **Class: First-In-Class** **Modality: peptide** **MoA: low-dose recombinant IL2** **Area: Nervous System Diseases** **Indication: Alzheimer's Disease** **Human Patients: 40** **Sponsor: Coya Therapeutics (COYA)**	Date: 24 Jul 2024 Quarter: Q3'24 Batch 19 Technical: FAILURE (statistically insignificant clinical benefit in ADAS-Cog13 or CDR-SB) Commercial: FAILURE (commercially insufficient clinical benefit in ADAS-Cog13 or CDR-SB)	Readout: 29 Oct 2024 **Lead Time: 97 days in advance** Interpretation: aldesleukin failed to meet the exploratory efficacy endpoints ADAS-Cog14 or CDR-SOB	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1441	**Uproleselan (GMI-1271)** **NCTID: NCT03616470** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: selective E-selectin antagonist** **Area: Neoplasms** **Indication: Relapsed/ Acute Myeloid Leukemia** **Human Patients: 388** **Sponsor: GlycoMimetics (GLYC)**	Date: 16 Feb 2024 Quarter: Q2'24 Batch 6 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in OS) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 29 Oct 2024 **Lead Time: 256 days in advance** Interpretation: uproleselan failed to achieve the EFS primary efficacy endpoint	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1463	**EYP-1901** **NCTID: NCT06099184** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: multi-kinase VEGFR/PDGFR inhibitor** **Area: Eye Diseases** **Indication: Diabetic Macular Edema** **Human Patients: 25** **Sponsor: EyePoint Pharmaceuticals (EYPT)**	Date: 14 Feb 2024 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit non-inferior to aflibercept in BCVA) Commercial: SUCCESS (commercially sufficient clinical benefit non-inferior to long-lasting aflibercept)	Readout: 28 Oct 2024 **Lead Time: 257 days in advance** Interpretation: EYP1901 achieved +9.9 letters in BCVA and 68 micron reduction in CST; superior to aflibercept's +3.2 letters in BCVA and 30.5 micron reduction in CST	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1765	**RMC-9805** **NCTID: NCT06040541** **Phase: Phase 1 Phase 2** **Class: First-In-Class**	Date: 27 Aug 2024 Quarter: Q4'24 Batch 14 Technical: SUCCESS (statistically significant (additive) clinical benefit in	Readout: 25 Oct 2024 **Lead Time: 59 days in advance** Interpretation: RMC9805 achieved 30% ORR; where is superior to the	Correct Prediction Conclusion: statistically significant (superior in ORR) and commercially TBD (OS data not

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Modality: small molecule **MoA: KRAS-G12D-ON inhibitor** **Area: Neoplasms** **Indication: KRAS G12D-Mutant Solid Tumors** **Human Patients: 444** **Sponsor: Revolution Medicines Inc. (RVMD)**	ORR/PFS superior to tumor-specific SoC) Commercial: FAILURE (commercially insufficient (additive) clinical benefit in OS non-superior to tumor-specific SoC)	SoC chemotherapy's 9%-16% ORR (see add'l link below)	mature) Classification: **True Positive (TP)**
1700	**TYRA-300** **NCTID: NCT05544552** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: N540K-mutation-specific FGFR3 antagonist** **Area: Neoplasms** **Indication: Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations** **Human Patients: 310** **Sponsor: Tyra Biosciences (TYRA)**	Date: 27 Jul 2024 Quarter: Q3'24 Batch 20 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS with superior-to-erdafitinib safety) Commercial: SUCCESS (commercially sufficient clinical benefit in OS/CR superior to erdafitinib)	Readout: 25 Oct 2024 **Lead Time: 90 days in advance** Interpretation: TYRA300 achieved 54.5% ORR and 10% SAE (Gr3 only no Gr4); superior to erdafitinib's 71% SAE (both Gr3 and Gr4) (Lancet DOI-10.1016/S1470-2045(21)00660-4)	Correct Prediction Conclusion: statistically significant (superior in safety) and commercially TBD (OS data not mature) Classification: **True Positive (TP)**
1202	**Ganaxalone** **NCTID: NCT05323734** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: 3beta-methylated synthetic analog of allopregnanolone** **Area: Nervous System Diseases** **Indication: Tuberous Sclerosis Complex related Epilepsy** **Human Patients: 128** **Sponsor: Marinus Pharmaceuticals (MRNS)**	Date: 14 Jul 2024 Quarter: Q3'24 Batch 16 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit in seizure frequency) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 24 Oct 2024 **Lead Time: 102 days in advance** Interpretation: ganaxolone did not meet the primary efficacy endpoint of seizure frequency despite numerical improvement (p=0.09)	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1130	**naporafenib (ERAS254)** **NCTID: NCT05907304** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: RAF inhibitor** **Area: Neoplasms** **Indication: RAS-mutant advanced solid tumors** **Human Patients: 115** **Sponsor: Erasca (ERAS)**	Date: 25 Jun 2023 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS against placebo) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 24 Oct 2024 **Lead Time: 487 days in advance** Interpretation: naporafenib + trametinib achieved only 30% ORR; non-superior to trametinib monotherapy that achieved 33% ORR for advanced melanoma (10.1002/onco.13795)	Correct Prediction Conclusion: statistically insignificant (in ORR) and commercially TBD (OS data not mature) Classification: **True Negative (TN)**
1718	**ALTO-100** **NCTID: NCT05712187** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: BDNF activator** **Area: Mental Disorders** **Indication: Major Depressive Disorder** **Human Patients: 301** **Sponsor: Alto Neuroscience (ANRO)**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 2 Technical: FAILURE (statistically maybe significant yet very weak (additive) clinical benefit in MADRS) Commercial: FAILURE (commercially insufficient (additive) clinical benefit in MADRS inferior to lumateperone)	Readout: 22 Oct 2024 **Lead Time: 77 days in advance** Interpretation: ALTO100 did not meet the primary efficacy endpoint MADRS	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1532	**Semaglutide** **NCTID: NCT03914326** **Phase: Phase 3** **Class: First-In-Class** **Modality: pepetide** **MoA: GLP1R agonist** **Area: Cardiovascular Diseases**	Date: 24 Mar 2024 Quarter: Q3'24 Batch 18 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive	Readout: 21 Oct 2024 **Lead Time: 211 days in advance** Interpretation: Semaglutide achieved 14% placebo-adjusted reduction in MACE (no FDA-approved SoC)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	and Nutritional and Metabolic Diseases **Indication: Cardiovascular Outcomes with Type 2 Diabetes** **Human Patients: 9651** **Sponsor: Novo Nordisk (NVO)**	clinical benefit)		
1329	**NX-5948** **NCTID: NCT05131022** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: BTK degrader** **Area: Neoplasms** **Indication: Relapsed/Refractory B-cell Malignancies** **Human Patients: 292** **Sponsor: Nurix Therapeutics (NRIX)**	Date: 20 Nov 2023 Quarter: 2H'23 Batch 28 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to SoC BTK inhibitors)	Readout: 19 Oct 2024 **Lead Time: 334 days in advance** Interpretation: NX5948 achieved 69.2%; which is inferior to acalabrutinib's 80-85% ORR (see doi.org/10.1182/bloodadvances.2023011307)	Correct Prediction Conclusion: statistically significant and commercially insufficient (inferior to SoC BTK inhibitors) Classification: **True Negative (TN)**
1551	**Belzupacap Sarotalocan (AU-011)** **NCTID: NCT05483868** **Phase: Phase 1** **Class: First-In-Class** **Modality: conjugate** **MoA: HPV nanoparticles conjugated with infrared-activated IR700 as a photodynamic therapy** **Area: Neoplasms** **Indication: Bladder Cancer** **Human Patients: 21** **Sponsor: Aura Biosciences (AURA)**	Date: 20 Apr 2024 Quarter: Q3'24 Batch 1 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in ORR/CR) Commercial: FAILURE (commerciall insufficient clinical benefit for AU011 with inferior-to-pembrolizumab/tebentafusp-monotherapy efficacy in OS)	Readout: 17 Oct 2024 **Lead Time: 180 days in advance** Interpretation: Bel-sar achieved 50% CR (4/8); inferior to pembrolizumab's 100% CR at any time (ASCO 19 KEYNOTE-057)	Correct Prediction Conclusion: statistically significant and commercially insufficient (weak clinical benefit) Classification: **True Negative (TN)**
1374	**AMX0035** **NCTID: NCT05676034** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: sodium phenylbutyrate + taurursodiol** **Area: Nervous System Diseases / Genetic Diseases** **Indication: Wolfram Syndrome** **Human Patients: 12** **Sponsor: Amylyx Pharmaceuticals (AMLX)**	Date: 13 Dec 2023 Quarter: Q1'24 Batch 10 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 17 Oct 2024 **Lead Time: 309 days in advance** Interpretation: AMX0035 achieved +36.7 min*ng/mL C-Peptide Response as the primary efficacy endpoint; and phase 2a safe and 100% participants meeting prespecified responding criteria (24 week -0.26% HbA1c; +7.6% target glucose range; +0.05 vision acuity; 62.5% CGIC and 75% PGIC).	Correct Prediction Conclusion: statistically probably significant and commercially probably sufficient Classification: **True Positive (TP)**
1742	**WVE-006** **NCTID: NCT06405633** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: base editing** **MoA: GalNAc-conjugated ADAR-dependent mRNA single-base modifier** **Area: Cardiovascular Diseases and Nutritional and Metabolic Diseases** **Indication: alpha-1 antitrypsin deficiency (AATD)** **Human Patients: 24** **Sponsor: Wave Life Sciences (WVE)**	Date: 10 Aug 2024 Quarter: Q4'24 Batch 5 Technical: SUCCESS (statistically significant additive clinical benefit in lung AAT/NE concentration) Commercial: SUCCESS (commercially sufficient additive clinical benefit in FEV1 superior to both fazirsiran and KB408)	Readout: 16 Oct 2024 **Lead Time: 67 days in advance** Interpretation: WVE-006 achieved 10.8 micromolar mean total AAT protein at day 15 (meeting the level that has been the basis for regulatory approval)	Correct Prediction Conclusion: statistically significant and commercially TBD (pending FEV1 data) Classification: **True Positive (TP)**
1748	**Depemokimab (GSK3511294)** **NCTID: NCT05281523** **Phase: Phase 3** **Class: Best-In-Class**	Date: 13 Aug 2024 Quarter: Q4'24 Batch 7 Technical: SUCCESS (statistically significant additive clinical benefit in	Readout: 14 Oct 2024 **Lead Time: 62 days in advance** Interpretation: Depemokimab achieved the efficacy primary	Correct Prediction Conclusion: statistically significant and commercially sufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Modality: monoclonal antibody **MoA: ultra-long-acting anti-IL5 mAb inhibitor** **Area: Respiratory Tract Diseases** **Indication: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)** **Human Patients: 264** **Sponsor: GSK (GSK)**	NPS/SNOT22 against placebo) Commercial: SUCCESS (commercially sufficient additive clinical benefit in NPS/SNOT22 non-superior-non-inferior to tezepelumab)	endpoint of total endoscopic nasal polyp score at week 52 and mean nasal obstruction score by week 52	Classification: **True Positive (TP)**
1747	**Depemokimab (GSK3511294)** **NCTID: NCT05274750** **Phase: Phase 3** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: ultra-long-acting anti-IL5 mAb inhibitor** **Area: Respiratory Tract Diseases** **Indication: Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)** **Human Patients: 276** **Sponsor: GSK (GSK)**	Date: 13 Aug 2024 Quarter: Q4'24 Batch 7 Technical: SUCCESS (statistically significant additive clinical benefit in NPS/SNOT22 against placebo) Commercial: SUCCESS (commercially sufficient additive clinical benefit in NPS/SNOT22 non-superior-non-inferior to tezepelumab)	Readout: 14 Oct 2024 **Lead Time: 62 days in advance** Interpretation: Depemokimab achieved the efficacy primary endpoint of total endoscopic nasal polyp score at week 52 and mean nasal obstruction score by week 52.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
477	**VK0214** **NCTID: NCT04973657** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: TRbeta agonist** **Area: Nervous System Diseases** **Indication: Adrenomyeloneuropathy Form (AMN) of X-linked Adrenoleukodystrophy (X-ALD)** **Human Patients: 36** **Sponsor: Viking Therapeutics (VKTX)**	Date: 12 Oct 2022 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 9 Oct 2024 **Lead Time: 728 days in advance** Interpretation: VK0214 achieved 37.9% placebo-adjusted VLCFA reduction at day 28 (p = 0.0105) and 24.9% placebo-adjusted LDL-C reduction at day 28 (p<0.0001)	Correct Prediction Conclusion: statistically significant and commercially sufficient (no FDA approved drug for X-ALD) Classification: **True Positive (TP)**
1589	**CLS-AX** **NCTID: NCT05891548** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: axitinib injectable suspension** **Area: Eye Diseases** **Indication: Wet Age-Related Macular Degeneration** **Human Patients: 60** **Sponsor: Clearside Biomedical (CLSD)**	Date: 10 May 2024 Quarter: Q3'24 Batch 4 Technical: partial SUCCESS (statistically significant yet moderate clinical benefit in BCVA) Commercial: FAILURE (commercially insufficient clinical benefit with non-superior-to-long-lasting-aflibercept efficacy in BCVA)	Readout: 9 Oct 2024 **Lead Time: 152 days in advance** Interpretation: CLS-AX achieved -1.9 BCVA score at week 36 whereas aflibercept in the active control arm achieved +1.5 BCVA score at week 36 (p=0.243); showing that CLS-AX is non-superior to aflibercept.	Correct Prediction Conclusion: statistically significant and commercially insufficient (non-superior to aflibercept) Classification: **True Negative (TN)**
1382	**SAGE-718 (dalzanemdor)** **NCTID: NCT05619692** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: NMDAR PAM** **Area: Nervous System Diseases** **Indication: Alzheimer's Diseas** **Human Patients: 174** **Sponsor: Sage Therapeutics (SAGE)**	Date: 20 Apr 2024 Quarter: Q3'24 Batch 1 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 8 Oct 2024 **Lead Time: 171 days in advance** Interpretation: dalzanemdor failed to meet the primary efficacy endpoint.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
528	**Apitegromab** **NCTID: NCT05156320** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: latent myostatin mAb**	Date: 6 Aug 2024 Quarter: Q4'24 Batch 3 Technical: FAILURE (statistically maybe significant yet very weak additive clinical benefit in HFMSE total score)	Readout: 7 Oct 2024 **Lead Time: 62 days in advance** Interpretation: apitegromab achieved 1.8 point HFMSE score difference at week 52 for the combined 10mg/kg and 20mg/kg populations (p=0.0192)	Correct Prediction Conclusion: statistically significant (yet weak benefit with negative dose-response relationship) and commercially insufficient (1.8 point is below the 3-point minimal

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	inhibitor **Area: Nervous System Diseases** **Indication: Spinal Muscular Atrophy (SMA)** **Human Patients: 188** **Sponsor: Scholar Rock Holding (SRRK)**	Commercial: FAILURE (commercially insufficient additive clinical benefit in HFMSE total score non-superior to nusinersen/risdiplam monotherapy)	yet only 1.4 point HFMSE score difference at week 52 for the 20mg/kg population (p=0.1149).	threshold of clinically meaningful improvement in HFMSE score doi.org/10.1007/s40120-024-00653-2) Classification: **True Negative (TN)**
1627	**Obinutuzumab** **NCTID: NCT04221477** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: type II anti-CD20 mAb inhibitor** **Area: Immune System Diseases** **Indication: Lupus Nephritis** **Human Patients: 252** **Sponsor: Roche Group (RHHBY)**	Date: 15 May 2024 Quarter: Q3'24 Batch 6 Technical: SUCCESS (statistically significant additive clinical benefit in CRR) Commercial: SUCCESS (commercially sufficient additive clinical benefit in eGFR)	Readout: 26 Sep 2024 **Lead Time: 134 days in advance** Interpretation: obinutuzumab achieved superiority over SoC alone in complete renal response at week 76 and in two other two secondary endpoints; yet eGFR secondary endpoint not met.	Overall Missed Prediction Note: due to suboptimal modelling of MoA with respect to the eGFR endpoint that has been materially impro… Conclusion: statistically significant and commercially maybe sufficient (FDA approved new medicine that hasn't demonstrated eGFR improvement in registrational trials) Classification: **False Positive (FP)**
1590	**EDP-323** **NCTID: NCT06170242** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: RSV L-protein inhibitor** **Area: Infections** **Indication: RSV Infection** **Human Patients: 114** **Sponsor: Enanta Pharmaceuticals (ENTA)**	Date: 10 May 2024 Quarter: Q3'24 Batch 4 Technical: SUCCESS (statistically significant yet moderate clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit with non-superior-to-palivizumab efficacy)	Readout: 26 Sep 2024 **Lead Time: 139 days in advance** Interpretation: EDP323 achieved 78%-66% reduction in total symptom score AUC (p<0.0001) featuring a negative dose-response relationship; without disclosure of RSV LRTD symptom resolution or all-cause mortality data.	Correct Prediction Conclusion: statistically significant (yet moderate benefit with negative dose-response relationship) and commercially TBD Classification: **True Positive (TP)**
1455	**tavapadon** **NCTID: NCT04201093** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: a selective D1R/D5R partial agonist** **Area: Nervous System Diseases** **Indication: early Parkinson's Disease** **Human Patients: 522** **Sponsor: AbbVie (ABBV)**	Date: 14 Feb 2024 Quarter: Q3'24 Batch 8 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially insufficient additive clinical benefit superior to levodopa for patients who receive tavapadon + MAOB inhibitor combotherapy); partial FAILURE (commercially insufficient clinical benefit non-superior to levodopa for patients who receive tavapadon monotherapy)	Readout: 26 Sep 2024 **Lead Time: 225 days in advance** Interpretation: tavapadon achieved -11.5 to -12 improvement (p< 0.0001) in MDS-UPDRS Parts II and III combined score at week 26; numerically slightly superior to -10.8 improvement in MDS-UPDRS total score achieved by Levodopa at week 26 (doi/full/10.1056/NEJMoa033447); thus commercially insufficient because levodopa is a generic.	Overall Correct Prediction Conclusion: statistically significant and commercially probably insufficient as monotherapy (combotherapy data TBD) Classification: **True Negative (TN)**
1782	**Patritumab Deruxtecan** **NCTID: NCT05338970** **Phase: Phase 3** **Class: First-In-Class** **Modality: ADC** **MoA: anti-HER3 ADC conjugated with a TOP1 inhibitor payload** **Area: Neoplasms** **Indication: advanced NSCLC** **Human Patients: 586** **Sponsor: Daiichi Sankyo Company / Merck & Co. (DSNKY/MRK)**	Date: 9 Sep 2024 Quarter: Q4'24 Batch 16 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in ORR/PFS numerically superior to chemotherapy yet numerically inferior to BL-B01D1); partial FAILURE (statistically insignificant clinical benefit in tolerability inferior to chemotherapy yet numerically superior to BL-B01D1) Commercial: FAILURE (commercially insufficient clinical benefit in OS inferior to chemotherapy yet numerically superior to BL-B01D1)	Readout: 24 Sep 2024 **Lead Time: 15 days in advance** Interpretation: statistically significant improvement in PFS over the SoC chemotherapy (without disclosure of the specific data and p-value; indicating probably weak efficacy in PFS).	Correct Prediction Conclusion: statistically probably weakly significant (in PFS) and commercially TBD (OS data not mature) Classification: **True Negative (TN)**
1595	**WVE-N531** **NCTID: NCT04906460** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: siRNA** **MoA: stereopure exon 53 skpping antisense**	Date: 12 May 2024 Quarter: Q3'24 Batch 6 Technical: partial SUCCESS (statistically significant clinical benefit in dystrophin protein level) partial FAILURE (statistically insignificant clinical benefit in	Readout: 24 Sep 2024 **Lead Time: 135 days in advance** Interpretation: a mean absolute dystrophin expression of 5.5%; which is relatively higher than competitor drugs.	Correct Prediction Note: Correct Technical prediction (commercial data TBD) Conclusion: statistically partially significant (dystrophin expression) and partially TBD (functional

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	oligonucleotides **Area: Musculoskeletal Diseases** **Indication: Duchenne Muscular Dystrophy (DMD)** **Human Patients: 11** **Sponsor: Wave Life Sciences (WVE)**	NSAA/10MRW/SV95C) Commercial: FAILURE (commercially insufficient clinical benefit in 6MWD non-superior and non-inferior to DYNE251 or SRP5051)		endpoints) and commercially TBD Classification: **True Positive (TP)**
1446	**Inebilizumab** **NCTID: NCT04524273** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-CD19 mAb inhibitor** **Area: Immune System Diseases** **Indication: generalized myasthenia gravis (gMG)** **Human Patients: 238** **Sponsor: Amgen (AMGN)**	Date: 5 Feb 2024 Quarter: Q3'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 24 Sep 2024 **Lead Time: 232 days in advance** Interpretation: inebilizumab achieved 1.9 placebo-adjusted MG-ADL score reduction at week 26 ($p < 0.0001$); numerically superior to efgartigimod's 1.6-1.7 placebo-adjusted MG-ADL score reduction at week 8-11 (doi-10.1212/WNL.0000000000007600); commercially sufficient for unsaturated market.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1445	**Rocatinlimab** **NCTID: NCT05651711** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-OX40 mAb inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Atopic Dermatitis** **Human Patients: 726** **Sponsor: Amgen (AMGN)**	Date: 10 Aug 2024 Quarter: Q4'24 Batch 6 Technical: SUCCESS (statistically significant clinical benefit in EASI75 against placebo) Commercial: SUCCESS (commercially sufficient clinical benefit in EASI75; superior to dupilumab/lebrikizumab; non-superior-and-non-inferior to amlitelimab; yet inferior to upadacitinib)	Readout: 24 Sep 2024 **Lead Time: 45 days in advance** Interpretation: rocatinlimab achieved 19.1% placebo-adjusted EASI75 at week 24; inferior to dupilumab nearly 40% placebo-adjusted EASI75 at week 16 (see 10.1056/NEJMoa1610020); and inferior to upadacitinib's nearly 60% placebo-adjusted EASI75 at week 24 (see 10.1016/S0140-6736(21)00588-2).	Overall Correct Prediction Conclusion: statistically significant and commercially maybe sufficient Classification: **True Positive (TP)**
1602	**BDTX1535** **NCTID: NCT05256290** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: 4th-gen CNS-penetrant EGFR masterkey inhibitor that targets classical; non-classical; and resistance EGFR mutations** **Area: Neoplasms** **Indication: advanced EGFRm-NSCLC** **Human Patients: 200** **Sponsor: Black Diamond Therapeutics (BDTX)**	Date: 12 May 2024 Quarter: Q3'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS) Commercial: FAILURE (commercially insufficient clinical benefit in OS with non-superior-to-osimertinib efficacy in the clinical setting of 1L EGFR-mutant NSCLC and non-superior-to-chemotherapy efficacy in the clinical setting of 2L EGFR-C797S-mutation NSCLC)	Readout: 23 Sep 2024 **Lead Time: 134 days in advance** Interpretation: 23% cORR (5/22) and 36% overall ORR (8/22); significantly better than placebo.	Correct Prediction Note: Correct Technical prediction (commercial data TBD) Conclusion: statistically significant and commercially TBD (OS data not available) Classification: **True Positive (TP)**
1682	**INV-202 (Monlunabant)** **NCTID: NCT05891834** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: peripherally selective beta-arrestin-2-biased CB1 inverse agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity and Metabolic Syndrome** **Human Patients: 243** **Sponsor: Novo Nordisk (NVO)**	Date: 17 Jul 2024 Quarter: Q3'24 Batch 18 Technical: partial SUCCESS (statistically significant yet weak clinical benefit in weight reduction against placebo with moderate toxicity) Commercial: FAILURE (commercially insufficient clinical benefit in weight reduction and adverse effect both inferior to semaglutide)	Readout: 20 Sep 2024 **Lead Time: 65 days in advance** Interpretation: monlunabant achieved 5.8% placebo-adjusted weight reduction in week 16; inferior to tirzepatide 9% placebo-adjusted weight reduction in week 16 (see 10.1056/NEJMoa2206038); Reporting mild-to-moderate psychiatric side effects in additional to typical GI adverse effects.	Correct Prediction Conclusion: statistically significant and commercially insufficient (inferior to tirzepatide in both efficacy and toxicity) Classification: **True Negative (TN)**
1601	**EDG-7500** **NCTID: NCT06347159** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral selective cardiac sarcomere modulator**	Date: 12 May 2024 Quarter: Q3'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit in LVOT-G) Commercial: SUCCESS (commercially sufficient clinical	Readout: 19 Sep 2024 **Lead Time: 130 days in advance** Interpretation: EDG7500 achieved 67% mean reduction in resting LVOT-G and 55% mean reduction in provokable LVOT-G at day 10; which are superior to aficamten's 44.8%	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Area: Cardiovascular Diseases **Indication: Hypertrophic Cardiomyopathy (HCM)** **Human Patients: 55** **Sponsor: Edgewise Therapeutics (EWTX)**	benefit with maybe-superior to-CK274 and superior-to-metoprolol-succinate efficacy in LVOT-G)	mean reduction in provokable LVOT-G at week 12 (DOI-10.1056/NEJMoa2401424)	
1734	**BTN211-01** **NCTID: NCT04503278** **Phase: Phase 1** **Class: First-In-Class** **Modality: CAR-T** **MoA: anti-CLDN6 CAR-T cell and CLDN6 mRNA vaccine** **Area: Neoplasms** **Indication: Advanced solid tumors** **Human Patients: 145** **Sponsor: BioNTech (BNTX)**	Date: 9 Aug 2024 Quarter: Q4'24 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in ORR/PFS as monotherapy or in combination with CLDN6 mRNA vaccine) Commercial: FAILURE (commercially insufficient clinical benefit in OS as monotherapy or in combination with CLDN6 mRNA vaccine)	Readout: 17 Sep 2024 **Lead Time: 39 days in advance** Interpretation: BTN211-01 with/without CARVac achieved 5% real ORR (not counting tumor marker responses; there were 3/64 patients who achieved PR or CR) in testicular/ovarian cancer; very low efficacy.	Correct Prediction Note: Correct Technical prediction (commercial data TBD) Conclusion: statistically maybe significant (against placebo) and commercially TBD Classification: **True Negative (TN)**
1732	**BNT327/PM8002** **NCTID: NCT05918445** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-PDL1 and anti-VEGF bsAb** **Area: Neoplasms** **Indication: advanced RCC** **Human Patients: 380** **Sponsor: BioNTech (BNTX)**	Date: 9 Aug 2024 Quarter: Q4'24 Batch 5 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS against placebo) Commercial: FAILURE (commercially insufficient clinical benefit in OS non-superior to pembrolizumab + lenvatinib)	Readout: 17 Sep 2024 **Lead Time: 39 days in advance** Interpretation: BNT327 achieved 25% cORR + 10.9-month mPFS as 2L for ccRCC; which is non-superior to to 43% ORR + 14.6-month mPFS achieved by Lenvatinib + Everolimus (Lancet doi-10.1016/S1470-2045(15)00290-9) and BNT327 achieved 36% cORR + 15.1-month mPFS as 1L for nccRCC; which is non-superior to 49% ORR + 17.9-month mPFS achieved by pembrolizumab + lenvatinib in KEYNOTE-B61 study (Lancet DOI-10.1016/S1470-2045(23)00276-0).	Correct Prediction Note: Correct Technical prediction (commercial data TBD) Conclusion: statistically significant (against placebo) and commercially TBD Classification: **True Positive (TP)**
1733	**BNT113** **NCTID: NCT04534205** **Phase: Phase 2** **Class: First-In-Class** **Modality: mRNA vaccine** **MoA: HPV16 E6/7 RNA-LPX mRNA vaccine** **Area: Neoplasms** **Indication: Head and Neck Cancer** **Human Patients: 285** **Sponsor: BioNTech (BNTX)**	Date: 9 Aug 2024 Quarter: Q4'24 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR/PFS against pembrolizumab) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS non-superior to pembrolizumab + chemotherapy as 1L SoC)	Readout: 17 Sep 2024 **Lead Time: 39 days in advance** Interpretation: BNT113 + pembrolizumab achieved 40% uORR + 3.9-month mPFS; which is non-superior to 36% ORR + 4.9-month mPFS achieved be chemo + pembrolizumab in KEYNOTE-048 (Lancet DOI-10.1016/S0140-6736(19)32591-7t).	Correct Prediction Conclusion: statistically maybe significant (yet weak additive efficacy) and commercially TBD Classification: **True Negative (TN)**
1731	**BNT327/PM8002** **NCTID: NCT05756972** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-PDL1 and anti-VEGF bsAb** **Area: Neoplasms** **Indication: Non-Small-Cell Lung** **Human Patients: 374** **Sponsor: BioNTech (BNTX)**	Date: 9 Aug 2024 Quarter: Q4'24 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR/PFS non-superior to carboplatin + pemetrexed combotherapy) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate additive clinical benefit in OS numerically superior to carboplatin + pemetrexed combotherapy)	Readout: 17 Sep 2024 **Lead Time: 39 days in advance** Interpretation: BNT327 + chemotherapy achieved 37% cORR; numerically superior to 29% cORR achieved by chemotherapy alone; BNT327 + chemotherapy achieved 61% Grade 3 TEAE; inferior to 20-40% Grade 3 TEAE achieved by chemotherapy alone (see 10.1177/1758834016644155).	Correct Prediction Conclusion: statistically maybe significant (slightly higher ORR with inferior tolerability) and commercially TBD Classification: **True Positive (TP)**
1607	**PBFT02** **NCTID: NCT04747431** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV1-mediated GRN gene therapy** **Area: Nervous System Diseases**	Date: 13 May 2024 Quarter: Q3'24 Batch 8 Technical: partial SUCCESS (statistically significant yet weak clinical benefit in CDR + NACC FTLD) Commercial: partial SUCCESS	Readout: 16 Sep 2024 **Lead Time: 126 days in advance** Interpretation: PBFT02 increased CSF PGRN expression up to 6-10 fold exceeding the range found in healthy adult controls; yet plasma PGRN expression remained below healthy reference levels.	Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Indication: Frontotemporal Dementia and Progranulin Mutations (FTD-GRN) **Human Patients: 15** **Sponsor: Passage Bio (PASG)**	(commercially maybe sufficient clinical benefit in CDR + NACC FTLD)		
660	**TransCon CNP** **NCTID: NCT05598320** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: peptide prodrug** **MoA: long-lasting c-type natriuretic peptide** **Area: Musculoskeletal Diseases** **Indication: Achondroplasia** **Human Patients: 84** **Sponsor: Ascendis Pharma (ASND)**	Date: 29 Aug 2024 Quarter: Q4'24 Batch 14 Technical: SUCCESS (statistically significant clinical benefit in AGV against placebo) Commercial: partial SUCCESS (commercially maybe sufficient yet moderate clinical benefit in AGV inferior to vosoritide due to suboptimal dosage)	Readout: 16 Sep 2024 **Lead Time: 18 days in advance** Interpretation: once-weekly TransCon CNP achieved an AGV with LS mean treatment difference 1.49 cm/year; which is lower than 1.57cm/year achieved by the once-daily SoC vosoritide.	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient (weaker efficacy yet better adherence with once-weekly administration) Classification: **True Positive (TP)**
1784	**BT8009** **NCTID: NCT04561362** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: bicycle toxin conjugate** **MoA: anti-nectin4 BTC with MMAE payload** **Area: Neoplasms** **Indication: metastatic urothelial cancer** **Human Patients: 329** **Sponsor: Bicycle Therapeutics (BCYC)**	Date: 12 Sep 2024 Quarter: Q4'24 Batch 17a Technical: partial SUCCESS (statistically significant (additive) clinical benefit in ORR/PFS numerically inferior to enfortumab vedotin in 2L/3L clinical setting for nectin4-overexpressing advance solid tumors) Commercial: SUCCESS (commercially sufficient (additive) clinical benefit in OS non-inferior-non-superior to enfortumab vedotin in 2L/3L clinical setting for nectin4-overexpressing advance solid tumors that don't have FDA-approved drugs)	Readout: 14 Sep 2024 **Lead Time: 2 days in advance** Interpretation: BT8009 achieved 36.8% cORR (14/38); lower than enfortumab vedotin 40.6% cORR (NEJM DOI-10.1056/NEJMoa2035807).	Correct Prediction Conclusion: statistically significant (numerically inferior to enfortumab vedotin) and commercially TBD Classification: **True Positive (TP)**
1778	**INCB0123667** **NCTID: NCT05238922** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: CDK2 inhibitor** **Area: Neoplasms** **Indication: Solid Tumors** **Human Patients: 340** **Sponsor: Incyte Corporation (INCY)**	Date: 9 Sep 2024 Quarter: Q4'24 Batch 16 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in ORR/PFS with moderate toxicity) Commercial: FAILURE (commercially insufficient clinical benefit in OS)	Readout: 14 Sep 2024 **Lead Time: 5 days in advance** Interpretation: INCB123667 achieved 24.3% ORR (<25% is generally accepted as weak efficacy) without positive dose-response relationship.	Overall Correct Prediction Conclusion: statistically maybe significant (yet weak efficacy) and commercially TBD Classification: **True Negative (TN)**
1416	**ponsegromab** **NCTID: NCT05546476** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-GDF15 mAb inhibitor** **Area: Neoplasms** **Indication: Cancer Cachexia** **Human Patients: 187** **Sponsor: Pfizer (PFE)**	Date: 15 Jan 2024 Quarter: Q1'24 Batch 15 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 14 Sep 2024 **Lead Time: 243 days in advance** Interpretation: ponsegromab exhibited non-positive dose-response relationship and failed to meet key secondary/exploratory endpoints (at most 4-point increase in FAACT-ACS; at most 2-point increase in FAACT-5IASS; CRCSD; physical activity; gait endpoints).	Correct Prediction Conclusion: statistically probably insignificant and commercially insufficient Classification: **True Negative (TN)**
661	**TransCon IL-2 $^{2/3}$ Pembrolizumab Chemotherapy drug TransCon TLR7/8 Agonist Surgery** **NCTID: NCT05081609** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: protein prodrug** **MoA: IL-2 $^{2/3}$ agonist** **Area: Neoplasms** **Indication: Solid Tumor**	Date: 29 Aug 2024 Quarter: Q4'24 Batch 14 Technical: partial SUCCESS (statistically significant additive clinical benefit for TransCon IL2 for certain cancer subindications only); partial FAILURE (statistically insignificant clinical benefit for TransCon TLR7/8) Commercial: partial SUCCESS	Readout: 13 Sep 2024 **Lead Time: 15 days in advance** Interpretation: TransCon chemotherapy achieved 11% cORR for PROC (2/18 including 4 discontinued patients); much lower than targeted therapy mirvetuximab soravtansine (32.4% ORR for FRalpha-expressing PROC).	Overall Correct Prediction Conclusion: statistically probably insignificant (very weak efficacy) and commercially TBD Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Malignancies **Human Patients: 473** **Sponsor: Ascendis Pharma (ASND)**	(commercially sufficient additive clinical benefit for TransCon IL2 for certain cancer subindications only); partial FAILURE (commercially insufficient clinical benefit for TransCon TLR7/8)		
1364	**Luvadaxistat** **NCTID: NCT05182476** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: DAAO inhibitor** **Area: Nervous System Diseases** **Indication: Schizophrenia** **Human Patients: 216** **Sponsor: Neurocrine Biosciences (NBIX)**	Date: 30 Nov 2023 Quarter: Q3'24 Batch 13 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 12 Sep 2024 **Lead Time: 287 days in advance** Interpretation: uvadaxistat failed to meet primary endpoint.	Overall Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1594	**SER-155** **NCTID: NCT04995653** **Phase: Phase 1** **Class: First-In-Class** **Modality: microbiome therapeutic** **MoA: oral 16-strain cultivated microbiome therapeutic** **Area: Immune System Diseases** **Indication: Graft vs. Host Disease (GvHD)** **Human Patients: 60** **Sponsor: Seres Therapeutics (MCRB)**	Date: 12 May 2024 Quarter: Q3'24 Batch 6 Technical: SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit with inferior-to-steroid-or-ruxolitinib efficacy)	Readout: 12 Sep 2024 **Lead Time: 123 days in advance** Interpretation: SER155 achieved a lower-than-placebo incidence of bacterial bloodstream infections (BSIs) (10% vs 42.9% p=0.0423) yet insignificant incidence of febrile neutropenia (p=0.4674).	Correct Prediction Conclusion: statistically bordline significant and commercially insufficient (weak efficacy) Classification: **True Negative (TN)**
1629	**Losmapimod** **NCTID: NCT05397470** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: p38±/²-MAPK sma molecule inhibitor** **Area: Musculoskeletal Diseases** **Indication: Facioscapulohumeral Muscular Dystrophy (FSHD)** **Human Patients: 260** **Sponsor: Fulcrum Therapeutics (FULC)**	Date: 25 Jul 2024 Quarter: Q4'24 Batch 9 Technical: FAILURE (statistically insignificant clinical benefit in RWS) Commercial: FAILURE (commercially insufficient clinical benefitin RWS for patients that are not stratified by p38MAPK expression levels)	Readout: 12 Sep 2024 **Lead Time: 49 days in advance** Interpretation: losmapimod failed to meet RWS primary endpoint.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1740	**dupilumab** **NCTID: NCT04180488** **Phase: Phase 3** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-IL4 and anti-IL13 mAb inhibitor** **Area: Immune System Diseases** **Indication: chronic spontaneous urticaria (CSU)** **Human Patients: 397** **Sponsor: Sanofi (SNY)**	Date: 10 Aug 2024 Quarter: Q4'24 Batch 5 Technical: SUCCESS (statistically significant yet moderate clinical benefit in ISS7/UAS7 against placebo in biologic-naïve refractory CSU patients) Commercial: FAILURE (commercially insufficient clinical benefit in ISS7/UAS7 inferior to both omalizumab and barzolvolimab in biologic-naïve refractory CSU patients)	Readout: 10 Sep 2024 **Lead Time: 31 days in advance** Interpretation: dupilumab achieved 12% placebo-adjusted CR at week 24 (p=0.02) vs. 31% placebo-adjusted CR at week 12 achieved by barzolvolimab in NCT05368285 vs 27% placebo-adjusted CR at week 12 achieved by omalizumab in ASTERIA I study.	Correct Prediction Conclusion: statistically significant and commercially insufficient (inferior to both omalizumab an barzolvolimab) Classification: **True Negative (TN)**
906	**VRDN 001** **NCTID: NCT05176639** **Phase: Phase 3** **Class: Best-In-Class** **Modality: monoclonal antibody** **MoA: anti-IGF1R mAb inhibitor** **Area: Eye Diseases** **Indication: Thyroid Eye Disease (TED)** **Human Patients: 154**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 1 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially sufficient clinical benefit non-superior to Tepezza)	Readout: 10 Sep 2024 **Lead Time: 209 days in advance** Interpretation: VRDN001 achieved 64% placebo-adjusted PRR at week 15 vs. 65% placebo-adjusted PRR at week 15 achieved by the SoC teprotumumab in NCT03298867.	Correct Prediction Conclusion: statistically significant and commercially sufficient (non-superior to teprotumumab) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Viridian Therapeutics (VRDN)			
1247	**NVL-655** **NCTID: NCT05384626** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: CNS-penetrant mutant-selective ALK inhibitor** **Area: Neoplasms** **Indication: Advanced NSCLC and Other Solid Tumors** **Human Patients: 400** **Sponsor: Nuvalent (NUVL)**	Date: 15 Aug 2024 Quarter: Q4'24 Batch 11 Technical: partial SUCCESS (statistically significant clinical benefit in ORR/PFS against placebo for all cohorts; non-superior to lorlatinib/alectinib for cohort 2c/2d/2e/2f) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in OS without mutation-specific stratification; superior to lorlatinib for cohort 2a/2b/2c/2d/2e/2f; non-superior to alectinib for cohort 2c/2d/2e/2f)	Readout: 9 Sep 2024 **Lead Time: 25 days in advance** Interpretation: NVL655 achieved 38% confirmed ORR vs. 48% confirmed ORR achieved by lorlatinib in NCT01970865.	Correct Prediction Conclusion: statistically significant (against placebo non-superior to lorlatinib) and commercially TBD Classification: **True Positive (TP)**
975	**RLY-2608** **NCTID: NCT05216432** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: pan-mutant-selective (H1047X; E542X; and E535X) PI3Kalpha inhibitor** **Area: Neoplasms** **Indication: Advanced Breast Cancer** **Human Patients: 400** **Sponsor: Relay Therapeutics (RLAY)**	Date: 11 Jul 2024 Quarter: Q3'24 Batch 16 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit in ORR/PFS non-superior to alpelisib; in combination with fulvestrant and/or palbociclib/ribociclib) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS inferior to alpelisib; in combination with fulvestrant and/or palbociclib/ribociclib)	Readout: 9 Sep 2024 **Lead Time: 60 days in advance** Interpretation: RLY2608 + fulvestrant achieved 30% confirmed ORR and 9.2months mPFS vs. 26.6% confirmed ORR and 11months mPFS achieved by alpelisib + fulvestrant.	Correct Prediction Note: Correct Technical prediction (commercial data TBD) Conclusion: statistically significant (ORR/PFS non-superior to alpelisib + fulvestrant) and commercially TBD Classification: **True Positive (TP)**
1698	**TERN-601** **NCTID: N/A (adapt NCT05762471 as reference)** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: oral small molecule GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 37** **Sponsor: Terns Pharmaceuticals (TERN)**	Date: 24 Jul 2024 Quarter: Q3'24 Batch 19 Technical: SUCCESS (statistically significant clinical benefit in weight reduction against placebo) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit in weight reduction inferior to VK2735; non-superior non-inferior to orforglipron/GSBR1290)	Readout: 9 Sep 2024 **Lead Time: 47 days in advance** Interpretation: TERN601 achieved 4.9% placebo-adjusted weight reduction at week 4 (N=9) vs. 3.2% placebo-adjusted weight reduction at week 4 achieved by orforglipron (N=57).	Correct Prediction Conclusion: statistically significant (placebo) and commercially sufficient (non-superior non-inferior to orforglipron) Classification: **True Positive (TP)**
1470	**Dapiglutide** **NCTID: NCT05788601** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: peptide** **MoA: dual GLP1R/GLP2R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 54** **Sponsor: Zealand Pharma (ZEAL.CO)**	Date: 15 Feb 2024 Quarter: Q2'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to tirzepatide)	Readout: 9 Sep 2024 **Lead Time: 207 days in advance** Interpretation: dapiglutide achieved 8.9% placebo-adjusted weight reduction at week 13 vs. 7% placebo-adjusted weight reduction at week 13 achieved by tirzepatide.	Correct Prediction Conclusion: statistically significant and commercially sufficient (superior to tirzepatide) Classification: **True Positive (TP)**
1666	**Ivonescimab (AK112)** **NCTID: NCT05499390** **Phase: Phase 3** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-PD-1 and anti-VEGF tetravalent bsAb** **Area: Neoplasms**	Date: 9 Jul 2024 Quarter: Q3'24 Batch 15 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS superior to pembrolizumab) Commercial: SUCCESS (commercially sufficient clinical	Readout: 8 Sep 2024 **Lead Time: 61 days in advance** Interpretation: Median PFS of 11.14 Months vs. 5.82 Months by pembrolizumab and serious TRAEs were 20.8% vs. 16.1%; respectively; in ivonescimab and pembrolizumab arms.	Correct Prediction Conclusion: statistically significant and commercially sufficient (superior) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Indication: Advanced Non-small-cell Lung Cancer **Human Patients: 398** **Sponsor: Summit Therapeutics (SMMT)**	benefit in OS superior to pembrolizumab)		
1749	**mepolizumab** **NCTID: NCT04133909** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-IL5 mAb inhibitor** **Area: Respiratory Tract Diseases** **Indication: Chronic Obstructive Pulmonary Disease (COPD)** **Human Patients: 806** **Sponsor: GSK (GSK)**	Date: 13 Aug 2024 Quarter: Q4'24 Batch 7 Technical: FAILURE (statistically insignificant additive clinical benefit in exacerbation ratio) Commercial: FAILURE (commercially insufficient additive clinical benefit in exacerbation ratio)	Readout: 6 Sep 2024 **Lead Time: 24 days in advance** Interpretation: primary endpoint of annualized exacerbation reduction was met with statistically significant and clinically meaningful efficacy.	Missed Prediction Note: due to suboptimal modelling of eosinophil count in the clinical setting of COPD. Conclusion: statistically significant and commercially sufficient Classification: **False Negative (FN)**
720	**Insulin Efsitora Alfa (LY3209590)** **Insulin Degludec** **NCTID: NCT05275400** **Phase: Phase 3** **Class: Best-In-Class** **Modality: protein biologic** **MoA: once-weekly insulin treatment** **Area: Nutritional and Metabolic Diseases** **Indication: Type 2 Diabetes** **Human Patients: 986** **Sponsor: Eli Lilly and Company (LLY)**	Date: 26 Nov 2022 Quarter: - Batch - Technical: SUCCESS (non-inferior) Commercial: SUCCESS (non-inferior)	Readout: 5 Sep 2024 **Lead Time: 649 days in advance** Interpretation: -0.86% (efsitora) vs -0.76% (degludec) HbA1C at week 26.	Correct Prediction Conclusion: statistically significant and commercially sufficient (non-inferior) Classification: **True Positive (TP)**
1628	**fosgonimeton (ATH-1017)** **NCTID: NCT04488419** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: HGF/MET agonist** **Area: Nervous System Diseases** **Indication: Alzheimer's Disease** **Human Patients: 554** **Sponsor: Athira Pharma (ATHA)**	Date: 24 Jun 2024 Quarter: Q3'24 Batch 14 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to lecanemab)	Readout: 3 Sep 2024 **Lead Time: 71 days in advance** Interpretation: none of the primary and secondary endpoints were met; with numerical treatment effect for APOE4 carriers.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1253	**DYNE-251** **NCTID: NCT05524883** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: siRNA** **MoA: dystrophin exon 51 skipping Fab** **Area: Musculoskeletal Diseases** **Indication: Duchenne Muscular Dystrophy (DMD)** **Human Patients: 88** **Sponsor: Dyne Therapeutics (DYN)**	Date: 21 Nov 2023 Quarter: Q1'24 Batch 7 Technical: partial SUCCESS (statistically significant clinical benefit in dystrophin protein level); partial FAILURE (statistically insignificant clinical benefit in NSAA/10MRW/FVC) Commercial: FAILURE (commercially insufficient clinical benefit in 6MWD)	Readout: 3 Sep 2024 **Lead Time: 287 days in advance** Interpretation: a mean absolute dystrophin expression of 3.71% of normal; yet weak functional efficacy(change from baseline in SV95C only meet EMA-defined minimal clinically important difference (MCID); whereas other functional efficacy endpoints NSAA/10MWR probably didn't reach MCID).	Overall Correct Prediction Conclusion: statistically partially significant (dystrophin expression) and partially insignificant (functional endpoints) and commercially probably insufficient (weak efficacy) Classification: **True Negative (TN)**
1598	**VAX-31** **NCTID: NCT06151288** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: vaccine** **MoA: 31-valent pneumococcal conjugate antigen-based vaccine** **Area: Infections** **Indication: invasive pneumococcal disease (IPD)** **Human Patients: 1015** **Sponsor: Vaxcyte (PCVX)**	Date: 12 May 2024 Quarter: Q3'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit non-inferior-and-non-superior-to PCV20) Commercial: SUCCESS (commercially sufficient clinical benefit non-inferior-and-non-superior-to PCV20)	Readout: 3 Sep 2024 **Lead Time: 114 days in advance** Interpretation: OPA response non-inferiority criteria met for all 20 serotypes against SoC PCV20 and regulatory immunogenicity met for all 31 serotypes.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1244	**PRAX-562** **NCTID: NCT05818553** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: anti-SCN8A antagonist** **Area: Nervous System Diseases** **Indication: Developmental and Epileptic Encephalopathies** **Human Patients: 20** **Sponsor: Praxis Precision Medicines (PRAX)**	Date: 5 Jan 2024 Quarter: Q2'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit more for SCN8A-mutant patients than for SCN2A-mutant patients) Commercial: SUCCESS (commercially sufficient clinical benefit for SCN8A-mutant patients)	Readout: 3 Sep 2024 **Lead Time: 242 days in advance** Interpretation: 46% placebo-adjusted reduction in monthly motor seizure and thus primary endpoint met (whether efficacy is better for SCN8A-DEE is pending for further data).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1428	**Tolebrutinib** **NCTID: NCT04410991** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: CNS-penetrant BTK inhibitor** **Area: Nervous System Diseases** **Indication: Relapsing Forms of Multiple Sclerosis (RMS)** **Human Patients: 899** **Sponsor: Sanofi (SNY)**	Date: 24 Jan 2024 Quarter: Q1'24 Batch 15 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to teriflunomide)	Readout: 2 Sep 2024 **Lead Time: 222 days in advance** Interpretation: superiority primary endpoint (Tolebrutinib vs teriflunomide in annualized replace rate reduction) not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1427	**Tolebrutinib** **NCTID: NCT04410978** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: CNS-penetrant BTK inhibitor** **Area: Nervous System Diseases** **Indication: Relapsing Forms of Multiple Sclerosis (RMS)** **Human Patients: 974** **Sponsor: Sanofi (SNY)**	Date: 24 Jan 2024 Quarter: Q1'24 Batch 15 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to teriflunomide)	Readout: 2 Sep 2024 **Lead Time: 222 days in advance** Interpretation: superiority primary endpoint (Tolebrutinib vs teriflunomide in annualized replace rate reduction) not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1377	**Vutrisiran Sterile Normal Saline (0.9% NaCl)** **NCTID: NCT04153149** **Phase: Phase 3** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: anti-TTR siRNA** **Area: Nutritional and Metabolic Diseases** **Indication: Transthyretin Amyloidosis (ATTR) With Cardiomyopathy** **Human Patients: 655** **Sponsor: Alnylam Pharmaceuticals (ALNY)**	Date: 22 Dec 2023 Quarter: Q1'24 Batch 11 Technical: FAILURE (statistically maybe significant yet weak clinical benefit for the composite endpoint) Commercial: FAILURE (commercially insufficient clinical benefit inferior to both tafamidis and acroramidis)	Readout: 30 Aug 2024 **Lead Time: 252 days in advance** Interpretation: composite primary endpoint met (1.2% ARR and 13.8% RRR at month 30); inferior to 6.4% ARR and 25% RRR at month 30 p<0.0001 for Acoramidis in ATTRIBUTE-cm study; and inferior to 13.4% ARR and 31.2% RRR at month 30 p=0.0006 for tafamidis in ATTR-ACT study); secondary endpoint 6MWD met p<0.025 (vs p<0.0001 for both Acoramidis and tafamidis); all cause modality met with p<0.05.	Correct Prediction Conclusion: statistically significant and commercially insufficient inferior to both Acoramidis and tafamidis Classification: **True Negative (TN)**
1661	**NBI-1117568** **NCTID: NCT05545111** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral CHRM4 agonist** **Area: Nervous System Diseases** **Indication: Schizophrenia** **Human Patients: 213** **Sponsor: Neurocrine Biosciences (NBIX)**	Date: 6 Jul 2024 Quarter: Q3'24 Batch 13 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in PANSS at week 6 against placebo featuring moderate toxicity) Commercial: FAILURE (commercially insufficient clinical benefit in PANSS and toxicity inferior to KarXT yet non-inferior/non-superior to emraclidine)	Readout: 28 Aug 2024 **Lead Time: 53 days in advance** Interpretation: achieved 7.5 point placebo-adjusted improvement in PNASS score; inferior to the SoC KarXT that showed 11.6-point placebo-adjusted improvement in phase 3 studies.	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1304	**Cabozantinib**	Date: 31 Oct 2023	Readout: 24 Aug 2024	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT03937219 **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: RTK inhibitor** **Area: Neoplasms** **Indication: Renal Cell Carcinoma** **Human Patients: 855** **Sponsor: Exelixis (EXEL)**	Quarter: Q1'24 Batch 3 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	**Lead Time: 298 days in advance** Interpretation: cabozantinib failed to achieve additive clinical benefit in OS	Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1358	**Tafasitamab Rituximab Lenalidomide Placebo** **NCTID: NCT04680052** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-CD19 Fc-enhanced mAb** **Area: Neoplasms** **Indication: Relapsed/(R/R) Follicular Lymp Marginal Zone Lymphoma** **Human Patients: 654** **Sponsor: Incyte Corporation (INCY)**	Date: 30 Nov 2023 Quarter: Q3'24 Batch 16 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit)	Readout: 15 Aug 2024 **Lead Time: 259 days in advance** Interpretation: superior to the SoC (Lenalidomide + Rituximab) for both PFS (primary endpoint met) and and CR (secondary endpoint met).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1560	**TBio-4101 Pembrolizumab** **NCTID: NCT05576077** **Phase: Phase 1** **Class: First-In-Class** **Modality: cell therapy** **MoA: autologous TIL cell therapy** **Area: Neoplasms** **Indication: Advanced Solid Tumors** **Human Patients: 60** **Sponsor: Turnstone Biologics (TSBX)**	Date: 23 Apr 2024 Quarter: Q3'24 Batch 2 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS)	Readout: 14 Aug 2024 **Lead Time: 113 days in advance** Interpretation: 25% ORR achieved by TBio-4101 + pembrolizumab for MSI-stable CRC vs 30%-40% ORR achieved by regorafenib+ novolumab (Fakih et al. Huyck 2023 eClinicalMedicine).	Correct Prediction Conclusion: statistically significant yet weak and commercially insufficient Classification: **True Negative (TN)**
1535	**LTX-315 Part 1 VP-315 Part 2** **NCTID: NCT05188729** **Phase: Phase 2** **Class: First-In-Class** **Modality: oncolytic peptide therapy** **MoA: oncolytic peptide immunotherapy derived from bovine lactoferrin** **Area: Neoplasms** **Indication: Basal Cell Carcinoma** **Human Patients: 80** **Sponsor: Verrica Pharmaceuticals (VRCA)**	Date: 9 Apr 2024 Quarter: Q2'24 Batch 14 Technical: SUCCESS (statistically significant clinical benefit in clinical clearance) Commercial: FAILURE (commercially insufficient clinical benefit inferior to imiquimod)	Readout: 14 Aug 2024 **Lead Time: 127 days in advance** Interpretation: 51% CR lower than 80% CR achieved by imiquimod (DOI- 10.1016/j.jaad.2003.11.066).	Correct Prediction Conclusion: statistically significant and commercially insufficient (inferior to imiquimod) Classification: **True Negative (TN)**
1743	**KZR-261** **NCTID: NCT05047536** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: small molecule SEC61 inhibitor** **Area: Neoplasms** **Indication: Advanced Solid Malignancies** **Human Patients: 61** **Sponsor: Kezar Life Sciences (KZR)**	Date: 10 Aug 2024 Quarter: Q4'24 Batch 6 Technical: FAILURE (statistically insignificant clinical benefit in ORR/PFS) Commercial: FAILURE (commercially insufficient clinical benefit in OS)	Readout: 13 Aug 2024 **Lead Time: 3 days in advance** Interpretation: 0% ORR and trial terminated	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1188	**Izokibep** **NCTID: NCT05905783**	Date: 22 Jul 2023 Quarter: - Batch -	Readout: 12 Aug 2024 **Lead Time: 387 days in advance**	Overall Correct Prediction Conclusion: statistically significant

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 3 **Class: Best-In-Class** **Modality: small protein scaffold-based biologic** **MoA: IL-17A Inhibitior** **Area: Immune System Diseases** **Indication: Hidradenitis Suppurativa** **Human Patients: 258** **Sponsor: Acelyrin (SLRN)**	Technical: SUCCESS (statistically significant) Commercial: SUCCESS (commercially sufficient clinical benefit superior to adalimumab and non-inferior to sonelokimab)	Interpretation: izokibep achieved 14% placebo-adjusted HiSCR100; superior to single-digit placebo-adjusted HiSCR100 achieved by adalimumab; and above the inferior threshold compared with 20%-30% placebo-adjusted HiSCR100 achieved by sonelokimab.	and commercially fairly sufficient (superior to adalimumab and non-inferior to sonelokimab) Classification: **True Positive (TP)**
1183	**Izokibep** **NCTID: NCT05355805** **Phase: Phase 2** **Class: First-In-Class** **Modality: small protein scaffold-based biologic** **MoA: IL-17A Inhibitior** **Area: Immune System Diseases** **Indication: Hidradenitis Suppurativa** **Human Patients: 176** **Sponsor: Acelyrin (SLRN)**	Date: 22 Jul 2023 Quarter: - Batch - Technical: SUCCESS (statistically significant) Commercial: SUCCESS (commercially sufficient clinical benefit superior to adalimumab and non-inferior to sonelokimab)	Readout: 12 Aug 2024 **Lead Time: 387 days in advance** Interpretation: izokibep achieved14% placebo-adjusted HiSCR100; superior to single-digit placebo-adjusted HiSCR100 achieved by adalimumab; and above the inferior threshold compared with 20%-30% placebo-adjusted HiSCR100 achieved by sonelokimab.	Overall Correct Prediction Conclusion: statistically significant and commercially fairly sufficient (superior to adalimumab and non-inferior to sonelokimab) Classification: **True Positive (TP)**
1625	**Tamibarotene Venetoclax Azacitidine** **NCTID: NCT04905407** **Phase: Phase 2** **Class: First-In-Class** **Modality: synthetic retinoid** **MoA: RARalpha agonist** **Area: Neoplasms** **Indication: Acute Myeloid Leukemia** **Human Patients: 95** **Sponsor: Syros Pharmaceuticals (SYRS)**	Date: 15 May 2024 Quarter: Q3'24 Batch 10 Technical: FAILURE (statistically insignificant additive clinical benefit in in CR) Commercial: FAILURE (commercially insufficient additive clinical benefit OS)	Readout: 12 Aug 2024 **Lead Time: 89 days in advance** Interpretation: CR/CRi achieved by tamibarotene + SoC vs 70% CR/CRi achieved by SoC; and trial terminated.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1695	**Epetraborole** **NCTID: NCT05327803** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: a novel bacterial leucyl-tRNA synthetase inhibitor** **Area: Respiratory Tract Diseases** **Indication: MAC Lung Disease** **Human Patients: 314** **Sponsor: AN2 Therapeutics (ANTX)**	Date: 24 Jul 2024 Quarter: Q3'24 Batch 19 Technical: FAILURE (statistically insignificant additive clinical benefit in clinical response as an adjunctive therapy to SoC) Commercial: FAILURE (commercially insufficient additive clinical benefit in reinfection/relapse as an adjunctive therapy to SoC)	Readout: 8 Aug 2024 **Lead Time: 15 days in advance** Interpretation: 13.9% placebo-adjusted difference (p=0.19) in PRO-based clinical response rate and trial discontinued for low efficacy.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
882	**Pegcetacoplan** **NCTID: NCT05067127** **Phase: Phase 3** **Class: First-In-Class** **Modality: PEGylated peptide** **MoA: PEGylated C3b inhibitor** **Area: Urogenital Diseases** **Indication: C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN)** **Human Patients: 90** **Sponsor: Apellis Pharmaceuticals (APLS)**	Date: 14 May 2024 Quarter: Q3'24 Batch 10 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit in eGFR)	Readout: 8 Aug 2024 **Lead Time: 86 days in advance** Interpretation: Pegcetacoplan achieved 68% placebo-adjusted reduction in proteinuria (p<0.0001) and statistically significant improvement in eGFR secondary endpoint.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1675	**Reproxalap Ophthalmic Solution (0.25%) Vehicle ophthalmic solution** **NCTID: NCT06424444** **Phase: Phase 3**	Date: 11 Jul 2024 Quarter: Q3'24 Batch 16 Technical: SUCCESS (statistically significant yet weak clinical benefit in treating ocular discomfort)	Readout: 8 Aug 2024 **Lead Time: 28 days in advance** Interpretation: statistically significant (p=0.004 without improvement data released (usually a sign of not strong	Correct Prediction Conclusion: statistically significant and commercially maybe sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: First-In-Class **Modality: small molecule** **MoA: RASP inhibitor** **Area: Eye Diseases** **Indication: Dry Eye Disease** **Human Patients: 400** **Sponsor: Aldeyra Therapeutics (ALDX)**	Commercial: partial SUCCESS (commercially maybe sufficient yet mixed clinical benefit in treating ocular symptoms)	efficacy); yet commercially sufficient for an unsaturated market.	
1554	**EO-3021** **NCTID: NCT05980416** **Phase: Phase 1** **Class: First-In-Class** **Modality: antibody-drug conjugate (ADC)** **MoA: DAR-2 anti-claudin18.2 ADC with MMAE as payload** **Area: Neoplasms** **Indication: Pancreas Neoplasm Stomach Neoplasm Gastrointestinal Neoplasms Digestive System Neoplasm Neoplasms by Site Neoplasms** **Human Patients: 120** **Sponsor: Elevation Oncology (ELEV)**	Date: 23 Apr 2024 Quarter: Q3'24 Batch 2 Technical: partial SUCCESS (statistically significant yet moderate additive clinical benefit due to dose-limiting toxicity whose degree depends on claudin 18.2 expression levels) Commercial: FAILURE (commercially insufficient additive clinical benefit with non-superior-to-zolbetuximab efficacy and non-superior-to-zolbetuximab toxicity)	Readout: 6 Aug 2024 **Lead Time: 105 days in advance** Interpretation: EO-3021 achieved 20% ORR which is significantly lower than 47% ORR achieved by EO-3021 in previous Chinese-only study; 42.8% ORR for CLDN18.2 > 20% and 0% ORR for Claudin 18.2 <20% Four dose-limiting toxicities at 2.9mg/kg dose.	Overall Correct Prediction Conclusion: statistically significant (moderate ORR) and commercially insufficient Classification: **True Negative (TN)**
1095	**Evorpacept (ALX148)** **NCTID: NCT05002127** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: anti-CD47 blocker** **Area: Neoplasms** **Indication: Advanced HER2+ Gastric Cancer** **Human Patients: 450** **Sponsor: ALX Oncology (ALXO)**	Date: 25 Jun 2024 Quarter: Q3'24 Batch 14 Technical: SUCCESS (statistically significant additive clinical benefit to trastuzumab + ramucirumab + paclitaxel in ORR as 2L/3L treatments for advanced HER2-overexpressing gastric cancer for phase 2) Commercial: SUCCESS (statistically significant additive clinical benefit to trastuzumab + ramucirumab + paclitaxel in OS as 2L/3L treatments for advanced HER2-overexpressing gastric cancer for phase 3)	Readout: 31 Jul 2024 **Lead Time: 36 days in advance** Interpretation: evorpacept+TRP achieved an ORR of 40.3% vs 26.6% achieved by TRP (a 13.7% delta which is lower than 30% delta at interim).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1677	**Biological- Human Acellular Vessel (HAV) Procedure-Arteriovenous fistula (AVF)** **NCTID: NCT03183245** **Phase: Phase 3** **Class: First-In-Class** **Modality: bioengineered acellular tissue (Device)** **MoA: tissue-enginner acellular vascular conduit** **Area: Renal Replacement Therapy** **Indication: Hemodialysis** **Human Patients: 240** **Sponsor: Humacyte (HUMA)**	Date: 14 Jul 2024 Quarter: Q3'24 Batch 17 Technical: SUCCESS (statistically significant clinical benefit in proportion of subjects with functional patency at month 6 non-inferior to AVF and proportion of subjects with secondary patency at month 12 superior to AVF) Commercial: SUCCESS (commercially sufficient clinical benefit in patency/infection/aneurysm increasingly superior to AVF as time progresses)	Readout: 31 Jul 2024 **Lead Time: 17 days in advance** Interpretation: functional patency at month 6 and secondary patency at month 12 jointly superior to SoC AV fistula (p=0.0071).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1557	**PGN-EDO51** **NCTID: NCT06079736** **Phase: Phase 2** **Class: First-In-Class** **Modality: peptide-conjugated antisense oligonucleotide ASO** **MoA: EDO cell-penetrating peptide conjugated with dystrophin exon 51 skipping oligonucleotide** **Area: Musculoskeletal Diseases** **Indication: Duchenne Muscular Dystrophy (DMD)** **Human Patients: 10**	Date: 23 Apr 2024 Quarter: Q3'24 Batch 2 Technical: SUCCESS (statistically significant clinical benefit in dystrophin protein level) Commercial: FAILURE (commercially insufficient clinical benefit in the registrational endpoint 6MWD non-superior-to and non-inferior-to SRP-5051)	Readout: 30 Jul 2024 **Lead Time: 98 days in advance** Interpretation: 5mg low-dose exon skipping level and dystrophin level comparable to SRP5051 20mg (NCT04004065).	Correct Prediction Note: Correct Technical prediction (commercial data TBD) Conclusion: statistically significant and commercially TBD (pending functional efficacy data) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: PepGen (PEPG)			
456	**Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX** **NCTID: NCT03941093** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-CTGF mAb inhibitor** **Area: Neoplasms** **Indication: Locally Advanced Pancreatic Cancer** **Human Patients: 284** **Sponsor: FibroGen (FGEN)**	Date: 15 May 2024 Quarter: Q3'24 Batch 12 Technical: partial SUCCESS (statistically maybe significant additive clinical benefit in ORR/PFS) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS)	Readout: 30 Jul 2024 **Lead Time: 76 days in advance** Interpretation: OS endpoint not met (p=0.55).	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
861	**Barzolvolimab Matching Placebo** **NCTID: NCT05405660** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: KIT receptor tyrosine kinase inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Chronic Inducible Urticaria** **Human Patients: 196** **Sponsor: Celldex Therapeutics (CLDX)**	Date: 19 Aug 2023 Quarter: 2H'23 Batch 16 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 29 Jul 2024 **Lead Time: 345 days in advance** Interpretation: CDX0159 achieved 40.6% placebo-adjusted CR.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1257	**VTX958** **NCTID: NCT05688852** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral selective allosteric TYK2 inhibitor** **Area: Immune System Diseases** **Indication: Crohn Disease** **Human Patients: 132** **Sponsor: Ventyx Biosciences (VTYX)**	Date: 23 Apr 2024 Quarter: Q3'24 Batch 3 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 29 Jul 2024 **Lead Time: 97 days in advance** Interpretation: primary endpoint in CDAI score not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1011	**Obicetrapib** **NCTID: NCT05425745** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: selective CETP inhibitor** **Area: Nutritional and Metabolic Diseases** **Indication: Heterozygous Familial Hypercholesterolemia (HeFH)** **Human Patients: 354** **Sponsor: NewAmsterdam Pharma (NAMS)**	Date: 12 May 2024 Quarter: Q3'24 Batch 6 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit of obicetrapib in LDL-C reduction with significantly increased toxicity-driven mortality) Commercial: FAILURE (commercially insufficient additive clinical benefit of obicetrapib in MACE or cardiovascular hospitalization with significantly increased toxicity-driven mortality)	Readout: 29 Jul 2024 **Lead Time: 78 days in advance** Interpretation: safe yet with 41.5% LDL-C reduction by Day 364 which is weaker than the market expected 50% LDL-C reduction.	Correct Prediction Conclusion: statistically significant yet commercially insufficient Classification: **True Negative (TN)**
1510	**CT1812** **NCTID: NCT03507790** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: allosteric sigma-2 receptor antagonist** **Area: Nervous System Diseases** **Indication: Mild to Moderate**	Date: 18 Mar 2024 Quarter: Q2'24 Batch 12 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit despite tolerable toxicity) Commercial: FAILURE (commercially insufficient clinical benefit inferior to	Readout: 29 Jul 2024 **Lead Time: 133 days in advance** Interpretation: safe yet none of the key exploratory efficacy endpoints was met (consistent trend only).	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Alzheimer's Disease **Human Patients: 153** **Sponsor: Cognition Therapeutics (CGTX)**	donanemab/lecanemab)		
1638	**BLZ945** **NCTID: NCT04066244** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: CSF1R inhibitor** **Area: Nervous System Diseases** **Indication: Amyotrophic Lateral Sclerosis (ALS)** **Human Patients: 28** **Sponsor: Novartis (NVS)**	Date: 1 Jul 2024 Quarter: - Batch - Technical: FAILURE (statistically insignificant additive clinical benefit with moderate toxicity to accelerate ALS disease progression) Commercial: FAILURE (commercially insufficient additive clinical benefit in ALSFRS-R)	Readout: 26 Jul 2024 **Lead Time: 25 days in advance** Interpretation: not disclosed yet trial terminated after internal review of efficacy and toxicity available data	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1413	**PF-07055480 / Giroctocogene Fitelparvovec** **NCTID: NCT04370054** **Phase: Phase 3** **Class: First-In-Class** **Modality: gene therapy** **MoA: rAAV6 vector carrying a B-domain-deleted F8 gene** **Area: Hematologic Diseases** **Indication: Hemophilia A** **Human Patients: 76** **Sponsor: Pfizer / Sangamo Therapeutics (PFE / SGMO)**	Date: 15 Jan 2024 Quarter: Q1'24 Batch 15 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially sufficient clinical benefit with superior-to-Roctavian efficacy and non-superior-to-Roctavian toxicity)	Readout: 24 Jul 2024 **Lead Time: 191 days in advance** Interpretation: superior efficacy (98.3% ABR reduction vs 84% ABR reduction by Roctavian) and non-superior toxicity (20% SAE vs 16.4% SAE).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1379	**SAGE-324** **NCTID: NCT05173012** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: steriod GABAAR PAM** **Area: Nervous System Diseases** **Indication: Essential Tremor** **Human Patients: 147** **Sponsor: Sage Therapeutics (SAGE)**	Date: 15 Dec 2023 Quarter: Q1'24 Batch 10 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 24 Jul 2024 **Lead Time: 222 days in advance** Interpretation: endpoints not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1404	**ION582** **NCTID: NCT05127226** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: intrathecal anti-UBE3A-AS ASO** **Area: Nervous System Diseases** **Indication: Angelman Syndrome** **Human Patients: 51** **Sponsor: Ionis Pharmaceuticals (IONS)**	Date: 3 Jan 2024 Quarter: Q2'24 Batch 8 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit non-superior non-inferior to GTX102)	Readout: 22 Jul 2024 **Lead Time: 201 days in advance** Interpretation: 97% patients have improvements in SAS-CGI-C endpoint and consistent improvements in multiple functions; advance to pivotal trial alone by Ionis.	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Positive (TP)**
1664	**LX2006** **NCTID: NCT05445323** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAVrh10-based gene therapy that deliver human FXN gene to cardiac cells** **Area: Nervous System Diseases** **Indication: Friedreich's Ataxia** **Human Patients: 9** **Sponsor: Lexeo Therapeutics**	Date: 7 Jul 2024 Quarter: Q3'24 Batch 13 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit in cardiac fibrosis/cardiac arrhythmia/exercise tolerance despite significantly increasing FXN expression level) Commercial: FAILURE (commercially insufficient clinical benefit in cardiac fibrosis/cardiac arrhythmia/exercise tolerance)	Readout: 15 Jul 2024 **Lead Time: 8 days in advance** Interpretation: 11.4% LVMI reduction at month 12; which falls in the lower end of the minimal clinically meaningful improvement threshold of 10-15% reduction in LVMI over 6 to 12 months.	Correct Prediction Conclusion: statistically maybe significant yet weak clinical benefit and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	(LXEO)			
1175	**RMC-6236** **NCTID: NCT05379985** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: pan-RAS-mutation ON inhibitor** **Area: Neoplasms** **Indication: RAS Mutant Advanced Solid Tumors** **Human Patients: 474** **Sponsor: Revolution Medicines (RVMD)**	Date: 16 Jul 2023 Quarter: 2H'23 Batch 11 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit non-superior to RAS(OFF) inhibitors)	Readout: 15 Jul 2024 **Lead Time: 365 days in advance** Interpretation: 20-21% ORR at week 14 vs 16% ORR achieved by Nal-IRI + 5-FU/LV for any PDAC (see add link for Nal-IRI data in Lancet) or 21% ORR achieved by Sotorasib in CodeBreaK 100 trial NEJM.	Correct Prediction Conclusion: statistically significant and commercially probably insufficient (weak ORR improvement) Classification: **True Negative (TN)**
1240	**Eftilagimod alpha Pembrolizumab** **NCTID: NCT04811027** **Phase: Phase 2** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: a Soluble LAG-3 Fusion Protein** **Area: Neoplasms** **Indication: Recurrent or Metastatic HNSCC** **Human Patients: 171** **Sponsor: Immutep (IMMP)**	Date: 4 Sep 2023 Quarter: 2H'23 Batch 17 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit)	Readout: 12 Jul 2024 **Lead Time: 312 days in advance** Interpretation: 35.5% ORR vs 30.8% ORR for chemo+pembrolizumab in CPS <1 population (Burtness et al. 2022 J. Clin Oncol).	Correct Prediction Conclusion: statistically significant (superior to SoC ORR) and commercially TBD (OS data pending) Classification: **True Positive (TP)**
908	**AMT-130** **NCTID: NCT05243017** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV gene therapy that delivers anti-HTT miRNA** **Area: Nervous System Diseases** **Indication: Early Manifest Huntington's Disease** **Human Patients: 15** **Sponsor: uniQure (QURE)**	Date: 13 May 2024 Quarter: Q3'24 Batch 8 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit in UHDRS) Commercial: FAILURE (commercially insufficient clinical benefit in UHDRS)	Readout: 9 Jul 2024 **Lead Time: 57 days in advance** Interpretation: externally statistically significant less cUHDRS (-0.2 vs -1 at Month 24 for high-dose only (p=0.007) but not low-dose (p=0.21); no statistical improvement in motor or cognitive function even for high-dose group.	Correct Prediction Conclusion: still statistically maybe significant (not strictly placebo-controlled) and commercially insufficient (no motor cognitive function improvement) Classification: **True Negative (TN)**
909	**AMT-130** **NCTID: NCT04120493** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV gene therapy that delivers anti-HTT miRNA** **Area: Nervous System Diseases** **Indication: Early Manifest Huntington's Disease** **Human Patients: 36** **Sponsor: uniQure (QURE)**	Date: 13 May 2024 Quarter: Q3'24 Batch 8 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit in UHDRS) Commercial: FAILURE (commercially insufficient clinical benefit in UHDRS)	Readout: 9 Jul 2024 **Lead Time: 57 days in advance** Interpretation: externally statistically significant less cUHDRS (-0.2 vs -1 at Month 24 for high-dose only (p=0.007) but not low-dose (p=0.21); no statistical improvement in motor or cognitive function even for high-dose group.	Correct Prediction Conclusion: still statistically maybe significant (not strictly placebo-controlled) and commercially insufficient (no motor cognitive function improvement) Classification: **True Negative (TN)**
396	**HIL-214** **NCTID: NCT05281094** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: virus-like particle vaccine** **MoA: norovirus bivalent GI.1/GII/4 VLP vaccine** **Area: Infections** **Indication: Norovirus** **Human Patients: 3085** **Sponsor: HilleVax (HLVX)**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 1 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 8 Jul 2024 **Lead Time: 145 days in advance** Interpretation: endpoints not met.	Missed Prediction Note: due to suboptimal disease model of norovirus that has been permanently corrected. Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**
934	**Buntanetap**	Date: 24 Mar 2024	Readout: 2 Jul 2024	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT05357989 **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: neurotoxic protein synthesis inhibitor** **Area: Nervous System Diseases** **Indication: Parkinson's Disease** **Human Patients: 523** **Sponsor: Annovis Bio (ANVS)**	Quarter: Q2'24 Batch 13 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	**Lead Time: 100 days in advance** Interpretation: primary efficacy endpoint not met in presentation rather than press release (x.com/adamfeuerstein/status/1808471091066581487)	Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1580	**Descartes-08** **NCTID: NCT04146051** **Phase: Phase 2b** **Class: First-In-Class** **Modality: CAR-T therapy** **MoA: autologous anti-BCMA CAR-T therapy** **Area: Immune System Diseases** **Indication: Generalized Myasthenia Gravis** **Human Patients: 30** **Sponsor: Cartesian Therapeutics (RNAC)**	Date: 26 Apr 2024 Quarter: Q3'24 Batch 3 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit with superior-to-efgartigimod efficacy)	Readout: 2 Jul 2024 **Lead Time: 67 days in advance** Interpretation: 46% placebo-adjusted >=5 MGC response at week 12 (vs efgartigimod 30% placebo-adjusted >=3 MGC response at week 26 ADAPT trial).	Correct Prediction Conclusion: statistically significant and commercially sufficient superior to efgartigimod Classification: **True Positive (TP)**
849	**RP-6306** **NCTID: NCT05147350** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: oral PKMYT1 inhibitor** **Area: Neoplasms** **Indication: Advanced Solid Tumors** **Human Patients: 36** **Sponsor: Repare Therapeutics (RPTX)**	Date: 15 Feb 2024 Quarter: Q2'24 Batch 5 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 26 Jun 2024 **Lead Time: 132 days in advance** Interpretation: 12% confirmed ORR (4/33) vs 30%-50% ORR for other X+FOLDIRI combotherspies.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1478	**LYL797** **NCTID: NCT05274451** **Phase: Phase 1** **Class: First-In-Class** **Modality: CAR-T therapy** **MoA: Epi-R-enhanced c-JUN-overexpressing anti-ROR1 CAR-T therapy** **Area: Neoplasms** **Indication: Solid Tumors** **Human Patients: 54** **Sponsor: Lyell Immunopharma (LYEL)**	Date: 18 Feb 2024 Quarter: Q2'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit in ORR/PFS/OS) Commercial: SUCCESS (commercially sufficient clinical benefit superior to other CAR-T therapies for ROR1+ advanced solid tumors)	Readout: 26 Jun 2024 **Lead Time: 129 days in advance** Interpretation: 40% ORR (superior to 27% placebo-adjusted ORR by trodelvy for advanced TNBC in ASCENT study) yet with 35% grade>3 TEAEs (pneumonitis and hypoxia).	Overall Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1398	**Molgramostim** **NCTID: NCT04544293** **Phase: Phase 3** **Class: First-In-Class** **Modality: recombinant protein biologic** **MoA: recombinant GM-CSF** **Area: Respiratory Tract Diseases** **Indication: Autoimmune Pulmonary Alveolar Proteinosis** **Human Patients: 160** **Sponsor: Savara (SVRA)**	Date: 1 Jan 2024 Quarter: Q2'24 Batch 5 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 26 Jun 2024 **Lead Time: 177 days in advance** Interpretation: lung function primary endpoint placebo-adjusted DLCO met at both 24 and 48 weeks (6 to 6.9 with p <0.001); yet 5/6 clinical benefit secondary endpoints (SRGQ total/activity scores and exercise capacity) not met at 24 weeks and 48 weeks with abnormal duration-response relationship.	Overall Correct Prediction Conclusion: statistically significant yet commercially insufficient clinical benefit Classification: **True Negative (TN)**
1246	**WVE-003** **NCTID: NCT05032196** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: stereopure antisense**	Date: 21 Nov 2023 Quarter: 2H'23 Batch 28 Technical: partial SUCCESS (statistically significant clinical benefit in reducing mHTT protein level);	Readout: 25 Jun 2024 **Lead Time: 217 days in advance** Interpretation: -46% mean reduction in mHTT yet insignificant improvement for TMS.	Correct Prediction Conclusion: statistically significant in mHTT and commercially insufficient in TMS

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	oligonucleotide **MoA: SNP3 mtHTT mRNA oligonucleotide** **Area: Nervous System Diseases** **Indication: Huntington's Disease** **Human Patients: 47** **Sponsor: Wave Life Sciences (WVE)**	partial FAILURE (statistically insignificant clinical benefit in modifying disease progression) Commercial: FAILURE (commercially insufficient clinical benefit in modifying disease progression despite significant reduction in mHTT protein)		Classification: **True Negative (TN)**
1585	**Xevinapant (Debio 1143)** **Cisplatin Intensity Modulation Radiation Therapy (IMRT)** **Placebo** **NCTID: NCT04459715** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: oral IAP inhibitor** **Area: Neoplasms** **Indication: Squamous Cell Carcinoma of the Head and Neck** **Human Patients: 730** **Sponsor: Merck KGaA (MKKGY)**	Date: 8 May 2024 Quarter: Q3'24 Batch 10 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR/EFS) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS)	Readout: 24 Jun 2024 **Lead Time: 47 days in advance** Interpretation: unlikely to meet EFS primary endpoints and discontinued.	Overall Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1610	**Xevinapant IMRT Placebo** **NCTID: NCT05386550** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: oral IAP inhibitor** **Area: Neoplasms** **Indication: Head and Neck Cancer** **Human Patients: 166** **Sponsor: Merck KGaA (MKKGY)**	Date: 14 May 2024 Quarter: - Batch - Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in DFS) Commercial: FAILURE (commercially insufficient additive clinical benefit in OS)	Readout: 24 Jun 2024 **Lead Time: 41 days in advance** Interpretation: unlikely to meet DFS primary endpoints and discontinued.	Overall Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
407	**Trilaciclib Placebo Gemcitabine Carboplatin** **NCTID: NCT04799249** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: CDK4/6 inhibitor** **Area: Neoplasms** **Indication: TNBC - Triple-Negative Breast Cancer** **Human Patients: 194** **Sponsor: G1 Therapeutics (GTHX)**	Date: 5 Feb 2024 Quarter: Q1'24 Batch 17 Technical: SUCCESS (statistically significant additive clinical benefit in OS) Commercial: SUCCESS (commercially sufficient additive clinical benefit in OS)	Readout: 24 Jun 2024 **Lead Time: 140 days in advance** Interpretation: OS endpoint not met	Missed Prediction Note: due to suboptimal combotherapy causal modeling in meastatic TNBC that has been permanently correcte… Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**
901	**ALT-801** **NCTID: NCT05295875** **Phase: Phase 2** **Class: Best-In-Class** **Modality: peptide biologic** **MoA: dual GLP1/glucagon receptor agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 391** **Sponsor: Altimmune (ALT)**	Date: 20 Nov 2023 Quarter: 2H'23 Batch 30 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 23 Jun 2024 **Lead Time: 216 days in advance** Interpretation: -13.2% placebo-adjusted weight loss at week 48 (vs -20% placebo-adjusted weight loss at week 48 for tirzepatide 15mg).	Correct Prediction Conclusion: statistically significant and commercially insufficient inferior to tirzepatide Classification: **True Negative (TN)**
1498	**ZP8396** **NCTID: NCT05613387** **Phase: Phase 1** **Class: First-In-Class** **Modality: peptide biologic** **MoA: long-lasting amylin analog** **Area: Nutritional and Metabolic Diseases**	Date: 6 Mar 2024 Quarter: Q2'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit in weight loss) Commercial: FAILURE (commercially insufficient clinical benefit for	Readout: 20 Jun 2024 **Lead Time: 106 days in advance** Interpretation: 6.9% weight loss in 16 weeks among male adults with 49 years old vs 13.1% weight loss in 12 weeks by Amycretin.	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Indication: Obesity **Human Patients: 68** **Sponsor: Zealand Pharma (ZEAL.CO)**	repeated-dose ZP8396; which is inferior to semaglutide with increasing toxicity for elderly obese population with comorbidities)		
776	**JZP385** **NCTID: NCT05122650** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: t-type calcium channel antagonist** **Area: Nervous System Diseases** **Indication: Essential Tremor** **Human Patients: 420** **Sponsor: Jazz Pharmaceuticals (JAZZ)**	Date: 21 Nov 2023 Quarter: Q1'24 Batch 1 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 20 Jun 2024 **Lead Time: 212 days in advance** Interpretation: endpoints not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
557	**PTC518** **NCTID: NCT05358717** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: HTT mRNA degradation** **Area: Nervous System Diseases** **Indication: Huntington's Disease** **Human Patients: 252** **Sponsor: PTC Therapeutics (PTCT)**	Date: 5 Mar 2024 Quarter: Q2'24 Batch 10 Technical: SUCCESS (statistically significant clinical benefit in lowering tHTT level) Commercial: FAILURE (commercially insufficient clinical benefit in UHDRS-TFC score)	Readout: 20 Jun 2024 **Lead Time: 107 days in advance** Interpretation: 43% mHTT lowering for 10mg; TMS (2.0 points worsening for 5mg and 1.3 points worsening for 10mg vs. 4.9 points worsening for placebo).	Correct Prediction Conclusion: statistically significant and commercially insufficient (TMS and UHDRS scores are both functional endpoints; pending for UHDRSdata) Classification: **True Negative (TN)**
1079	**ZN-c3** **NCTID: NCT04814108** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: Wee1 inhibitor** **Area: Neoplasms** **Indication: Uterine Serous Carcinoma** **Human Patients: 76** **Sponsor: Zentalis Pharmaceuticals (ZNTL)**	Date: 25 May 2023 Quarter: Q2'23 Batch 21a Technical: FAILURE (statistically insignificant clinical efficacy in ORR in placebo-controlled trial and moderate clinical toxicity) Commercial: FAILURE (commercially insufficient clinical benefit regardless of CCNE1 expression)	Readout: 18 Jun 2024 **Lead Time: 390 days in advance** Interpretation: high toxicity resulting in clinical hold.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1077	**ZN-c3** **NCTID: NCT04158336** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: Wee1 inhibitor** **Area: Neoplasms** **Indication: Solid Tumors** **Human Patients: 146** **Sponsor: Zentalis Pharmaceuticals (ZNTL)**	Date: 25 May 2023 Quarter: - Batch - Technical: FAILURE (statistically insignificant clinical efficacy and high clinical toxicity) Commercial: FAILURE (commercially insufficient clinical benefit regardless of CCNE1 expression)	Readout: 18 Jun 2024 **Lead Time: 390 days in advance** Interpretation: high toxicity resulting in clinical hold.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1078	**ZN-c3** **NCTID: NCT05128825** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: Wee1 inhibitor** **Area: Neoplasms** **Indication: High-Grade Serous Ovarian; Fallopian Tube or Primary Peritoneal Cancer** **Human Patients: 102** **Sponsor: Zentalis Pharmaceuticals (ZNTL)**	Date: 25 May 2023 Quarter: - Batch - Technical: partial SUCCESS (statistically significant additive clinical benefit in patients with high CCNE1 expression) Commercial: FAILURE (commercially insufficient additive clinical benefit regardless of CCNE1 expression)	Readout: 18 Jun 2024 **Lead Time: 390 days in advance** Interpretation: high toxicity resulting in clinical hold.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1464	**TSHA-102** **NCTID: NCT06152237** **Phase: Phase 1** **Class: First-In-Class** **Modality: AAV9-based gene therapy** **MoA: scAAV9-delivered miniMECP2 gene therapy** **Area: Nervous System Diseases** **Indication: Rett Syndrome** **Human Patients: 6** **Sponsor: Taysha Gene Therapies (TSHA)**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 2 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 18 Jun 2024 **Lead Time: 125 days in advance** Interpretation: weak efficacy in seizure reduction (none is seizure free without anti-seizure medication).	Correct Prediction Conclusion: statistically maybe significant and commercially insufficient Classification: **True Negative (TN)**
353	**Lumateperone** **NCTID: NCT05061706** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: D1R/D2R/D4R/5TH2AR antagonist** **Area: Mental Disorders** **Indication: Major Depressive Disorder** **Human Patients: 480** **Sponsor: Intra-Cellular Therapies (ITCI)**	Date: 9 Jan 2024 Quarter: Q2'24 Batch 5 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit)	Readout: 18 Jun 2024 **Lead Time: 161 days in advance** Interpretation: 4.5 point placebo-adjusted reduction in MADRS.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1440	**AV-101** **NCTID: NCT05036135** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: dry powder inhaled formulation** **MoA: inhaled imatinib as a tyrosine kinase inhibitor** **Area: Respiratory Tract Diseases** **Indication: Pulmonary Arterial Hypertension** **Human Patients: 462** **Sponsor: Aerovate Therapeutics (AVTE)**	Date: 27 Jan 2024 Quarter: Q2'24 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in PVR); partial FAILURE (statistically insignificant clinical benefit in 6MWD) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 17 Jun 2024 **Lead Time: 142 days in advance** Interpretation: no dose met the primary efficacy endpoint PVR and no dose achieved minimally clinical meaningful improvement in 6MWD (30 meters).	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1593	**Soticlestat** **NCTID: NCT04940624** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: CH24H inhibitor** **Area: Nervous System Diseases** **Indication: Dravet Syndrome** **Human Patients: 144** **Sponsor: Takeda Pharmaceutical / Ovid Therapeutics (TAK / OVID)**	Date: 11 May 2024 Quarter: Q3'24 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit to SoC) Commercial: FAILURE (commercially insufficient additive clinical benefit with inferior-to-cannabidiol-or-fenfluramine efficacy in seizure frequency reduction)	Readout: 17 Jun 2024 **Lead Time: 37 days in advance** Interpretation: primary endpoint not met despite meeting several secondary endpoints.	Correct Prediction Conclusion: statistically insignificant and inferior to SoC Classification: **True Negative (TN)**
965	**Efgartigimod** **NCTID: NCT05633407** **Phase: Phase 2** **Class: First-In-Class** **Modality: antibody fragment biologic** **MoA: anti-FcRn antibody fragment** **Area: Nervous System Diseases** **Indication: Postural Orthostatic Tachycardia Syndrome** **Human Patients: 53** **Sponsor: argenx (ARGX)**	Date: 4 Jul 2023 Quarter: 2H'23 Batch 9 Technical: partial SUCCESS (statistically significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 17 Jun 2024 **Lead Time: 349 days in advance** Interpretation: no clinically meaningful improvements compared to placebo on both total MaPS score and COMPASS31 and trial discontinued.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1359	**CABA-201**	Date: 30 Nov 2023 Quarter: Q1'24 Batch 12	Readout: 14 Jun 2024 **Lead Time: 197 days in advance**	Overall Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT06121297 **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: cell therapy** **MoA: anti-CD19 CAR T** **Area: Immune System Diseases** **Indication: Systemic Lupus Erythematosus (SLE)** **Human Patients: 12** **Sponsor: Cabaletta Bio (CABA)**	Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially sufficient clinical benefit despite moderate toxicity)	Interpretation: CABA201 reduced SLEDAI-2K score from 26 at baseline to 10 at week 4 of follow-up; an LN patient experienced dose-limiting Grade 4 ICANS.	Conclusion: statistically significant and commercially sufficient (despite moderate toxicity) Classification: **True Positive (TP)**
614	**SL-172154** **NCTID: NCT05275439** **Phase: Phase 1** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: CD47-CD40 fusion protein** **Area: Neoplasms** **Indication: Acute Myeloid Leukemia (AML) / Myelodysplastic Syndrome (MDS)** **Human Patients: 160** **Sponsor: Shattuck Labs (STTK)**	Date: 25 Jun 2023 Quarter: 2H'23 Batch 7 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 14 Jun 2024 **Lead Time: 355 days in advance** Interpretation: 67% ORR (MDS vs 73% ORR and 73% CR/mCR for azacitidine) and 43% ORR (AML; vs 69% ORR and 45% CR for a azacitidine + magrolimab as 1L for TP53 mutant AML).	Correct Prediction Conclusion: no additive efficacy compared with SoC 1L; thus commercially insufficient Classification: **True Negative (TN)**
1024	**DISC-0974** **NCTID: NCT05320198** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: hemojuvelin mAb inhibitor** **Area: Hemic and Lymphatic Diseases** **Indication: Anemia** **Human Patients: 56** **Sponsor: Disc Medicine (IRON)**	Date: 5 Oct 2023 Quarter: 2H'23 Batch 21 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 14 Jun 2024 **Lead Time: 253 days in advance** Interpretation: 55% TI vs 32% for decitabine vs 50% achieved by Luspatercept in phase 3 BELIEVE trial NCT02604433.	Correct Prediction Conclusion: statistically significant and commercially sufficient (superior efficacy compared with SoC and numerically superior to Luspatercept) Classification: **True Positive (TP)**
940	**SNDX-5613 (Revumenib)** **Chemotherapy Regimen 1** **Chemotherapy Regimen 2** **NCTID: NCT05326516** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: menin/KMT2A inhibitor** **Area: Neoplasms** **Indication: R/R Acute** **Human Patients: 30** **Sponsor: Syndax Pharmaceuticals (SNDX)**	Date: 18 Jun 2023 Quarter: 2H'23 Batch 13 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 14 Jun 2024 **Lead Time: 362 days in advance** Interpretation: 52% confirmed CR (vs 81% CR for CLT019).	Correct Prediction Conclusion: statistically significant yet non-superior compared with SoC CAR-T; thus commercial insufficient Classification: **True Negative (TN)**
1001	**AOC 1020** **NCTID: NCT05747924** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: anti-DUX4 siRNA oligonucleotide** **Area: Musculoskeletal Diseases** **Indication: Facioscapulohumeral Muscular Dystrophy (FSHD)** **Human Patients: 72** **Sponsor: Avidity Biosciences (RNA)**	Date: 30 Nov 2023 Quarter: Q1'24 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 12 Jun 2024 **Lead Time: 195 days in advance** Interpretation: 50% mean reduction in DUX4-targeted genes; yet with statistically insignificant trends of functional improvement.	Correct Prediction Conclusion: statistically significant and commercially insufficient (weak functional efficacy) Classification: **True Negative (TN)**
1414	**PF-06939926** **NCTID: NCT04281485** **Phase: Phase 3**	Date: 15 Jan 2024 Quarter: Q1'24 Batch 15 Technical: FAILURE (statistically	Readout: 12 Jun 2024 **Lead Time: 149 days in advance** Interpretation: statistically insignificant	Correct Prediction Conclusion: statistically insignificant and commercially

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: Best-In-Class **Modality: gene therapy** **MoA: rAAV9 vector carrying a minidystrophin gene** **Area: Musculoskeletal Diseases** **Indication: Duchenne Muscular Dystrophy (DMD)** **Human Patients: 122** **Sponsor: Pfizer (PFE)**	insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit with inferior-to-SRP9001 efficacy)	for all primary/secondary endpoints.	insufficient (SRP9001 at least meet some secondary endpoints) Classification: **True Negative (TN)**
1489	**AFM13 AB-101** **Cyclophosphamide Fludarabine Interleukin-2** **NCTID: NCT05883449** **Phase: Phase 2** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: CD30 x CD16A tetravalent NK cell engager** **Area: Neoplasms** **Indication: Relapsed or Refractory Hodgkin Lymphoma Peripheral T Cell Lymphoma** **Human Patients: 154** **Sponsor: Affimed (AFMD)**	Date: 29 Feb 2024 Quarter: Q2'24 Batch 9 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 12 Jun 2024 **Lead Time: 104 days in advance** Interpretation: 87.5% ORR (lower than 100% ORR for AFMD alone).	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1260	**Povetacicept (ALPN-303)** **NCTID: NCT05732402** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: Fc fusion protein** **MoA: dual APRIL/BAFF antagonist** **Area: Immune System Diseases** **Indication: immunoglobulin A (IgA) nephropathy; membranous nephropathy; lupus-related kidney disease (lupus nephritis); anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis** **Human Patients: 56** **Sponsor: ALPN Alpine Immune Sciences / Vertex Pharmaceuticals (ALPN (VRTX))**	Date: 2 Oct 2023 Quarter: 2H'23 Batch 19 Technical: SUCCESS (statistically significant clinical benefit for proteinuria) Commercial: FAILURE (commercially insufficient clinical benefit due to low clinical efficacy on eGFR)	Readout: 12 Jun 2024 **Lead Time: 254 days in advance** Interpretation: -47% UPCR and -0.2mL eGFR at 24 weeks (vs -18% UPCR and +1.0mL eGFR at 24 weeks by Tarpeyo).	Correct Prediction Conclusion: statistically significant in UPCR and commercially insufficient for eGFR Classification: **True Negative (TN)**
1381	**SAGE-718** **NCTID: NCT05358821** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: NMDAR PAM** **Area: Nervous System Diseases** **Indication: Huntington's Disease** **Human Patients: 69** **Sponsor: Sage Therapeutics (SAGE)**	Date: 20 Apr 2024 Quarter: Q3'24 Batch 1 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 11 Jun 2024 **Lead Time: 52 days in advance** Interpretation: only trends of functional improvement IN HD-CAB thus statistically insignificant.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
647	**Renal Autologous Cell Therapy** **NCTID: NCT05018416** **Phase: Phase 2** **Class: First-In-Class** **Modality: Cell Therapy** **MoA: renal autologous kidney progenitor cell therapy** **Area: Nutritional and Metabolic Diseases and Urogenital Diseases** **Indication: Type 1 or 2 Diabetes and Chronic Kidney Disease** **Human Patients: 53** **Sponsor: ProKidney (PROK)**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 1 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 10 Jun 2024 **Lead Time: 117 days in advance** Interpretation: average eGFR change from baseline to 18 months was -1.3 ml/min/1.73m2 (given no-zero placebo average eGFR change; the placebo-adjusted eGFR change of REACT would probably be smaller than the SoC Empagliflozin (DOI-10.1056/NEJMoa2204233).	Overall Correct Prediction Conclusion: statistically probably insignificant and commercially probably insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
543	**Relacorilant** **NCTID: NCT03697109** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: oral non-steroidal glucocorticoid receptor antagonist** **Area: Endocrine System Diseases** **Indication: Cushing Syndrome** **Human Patients: 152** **Sponsor: Corcept Therapeutics (CORT)**	Date: 22 Oct 2022 Quarter: Q3'24 Batch 1 Technical: FAILURE (statistical insignificant clinical benefit in the randomized-withdrawal phase) Commercial: FAILURE (commercially insufficient clinical benefit in the randomized-withdrawal phase)	Readout: 7 Jun 2024 **Lead Time: 594 days in advance** Interpretation: primary endpoint loss of response met with borderline statistical significance (p=0.02) secondary endpoint 24h SBP achieved statistical significance (P-0.0025) yet 24h DBP didn't achieve statistical significance (P=0.046); neither body weight (P=0.09) nor HbA1c (P=0.04) achieved statistical significance.	Overall Correct Prediction Conclusion: statistically borderline significant and commercially insufficient Classification: **True Negative (TN)**
1492	**BMF-219** **NCTID: NCT06152042** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral small molecule MENIN inhibitor** **Area: Nutritional and Metabolic Diseases** **Indication: Type 1 Diabetes Mellitus** **Human Patients: 190** **Sponsor: Biomea Fusion (BMEA)**	Date: 29 Feb 2024 Quarter: - Batch - Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit for T1DM patients)	Readout: 6 Jun 2024 **Lead Time: 98 days in advance** Interpretation: full clinical hold due to hepatitoxicity	Correct Prediction Conclusion: statistically insignificant and commercially insufficient (hepatitoxicity) Classification: **True Negative (TN)**
1005	**4D-710** **NCTID: NCT05248230** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: aerosol delivered human-mAb-resistant AAV transgene payload expressing CFTR** **Area: Respiratory Tract Diseases** **Indication: Cystic Fibrosis** **Human Patients: 24** **Sponsor: 4D Molecular Therapeutics (FDMT)**	Date: 11 May 2024 Quarter: Q3'24 Batch 5 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 6 Jun 2024 **Lead Time: 26 days in advance** Interpretation: achieved 5-6% ppFEV1 from baseline by month 12; which is inferior to vertex's SoC's 14% improvement in 4 weeks.	Correct Prediction Conclusion: statistically probably insignificant and commercially insufficient Classification: **True Negative (TN)**
1447	**Inebilizumab** **NCTID: NCT04540497** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: anti-CD19 mAb inhibitor** **Area: Immune System Diseases** **Indication: IgG4 Related Disease** **Human Patients: 135** **Sponsor: Amgen (AMGN)**	Date: 5 Feb 2024 Quarter: Q3'24 Batch 11 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 5 Jun 2024 **Lead Time: 121 days in advance** Interpretation: -87% risk reduction in IgG4-RD flare compared with placebo.	Missed Prediction Note: due to suboptimal IgG4-RD disease model that has been permanently corrected. Conclusion: statistically significant and commercially sufficient Classification: **False Negative (FN)**
1198	**Bemnifosbuvir Ruzasvir** **NCTID: NCT05904470** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: viral RNA polymerase inhibitor** **Area: Infections** **Indication: Chronic Hepatitis C Virus** **Human Patients: 275** **Sponsor: Atea Pharmaceuticals (AVIR)**	Date: 1 Dec 2023 Quarter: Q1'24 Batch 6 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 5 Jun 2024 **Lead Time: 187 days in advance** Interpretation: achieved 97% SVR12	Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**
1481	**S-309309**	Date: 26 Feb 2024 Quarter: Q2'24 Batch 8	Readout: 4 Jun 2024 **Lead Time: 99 days in advance**	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT05925114 **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: MGAT2 inhibitor** **Area: Nutritional and Metabolic Diseases** **Indication: Obesity** **Human Patients: 365** **Sponsor: Shionogi & Co (SGIOY)**	Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in weight loss) Commercial: FAILURE (commercially insufficient clinical benefit inferior to semaglutide/tirzepatide)	Interpretation: S309309 achieved less than 5% absolute weight reduction in week 24; inferior to semaglutide 10.9% absolute weight reduction in week 24 (see 10.1001/jamanetworkopen.2022.31982)	Conclusion: statistically maybe significant and commercially insufficient (inferior to semaglutide in weight loss efficacy) Classification: **True Negative (TN)**
846	**EQ101** **NCTID: NCT05589610** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: tri-specific IL2/IL9/IL15 inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Moderate to Severe Alopecia Areata** **Human Patients: 36** **Sponsor: Equillium (EQ)**	Date: 18 Feb 2024 Quarter: Q2'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 4 Jun 2024 **Lead Time: 107 days in advance** Interpretation: 20-29% <20 SALT score at week 24 achieved by EQ101) (vs 23% <20 SALT score at week 24 achieved by ritlectinib 50mg King et al. 2023 Lancet in NCT03732807).	Correct Prediction Conclusion: statistically significant and commercially sufficient (only one approved treatment so far) Classification: **True Positive (TP)**
475	**VK2809** **NCTID: NCT04173065** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: liver-selective thyroid hormone receptor beta agonist** **Area: Nutritional and Metabolic Diseaseses** **Indication: NASH - Nonalcoholic Steatohepatitis** **Human Patients: 248** **Sponsor: Viking Therapeutics (VKTX)**	Date: 16 Oct 2023 Quarter: Q1'24 Batch 4 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 4 Jun 2024 **Lead Time: 232 days in advance** Interpretation: 39.7% NASH resolution without worsening of fibrosis combined and 17% fibrosis improvement without worsening of NASH (vs 16-20% and 10-12% for resmetirom).	Correct Prediction Conclusion: statistically significant and commercially sufficient (superior to resmetirom) Classification: **True Positive (TP)**
344	**ANX005** **NCTID: NCT04701164** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody** **MoA: C1q mAb inhibitor** **Area: Immune System Disease** **Indication: Guillain-Barre Syndrome** **Human Patients: 216** **Sponsor: Annexon (ANNX)**	Date: 22 Dec 2023 Quarter: Q1'24 Batch 12 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 4 Jun 2024 **Lead Time: 165 days in advance** Interpretation: primary endpoint (GBS-DS) with lower dosage 30mg/kg yet not met with higher dosage 75mg/kg; none of the secondary endpoints met.	Correct Prediction Conclusion: statistically mostly insignificant (negative dose-response relationship) and commercially insufficient Classification: **True Negative (TN)**
661	**TransCon IL-2 ²/³** **Pembrolizumab Chemotherapy drug TransCon TLR7/8 Agonist Surgery** **NCTID: NCT05081609** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: protein prodrug** **MoA: IL-2 ²/³ agonist** **Area: Neoplasms** **Indication: Solid Tumor Malignancies** **Human Patients: 473** **Sponsor: Ascendis Pharma (ASND)**	Date: 12 Apr 2023 Quarter: Q2'23 Batch 8 Technical: SUCCESS (mono); SUCCESS (combo + pembrolizumab); SUCCESS (combo + chemo); FAILURE (combo + TransCon TLR7/8) Commercial: SUCCESS (mono); SUCCESS (combo + pembrolizumab); SUCCESS (combo + chemo); FAILURE (combo + TransCon TLR7/8)	Readout: 3 Jun 2024 **Lead Time: 418 days in advance** Interpretation: 40% ORR (IL2 + TLR7/8) for advanced melanoma (40-48% for BRAF-mutated BRAF/MEK inhibitors or 29% for BRAF-wild-type ipilimumab + pembrolizumab); 25% ORR (IL2) for colorectal cancer (vs 12-16.4% ORR for regorafenib + ICI or cetuximab + chemo); 100% ORR (IL2 + pembro) for SCLC (40% ORR for tarlatamab).	Correct Prediction Conclusion: statistically significant and commercially partially insufficient (IL2 + TLR7/8) yet commercially partially sufficient (other arms) Classification: **True Negative (TN)**
1060	**CRN04894** **NCTID: NCT05804669**	Date: 14 Aug 2023 Quarter: - Batch -	Readout: 3 Jun 2024 **Lead Time: 294 days in advance**	Correct Prediction Conclusion: statistically significant

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 1 Phase 2 **Class: First-In-Class** **Modality: small molecule** **MoA: oral ACTH MC2R antagonist** **Area: Endocrine System Diseases** **Indication: ACTH-Dependent Cushing's Syndrome (ADCS)** **Human Patients: 18** **Sponsor: Crinetics Pharmaceuticals (CRNX)**	Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Interpretation: 100% Urinary free cortisol level for ADCS.	and commercially sufficient Classification: **True Positive (TP)**
1208	**CRN04894** **NCTID: NCT05907291** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral ACTH MC2R antagonist** **Area: Urogenital Diseases** **Indication: Congenital Adrenal Hyperplasia (CAH)** **Human Patients: 30** **Sponsor: Crinetics Pharmaceuticals (CRNX)**	Date: 14 Aug 2023 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 3 Jun 2024 **Lead Time: 294 days in advance** Interpretation: 100% A4 normal for CAH.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
793	**ARO-APOC3** **NCTID: NCT05089084** **Phase: Phase 3** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: siRNA-GalNAc conjugate that supresses APOC3 mRNA** **Area: Nutritional and Metabolic Diseases** **Indication: Familial Chylomicronemia** **Human Patients: 75** **Sponsor: Arrowhead Pharmaceuticals (ARWR)**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 3 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 3 Jun 2024 **Lead Time: 110 days in advance** Interpretation: 80% triglyceride reduction; 94% APOC3 reduction.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1266	**GSBR-1290** **NCTID: NCT05762471** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small-molecule** **MoA: an oral and biased small molecule GLP1R agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Overweight or Obesity Type2 Diabetes Mellitus** **Human Patients: 142** **Sponsor: Structure Therapeutics (GPCR)**	Date: 6 Mar 2024 Quarter: Q2'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit in weight loss) Commercial: partial SUCCESS (commercially insufficient clinical benefit inferior to VK2735 for obesity)	Readout: 3 Jun 2024 **Lead Time: 89 days in advance** Interpretation: 6.2-6.9% placebo-adjust weight loss at week 12 (vs 13.1% at week 12 by Amycretin (on a par with VK2735) and 6-7% by ordorglipron at week 12).	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1546	**CNTY-101 IL-2 Lymphodepleting Chemotherapy** **NCTID: NCT05336409** **Phase: Phase 1** **Class: First-In-Class** **Modality: CAR-NK cell therapy** **MoA: allogeneic anti-CD19 CAR-iNK cells with Allo-Evasion edits; IL-15 support; and EGFR safety switch** **Area: Neoplasms** **Indication: CD19-Positive B-Cell Malignancies** **Human Patients: 75**	Date: 14 Apr 2024 Quarter: Q3'24 Batch 1 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to anti-CD19 CAR-T cell therapies)	Readout: 3 Jun 2024 **Lead Time: 50 days in advance** Interpretation: 40-60% ORR (vs 74.1% ORR Anti-CD19 CAR-T cell therapy HR001).	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Century Therapeutics (IPSC)			
910	**Tildacerfont** **NCTID: NCT05370521** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: CRF1R antagonist** **Area: Neoplasms** **Indication: Polycystic Ovary Syndrome** **Human Patients: 27** **Sponsor: Spruce Biosciences (SPRB)**	Date: 7 Aug 2023 Quarter: 2H'23 Batch 8 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 3 Jun 2024 **Lead Time: 301 days in advance** Interpretation: significant reduction in DHEAS -12.4% vs placebo +5.7% was observed (p = 0.020; vs -12% by metformin).	Overall Correct Prediction Conclusion: statistically significant and commercially insufficient (non-superior) Classification: **True Negative (TN)**
1334	**Darovasertib** **NCTID: NCT05907954** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: potent selective oral PKC inhibitor** **Area: Neoplasms** **Indication: Localized Ocular Melanoma** **Human Patients: 82** **Sponsor: IDEAYA Biosciences (IDYA)**	Date: 18 Mar 2024 Quarter: Q2'24 Batch 12 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 3 Jun 2024 **Lead Time: 77 days in advance** Interpretation: 75% confirmed eye saved.	Correct Prediction Conclusion: statistically significant and commercially sufficient (no neoadjuvant SoC established for ocular melanoma) Classification: **True Positive (TP)**
1494	**Biological NTLA-2002 Normal Saline IV Administration** **NCTID: NCT05120830** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: LNP-deliverd CRISPR/CAS9-based anti-KLKB1 gene therapy** **Area: Cardiovascular Diseases** **Indication: Hereditary Angioedema** **Human Patients: 37** **Sponsor: Intellia Therapeutics (NTLA)**	Date: 3 Mar 2024 Quarter: Q2'24 Batch 10 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 2 Jun 2024 **Lead Time: 91 days in advance** Interpretation: -98% mean monthly HAE attacks vs -85% by PHVS's deucrictibant.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
506	**AB680 Etrumadenant Zimberelimab Bevacizumab m-FOLFOX-6 regimen Regorafenib** **NCTID: NCT04660812** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: selective dual antagonist of the A2a and A2b receptors** **Area: Neoplasms** **Indication: Metastatic Colorectal Cancer** **Human Patients: 227** **Sponsor: Gilead Sciences / Arcus Bioscience (GILD/RCUS)**	Date: 18 Jun 2023 Quarter: Q1'24 Batch 5 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 2 Jun 2024 **Lead Time: 350 days in advance** Interpretation: 17.3% ORR and 19.7 months mOS (vs 19% ORR and 21.4months OS by the FOLFIRI/bevacizumab alone without zimberelimab as 2L mCRC treatment in the SPIRITT trial).	Overall Correct Prediction Conclusion: statistically significant yet commercially insufficient (non-superior) pending more cohorts data Classification: **True Negative (TN)**
1094	**Evorpacept (ALX148) Enfortumab Vedotin** **NCTID: NCT05524545** **Phase: Phase 1** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: anti-CD47 blocker** **Area: Neoplasms** **Indication: Urothelial Carcinoma**	Date: 22 Jul 2023 Quarter: - Batch - Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 2 Jun 2024 **Lead Time: 316 days in advance** Interpretation: 50% ORR (20 patients receiving treatments) vs. 64.5% ORR for pembrolizumab + enfortumab).	Overall Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Human Patients: 30 **Sponsor: ALX Oncology (ALXO)**			
1041	**DTX401 Placebo Oral corticosteroids Placebo for oral corticosteroids** **NCTID: NCT05139316** **Phase: Phase 3** **Class: First-In-Class** **Modality: gene therapy** **MoA: intravenous AAV8 G6PC gene therapy** **Area: Congenital; Hereditary; and Neonatal Diseases and Abnormalities** **Indication: Glycogen Storage Disease Type IA (GSDIa)** **Human Patients: 46** **Sponsor: Ultragenyx Pharmaceutical (RARE)**	Date: 3 Jan 2024 Quarter: Q1'24 Batch 13 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 30 May 2024 **Lead Time: 148 days in advance** Interpretation: 31% placebo-controlled reduction in daily cornstarch intake.	Correct Prediction Conclusion: statistically significant and commercially sufficient (no drug approved for this indication) Classification: **True Positive (TP)**
1495	**Sacituzumab Govitecan-hziy Paclitaxel Docetaxel Vinflunine** **NCTID: NCT04527991** **Phase: Phase 3** **Class: First-In-Class** **Modality: ADC** **MoA: anti-TROP2 ADC with SN38 payload for lysosomal-degradation-mediated intracellular release** **Area: Neoplasms** **Indication: Metastatic or Locally Advanced Unresectable Urothelial Cancer** **Human Patients: 696** **Sponsor: Gilead Sciences (GILD)**	Date: 5 Mar 2024 Quarter: Q2'24 Batch 10 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit with superior-to-chemotherapy efficacy in OS)	Readout: 30 May 2024 **Lead Time: 86 days in advance** Interpretation: OS primary endpoint not met.	Missed Prediction Note: due to suboptimal drug MoA modeling that has been permanently corrected. Conclusion: statistically insignificant and commercially insufficient (non-superior) Classification: **False Positive (FP)**
1186	**Ionigutamab** **NCTID: NCT05683496** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: IGF1R inhibitor** **Area: Eye Diseases** **Indication: Thyroid Eye Disease (TED)** **Human Patients: 38** **Sponsor: Acelyrin (SLRN)**	Date: 20 Nov 2023 Quarter: 2H'23 Batch 29 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit non-superior to Tepezza)	Readout: 29 May 2024 **Lead Time: 191 days in advance** Interpretation: 50% and 25% placebo-adjusted reduction in proptosis and diplopia at week 6 (vs 49% and 46% placebo-adjusted reduction in proptosis and diplopia achieved by tepezza at week 6 in similar clinical settings Douglas et Al. 2020 NEJM).	Correct Prediction Conclusion: statistically significant and commercially insufficient (non-superior) Classification: **True Negative (TN)**
792	**ARO-APOC3** **NCTID: NCT04998201** **Phase: Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: siRNA-GalNAc conjugate that supresses APOC3 mRNA** **Area: Nutritional and Metabolic Diseases** **Indication: Mixed Dyslipidemia** **Human Patients: 353** **Sponsor: Arrowhead Pharmaceuticals (ARWR)**	Date: 14 Feb 2024 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 28 May 2024 **Lead Time: 104 days in advance** Interpretation: 50-62% triglyceride reduction; superior to 30-50% achieved by SoC (Fibrates).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1461	**ARCT-032** **NCTID: NCT05712538** **Phase: Phase 1** **Class: First-In-Class**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 3 Technical: SUCCESS (statistically significant clinical benefit)	Readout: 28 May 2024 **Lead Time: 104 days in advance** Interpretation: 4% FEV1 improvement at day 8 (no SoC for	Correct Prediction Conclusion: statistically significant and commercially sufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Modality: mRNA medicine **MoA: LNP-delivered CTFR mRNA medicine** **Area: Respiratory Tract Diseases** **Indication: Cystic Fibrosis** **Human Patients: 38** **Sponsor: Arcturus Therapeutics (ARCT)**	Commercial: SUCCESS (commercially sufficient clinical benefit)	mutation-agnostic CF).	Classification: **True Positive (TP)**
432	**Brensocatib** **NCTID: NCT04594369** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: oral reversible DDP-1 inhibitor** **Area: Respiratory Tract Diseases** **Indication: Non-Cystic Fibrosis Bronchiectasis** **Human Patients: 1767** **Sponsor: Insmed (INSM)**	Date: 1 Jan 2024 Quarter: Q2'24 Batch 5 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit with reduced efficacy from increased dosage) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 28 May 2024 **Lead Time: 148 days in advance** Interpretation: 19.4%-21.1% reduction in APE (vs 30%-50% reduction achieved by azithromycin in similar clinical settings); clearly weak efficacy (vs azithromycin) and clearly negative dose-response relationship (in both primary and other secondary endpoints).	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
406	**Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy** **NCTID: NCT05113966** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: CDK4/6 inhibitor** **Area: Neoplasms** **Indication: Triple Negative Breast Cancer** **Human Patients: 30** **Sponsor: G1 Therapeutics (GTHX)**	Date: 28 Apr 2023 Quarter: Q2'23 Batch 18 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit for Trodelvy)	Readout: 28 May 2024 **Lead Time: 396 days in advance** Interpretation: 17.9 mOS vs 12.1 OS (trodelvy alone).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
435	**Treprostinil Palmitil** **NCTID: NCT05176951** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: synthetic prostacyclin analog** **Area: Respiratory Tract Diseases** **Indication: Pulmonary Hypertension** **Human Patients: 39** **Sponsor: Insmed (INSM)**	Date: 1 Jan 2024 Quarter: Q1'24 Batch 12 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 28 May 2024 **Lead Time: 148 days in advance** Interpretation: significant better tolerability than placebo and 30 meter placebo-adjusted 6MWD improvement (exploratory endpoint with large CI).	Correct Prediction Conclusion: statistically significant and commercially sufficient for phase 2a Classification: **True Positive (TP)**
1303	**IK-930** **NCTID: NCT05228015** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: oral TEAD inhibitor** **Area: Neoplasms** **Indication: Advanced Solid Tumors** **Human Patients: 198** **Sponsor: Ikena Oncology (IKNA)**	Date: 31 Oct 2023 Quarter: 2H'23 Batch 25 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 28 May 2024 **Lead Time: 210 days in advance** Interpretation: 0% ORR.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1542	**CG0070 Pembrolizumab Injection** **n-dodecyl-B-D-maltoside** **NCTID: NCT04387461** **Phase: Phase 2** **Class: First-In-Class** **Modality: oncolytic virus therapy** **MoA: oncolytic adenovirus genetically engineered with an E2F1 promoter region to**	Date: 15 Apr 2023 Quarter: Q2'24 Batch 15 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit with superior-to-pembrolizumab-monotherapy efficacy in CR/PFS/OS)	Readout: 24 May 2024 **Lead Time: 405 days in advance** Interpretation: 54% CR (vs 42% CR for pembrolizumab alone).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	replicate only in Rb-defective cells and a GM-CSF transgene **Area: Neoplasms** **Indication: Non-Muscle Invasive Bladder Cancer** **Human Patients: 35** **Sponsor: CG Oncology (CGON)**			
1587	**M9140 M9140 Bevacizumab Capecitabine** **NCTID: NCT05464030** **Phase: Phase 1** **Class: First-In-Class** **Modality: antibody-drug conjugate (ADC)** **MoA: anti-CEACAM5 ADC that delivers a payload inhibiting TOP1** **Area: Neoplasms** **Indication: Colorectal Cancer** **Human Patients: 200** **Sponsor: Merck KGaA (MKKGY)**	Date: 8 May 2024 Quarter: - Batch - Technical: FAILURE (statistically maybe significant yet weak (additive) clinical benefit in ORR) Commercial: FAILURE (commercially insufficient (additive) clinical benefit in OS)	Readout: 23 May 2024 **Lead Time: 15 days in advance** Interpretation: 7.5% cORR and 12.9-13.9 months OS and 15% TEAE discontinuation (vs 39% ORR for SoC FOLFOX + bevacizumab) (Source-ASCO abstract 231480).	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
993	**sigvotatug vedotin (SGN-B6A) pembrolizumab cisplatin carboplatin** **NCTID: NCT04389632** **Phase: Phase 1** **Class: First-In-Class** **Modality: antibody-drug conjugate (ADC)** **MoA: anti-alphavbeta6 integrin ADC that delivers MMAE as payload** **Area: Neoplasms** **Indication: Carcinoma Non-Small Cell Lung Squamous Cell Carcinoma of Head and Neck HER2 Negative Breast Neoplasms Esophageal Squamous Cell Carcinoma Esophageal Adenocarcinoma Gastroesophageal Junction Adenocarcinoma Ovarian Neoplasms Cutaneous Squamous Cell Cancer Exocrine Pancreatic Adenocarcinoma Urinary Bladder Neoplasms Uterine Cervical Neoplasms Stomach Neoplasms** **Human Patients: 824** **Sponsor: Pfizer (PFE)**	Date: 15 Apr 2023 Quarter: Q2'23 Batch 14 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (superior to anti-TROP2 ADC)	Readout: 23 May 2024 **Lead Time: 404 days in advance** Interpretation: 20% ORR NSCLC and 3.5 months PFS and 13% TEAE discontinuation (vs 17% ORR for Trodelvy Heist et al. Camidge 2017 J Clinical Onco).	Correct Prediction Conclusion: statistically significant and commercially numerically superior to anti-TROP2 ADC Classification: **True Positive (TP)**
1422	**Brentuximab Vedotin With Pembrolizumab** **NCTID: NCT04609566** **Phase: Phase 2** **Class: First-In-Class** **Modality: antibody-drug conjugate (ADC)** **MoA: anti-CD30 ADC with MMAE as payload** **Area: Neoplasms** **Indication: Melanoma Non-small Cell Lung Cancer Squamous Cell Carcinoma of the Head and Neck** **Human Patients: 140** **Sponsor: Pfizer (PFE)**	Date: 15 Jan 2024 Quarter: Q1'24 Batch 5 Technical: partial SUCCESS (statistically significant yet weak additive clinical benefit to pembrolizumab more for melanoma than for NSCLC or HNSCC) Commercial: FAILURE (commercially insufficient additive clinical benefit with non-superior-to-SoC efficacy in ORR/PFS/OS)	Readout: 23 May 2024 **Lead Time: 129 days in advance** Interpretation: 13-21% ORR and 12.9-13.9 months OS and 17% TEAE discontinuation (vs 11.5-12 months OS for chemo alone or more for chemo+X).	Correct Prediction Conclusion: statistically significant and commercially non-superior to SoC (chemo alone) Classification: **True Negative (TN)**
1420	**PF-07248144 Fulvestrant Letrozole Palbociclib PF-07220060** **NCTID: NCT04606446** **Phase: Phase 1**	Date: 15 Jan 2024 Quarter: Q1'24 Batch 5 Technical: FAILURE (statistically insignificant additive clinical benefit)	Readout: 23 May 2024 **Lead Time: 129 days in advance** Interpretation: 11.4% ORR (mono 5 prior therapy) and 30.4% ORR (PF07248144 + fulvestrant 1 prior	Overall Correct Prediction Conclusion: statistically significant and commercially non-superior to SoC (enhertu)

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: First-In-Class **Modality: small molecule** **MoA: anti-KAT6A/KAT6B inhibitor** **Area: Neoplasms** **Indication: Locally Advanced or Metastatic ER+ HER2- Breast Cancer Locally Advanced or Metastatic Castration-resistant Prostate Cancer Locally Advanced or Metastatic Non-small Cell Lung Cancer** **Human Patients: 186** **Sponsor: Pfizer (PFE)**	Commercial: FAILURE (commercially insufficient additive clinical benefit)	therapy) vs 7-10% fulvestrant (mono) vs 52.3% ORR enhertu destiny-breast04.	Classification: **True Negative (TN)**
1292	**AN0025 and Chemoradiotherapy** **NCTID: NCT05191667** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: PGE2 EP4 inhibitor** **Area: Neoplasms** **Indication: Esophageal Cancer** **Human Patients: 32** **Sponsor: Adlai Nortye (ANL)**	Date: 19 Oct 2023 Quarter: - Batch - Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 23 May 2024 **Lead Time: 217 days in advance** Interpretation: 50% ORR (6/12) vs 63.5% ORR (1L tislelizumab + chemo; 68-88% ORR for CRT alone doi- 10.3390/cancers15010010).	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
428	**AFM24 Atezolizumab 840 MG in 14 ML Injection** **NCTID: NCT05109442** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: EGFR x CD16A tetravalent NK cell engager** **Area: Neoplasms** **Indication: Selected Advanced/Metastatic EGFR-expressing Cancers** **Human Patients: 148** **Sponsor: Affimed (AFMD)**	Date: 29 Feb 2024 Quarter: Q2'24 Batch 9 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit for refractory/relapsed EGFRwt and EGFRmut solid tumors)	Readout: 23 May 2024 **Lead Time: 84 days in advance** Interpretation: 6.6% ORR and 5.9 month PFS vs 35-50% ORR and 4.7-6.4 month PFS for SoC (nintedanib plus docetaxel VARGADO study doi-10.1016/j.esmoop.2023.100879).	Correct Prediction Conclusion: statistically significant and commercially insufficient (non-superior to SoC) Classification: **True Negative (TN)**
1025	**BLU-222 Carboplatin Ribociclib Fulvestrant** **NCTID: NCT05252416** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: CDK2 inhibitor** **Area: Neoplasms** **Indication: Advanced Solid Tumors** **Human Patients: 366** **Sponsor: Blueprint Medicines (BPMC)**	Date: 28 Apr 2023 Quarter: Q2'23 Batch 18 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit as monotherapy or combotherapy)	Readout: 23 May 2024 **Lead Time: 391 days in advance** Interpretation: <5% ORR (unconfirmed) vs 22-23% ORR for SoC (16% ORR for chemo & 37-55% ORR enhertu).	Correct Prediction Conclusion: statistically significant and commercially inferior to SoC Classification: **True Negative (TN)**
1196	**CTX-471 pembrolizumab** **NCTID: NCT03881488** **Phase: Phase 1** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: CD137 agonist** **Area: Neoplasms** **Indication: Metastatic or Locally Advanced Malignancies** **Human Patients: 157** **Sponsor: Compass Therapeutics (CMPX)**	Date: 26 Jul 2023 Quarter: 2H'23 Batch 8 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit yet maybe non-superior to SoC)	Readout: 23 May 2024 **Lead Time: 302 days in advance** Interpretation: 26% ORR vs 22-23% ORR for SoC (ARX517); OS data pending.	Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**
764	**ARV-766 Part A&B ARV-766 + Abiraterone Part C&D**	Date: 13 May 2024 Quarter: Q3'24 Batch 8	Readout: 23 May 2024 **Lead Time: 10 days in advance**	Correct Prediction Conclusion: statistically significant

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT05067140 **Phase: Phase 1** **Class: First-In-Class** **Modality: PROTAC** **MoA: PROTAC-based AR remover** **Area: Neoplasms** **Indication: Metastatic Prostate Cancer** **Human Patients: 220** **Sponsor: Arvinas (ARVN)**	Technical: SUCCESS (statistically significant clinical benefit in PSA/PFS) Commercial: SUCCESS (commercially sufficient clinical benefit for the ARV766 + abiraterone combotherapy in OS)	Interpretation: 50% PSA50 and 10% TEAE-related discontinuation vs 45% PSA50 for docetaxel doi-10.1002/pros.22844.	and commercially sufficient TBD Classification: **True Positive (TP)**
1122	**KT-253** **NCTID: NCT05775406** **Phase: Phase 1** **Class: Best-In-Class** **Modality: small molecule** **MoA: MDM degrader** **Area: Neoplasms** **Indication: relapsed or refractory (R/R) high grade myeloid malignancies; acute lymphocytic leukemia (ALL); R/R lymphoma; and R/R solid tumors** **Human Patients: 70** **Sponsor: Kymera Therapeutics (KYMR)**	Date: 14 Aug 2023 Quarter: Q1'24 Batch 5 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit in ORR/PFS) Commercial: FAILURE (commercially insufficient clinical benefit in OS inferior to SoC)	Readout: 23 May 2024 **Lead Time: 283 days in advance** Interpretation: 15.8% ORR far lower than 40% ORR by SoC (doi-10.1177/2040620720955006).	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1462	**MCLA-158 + Pembrolizumab** **NCTID: NCT03526835** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-EGFR-LGR5 bispecific antibody** **Area: Neoplasms** **Indication: 1L HNSCC** **Human Patients: 567** **Sponsor: Merus (MRUS)**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 3 Technical: SUCCESS (statistically significant additive clinical benefit as 1L treatment for HNSCC) Commercial: SUCCESS (commercially sufficient additive clinical benefit as 1L treatment in OS superior to chemo + pembrolizumab)	Readout: 23 May 2024 **Lead Time: 99 days in advance** Interpretation: 67% ORR for combo superior to 27.3% ORR for SoC.	Correct Prediction Conclusion: statistically significant and commercially TBD (pending OS data) Classification: **True Positive (TP)**
419	**Aglatimagene besadenovec (CAN-2409)** **NCTID: NCT04495153** **Phase: Phase 2** **Class: First-In-Class** **Modality: oncolytic viral gene therapy** **MoA: AAV-mediated intratumoral delivery of HSV-TK as an oncolytic viral therapy** **Area: Neoplasms** **Indication: Stage III/IV NSCLC** **Human Patients: 90** **Sponsor: Candel Therapeutics (CADL)**	Date: 9 Apr 2024 Quarter: Q2'24 Batch 15 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in ORR/PFS/OS) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 23 May 2024 **Lead Time: 44 days in advance** Interpretation: 20.6 months mOS (vs 11.6 mOS by docetaxel in a similar setting; yet the data's rigor has been questioned; and the SoC may be docetaxel + X combo (doi.org/10.1136/esmoopen-2017-000236).	Correct Prediction Conclusion: statistically significant and commercially maybe insufficient Classification: **True Negative (TN)**
977	**MCLA-145** **NCTID: NCT03922204** **Phase: Phase 1** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: anti-PD-L1 and anti-CD137 bispecific antibody** **Area: Neoplasms** **Indication: Advanced or Metastatic Malignancies** **Human Patients: 118** **Sponsor: Merus (MRUS)**	Date: 16 Jun 2023 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit anti-PD1 mono clinical efficacy)	Readout: 23 May 2024 **Lead Time: 342 days in advance** Interpretation: 9.6% ORR for mono and 10.5% ORR for combo.	Correct Prediction Conclusion: statistically significant and partially commercially sufficient (ORR is superior to pembrolizumab monotherapy) Classification: **True Positive (TP)**
1541	**SPN-817** **NCTID: NCT05518578**	Date: 11 Apr 2024 Quarter: Q2'24 Batch 15	Readout: 23 May 2024 **Lead Time: 42 days in advance**	Correct Prediction Conclusion: statistically significant

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Phase: Phase 2 **Class: First-In-Class** **Modality: small molecule** **MoA: a novel synthetic form of Huperzine A; potentially as an acetylcholinesterase inhibitor and an NMDAR antagonist** **Area: Nervous System Diseases** **Indication: Resistant Epilepsy** **Human Patients: 35** **Sponsor: Supernus Pharmaceuticals (SUPN)**	Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit in motor seizure frequency reduction) Commercial: FAILURE (commercially insufficient clinical benefit)	Interpretation: 75% mean focal seizure reduction; 25% TEAE-related discontinuation; high efficacy and high toxicity.	yet commercially insufficient (high toxicity is usually not tolerated for anti-seizure medicine) Classification: **True Negative (TN)**
1443	**Tezepelumab** **NCTID: NCT04039113** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-TSLP alarmin mAb inhibitor** **Area: Respiratory Tract Diseases** **Indication: Chronic Obstructive Pulmonary Disease (COPD)** **Human Patients: 337** **Sponsor: Amgen (AMGN)**	Date: 5 Feb 2024 Quarter: Q1'24 Batch 17 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 19 May 2024 **Lead Time: 104 days in advance** Interpretation: 17% reduced annualized rate of COPD exacerbation compared with placebo (p=0.1042).	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
666	**ERAS-007 Encorafenib Cetuximab Palbociclib** **NCTID: NCT05039177** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: ERK1/2 inhibitor** **Area: Neoplasms** **Indication: Advanced Gastrointestinal Malignancies** **Human Patients: 102** **Sponsor: Erasca (ERAS)**	Date: 1 Dec 2023 Quarter: Q1'24 Batch 1 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 17 May 2024 **Lead Time: 168 days in advance** Interpretation: 40% ORR for treatment-naive cohort which is inferior to the 47.7% cORR achieved by EC+binimetinib (DOI-10.1200/JCO.22.01693); terminated due to low efficacy.	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1566	**BIIB105** **NCTID: NCT04494256** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: anti-ATXN2 ASO** **Area: Nervous System Diseases** **Indication: Amyotrophic Lateral Sclerosis and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation** **Human Patients: 99** **Sponsor: Biogen / Ionis Pharmaceuticals (BIIB/IONS)**	Date: 23 Apr 2024 Quarter: Q3'24 Batch 3 Technical: FAILURE (statistically insignificant additive clinical benefit to SoC regardless of the CAG repeat expansion level in the ATXN2 gene) Commercial: FAILURE (commercially insufficient additive clinical benefit to SoC regardless of the CAG repeat expansion level in the ATXN2 gene)	Readout: 16 May 2024 **Lead Time: 23 days in advance** Interpretation: no reduction in ALS biomarkers; discontinued.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
721	**Insulin Efsitora Alfa (LY3209590) Insulin Degludec** **NCTID: NCT05362058** **Phase: Phase 3** **Class: Best-In-Class** **Modality: protein biologic** **MoA: once-weekly insulin treatment** **Area: Nutritional and Metabolic Diseases** **Indication: Type 2 Diabetes** **Human Patients: 928** **Sponsor: Eli Lilly and Company (LLY)**	Date: 26 Nov 2022 Quarter: - Batch - Technical: SUCCESS Commercial: SUCCESS (non-inferior)	Readout: 16 May 2024 **Lead Time: 537 days in advance** Interpretation: -1.34% (efsitora) vs -1.26% (degludec) HbA1C at week 52; non-inferior.	Correct Prediction Conclusion: statistically significant and commercially sufficient (once-weekly is more convenient than SoC's once-daily dosage) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
704	**LY3209590** **NCTID: NCT05462756** **Phase: Phase 3** **Class: Best-In-Class** **Modality: protein biologic** **MoA: once-weekly insulin treatment** **Area: Nutritional and Metabolic Diseases** **Indication: Type 2 Diabetes** **Human Patients: 730** **Sponsor: Eli Lilly and Company (LLY)**	Date: 21 Nov 2022 Quarter: - Batch - Technical: SUCCESS Commercial: SUCCESS (non-inferior)	Readout: 16 May 2024 **Lead Time: 542 days in advance** Interpretation: -1.34% (efsitora) vs -1.26% (degludec) HbA1C at week 52; non-inferior.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1239	**CAB-ROR2-ADC PD-1 inhibitor** **NCTID: NCT03504488** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: antibody-drug conjugate (ADC)** **MoA: anti-ROR2 ADC** **Area: Neoplasms** **Indication: TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)** **Human Patients: 420** **Sponsor: BioAtla (BCAB)**	Date: 30 Nov 2023 Quarter: - Batch - Technical: partial SUCCESS (statistically significant yet weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 14 May 2024 **Lead Time: 166 days in advance** Interpretation: 7% ORR for melanoma (vs 21-36% ORR by anti-PD1 + anti-CLTA4 / TIL cell therapy).	Correct Prediction Conclusion: statistically significant yet commercially insufficient Classification: **True Negative (TN)**
1235	**Ozuriftamab Vedotin (BA3021)** **PD-1 inhibitor** **NCTID: NCT05271604** **Phase: Phase 2** **Class: First-In-Class** **Modality: antibody-drug conjugate (ADC)** **MoA: anti-ROR2 ADC** **Area: Neoplasms** **Indication: Head and Neck Cancer** **Human Patients: 80** **Sponsor: BioAtla (BCAB)**	Date: 3 Sep 2023 Quarter: 2H'23 Batch 18 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 14 May 2024 **Lead Time: 254 days in advance** Interpretation: 15% ORR for SCCHN (vs 13-16% ORR by anti-PD1).	Correct Prediction Conclusion: statistically significant yet commercially insufficient Classification: **True Negative (TN)**
1530	**NNC0365-3769 (Mim8)** **NCTID: NCT05053139** **Phase: Phase 3** **Class: First-In-Class** **Modality: bispecific antibody** **MoA: a factor VIIIa-mimetic anti-FIXa/anti-FX bispecific antibody activator** **Area: Hematologic Diseases** **Indication: Haemophilia A** **Human Patients: 267** **Sponsor: Novo Nordisk (NVO)**	Date: 24 Mar 2024 Quarter: Q2'24 Batch 13 Technical: SUCCESS (statistically significant clinical benefit for patients with and without prophylaxis with and without inhibitors) Commercial: SUCCESS (commercially sufficient clinical benefit for patients with and without prophylaxis with and without inhibitors with numerically-superior-to-emicizumab efficacy)	Readout: 13 May 2024 **Lead Time: 50 days in advance** Interpretation: 99% no-prophylaxis-adjusted reduction in treated bleeds for mim8 (vs 96-97% for emicizumab Mahlangu et al. Kruse-Jarres 2018 NEJM).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1212	**RPT193** **NCTID: NCT05399368** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral CCR4 inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Atopic Dermatitis** **Human Patients: 229** **Sponsor: RAPT Therapeutics (RAPT)**	Date: 10 Aug 2023 Quarter: - Batch - Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 9 May 2024 **Lead Time: 273 days in advance** Interpretation: terminated due to clinical holds.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1213	**RPT193**	Date: 10 Aug 2023 Quarter: - Batch -	Readout: 9 May 2024 **Lead Time: 273 days in advance**	Correct Prediction

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT05935332 **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral CCR4 inhibitor** **Area: Respiratory Tract Diseases** **Indication: Moderate to Severe T2-high Asthma** **Human Patients: 38** **Sponsor: RAPT Therapeutics (RAPT)**	Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Interpretation: terminated due to clinical holds.	Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
822	**Imsidolimab (ANB019)** **NCTID: NCT05352893** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-IL36R mAb inhibitor** **Area: Immune System Diseases** **Indication: Generalized Pustular Psoriasis** **Human Patients: 45** **Sponsor: AnaptysBio (ANAB)**	Date: 27 Dec 2022 Quarter: - Batch - Technical: SUCCESS Commercial: SUCCESS	Readout: 9 May 2024 **Lead Time: 499 days in advance** Interpretation: 40% placebo-adjusted GPPPGA score 0/1 (p=0.0131) in GEMINI1.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1386	**Imsidolimab (ANB019)** **NCTID: EUCT2021-001448-90** **Phase: Phase 3** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-IL36R mAb inhibitor** **Area: Immune System Diseases** **Indication: Generalized Pustular Psoriasis** **Human Patients: 16** **Sponsor: AnaptysBio (ANAB)**	Date: 17 Dec 2023 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 9 May 2024 **Lead Time: 144 days in advance** Interpretation: 75% placebo-adjusted GPPPGA score 0/1 maintenance and 63% placebo-adjust flare-free maintenance in GEMINI2.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
812	**Vobramitamab Duocarmazine** **NCTID: NCT05551117** **Phase: Phase 2** **Class: First-In-Class** **Modality: ADC** **MoA: anti-B7-H3 ADC with DUBA payload for lysosomal-protease-clevage-mediated intracellular release** **Area: Neoplasms** **Indication: Metastatic Castration Resistant Prostate Cancer** **Human Patients: 382** **Sponsor: MacroGenics (MGNX)**	Date: 3 Mar 2024 Quarter: Q2'24 Batch 10 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit with high toxicity) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 9 May 2024 **Lead Time: 67 days in advance** Interpretation: 25% ORR (vs 30% ORR for 177Lu-PSMA-617 + SoC in the same setting of 2L mCRPC in phase 3); 93%-95% TEAEs.	Correct Prediction Conclusion: commercially insufficient due to weak efficacy and high toxicity. Classification: **True Negative (TN)**
669	**LYR-210 Sham procedure control Background Therapy** **NCTID: NCT05219968** **Phase: Phase 3** **Class: First-In-Class** **Modality: medical device** **MoA: long-acting glucocorticoid receptor agonist** **Area: Respiratory Tract Diseases** **Indication: Chronic Rhinosinusitis** **Human Patients: 196** **Sponsor: Lyra Therapeutics (LYRA)**	Date: 15 Dec 2023 Quarter: Q1'24 Batch 11 Technical: partial SUCCESS (statistically significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 6 May 2024 **Lead Time: 143 days in advance** Interpretation: 3CS primary endpoint not met yet with positive trend (not significant).	Overall Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1142	**EYP-1901 Sham IVT** **NCTID: NCT05383209** **Phase: Phase 2**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 2 Technical: SUCCESS (statistically	Readout: 6 May 2024 **Lead Time: 82 days in advance** Interpretation: DRSS>2 score primary	Missed Prediction Note: due to suboptimal modelling of non-proliferation diabetic

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: First-In-Class **Modality: small molecule** **MoA: intravitreally delivered vorolanib** **Area: Eye Diseases** **Indication: Nonproliferative Diabetic Retinopathy** **Human Patients: 105** **Sponsor: EyePoint Pharmaceuticals (EYPT)**	significant clinical benefit non-inferior to aflibercept in BCVA) Commercial: SUCCESS (commercially sufficient clinical benefit non-inferior to long-lasting aflibercept)	endpoint not met.	retinopathy which has been permanently co… Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**
1441	**Uproleselan (GMI-1271)** **NCTID: NCT03616470** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: selective E-selectin antagonist** **Area: Neoplasms** **Indication: Relapsed/ Acute Myeloid Leukemia** **Human Patients: 388** **Sponsor: GlycoMimetics (GLYC)**	Date: 16 Feb 2024 Quarter: Q2'24 Batch 6 Technical: partial SUCCESS (statistically maybe significant yet weak additive clinical benefit in OS) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 6 May 2024 **Lead Time: 80 days in advance** Interpretation: OS primary endpoint not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
744	**Setanaxib Pembrolizumab** **NCTID: NCT05323656** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: NOX1/NOX4 dual inhibitor** **Area: Neoplasms** **Indication: Squamous Cell Carcinoma of Head and Neck (SCCHN)** **Human Patients: 55** **Sponsor: Calliditas Therapeutics (CALT)**	Date: 22 Dec 2023 Quarter: Q1'24 Batch 11 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 6 May 2024 **Lead Time: 136 days in advance** Interpretation: base percentage change in tumor size primary endpoint not met yet PFS/OS secondary endpoints showed positive trends (not significant).	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1543	**CG0070** **n-dodecyl-B-D-maltoside** **NCTID: NCT04452591** **Phase: Phase 3** **Class: First-In-Class** **Modality: oncolytic virus therapy** **MoA: oncolytic adenovirus genetically engineered with an E2F1 promoter region to replicate only in Rb-defective cells and a GM-CSF transgene** **Area: Neoplasms** **Indication: Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin** **Human Patients: 190** **Sponsor: CG Oncology (CGON)**	Date: 15 Apr 2024 Quarter: Q2'24 Batch 15 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit with maybe inferior-to-pembrolizumab efficacy in CR/PFS)	Readout: 3 May 2024 **Lead Time: 18 days in advance** Interpretation: 75.2% CR any time at month 12 (vs 100% CR any time for pembrolizumab at month 12. ASCO 19 KEYNOTE-057); no grade 3 TEAE.	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
935	**Buntanetap/Posiphen** **NCTID: NCT05686044** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: neurotoxic protein synthesis inhibitor** **Area: Nervous System Diseases** **Indication: Alzheimer Disease** **Human Patients: 320** **Sponsor: Annovis Bio (ANVS)**	Date: 24 Mar 2024 Quarter: Q2'24 Batch 13 Technical: FAILURE (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 29 Apr 2024 **Lead Time: 36 days in advance** Interpretation: key efficacy endpoints ADAS-COG11; ADCS-CGIC; ADCS-ADL not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1373	**Trastuzumab deruxtecan** **Capecitabine Paclitaxel** **Nab-Paclitaxel**	Date: 12 Dec 2023 Quarter: Q1'24 Batch 10 Technical: SUCCESS (statistically	Readout: 29 Apr 2024 **Lead Time: 139 days in advance** Interpretation: PFS superior to SoC;	Correct Prediction Conclusion: statistically significant and commercially probably

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	NCTID: NCT04494425 **Phase: Phase 3** **Class: First-In-Class** **Modality: ADC** **MoA: anti-HER2 mAb inhibitor conjugated with TOP1 inhibitor** **Area: Neoplasms** **Indication: Metastatic Breast Cancer** **Human Patients: 866** **Sponsor: AstraZeneca / Daiichi Sankyo Company (AZN / DSNKY)**	significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to chemotherapy)	OS not mature yet with early positive trend.	sufficient Classification: **True Positive (TP)**
893	**JNJ-40411813** **NCTID: NCT04836559** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: mGluR2 PAM** **Area: Nervous System Diseases** **Indication: Focal Onset Seizures** **Human Patients: 110** **Sponsor: Johnson & Johnson / Addex Therapeutics (JNJ / ADXN)**	Date: 9 Apr 2024 Quarter: Q2'24 Batch 14 Technical: partial SUCCESS (statistically maybe significant yet very weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 29 Apr 2024 **Lead Time: 20 days in advance** Interpretation: primary endpoint not met; development discontinued	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1493	**ACR-368 Gemcitabine OncoSignature** **NCTID: NCT05548296** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: CHEK1/CHEK2 small molecule inhibitor with OncoSignature predictive biomarkers** **Area: Neoplasms** **Indication: Ovarian Carcinoma; Endometrial Adenocarcinoma; and Urothelial Carcinoma** **Human Patients: 390** **Sponsor: Acrivon Therapeutics (ACRV)**	Date: 3 Mar 2024 Quarter: Q2'24 Batch 10 Technical: SUCCESS (statistically significant clinical benefit in the OncoSignature positive arm) Commercial: SUCCESS (commercially sufficient clinical benefit in the OncoSignature positive monotherapy arm with superior efficacy over the OncoSignature negative combotherapy arm)	Readout: 24 Apr 2024 **Lead Time: 52 days in advance** Interpretation: 50% ORR for oncosignature positive arm vs 0% Orr for oncosignature negative arm (p=0.0038) vs 42.3% ORR of mirvetuximab soravtansine for patients selected by FOLRalpha; anti-correlation between dosage and efficacy.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1272	**Semaglutid** **NCTID: NCT05064735** **Phase: Phase 3** **Class: First-In-Class** **Modality: peptide** **MoA: GLP1R agonist** **Area: Immune System Diseases** **Indication: Knee Osteoarthritis** **Human Patients: 407** **Sponsor: Novo Nordisk (NVO)**	Date: 9 Oct 2023 Quarter: 2H'23 Batch 22 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 23 Apr 2024 **Lead Time: 197 days in advance** Interpretation: semaglutide achieved a placebo-adjusted -14.2 WOMAC pain reduction (P<0.001)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1362	**NBI-1065845** **NCTID: NCT05203341** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: AMPAR PAM** **Area: Mental Disorders** **Indication: Major Depressive Disorder** **Human Patients: 183** **Sponsor: Neurocrine Biosciences (NBIX)**	Date: 30 Nov 2023 Quarter: - Batch - Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 23 Apr 2024 **Lead Time: 145 days in advance** Interpretation: significant MADRS for one dose (likely low dose) yet insignificant for another dose (likely high dose); anti-correlation between dosage and efficacy.	Correct Prediction Conclusion: overall statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1454	**Tavapadon** **NCTID: NCT04542499** **Phase: Phase 3**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 4 Technical: FAILURE (statistically	Readout: 18 Apr 2024 **Lead Time: 64 days in advance** Interpretation: on time 1.7 hours vs	Correct Prediction Conclusion: overall statistically insignificant and commercially

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: First-In-Class **Modality: small molecule** **MoA: a selective D1R/D5R partial agonist** **Area: Nervous System Diseases** **Indication: Parkinson's Disease** **Human Patients: 507** **Sponsor: AbbVie / Cerevel Therapeutics (ABBV / CERE)**	insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	0.6 hours (p<0.0001); key registrational endpoint MDS-UPDRS not met; key registrational endpoint off time reduction met yet fail to reach the minimally clinically meaningful threshold (-1.0 hour and -3.5 points [10.1002/mds.23638.]).	insufficient Classification: **True Negative (TN)**
1380	**SAGE-718** **NCTID: NCT05318937** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: NMDAR PAM** **Area: Nervous System Diseases** **Indication: Parkinson Disease Cognitive Dysfunction** **Human Patients: 86** **Sponsor: Sage Therapeutics (SAGE)**	Date: 15 Dec 2023 Quarter: Q1'24 Batch 10 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commerciall sufficient clinical benefit)	Readout: 17 Apr 2024 **Lead Time: 124 days in advance** Interpretation: WAIS-IV primary efficacy endpoint not met	Missed Prediction Note: due to suboptimal modelling of SAGE718 MoA that has been permanently corrected. Conclusion: statistically insignificant and commercially insufficient Classification: **False Positive (FP)**
716	**Tirzepatide** **NCTID: NCT05412004** **Phase: Phase 3** **Class: First-In-Class** **Modality: synthetic peptide** **MoA: GLP1R/GIPR-biased dual agonist** **Area: Respiratory Tract Diseases** **Indication: Obstructive Sleep Apnea** **Human Patients: 469** **Sponsor: Eli Lilly and Company (LLY)**	Date: 9 Oct 2023 Quarter: 2H'23 Batch 22 Technical: SUCCESS (statistically significant clinical benefit more for GPI2 cohort (tirzepatide + CPAP) than for GPI1 cohort (tirzepatide alone)) Commercial: partial SUCCESS (commercially sufficient clinical benefit for tirzepatide + CPAP more than for tirzepatide alone)	Readout: 17 Apr 2024 **Lead Time: 191 days in advance** Interpretation: (-30 AHI -63% AHI%) GPI2 Tirzepatide + CPAP > (-27 AHI -55% AHI%) GPI1 Tirzepatide > (33-48% AHI%) GPI2 CPAP [Ravesloot and Vries 2011 Sleep] > (-5 AHI -5% AHI%) GPI1 placebo.	Correct Prediction Note: with a minor miss in GPI2 CPAP Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1502	**BHV-1300** **NCTID: N/A (adapt the NCT06041269 trial design)** **Phase: Phase 1** **Class: First-In-Class** **Modality: bispecific molecular degrader** **MoA: bispecific molecule IgG degrader** **Area: Immune System Diseases** **Indication: Rheumatoid Arthritis** **Human Patients: 420** **Sponsor: Biohaven (BHVN)**	Date: 6 Mar 2024 Quarter: Q2'24 Batch 11 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit with inferior-to-SoC efficacy and non-superior-to-efgartigimod toxicity)	Readout: 17 Apr 2024 **Lead Time: 42 days in advance** Interpretation: unremarkable IGG data (-37%) inferior to the SoC efgatigimod IGG data (-75%).	Correct Prediction Conclusion: statistically weak and commercially insufficient compared with efgartigimod Classification: **True Negative (TN)**
352	**Lumateperone** **NCTID: NCT04985942** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: D1R/D2R/D4R/5TH2AR antagonist** **Area: Mental Disorders** **Indication: Major Depressive Disorder** **Human Patients: 485** **Sponsor: Intra-Cellular Therapies (ITCI)**	Date: 9 Jan 2024 Quarter: Q1'24 Batch 15 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit)	Readout: 16 Apr 2024 **Lead Time: 98 days in advance** Interpretation: -4.9 placebo-adjusted delta in MADRS score (p<0.0001) & CGI-S (p<0.0001).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1128	**GTX-102** **NCTID: NCT04259281** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense**	Date: 3 Jan 2024 Quarter: Q1'24 Batch 13 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS	Readout: 15 Apr 2024 **Lead Time: 103 days in advance** Interpretation: rapid and clinically significant improvement resulting a total MRDI response of +2.0 (p<0.0001) at Day 170 and +2.0	Correct Prediction Conclusion: statistically significant and commercially sufficient (no SoC) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	oligonucleotide **MoA: intrathecal UBE3A-AS ASO** **Area: Nervous System Diseases** **Indication: Angelman Syndrome** **Human Patients: 74** **Sponsor: Ultragenyx Pharmaceutical (RARE)**	(commercially sufficient clinical benefit)	(p=0.0007) at Day 338.	
1508	**ELVN-001** **NCTID: NCT05304377** **Phase: Phase 1 a/1b** **Class: Best-In-Class** **Modality: small molecule** **MoA: BCR-ABL1 and T315I selective tyrosine kinase inhibitor** **Area: Neoplasms** **Indication: Chronic Myeloid Leukemia** **Human Patients: 180** **Sponsor: Enliven Therapeutics (ELVN)**	Date: 18 Mar 2024 Quarter: Q2'24 Batch 12 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 11 Apr 2024 **Lead Time: 24 days in advance** Interpretation: 44% cumulative MRR even for previously treated with asciminib.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1211	**FLX475 Pembrolizumab** **NCTID: NCT03674567** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: CCR4 antagonist** **Area: Neoplasms** **Indication: Advanced Cancer** **Human Patients: 323** **Sponsor: RAPT Therapeutics (RAPT)**	Date: 10 Aug 2023 Quarter: 2H'23 Batch 12 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 10 Apr 2024 **Lead Time: 244 days in advance** Interpretation: 15.6% ORR (vs 27.3% ORR by pembrolizumab alone as 2L for advanced HNSCC in KEYNOTE-048.	Overall Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1268	**ALKS 2680** **NCTID: ISRCTN98204977** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: HCRTR2 agonist** **Area: Nervous System Diseases** **Indication: Narcolepsy** **Human Patients: 147** **Sponsor: Alkermes (ALKS)**	Date: 5 Oct 2023 Quarter: 2H'23 Batch 21 Technical: partial SUCCESS (statistically significant clinical benefit in efficacy); partial FAILURE (statistically insignificant clinical benefit in toxicity worse for NT1 than for NT2) Commercial: FAILURE (commercially insufficient clinical benefit due to on-target toxicity non-superior to TAK994 or JZP441)	Readout: 10 Apr 2024 **Lead Time: 188 days in advance** Interpretation: safe and effective; advance to NT1/NT2 only; not IH	Overall Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Negative (TN)**
1137	**Ac225-PSMA I&T** **NCTID: NCT05219500** **Phase: Phase 2** **Class: First-In-Class** **Modality: radioligand therapy** **MoA: anti-PSMA mAb conjugated to alpha particle-emitting cytotoxic isotope Actinium-225** **Area: Neoplasms** **Indication: Metastatic Castration Resistant Prostate Cancer (mCRPC)** **Human Patients: 115** **Sponsor: Fusion Pharmaceuticals (FUSN)**	Date: 1 Dec 2023 Quarter: Q1'24 Batch 1 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially sufficient clinical benefit non-inferior and non-superior to SoC)	Readout: 9 Apr 2024 **Lead Time: 130 days in advance** Interpretation: 50% PSA50 33% ORR (vs 57.6% PSA50 and 50.7% ORR of Pluvicto or 42% ORR PSA50 and 60% ORR of PNT2002 in advanced mCRPC).	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Positive (TP)**
1482	**VIP236** **NCTID: NCT05712889** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule drug conjugate (SMDC)**	Date: 26 Feb 2024 Quarter: Q2'24 Batch 8 Technical: SUCCESS (statistically significant clinical benefit in PFS/OS/ORR)	Readout: 8 Apr 2024 **Lead Time: 42 days in advance** Interpretation: safer yet with 0% ORR.	Missed Prediction Note: due to suboptimal modelling of linker that has been permanently corrected Conclusion: statistically

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	MoA: alpha5beta3-integrin-specific SMDC with NE-cleavage-mediated release of CPT payload **Area: Neoplasms** **Indication: Advanced Cancer** **Human Patients: 24** **Sponsor: Vincerx Pharma (VINC)**	Commercial: SUCCESS (commercially sufficient clinical benefit)		insignificant and commercially insufficient Classification: **False Positive (FP)**
870	**INZ-701** **NCTID: NCT05030831** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: fusion protein biologic** **MoA: soluble recombinant ENPP1 enzyme** **Area: Cardiovascular Diseases** **Indication: ABCC6 Deficiency Causing Pseudoxanthoma Elasticum (PXE)** **Human Patients: 10** **Sponsor: Inozyme Pharma (INZY)**	Date: 16 Jan 2024 Quarter: Q1'24 Batch 15 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 8 Apr 2024 **Lead Time: 83 days in advance** Interpretation: safe with clinical improvement in multiple exploratory efficacy endpoints.	Correct Prediction Conclusion: statistically significant (phase 1/2) and commerically TBD Classification: **True Positive (TP)**
788	**ARO-APOC3** **NCTID: NCT04720534** **Phase: Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: siRNA-GalNAc conjugate that supresses APOC3 mRNA** **Area: Nutritional and Metabolic Diseases** **Indication: Severe Hypertriglyceridemia** **Human Patients: 229** **Sponsor: Arrowhead Pharmaceuticals (ARWR)**	Date: 14 Feb 2024 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 7 Apr 2024 **Lead Time: 53 days in advance** Interpretation: 86% triglyceride reduction superior to 30-50% achieved by SoC (Fibrates).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1512	**Semaglutide** **NCTID: NCT04916470** **Phase: Phase 3** **Class: First-In-Class** **Modality: pepetide** **MoA: GLP1R agonist** **Area: Cardiovascular Diseases and Nutritional and Metabolic Diseases** **Indication: Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus Type 2** **Human Patients: 610** **Sponsor: Novo Nordisk (NVO)**	Date: 23 Mar 2024 Quarter: Q2'24 Batch 13 Technical: FAILURE (statistically insignificant additive clinical benefit in KCCQ and 6MWD as an adjunctive therapy) Commercial: FAILURE (commercially insufficient additive clinical benefit in KCCQ and 6MWD as an adjunctive therapy)	Readout: 7 Apr 2024 **Lead Time: 15 days in advance** Interpretation: 7.3 point improvement in KCCQ-CSS (5 is the minimum clinically meaningful standard) & 14.3m improvement in 6MWD vs 80m as sufficient for an quality-of-life improvement (Morbach et al. 2024 Clinical Research In Cardiology); 25m as clinically meaningful improvement (Jain et al. Arnold 2021 Circulation Heart Failure).	Overall Correct Prediction Conclusion: statistically significant (placebo) yet commercially insufficient (small 6MWD; Novo Nordisk decided not to file an NDA for marketing approval) Classification: **True Negative (TN)**
1376	**Zilebesiran Olmesartan Amlodipine Indapamide** **NCTID: NCT05103332** **Phase: Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: anti-AGT siRNA** **Area: Cardiovascular Diseases** **Indication: Hypertension** **Human Patients: 672** **Sponsor: Alnylam Pharmaceuticals (ALNY)**	Date: 15 Dec 2023 Quarter: Q1'24 Batch 11 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 7 Apr 2024 **Lead Time: 114 days in advance** Interpretation: statistically insignificant changes in 24-Hour Mean SBP for the SoC olmesartan ((p=0.036 by phase 3 standard; Paz et so. Coll-de-Tuero 2016 Medicine; Chrysant et Al. Robinson 2003 J of Human Hypertension) in both primary/secondary endpoints.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1474	**OTX-TIC (Travoprost)** **NCTID: NCT05335122** **Phase: Phase 2** **Class: Best-In-Class** **Modality: medical device** **MoA: travoprost intracameral implant** **Area: Eye Disease** **Indication: Open Angle Glaucoma Ocular Hypertension** **Human Patients: 105** **Sponsor: Ocular Therapeutix (OCUL)**	Date: 16 Feb 2024 Quarter: Q2'24 Batch 6 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit non-inferior to durysta)	Readout: 6 Apr 2024 **Lead Time: 50 days in advance** Interpretation: 24-30% IOP reduction at 6 months (vs 23-33% for durtsta or timolol) with 81.3% eyes requiring no additional treatment at 6 month (vs 81.8% for durysta and 90% for timolol).	Correct Prediction Conclusion: statistically significant and commercially sufficient (non-inferior) Classification: **True Positive (TP)**
1486	**Flu mRNA** **NCTID: NCT05823974** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: mRNA medicine** **MoA: Multivalent anti-hemagglutinin mRNA vaccine** **Area: Infections** **Indication: Influenza** **Human Patients: 1256** **Sponsor: GSK / CureVac (GSK / CVAC)**	Date: 27 Feb 2024 Quarter: Q2'24 Batch 9 Technical: partial SUCCESS (statistically significant clinical benefit for A/H3N2 for >=65 ysd participants); partial FAILURE (statistically insignificant clinical benefit for B/Victoria; B/Yamagata; and A/H1N1 for >=65 ysd participants) Commercial: partial SUCCESS (commercially sufficient yet moderate clinical benefit with non-inferior-to-FDQ21A-NH anti-ILI efficacy for A/H3N2 for >=65 ysd participants); partial FAILURE (commercially insufficient clinical benefit with inferior-to-FDQ21A-NH anti-ILI efficacy for B/Victoria; B/Yamagata; and A/H1N1 for >=65 ysd participants)	Readout: 4 Apr 2024 **Lead Time: 37 days in advance** Interpretation: numerically higher geometric mean titers for influenza A in both young and elderly age groups and lower geometric mean titers for influenza B in both young and elederly age groups.	Correct Prediction Conclusion: statistically significant against placebo yet commercially insufficient (especially for influenza B as we accurately predicted) Classification: **True Negative (TN)**
1345	**KPL-404** **NCTID: NCT05198310** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-CD40 mAb inhibitor** **Area: Immune System Diseases** **Indication: Rheumatoid Arthritis** **Human Patients: 145** **Sponsor: Kiniksa Pharmaceuticals (KNSA)**	Date: 26 Nov 2023 Quarter: Q1'24 Batch 7 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 2 Apr 2024 **Lead Time: 128 days in advance** Interpretation: DAS28-CRP primary endpoint not met for cohort 3 and cohort 4.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1344	**GRT-C901 GRT-R902 Atezolizumab Ipilimumab Fluoropyrimidine plus leucovorin Bevacizumab** **NCTID: NCT05141721** **Phase: Phase 2 Phase 3** **Class: First-In-Class** **Modality: cancer vaccine** **MoA: modified-chimpanzee-adenoviral patient-specific neoantigen vaccine** **Area: Neoplasms** **Indication: Metastatic Colorectal Cancer** **Human Patients: 700** **Sponsor: Gritstone bio (GRTS)**	Date: 26 Nov 2023 Quarter: Q1'24 Batch 7 Technical: SUCCESS (statistically significant yet weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 1 Apr 2024 **Lead Time: 127 days in advance** Interpretation: weak PFS trend that's not statistically significant yet.	Correct Prediction Conclusion: statistically significant yet commercially insufficient (weak efficacy) Classification: **True Negative (TN)**
1307	**CT-0508 Pembrolizumab** **NCTID: NCT04660929** **Phase: Phase 1** **Class: First-In-Class** **Modality: CAR-Macrophage therapy** **MoA: anti-HER2 CAR-M1**	Date: 31 Oct 2023 Quarter: 2H'23 Batch 26 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 1 Apr 2024 **Lead Time: 153 days in advance** Interpretation: safe yet terminated due to insufficient efficacy.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Area: Neoplasms **Indication: HER2-positive Adenocarcinoma Bile Duct Cancer Biliary Tract Cancer Bladder Cancer Breast CancerBreast Neoplasm Carcinoma Ductal Carcinoma Hepatocellular Cancer Lung Cancer Non-Small Cell Carcinoma Ovarian Epithelial Carcinoma Small Cell Carcinoma Squamous Carcinoma Transitional Cell Colorectal Cancer Esophagogastric Junction Neoplasms Inflammatory Breast Cancer Stomach Neoplasms Malignant Neoplasms Ovarian Neoplasms Pancreatic Cancer HER2-positive Solid Tumors HER2-positive Breast Cancer HER2-positive Gastric Cancer HER-2 Protein Overexpression HER-2 Gene Amplification Prostate Cancer Head and Neck Cancer Endometrial Cancer Lung Cancer Small Cel** **Human Patients: 48** **Sponsor: Carisma Therapeutics (CARM)**			
845	**EQ001 (Itolizumab)** **NCTID: NCT04128579** **Phase: Phase 1** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: anti-CD6 mAb inhibitor** **Area: Immune System Diseases** **Indication: Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis** **Human Patients: 55** **Sponsor: Equillium (EQ)**	Date: 18 Feb 2024 Quarter: Q2'24 Batch 7 Technical: SUCCESS (statistically significant yet moderate clinical benefit) Commercial: partial SUCCESS (commercially maybe sufficient clinical benefit)	Readout: 1 Apr 2024 **Lead Time: 43 days in advance** Interpretation: 80% ORR in UPCR.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1022	**DISC-1459** **NCTID: ACTRN12622000799752** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: GLYT1 small molecule inhibitor** **Area: Digestive System Diseases** **Indication: Erythropoietic Protoporphyria (EEP)** **Human Patients: 22** **Sponsor: Disc Medicine (IRON)**	Date: 24 Apr 2023 Quarter: Q2'23 Batch 18 Technical: partial SUCCESS (statistically significant yet weak clinical benefit) Commercial: FAILURE (comercially insufficient clinical benefit)	Readout: 1 Apr 2024 **Lead Time: 343 days in advance** Interpretation: primary endpoint met yet key secondary endpoint (light tolerance) not met.	Overall Correct Prediction Conclusion: statistically significant yet weak and commercially insufficient. Original correct prospective prediction No.1022 in Q2'23; then modified to the false prediction misled by later released preliminary data. Classification: **True Negative (TN)**
466	**Apraglutide** **NCTID: NCT05415410** **Phase: Phase 2** **Class: Best-In-Class** **Modality: peptide drug** **MoA: GLP2R agonist** **Area: Immune System Diseases** **Indication: Graft Versus Host Disease (GVHD).** **Human Patients: 31** **Sponsor: Ironwood Pharmaceuticals (IRWD)**	Date: 5 Jan 2024 Quarter: Q1'24 Batch 17 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 28 Mar 2024 **Lead Time: 83 days in advance** Interpretation: phase 2a safety primary endpoint met and showed sustained response.	Correct Prediction Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**
900	**HepTcell** **NCTID: NCT04684914** **Phase: Phase 2**	Date: 20 Nov 2023 Quarter: Q1'24 Batch 2 Technical: partial SUCCESS	Readout: 27 Mar 2024 **Lead Time: 128 days in advance** Interpretation: terminated due to lack	Correct Prediction Conclusion: statistically insignificant and commercially

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: First-In-Class **Modality: peptide drug** **MoA: HPV-derived peptides** **Area: Infections** **Indication: Chronic Hepatitis B** **Human Patients: 87** **Sponsor: Altimmune (ALT)**	(statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	of efficacy	insufficient Classification: **True Negative (TN)**
984	**NovoTTF-200M device Best Standard of Care** **NCTID: NCT02831959** **Phase: Phase 3** **Class: First-In-Class** **Modality: medical device** **MoA: a device delivering low-intensity; wave-like alternating electric fields to the location of the tumor** **Area: Neoplasms** **Indication: Brain Metastases From Non-small Cell Lung Cancer (NSCLC)** **Human Patients: 270** **Sponsor: NovoCure (NVCR)**	Date: 22 Dec 2023 Quarter: Q1'24 Batch 12 Technical: partial SUCCESS (statistically significant yet weak additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 27 Mar 2024 **Lead Time: 96 days in advance** Interpretation: 21.9month vs 11.3month time to intracranial progression (p=0.016) OS secondary endpoint not met.	Correct Prediction Conclusion: statistically significant yet commercially insufficient (no OS benefit) Classification: **True Negative (TN)**
1056	**serdexmethylphenidate (SDX)** **NCTID: NCT05668754** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: norepinephrine/dopamine reuptake inhibitors** **Area: Nervous System Diseases** **Indication: Idiopathic Hypersomnia** **Human Patients: 50** **Sponsor: Zevra Therapeutics (ZVRA)**	Date: 14 Feb 2024 Quarter: Q2'24 Batch 3 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 26 Mar 2024 **Lead Time: 41 days in advance** Interpretation: primary safety endpoint met and secondary efficacy endpoints meaningful.	Correct Prediction Conclusion: statistically significant and commercially sufficient to advance to phase 3 Classification: **True Positive (TP)**
476	**VK2735** **NCTID: NCT05204237** **Phase: Phase 1** **Class: Best-In-Class** **Modality: pepetide drug** **MoA: GLP1R/GIPR-biased dual agonist** **Area: Nutritional and Metabolic Diseases** **Indication: Weight Loss NASH** **Human Patients: 136** **Sponsor: Viking Therapeutics (VKTX)**	Date: 16 Oct 2023 Quarter: Q1'24 Batch 4 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to GSBR1289 and orforglipron)	Readout: 26 Mar 2024 **Lead Time: 162 days in advance** Interpretation: 5.3% from baseline and 3.3% placebo-adjust weight reduction at 4 weeks vs 3% from baseline and 2% placebo-adjusted weight reduction for tirzapatide.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1397	**STAR-0215** **NCTID: NCT05695248** **Phase: Phase 1 Phase 2** **Class: Best-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: YTE-modified anti-kallikrein mAb inhibitor** **Area: Cardiovascular Diseases** **Indication: Hereditary Angioedema** **Human Patients: 28** **Sponsor: Astria Therapeutics (ATXS)**	Date: 21 Dec 2023 Quarter: Q1'24 Batch 11 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit with superior-to-lanadelumab efficacy and durability)	Readout: 25 Mar 2024 **Lead Time: 95 days in advance** Interpretation: -93% mean monthly HAE attacks vs -85% by PHVS's deucrictibant; -92%-100% moderate to severe HAE attacks vs 83% by Takeda's lanadelumab.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
896	**AXS-12 (reboxetine)** **NCTID: NCT05059223** **Phase: Phase 3**	Date: 1 Dec 2023 Quarter: Q1'24 Batch 2 Technical: SUCCESS (statistically	Readout: 25 Mar 2024 **Lead Time: 115 days in advance** Interpretation: 83% cataplexy attack	Correct Prediction Conclusion: statistical significant and commercially sufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Class: Best-In-Class **Modality: small molecule** **MoA: selectively inhibitor of the reuptake of norepinephrine** **Area: Nervous System Diseases** **Indication: Narcolepsy** **Human Patients: 90** **Sponsor: Axsome Therapeutics (AXSM)**	significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	reduction achieved by AXS12; superior to 49-69% cataplexy attack reduction achieved by the SoC Sodium oxybate (doi.org/10.1016/j.sleep.2003.11.002) primary and secondary endpoints met.	Classification: **True Positive (TP)**
1058	**Paltusotine** **NCTID: NCT05192382** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: SST2R agonist** **Area: Musculoskeletal Diseases** **Indication: Acromegaly** **Human Patients: 111** **Sponsor: Crinetics Pharmaceuticals (CRNX)**	Date: 14 Aug 2023 Quarter: Q1'24 Batch 2 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to octreotide)	Readout: 19 Mar 2024 **Lead Time: 218 days in advance** Interpretation: 56% patients achieved IGF1 level < 1.0% and -2.67 ASD score; sueprior to the SoC octreitide LAR achieved 23.3% patients achieved IGF1 level < 1.0% and -2.67 ASD score.	Correct Prediction Conclusion: statistical significant and commercially sufficient Classification: **True Positive (TP)**
1370	**Lanifibranor (IVA337) Placebo Empagliflozin** **NCTID: NCT05232071** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: It is a pan-PPAR agonist** **Area: Nutritional and Metabolic Diseaseses** **Indication: NASH and Type 2 Diabetes Mellitus** **Human Patients: 42** **Sponsor: Inventiva Pharma (IVA)**	Date: 2 Dec 2023 Quarter: Q1'24 Batch 9 Technical: partial SUCCESS (statistically significant yet moderate clinical benefit for lanifibranor + empagliflozin) Commercial: FAILURE (commercially insufficient clinical benefit for lanifibranor + empagliflozin; inferior to tirzepatide)	Readout: 18 Mar 2024 **Lead Time: 107 days in advance** Interpretation: -1.15% & -1.6% HbA1c (mono and combo) at week 24; inferior to the SoC tirzepatide -1.6-2.4% HbA1c at week 26.	Correct Prediction Conclusion: statistical significant and commercially insufficient Classification: **True Negative (TN)**
911	**Tildacerfont** **NCTID: NCT04457336** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral small molecule CRF1R antagonist** **Area: Urogenital Diseases** **Indication: Congenital Adrenal Hyperplasia** **Human Patients: 96** **Sponsor: Spruce Biosciences (SPRB)**	Date: 30 Nov 2023 Quarter: Q1'24 Batch 5 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 13 Mar 2024 **Lead Time: 104 days in advance** Interpretation: primary endpoint not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1059	**Paltusotine** **NCTID: NCT05361668** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: SST2R agonist** **Area: Neoplasms** **Indication: Carcinoid Syndrome** **Human Patients: 36** **Sponsor: Crinetics Pharmaceuticals (CRNX)**	Date: 14 Aug 2023 Quarter: 2H'23 Batch 12 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to octreotide)	Readout: 12 Mar 2024 **Lead Time: 211 days in advance** Interpretation: 63% reduction flushing frequency and 60% reduction in bowel movement frequency p<0.0001; both superior to the 20-35% reduction in flushing and bowel movement achieved by SoC (DOI- 10.1093/annonc/mdy293.007).	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1346	**Pimavanserin** **NCTID: NCT04531982** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: 5HT2AR/5HT2CR antagonist** **Area: Nervous System Diseases** **Indication: Schizophrenia**	Date: 27 Nov 2023 Quarter: Q1'24 Batch 6 Technical: SUCCESS (statistically significant additive clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit non-inferior to KarXT)	Readout: 11 Mar 2024 **Lead Time: 105 days in advance** Interpretation: primary endpoint not met.	Missed Prediction Note: due to suboptimal modeling of drug MoA that has been permanently corrected. Conclusion: statistically insignificant and commercially insufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Human Patients: 454 **Sponsor: Acadia Pharmaceuticals (ACAD)**			Classification: **False Positive (FP)**
717	**Lebrikizumab (LY3650150)** **NCTID: NCT05372419** **Phase: Phase 3** **Class: Best-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: IL-13 mAb inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Atopic Dermatitis and Skin of Color** **Human Patients: 80** **Sponsor: Eli Lilly and Company (LLY)**	Date: 26 Nov 2022 Quarter: - Batch - Technical: SUCCESS Commercial: SUCCESS	Readout: 11 Mar 2024 **Lead Time: 471 days in advance** Interpretation: 68% EASI75 and 46% EASI90 55% itch reduction and 39% clear of skin; which is superior to 49% EASI75 achieved by dupilumab.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1185	**Izokibep** **NCTID: NCT05623345** **Phase: Phase 2 Phase 3** **Class: Best-In-Class** **Modality: small protein scaffold-based biologic** **MoA: IL-17A Inhibitior** **Area: Musculoskeletal Diseases** **Indication: Psoriatic Arthritis** **Human Patients: 351** **Sponsor: Acelyrin (SLRN)**	Date: 20 Nov 2023 Quarter: Q1'24 Batch 2 Technical: SUCCESS (statistically significant clinical benefit) Commercial: partial SUCCESS (commercially insufficient clinical benefit with non-superior-to-bimekizumab efficacy and inferior-to-bimekizumab toxicity)	Readout: 11 Mar 2024 **Lead Time: 112 days in advance** Interpretation: 28% placebo-controlled ACR50 response at wk 16 with 2.5% discontinuation rate; which is infereior to 36% placebo-controlled ACR50 response at wk 16 and 0.4% discontinuation rate; achieved by bimekizumab (DOI-10.1016/S0140-6736(22)02303-0).	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
342	**AMX0035** **NCTID: NCT05021536** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: sodium phenylbutyrate + taurursodiol** **Area: Nervous System Diseases** **Indication: Amyotrophic Lateral Sclerosis** **Human Patients: 600** **Sponsor: Amylyx Pharmaceuticals (AMLX)**	Date: 18 Feb 2024 Quarter: Q2'24 Batch 2 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 8 Mar 2024 **Lead Time: 19 days in advance** Interpretation: endpoints not met.	Missed Prediction Note: due to suboptimal modelling of ALS that has been permanently corrected. Conclusion: statistical insignificant and commercially insufficient Classification: **False Positive (FP)**
1047	**BMF-219** **NCTID: NCT05731544** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: oral small molecule MENIN inhibitor** **Area: Nutritional and Metabolic Diseases** **Indication: Type 2 Diabetes Mellitus** **Human Patients: 414** **Sponsor: Biomea Fusion (BMEA)**	Date: 29 Feb 2024 Quarter: Q2'24 Batch 9 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit for T2DM patients)	Readout: 6 Mar 2024 **Lead Time: 6 days in advance** Interpretation: -0.4% to -1.4% HbA1c at week 26; which is inferior to tirzepatide's -1.6 to -2.4% HbA1c at week 26; full clinical hold due to hepatitoxicity	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
999	**AOC 1001** **NCTID: NCT05027269** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: anti-DMPK siRNA** **Area: Musculoskeletal Diseases** **Indication: Myotonic Dystrophy Type 1 (DM1)** **Human Patients: 38**	Date: 22 Apr 2023 Quarter: Q2'23 Batch 16 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commerciall insufficient clinical benefit)	Readout: 4 Mar 2024 **Lead Time: 317 days in advance** Interpretation: no change in toxicity or efficacy in OLE	Correct Prediction Conclusion: statistical insignificant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Avidity Biosciences (RNA)			
1431	**PQ912** **NCTID: NCT04498650** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: QPCT/QPCTL inhibitor** **Area: Nervous System Diseases** **Indication: Early Alzheimers Disease Mild Cognitive Impairment Due to AD** **Human Patients: 259** **Sponsor: Vivoryon Therapeutics (VVY)**	Date: 20 Jan 2024 Quarter: Q1'24 Batch 16 Technical: partial SUCCESS (statistically maybe significant yet very weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to donanemab or lecanemab)	Readout: 4 Mar 2024 **Lead Time: 44 days in advance** Interpretation: primary/secondary endpoint not met.	Overall Correct Prediction Conclusion: statistical insignificant and commercially insufficient Classification: **True Negative (TN)**
463	**Apraglutide** **NCTID: NCT04627025** **Phase: Phase 3** **Class: Best-In-Class** **Modality: peptide drug** **MoA: GLP2R agonist** **Area: Digestive System Diseases** **Indication: Short Bowel Syndrome with Intestinal Failure (SBS-IF)** **Human Patients: 164** **Sponsor: Ironwood Pharmaceuticals (IRWD)**	Date: 5 Jan 2024 Quarter: Q1'24 Batch 17 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 29 Feb 2024 **Lead Time: 55 days in advance** Interpretation: 13% placebo-adjusted actual weekly PS volume change (p=0.001) & at least 1 day/week (p=0.04) at week 24 vs 17% actual weekly PS volume change (p<0.001) for once-daily teduglutide; effective for stoma population but not effective for colon-in-continuity population with less intestine resection.	Overall Correct Prediction Conclusion: statistically significant; once-weekly apraglutide commercially sufficient non-inferior to once-daily teduglutide Classification: **True Positive (TP)**
929	**PL9643 Vehicle Opthalmic Solution Opthalmic Solution** **NCTID: NCT05201170** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: MC1R/MC5R agonist** **Area: Eye Diseases** **Indication: Dry Eye** **Human Patients: 240** **Sponsor: Palatin Technologies (PTN)**	Date: 7 Mar 2023 Quarter: - Batch - Technical: FAILURE Commercial: FAILURE	Readout: 28 Feb 2024 **Lead Time: 358 days in advance** Interpretation: key primary and secondary endpoints not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1290	**VK2735** **NCTID: NCT06068946** **Phase: Phase 2** **Class: Best-In-Class** **Modality: synthetic peptide** **MoA: GLP1R/GIPR-biased dual agonist** **Area: Nutritional and Metabolic Diseaseses** **Indication: Weight Loss** **Human Patients: 176** **Sponsor: Viking Therapeutics (VKTX)**	Date: 15 Oct 2023 Quarter: 2H'23 Batch 24 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to GSBR1289 and orforglipron)	Readout: 27 Feb 2024 **Lead Time: 135 days in advance** Interpretation: 13.1% placebo-adjusted weight loss at week 13 vs 7% of tirzepatide at week 13; no plateau.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1336	**ARS-1** **NCTID: NCT05496465** **Phase: Phase 2** **Class: Best-In-Class** **Modality: medical device** **MoA: epinephrine spray** **Area: Skin and Connective Tissue Diseases** **Indication: Urticaria** **Human Patients: 24** **Sponsor: ARS Pharmaceuticals (SPRY)**	Date: 20 Nov 2023 Quarter: 2H'23 Batch 30 Technical: partial SUCCESS (statistically maybe significant yet weak clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 26 Feb 2024 **Lead Time: 98 days in advance** Interpretation: primary endpoint met with p<0.05 that's not comparable with CDX0159 that achieved 40.6% placebo-adjusted CR.	Correct Prediction Conclusion: statistically significant yet weak and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
1466	**Gepotidacin Ceftriaxone Azithromycin** **NCTID: NCT04010539** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: oral inhibitor of bacterial DNA gyrase and topoisomerase IV** **Area: Infections** **Indication: Urinary Tract Infections** **Human Patients: 628** **Sponsor: GSK (GSK)**	Date: 15 Feb 2024 Quarter: Q2'24 Batch 1 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 26 Feb 2024 **Lead Time: 11 days in advance** Interpretation: primary endpoint of non-inferiority to SoC met.	Correct Prediction Conclusion: statistically significant and commercially sufficient (non-inferiority is sufficient given the high efficacy of antiboitics and high rate of resistance). Classification: **True Positive (TP)**
1412	**TP-05** **NCTID: NCT05387083** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: anti-GABACl inhibitor** **Area: Infections** **Indication: Lyme Disease** **Human Patients: 30** **Sponsor: Tarsus Pharmaceuticals (TARS)**	Date: 15 Jan 2024 Quarter: Q1'24 Batch 15 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 22 Feb 2024 **Lead Time: 38 days in advance** Interpretation: primary endpoint and key secondary endpoint met 97% vs 5% tick mortality p<0.0001.	Correct Prediction Conclusion: statistically significant and commercially sufficient (theoretical efficacy upper limit) Classification: **True Positive (TP)**
1341	**SAR443820** **NCTID: NCT05237284** **Phase: Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: RIPK1 inhibitor** **Area: Nervous System Diseases** **Indication: Amyotrophic Lateral Sclerosis** **Human Patients: 305** **Sponsor: Denali Therapeutics / Sanofi (DNLI/SNY)**	Date: 21 Nov 2023 Quarter: Q1'24 Batch 7 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 16 Feb 2024 **Lead Time: 87 days in advance** Interpretation: primary endpoint not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1068	**KVD900** **NCTID: NCT05259917** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: plasma kallikrein inhibitor** **Area: Cardiovascular Diseases** **Indication: Hereditary Angioedema** **Human Patients: 136** **Sponsor: KalVista Pharmaceuticals (KALV)**	Date: 25 May 2023 Quarter: 2H'23 Batch 2 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (Commercially sufficient clinical benefit non-inferior to lanadelumab)	Readout: 13 Feb 2024 **Lead Time: 264 days in advance** Interpretation: met all primary and secondary endpoints.	Correct Prediction Conclusion: statistically significant and commercially sufficient as a non-inferior oral on-demand treatment Classification: **True Positive (TP)**
1006	**4D-310** **NCTID: NCT05629559** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV GLA gene therapy** **Area: Nervous System Diseases** **Indication: Fabry Disease** **Human Patients: 18** **Sponsor: 4D Molecular Therapeutics (FDMT)**	Date: 2 Dec 2023 Quarter: Q1'24 Batch 8 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 12 Feb 2024 **Lead Time: 72 days in advance** Interpretation: weak efficacy in cardiac endpoints (minimal clinically important difference (MCID) no key renal endpoints with previous clinical hold due to toxcicity.	Correct Prediction Conclusion: more likely to be statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1409	**CTI-1601** **NCTID: NCT05579691** **Phase: Phase 2** **Class: First-In-Class** **Modality: fusion protein biologic**	Date: 7 Jan 2024 Quarter: Q1'24 Batch 14 Technical: partial SUCCESS (statistically significant yet weak clinical benefit due to TAT delivery)	Readout: 12 Feb 2024 **Lead Time: 36 days in advance** Interpretation: insignificant FXN levels	Correct Prediction Conclusion: statistically significant yet weak and commercially insufficient

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	MoA: TAT-delivered FXN recombinant fusion protein **Area: Nervous System Diseases** **Indication: Friedreich Ataxia** **Human Patients: 28** **Sponsor: Larimar Therapeutics (LRMR)**	Commercial: FAILURE (commercially insufficient clinical benefit inferior to omaveloxolone)		Classification: **True Negative (TN)**
1181	**ADVM-022** **NCTID: NCT05536973** **Phase: Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV aflibercept gene therapy** **Area: Eye Diseases** **Indication: Neovascular Age-related Macular Degeneration** **Human Patients: 69** **Sponsor: Adverum Biotechnologies (ADVM)**	Date: 18 Jul 2023 Quarter: 2H'23 Batch 7 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to aflibercept)	Readout: 8 Feb 2024 **Lead Time: 205 days in advance** Interpretation: -1.7 BCVA 26 weeks vs +4 BCVA for 24 weeks achieved by ranibizumab; negative dose-response relationship	Overall Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
709	**Tirzepatide (LY3298176)** **NCTID: NCT04166773** **Phase: Phase 2** **Class: First-In-Class** **Modality: synthetic peptide** **MoA: GLP1R/GIPR-biased dual agonist** **Area: Nutritional and Metabolic Diseaseses** **Indication: Nonalcoholic Steatohepatitis (NASH)** **Human Patients: 196** **Sponsor: Eli Lilly and Company (LLY)**	Date: 26 Nov 2022 Quarter: - Batch - Technical: SUCCESS Commercial: SUCCESS	Readout: 6 Feb 2024 **Lead Time: 437 days in advance** Interpretation: 61% placebo-adjusted absence of NASH with no worsening of fibrosis; which is superior to 16-20% achieved by the SoC resmetirom	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
1276	**VX-121/TEZ/D-IVA ELX/TEZ/IVA IVA** **NCTID: NCT05033080** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: CFTR modulator** **Area: Respiratory Tract Diseases** **Indication: Cystic Fibrosis** **Human Patients: 435** **Sponsor: Vertex Pharmaceuticals (VRTX)**	Date: 3 Dec 2023 Quarter: Q1'24 Batch 22 Technical: SUCCESS (statistically significant clinical benefit non-inferior and non-superior to Trikafta) Commercial: SUCCESS (commercially sufficient clinical benefit with once-daily dosing regimen)	Readout: 5 Feb 2024 **Lead Time: 64 days in advance** Interpretation: all primary and key secondary endpoints of non-inferiority are met	Correct Prediction Conclusion: statistically significant and commercially sufficient (once-daily) Classification: **True Positive (TP)**
1277	**VX-121/TEZ/D-IVA ELX/TEZ/IVA IVA** **NCTID: NCT05076149** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: CFTR modulator** **Area: Respiratory Tract Diseases** **Indication: Cystic Fibrosis** **Human Patients: 597** **Sponsor: Vertex Pharmaceuticals (VRTX)**	Date: 3 Dec 2023 Quarter: Q1'24 Batch 9 Technical: SUCCESS (statistically significant clinical benefit non-inferior and non-superior to Trikafta) Commercial: SUCCESS (commercially sufficient clinical benefit with once-daily dosing regimen)	Readout: 5 Feb 2024 **Lead Time: 64 days in advance** Interpretation: all primary and key secondary endpoints of non-inferiority are met	Correct Prediction Conclusion: statistically significant and commercially sufficient (once-daily) Classification: **True Positive (TP)**
1278	**VX-121/TEZ/D-IVA** **NCTID: NCT05422222** **Phase: Phase 3** **Class: Best-In-Class** **Modality: small molecule** **MoA: CFTR modulator** **Area: Respiratory Tract Diseases**	Date: 12 Oct 2023 Quarter: Q1'24 Batch 9 Technical: SUCCESS (statistically significant clinical benefit non-inferior and non-superior to Trikafta) Commercial: SUCCESS	Readout: 5 Feb 2024 **Lead Time: 116 days in advance** Interpretation: all primary and key secondary endpoints of non-inferiority are met.	Correct Prediction Conclusion: statistically significant and commercially sufficient (once-daily) Classification: **True Positive (TP)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Indication: Cystic Fibrosis **Human Patients: 210** **Sponsor: Vertex Pharmaceuticals (VRTX)**	(commercially sufficient clinical benefit with once-daily dosing regimen)		
1004	**4D-150 IVT Aflibercept IVT** **NCTID: NCT05197270** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV aflibercept and VEGFC RNAi gene therapy** **Area: Eye Diseases** **Indication: Neovascular (Wet) Age-Related Macular Degeneration** **Human Patients: 150** **Sponsor: 4D Molecular Therapeutics (FDMT)**	Date: 3 Dec 2023 Quarter: Q1'24 Batch 8 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to aflibercept)	Readout: 3 Feb 2024 **Lead Time: 62 days in advance** Interpretation: #ERROR!	Overall Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1347	**Ziftomenib** **NCTID: NCT04067336** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: Menin-MLL1 inhibitor** **Area: Neoplasms** **Indication: Relapsed or Refractory Acute Myeloid Leukemia** **Human Patients: 199** **Sponsor: Kura Oncology (KURA)**	Date: 28 Nov 2023 Quarter: - Batch - Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 30 Jan 2024 **Lead Time: 63 days in advance** Interpretation: 65% ORR with 70% Top CR; non-superior to chemo's 60%-70% CR.	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1284	**VX-548** **NCTID: NCT05558410** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: NaV1.8 inhibitor** **Area: Nervous System Diseases** **Indication: Acute Pain After an Abdominoplasty** **Human Patients: 1118** **Sponsor: Vertex Pharmaceuticals (VRTX)**	Date: 12 Oct 2023 Quarter: 2H'23 Batch 23 Technical: SUCCESS (statistically significant clinical benefit compared with placebo) Commercial: FAILURE (commercially insufficient clinical benefit due to non-superior-to-HB/APAP efficacy and inferior-to-HB/APAP toxicity leading to significant risk of post-marketing withdrawal)	Readout: 30 Jan 2024 **Lead Time: 110 days in advance** Interpretation: statistically significant than placebo; non-superior to HB/APAP in all endpoints.	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**
1285	**VX-548 HB/APAP** **NCTID: NCT05553366** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: NaV1.8 inhibitor** **Area: Nervous System Diseases** **Indication: Acute Pain After a Bunionectomy** **Human Patients: 1075** **Sponsor: Vertex Pharmaceuticals (VRTX)**	Date: 12 Oct 2023 Quarter: 2H'23 Batch 23 Technical: SUCCESS (statistically significant clinical benefit compared with placebo) Commercial: SUCCESS (commercially sufficient clinical benefit due to superior-to-HB/APAP efficacy and non-inferior-to-HB/APAP toxicity)	Readout: 30 Jan 2024 **Lead Time: 110 days in advance** Interpretation: statistically significant than placebo; VX-548 is superior to HB/APAP inSPID48 for bunionectomy (P=0.0016) and non-superior in other endpoints.	Overall Correct Prediction Conclusion: statistically significant and overall commercially sufficient Classification: **True Positive (TP)**
1408	**Sacituzumab Govitecan-hziy (SG) Docetaxel** **NCTID: NCT05089734** **Phase: Phase 3** **Class: First-In-Class** **Modality: ADC** **MoA: anti-TROP2 ADC with SN38 payload for lysosomal-degradation-mediated intracellular release** **Area: Neoplasms** **Indication: Non-Small Cell Lung**	Date: 5 Jan 2024 Quarter: Q1'24 Batch 13 Technical: partial SUCCESS (statistically maybe significant yet weak additional clinical benefit in OS compared with docetaxel) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 22 Jan 2024 **Lead Time: 17 days in advance** Interpretation: OS primary endpoint not met.	Correct Prediction Conclusion: statistically insignificant and commercial insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Cancer (NSCLC) **Human Patients: 603** **Sponsor: Gilead Sciences (GILD)**			
1400	**Donidalorsen (ISIS 721744 or IONIS-PKK-LRx)** **NCTID: NCT05139810** **Phase: Phase 3** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: GalNAc3-conjugated anti-prekallikrein ASO** **Area: Cardiovascular Diseases** **Indication: Hereditary Angioedema** **Human Patients: 91** **Sponsor: Ionis Pharmaceuticals (IONS)**	Date: 3 Jan 2024 Quarter: Q1'24 Batch 13 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit non-superior non-inferior to deucrictibant)	Readout: 22 Jan 2024 **Lead Time: 19 days in advance** Interpretation: primary and secondary endpoints met with 87% lower attack rate vs 85% lower attack rate achieved by deucrictibant.	Correct Prediction Conclusion: statistically significant and commercial sufficient (no approved drug for this MoA). Classification: **True Positive (TP)**
508	**AB680 Zimberelimab Nab-paclitaxel Gemcitabine** **NCTID: NCT04104672** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: CD73 inhibitor** **Area: Neoplasms** **Indication: Advanced Pancreatic Cancer** **Human Patients: 195** **Sponsor: Arcus Biosciences (RCUS)**	Date: 18 Jun 2023 Quarter: Q1'24 Batch 5 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 16 Jan 2024 **Lead Time: 212 days in advance** Interpretation: ORR/OS/PFS endpoints not met for both Q+ SoC and QZ+ SoC with mOS trend (15 vs 12 months for SoC).	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1161	**RGX-314 Ranibizumab Local steroid Topical steroid** **NCTID: NCT04514653** **Phase: Phase 2** **Class: First-In-Class** **Modality: gene therapy** **MoA: AAV anti-VEGF gene therapy** **Area: Eye Diseases** **Indication: Neovascular Age-Related Macular Degeneration (nAMD)** **Human Patients: 115** **Sponsor: AbbVie / REGENXBIO (ABBV/RGNX)**	Date: 9 Jul 2023 Quarter: - Batch - Technical: FAILURE (statistically insignificant clinical benefit inferior to ranibizumab) Commercial: FAILURE (commercially insufficient clinical benefit inferior to ranibizumab)	Readout: 16 Jan 2024 **Lead Time: 191 days in advance** Interpretation: -1 to -2.8 BCVA 6 months vs +4 for ranibizumab.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
1089	**Lirentelimab (AK002)** **NCTID: NCT05155085** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: SIGLEC8 mAb inhibitor** **Area: Skin and Connective Tissue Diseases** **Indication: Atopic Dermatitis** **Human Patients: 131** **Sponsor: Allakos (ALLK)**	Date: 6 Jun 2023 Quarter: 2H'23 Batch 3 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit for refractory patients superior to omalizumab)	Readout: 16 Jan 2024 **Lead Time: 224 days in advance** Interpretation: primary endpoint not met.	Missed Prediction Note: due to suboptimal drug MoA modelling that has been permanently corrected. Conclusion: statistically insignificant commercially insufficient Classification: **False Positive (FP)**
770	**ATI-1777** **NCTID: NCT05432596** **Phase: Phase 2** **Class: Best-In-Class** **Modality: small molecule** **MoA: JAK1/JAK3 inhibitor** **Area: Skin and Connective**	Date: 7 Jan 2024 Quarter: Q1'24 Batch 14 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit due to	Readout: 10 Jan 2024 **Lead Time: 3 days in advance** Interpretation: ATI1777 achieved 70% EASI with 11% delta vs dupilumab that achieved 72-80% EASI with 40% delta.	Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Tissue Diseases **Indication: Atopic Dermatitis** **Human Patients: 250** **Sponsor: Aclaris Therapeutics (ACRS)**	crowded market)		
1279	**ORIC-944** **NCTID: NCT05413421** **Phase: Phase 1** **Class: First-In-Class** **Modality: small molecule** **MoA: PRC2 inhibitor** **Area: Neoplasms** **Indication: Metastatic Prostate Cancer** **Human Patients: 42** **Sponsor: ORIC Pharmaceuticals (ORIC)**	Date: 11 Oct 2023 Quarter: Q1'24 Batch 9 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 8 Jan 2024 **Lead Time: 89 days in advance** Interpretation: no efficacy data on key secondary endpoints ORR/PFS yet advancing combination therapy forward only (widely accepted strong sign of weak efficacy).	Correct Prediction Conclusion: commercial insufficiet Classification: **True Negative (TN)**
1271	**PRX012** **NCTID: TBD** **Phase: Phase 1** **Class: Best-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: amyloid beta mAb inhibitor** **Area: Nervous System Diseases** **Indication: Alzheimer Disease** **Human Patients: 100** **Sponsor: Prothena Corporation (PRTA)**	Date: 6 Oct 2023 Quarter: 2H'23 Batch 21 Technical: SUCCESS (statistically significant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit inferior to both donanemab and lecanemab)	Readout: 8 Jan 2024 **Lead Time: 94 days in advance** Interpretation: encouraging amyloid beta reduction without numbers (widely accepted strong sign of weak efficacy).	Correct Prediction Conclusion: commercial insufficient inferior to both donanemab and lecanemab Classification: **True Negative (TN)**
961	**ARGX-117** **NCTID: NCT05225675** **Phase: Phase 2** **Class: First-In-Class** **Modality: monoclonal antibody (mAb)** **MoA: C2 mAb inhibitor** **Area: Nervous System Diseases** **Indication: Multifocal Motor Neuropathy** **Human Patients: 54** **Sponsor: argenx (ARGX)**	Date: 30 Nov 2023 Quarter: Q1'24 Batch 4 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit)	Readout: 8 Jan 2024 **Lead Time: 39 days in advance** Interpretation: 91% placebo-adjusted reduction in the need for IVIg rescue.	Correct Prediction Conclusion: statistically significant and commercially sufficient (no approved SoC for reducing IVIg rescue Classification: **True Positive (TP)**
1312	**AT-001** **NCTID: NCT04083339** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: Aldose Reductase inhibitor** **Area: Cardiovascular Diseases** **Indication: Diabetic Cardiomyopathy** **Human Patients: 675** **Sponsor: Applied Therapeutics (APLT)**	Date: 2 Nov 2023 Quarter: 2H'23 Batch 27 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 8 Jan 2024 **Lead Time: 67 days in advance** Interpretation: primary efficacy endpoint peak VO2 not met.	Correct Prediction Conclusion: statistically insignificant and commercial insufficient Classification: **True Negative (TN)**
1110	**Mitapivat** **NCTID: NCT04770753** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: small molecule PKR activator** **Area: Hematologic Diseases** **Indication: Non-Transfusion-Dependent Alpha- or Beta-Thalassemia** **Human Patients: 194**	Date: 14 Nov 2023 Quarter: Q1'24 Batch 1 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 3 Jan 2024 **Lead Time: 50 days in advance** Interpretation: 48.8% placebo-adjusted Hemoglobin response an increase of average hemoglobin concentrations from week 12 through week 24 compared with baseline for beta-thalassemia (vs 77.7% placebo-adjusted hemoglobin response achieved by the SoC in phase 2 beyond trial) 6MWT not met.	Overall Correct Prediction Conclusion: statistically significant and commercially insufficient Classification: **True Negative (TN)**

Validated Trial Evidence: Complete Prediction-Outcome Registry

#	Clinical Trial	Certified Prediction	Validation	Result
	Sponsor: Agios Pharmaceuticals (AGIO)			
1254	**DYNE-101** **NCTID: NCT05481879** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small interfering RNA (siRNA) antisense oligonucleotide** **MoA: anti-DMPK siRNA** **Area: Musculoskeletal Diseases** **Indication: Myotonic Dystrophy Type 1** **Human Patients: 72** **Sponsor: Dyne Therapeutics (DYN)**	Date: 21 Nov 2023 Quarter: Q1'24 Batch 7 Technical: SUCCESS (statistically significant clinical benefit in toxicity) Commercial: FAILURE (commercially insufficient clinical benefit in 10MWR)	Readout: 3 Jan 2024 **Lead Time: 43 days in advance** Interpretation: 40% DMPK knowddown and 3.8 second benefit in myotonia at 6 months; no report of key 10MWR functional endpoints.	Correct Prediction Note: correct technical prediction (commercial data TBD) Conclusion: statistically significant and commercially TBD Classification: **True Positive (TP)**
1259	**LP352** **NCTID: NCT05364021** **Phase: Phase 1 Phase 2** **Class: First-In-Class** **Modality: small molecule** **MoA: 5HT2C superagonist** **Area: Nervous System Diseases** **Indication: Developmental and Epileptic Encephalopathies** **Human Patients: 52** **Sponsor: Longboard Pharmaceuticals (LBPH)**	Date: 2 Oct 2023 Quarter: 2H'23 Batch 19 Technical: FAILURE (statistically insignificant clinical benefit) Commercial: FAILURE (commercially insufficient clinical benefit)	Readout: 2 Jan 2024 **Lead Time: 92 days in advance** Interpretation: 32.5% motor seizable frequency reduction compared with placebo.	Missed Prediction Note: due to suboptimal MoA modelling that has been permanently corrected. Conclusion: statistically significant and commercially sufficient Classification: **False Negative (FN)**
927	**Aficamten (CK-3773274)** **NCTID: NCT05186818** **Phase: Phase 3** **Class: First-In-Class** **Modality: small molecule** **MoA: cardiac myosin inhibitor** **Area: Cardiovascular Diseases** **Indication: Obstructive Hypertrophic Cardiomyopathy (oHCM)** **Human Patients: 282** **Sponsor: Cytokinetics (CYTK)**	Date: 21 Aug 2023 Quarter: 2H'23 Batch 16 Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient clinical benefit superior to metoprolol succinate)	Readout: 27 Dec 2023 **Lead Time: 128 days in advance** Interpretation: primary endpoint met with 1.74/mL/kg/min placebo-adjusted pVO2 improvement superior to the previous best treatment metoprolol succinate; and all endpoints met with high sttistical significane (p<0.0001) even for patients who have received background beta-blockers.	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**
963	**Efgartigimod** **NCTID: NCT04598451** **Phase: Phase 3** **Class: First-In-Class** **Modality: antibody fragment biologic** **MoA: anti-FcRn antibody fragment** **Area: Skin and Connective Tissue Diseases** **Indication: Pemphigus** **Human Patients: 222** **Sponsor: argenx (ARGX)**	Date: 4 Jul 2023 Quarter: 2H'23 Batch 9 Technical: FAILURE (statistically insignificant additive clinical benefit) Commercial: FAILURE (commercially insufficient additive clinical benefit)	Readout: 20 Dec 2023 **Lead Time: 169 days in advance** Interpretation: primary or secondary endpoints not met.	Correct Prediction Conclusion: statistically insignificant and commercially insufficient Classification: **True Negative (TN)**
973	**Semaglutide** **NCTID: NCT03574597** **Phase: Phase 3** **Class: First-In-Class** **Modality: pepetide** **MoA: GLP1R agonist** **Area: Cardiovascular Diseases and Nutritional and Metabolic Diseases** **Indication: Cardiovascular risk in obesity patients** **Human Patients: 17604** **Sponsor: Novo Nordisk (NVO)**	Date: 20 May 2023 Quarter: 1H'23 Batch Update Technical: SUCCESS (statistically significant clinical benefit) Commercial: SUCCESS (commercially sufficient additive clinical benefit)	Readout: 8 Aug 2023 **Lead Time: 80 days in advance** Interpretation: semaglutide + SoC achieved 20% reduction in MACE-3 compared with placebo + SoC (6.5% vs 8.0%; HR = 0.80; P < 0.001) (see add'l link below)	Correct Prediction Conclusion: statistically significant and commercially sufficient Classification: **True Positive (TP)**

Appendix: Statistical Methodology & Glossary

KPI FORMULAS

Accuracy
`(TP + TN) / (TP + TN + FP + FN)`

Precision (PPV)
`TP / (TP + FP)`

NPV
`TN / (TN + FN)`

F1-Score
`2 × TP / (2 × TP + FP + FN)`

DOR
`(TP × TN) / (FP × FN)`

Sensitivity
`TP / (TP + FN)`

Specificity
`TN / (TN + FP)`

GLOSSARY

Ex-Ante / Prospective	Prediction issued before outcome is known; timestamped proof
TP	True Positive — predicted blockbuster drug-indication pair with moderately or strongly superior to SoC clinical benefit with HR < 0.6, confirmed by clinical readout
TN	True Negative — predicted non-blockbuster drug-indicatpion pair with weakly superior or inferior to SoC clinical benefit with HR > 0.6, confirmed by clinical readout
FP	False Positive — predicted blockbuster drug-indication pair with moderately or strongly superior to SoC clinical benefit with HR < 0.6, contradicted by clinical readout
FN	False Negative — predicted non-blockbuster drug-indicatpion pair with weakly superior or inferior to SoC clinical benefit with HR > 0.6, contradicted by clinical readout
FIC	First-In-Class — novel mechanism of action and indication pair, no approved precedent
BIC	Best-In-Class — improved agent within an established class
DOR	Diagnostic Odds Ratio — measures discriminative power
MoA	Mechanism of Action — how a drug exerts its therapeutic effect
SoC	Standard of Care — current best available treatment
NCTID	ClinicalTrials.gov trial identifier (e.g., NCT12345678)

DATA PROVENANCE

- All predictions in this dossier are sourced from the BioinvestGPT validated prediction database.
- Each prediction is independently verifiable via its unique index number on data.bioinvestgpt.com.
- Clinical readout outcomes are sourced from official company press releases, ClinicalTrials.gov results, and peer-reviewed literature.
- This dossier was generated on April 8, 2026.

Important Disclaimers

Informational Purposes Only

This Evidence Dossier is provided for informational and analytical purposes only. The data, analyses, and conclusions presented herein are based on BioinvestGPT's proprietary prediction methodology and publicly available clinical trial outcomes. Nothing in this document constitutes medical, pharmaceutical, financial, or investment advice.

No Investment Advice

The information contained in this dossier should not be construed as a recommendation to buy, sell, or hold any security, nor as an endorsement of any pharmaceutical company, drug candidate, or clinical program. Past prediction accuracy does not guarantee future performance. Investors should conduct their own due diligence and consult qualified financial advisors before making investment decisions.

Clinical Trial Uncertainty

Clinical trials are inherently uncertain. Regulatory approval, commercial success, and patient outcomes depend on numerous factors beyond the scope of this analysis, including but not limited to: regulatory authority decisions, manufacturing capabilities, competitive dynamics, payer coverage, and post-marketing safety signals.

No Guarantee of Future Performance

While BioinvestGPT has demonstrated strong predictive accuracy in validated trials to date, this historical performance does not guarantee equivalent accuracy on future predictions. The pharmaceutical development landscape is dynamic, and novel therapeutic modalities, regulatory frameworks, and clinical trial designs may impact prediction accuracy.

Data Accuracy

BioinvestGPT makes reasonable efforts to ensure the accuracy of data presented in this dossier. However, data is sourced from public clinical trial registries, company announcements, and regulatory filings, which may contain errors or omissions. BioinvestGPT disclaims liability for any inaccuracies in source data.

Confidentiality Notice

This document is intended solely for the use of the individual or entity to which it is addressed. If you are not the intended recipient, please notify the sender immediately and destroy all copies. Unauthorized disclosure, copying, distribution, or use of this document is strictly prohibited.

BioinvestGPT

Evidence Dossier

Data-Free Head-to-Head Virtual Clinical Trials

with > 90% Ex-Ante Accuracy

April 8, 2026

data.bioinvestgpt.com

Scan to access live evidence dashboard